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Abstract 
The selective hydrogenation and dehydrogenation of organic molecules is a 
fundamentally challenging and an attractive transformation for both, industry and 
academia. However, catalysts capable of undergoing both transformations under 
environmentally benign conditions are rare. In this thesis, our contribution to the 
development of a “universal” catalyst capable of achieving both hydrogenation and 
dehydrogenation of a wide range of organic compounds under mild conditions is 
presented.  
A general introduction covering the recent developments in the area of transfer 
hydrogenation of C=X (X = O, N) bonds, relevant applications of cyclometalated 
half-sandwich complexes and previous work in the area developed within our group 
is described in Chapter 1. In Chapter 2, Cyclometalated iridium complexes are 
shown to be highly efficient and chemoselective catalysts for the transfer 
hydrogenation of a wide range of carbonyl groups with formic acid in water. 
Examples include α-substituted ketones (α-ether, α-halo, α-hydroxy, α-amino, α-
nitrile, α-ester), α-keto esters, β-keto esters, and α,β-unsaturated aldehydes. The 
reduction was carried out at substrate/catalyst ratios of up to 50000 at pH 4.5, 
requiring no organic solvent. The protocol provides a practical, easy and efficient 
way for the synthesis of β-functionalised secondary alcohols, such as β-
hydroxyethers, β-hydroxyamines and β-hydroxyhalo compounds, which are valuable 
intermediates in pharmaceutical, fine chemical, perfume and agrochemical synthesis. 
In Chapter 3, the cyclometalated iridium complexes are shown to catalyse the 
transfer hydrogenation of various nitrogen heterocycles, including but not limited to 
quinolines, isoquinolines, indoles and pyridiniums, in aqueous solution under mild 
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conditions. The catalyst shows excellent functional group compatibility and high 
turnover number (up to 7500), with loading as low as 0.01% being feasible. 
In Chapter 4, cyclometalated iridium complexes are found to be versatile catalysts 
for the direct reductive amination of carbonyls to give primary amines under transfer 
hydrogenation conditions with ammonium formate as both the nitrogen and 
hydrogen source. The activity and chemoselectivity of the catalyst towards primary 
amines is excellent, with a substrate to catalyst ratio of 1000 being feasible. Both 
aromatic and aliphatic primary amines were obtained in high yields. Moreover, a 
first example of a homogeneously catalysed transfer hydrogenative direct reductive 
amination (DRA) has been achieved for -keto ethers, leading to the corresponding 
-amino ethers. In addition, non-natural -amino acids could also be obtained in 
excellent yields with this method. 
Following the success of hydrogenation, cyclometalated iridium complexes were 
also found to be versatile catalysts for the oxidant-free, acceptorless dehydrogenation 
of various N-heterocycles, including tetrahydroquinolines, tetrahydroisoquinolines, 
tetrahydroquinoxalines and indolines. This protocol was also successfully applied to 
the total synthesis of alkaloids as presented in Chapter 5. 
Chapter 6 describes the development of a new strategy for the oxidant- and base-free 
dehydrogenative coupling of N-heterocycles at mild conditions. Under the action of 
an iridium cyclometalated catalyst, N-heterocycles undergo multiple sp
3
 C-H 
activation, generating a nucleophilic enamine that reacts in situ with various 
electrophiles to give highly functionalised products. The dehydrogenative coupling 
can be cascaded with Friedel-Crafts addition, resulting in double functionalisation of 
the N-heterocycles. The dehydrogenation products could also be saturated under 
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either hydrogenation or transfer hydrogenation conditions, giving rise to structurally 
diverse products. 
Final conclusion and perspectives of the research covered in this PhD thesis are 
presented in Chapter 7. 
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1.1 Introduction 
The reduction of C=X (X = O, N) bonds is one of the most important 
transformations in both academia and industry.
[1]
 The resulting products, alcohols 
and amines, are both important intermediates in fine chemicals, agrochemicals, 
pharmaceuticals and advanced material synthesis.
[2]
 In fact, these functional groups 
are present in numerous bioactive molecules and natural products (Scheme 1.1).
[3,4]
 
 
Scheme 1.1: Representative examples of bioactive molecules containing alcohol and amine moiety. 
Such reactions are typically performed with a stoichiometric reducing agent such as 
metal hydrides based on boron or aluminium. Since their discovery both LiAlH4 and 
NaBH4 have been the choice of reducing agents for the carbonyl reduction.
[5]
  They 
have been routinely implemented in the pharmaceutical industry with numerous 
applications due to their robustness and reliability.
[6]
 NaBH4 is cheaper and tolerates 
more functional groups (i.e. esters, amides, nitriles) than LiAlH4; thus it is the 
preferred reagent on large scale synthesis.
[7]
 However, for the reductive amination 
(RA), NaBH(OAc)3 is preferred as it is more selective than NaBH4.
[8,9]
 
NaBH(OAc)3, at pH 5-6, reduces imines but not ketones whereas NaBH4 reduces 
both imines and ketones. Although these metal hydrides are robust, the 
stoichiometric inorganic waste that is generated after the work up is an 
environmental concern, especially in industrial or scale up processes. Work up also 
Chapter 1 
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includes an aqueous quench, sometimes acidic to destroy the residual borohydride. 
This process is exothermic and evolves hydrogen gas that raises safety issues.
[10]
 
Thus other reduction systems have been developed as greener alternatives, which are 
catalytic and encourage waste minimisation.
[11]
 These include biocatalytic
[12]
 and 
organocatalytic
[13]
 systems, but heterogeneous and homogeneous catalysts based on 
transition metals are the most promising and widely studied systems.
[14,15]
 
Heterogeneous catalysts are widely applied to the reduction of carbonyl and imino 
bonds; however these catalysts are beyond the scope of this chapter and have been 
highlighted in excellent reviews.
[15,16]
 Homogeneous catalysts, depending on the 
hydride source used, can be divided into two categories:  
 Metal catalysed hydrogenation where H2 gas is used as the hydrogen source.  
 Metal catalysed transfer hydrogenation where hydride source other than H2 is 
used (typically HCO2H or 
i
PrOH).  
The latter is more desirable as it circumvents the use of potentially explosive H2 and 
the handling of high pressure reactors.
[17]
 Moreover, hydrogen sources such as 
formates and 
i
PrOH are cheap, air stable, easy to handle and do not require any 
specialised equipments to conduct reactions.
[18]
 Thus this chapter will focus on 
advances in homogeneous transition metal catalysed transfer hydrogenation (TH) of 
C=X (X = O, N) bonds. 
1.2 TH of ketones in organic media 
The first TH of carbonyls to alcohols was reported in 1925, known as Meerwein-
Ponndorf-Verley (MPV) reduction.
[19]
 The reaction proceeds via a six-membered 
transition state, where a hydride from an α carbon of the alcohol is transferred to the 
Chapter 1 
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carbonyl (Scheme 1.2).
[20]
 The reaction is catalysed by Al(O
i
Pr)3 and the reverse of 
such reaction is known as Oppenauer oxidation (OPP).
[19,20]
  
 
Scheme 1.2: Meerwein-Ponndorf-Verley (MPV) reduction. 
Since then, much attention was devoted to the development of heterogeneous 
catalysis based on various transition metals. However the homogeneous catalysts for 
TH of ketones did not gain much attention until the early 1980’s, when ruthenium 
complexes were shown to catalyse the dehydrogenation of alcohols.
[2]
 It was also 
reported that the addition of a base such as NaOH significantly improved the 
dehydrogenation of alcohols. Thus, Bäckvall and co-workers reported that 
[RuCl2(PPh3)3] could catalyse the TH of ketones in 
i
PrOH using catalytic amounts of 
NaOH under mild conditions (82 °C).
[21]
 The yields obtained were moderate and no 
reduction proceeded in the absence of NaOH (Scheme 1.3). These results however 
presented a significant improvement when using 
i
PrOH as a hydride source, as the 
earlier examples reported with Ru required elevated temperatures (150-200 °C).
[21]
 
When 
i
PrOH is used as the hydrogen source, the equilibrium involving the 
i
PrOH 
and acetone sets a limit to the conversion of ketones. Therefore, to achieve useful 
conversions the reaction is usually carried out in large excess of 
i
PrOH (low 
substrate concentration of about 0.1 M) or by removal of acetone from the reaction 
mixture in situ.
[2]
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Scheme 1.3: TH of ketones catalysed by [RuCl2(PPh3)3] in 
i
PrOH. 
Highly active catalysts for the TH of ketones started emerging by the end of 1990’s, 
prior to that the reaction rate and the productivity of the catalysts were low.  Van 
Koten and co-workers reported the Ru(II) pincer complexes containing a terdentate 
bis(phosphanyl)aryl (PCP) ligand (Scheme 1.4).
[22]
 TOFs of up to 10000 h
-1
 were 
achieved for the TH of cyclohexanone using just 0.01 mol% 1, with KOH as the 
promoter in 
i
PrOH at 82 °C. In contrast, when the cationic variant 2 was used TOFs 
of up to 27000 h
-1
 were achieved. These values were superior to those obtained 
earlier with Ru(II) complexes bearing only monodentate phosphane ligands, such as 
[RuCl2(PPh3)3].
[21]
 The reaction only proceeded under inert atmosphere and a low 
KOH concentration was necessary to inhibit the side aldol products.  
 
Scheme 1.4: Pincer-type Ru(II) complexes containing terdentate PCP ligands. 
In addition, Barrata and co-workers independently prepared a diverse series of 
cyclometalated Ru(II) complexes (Scheme 1.5), and subsequently applied them to 
the TH of ketones in 
i
PrOH under basic conditions.
[23,24]
 Complex 3, containing a 
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bidentate ethylendiamine coligand at 0.1 mol% loading, was found to transfer-
hydrogenate acetophenone in quantitative yields in 30 min, using NaOH as a base in 
i
PrOH. Remarkably, considerable rate acceleration was observed when 
ethylendiamine coligand was replaced with 1-(pyridin-2-yl)methanamine (Pyme); 
the same reaction finished in only 5 min using only 0.05 mol % 4 with TOF reaching 
up to 60000 h
-1
. However, when the analogous 2-(pyridine-2-yl)ethanamine was 
used as coligand instead of Pyme, this resulted in much less active reduction (TOF 
4000 h
-1
),
[23]
 suggesting that the Pyme coligand is essential for the catalytic activity. 
Their system was also applicable on a gram scale as demonstrated by the TH of 
benzophenone with 0.01 mol% catalyst loading (90% isolated yield of 
benzhydrol).
[23]
  
 
Scheme 1.5: Series of diverse cyclometalated Ru(II) complexes and their activity in TH of ketones. 
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Subsequently, the cyclometalated carbene Pyme and terdentate CNN ruthenium 
complexes 5 and 6 were reported (Scheme 1.5).
[24,25]
 Complex 5 is highly efficient in 
the reduction of numerous ketones, including alkyl and dialkyl ketones with TOF up 
to 1.2 x 10
5
 h
-1
 using 0.05 mol% catalyst.
[24]
 This high activity could be ascribed to 
the relative strong bonding of the carbene ligand. Complex 6 is also highly robust. 
For example at an S/C ratio of 20000:1, 1-phenylethanol was quantitatively obtained 
within 5 min of TH of acetophenone with a remarkable TOF of up to 1.1 x 10
6
 h
-1
 in 
i
PrOH.
[25]
 Addition of further amounts of acetophenone into the reaction mixture 
also resulted in complete reduction, showing the high catalytic activity of the 
catalyst. This TH was also demonstrated on a gram scale at S/C of 100000:1. The 
high catalytic activity is probably due to the role of the NH2 group in assisting the 
TH of ketone. The NH2 group offers metal-ligand bifunctionality; thus when it was 
replaced with NMe2 group the activity decreased. Rigid framework built by the CNN 
ligand together with chelating diphosphine retarded the deactivation of catalyst.
[25]
  
Complexes based on iridium and rhodium are also known to be effective for the TH 
of ketones by 
i
PrOH.
[26-34]
 Inspired by the seminal work of Bianchini on Ir 
complexes featuring aminodiphosphine ligands,
[26]
 Rashid and co-workers developed 
the bifunctional pincer complex 7.
[27]
 Indeed, complex 7 was found to be highly 
active for the TH of ketones in the absence of a base in 
i
PrOH, with acetophenone 
being converted into the corresponding alcohol using only 0.001 mol% catalyst 
loading (Scheme 1.6). The high activity of this complex was due to the availability 
of the hydrogen on the nitrogen donor, which plays an important role for the 
reactivity with concerted hydrogen transfer from both NH and Ir-H to the ketone.
[27]
 
Earlier Bianchini and co-workers had reported similar aminodiphosphine ligands 
with a NR moiety (where R represents an alkyl substituent) instead of an NH; 
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however the catalytic performance was much lower, highlighting the importance of 
NH.
[26,27]
  
 
Scheme 1.6: Iridium catalysed TH of ketones. 
Nolan and co-workers reported the use of cationic Ir(I) mono-carbene complex 8 for 
the TH of ketones.
[28]
 This catalyst is analogous to Crabtree’s [Ir(cod)(py)(PCy3)]PF6 
hydrogenation catalyst.
[29]
 Complex 8 catalysed the reduction of simple ketones 
using 
i
PrOH/KOH under reflux, with a low catalyst loading and short reaction times 
(Scheme 1.7). The same catalyst also exhibits activity toward the reduction of C=C 
bond and NO2 group. Consequently, Crabtree and co-workers developed a series of 
bis(N-heterocyclic carbene) complexes based on Rh(III)
[30]
 and Ir(III)
[31]
 that are air 
and moisture stable. The two carbene moieties were linked by a methylene bridge. 
The stability of the complexes was attributed to the chelate effect of the bis-carbene 
that resists degradation under catalytic conditions. Ir(III) complexes were much more 
active than their Rh(III) counterparts for the TH of ketones. The catalytic activity 
was highly influenced by the nature of the R group on the carbene (Scheme 1.8).
[31]
 
For example when complex 9a (R = Me) was used for the TH of benzophenone in 
i
PrOH under reflux condition, the corresponding alcohol was achieved in 98% 
conversion after 90 min with a TOF of up to 2000 h
-1
. In contrast, when 9c (R = 
neopentyl) was used under the same condition, the reaction was completed in only 4 
min with a TOF of up to 50000 h
-1
 being achieved at 50% conversion. With complex 
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9b (R = Bn) the reaction was much slower (98% conversion in 20 h), however. The 
activity of these bis-carbene complexes is significantly higher than that observed for 
related mono-carbene complex 8.
[28]
  
 
Scheme 1.7: TH of simple ketones catalysed by [Ir(cod)(py)ICy]PF6 in 
i
PrOH. 
 
Scheme 1.8: TH of ketones with Ir and Rh bis(N-heterocyclic carbene) complexes. 
Among the half-sandwich Ir(III) NHC complexes, complex 11, reported by Peris and 
co-workers is an interesting catalyst.
[32]
 The Cp* is tethered to the NHC leaving the 
complex with two possible vacant coordination sites. Thus, complex 11 was found to 
be much more active than its analogous complex 12,
[33]
 providing the reduction of a 
range of ketones at low catalyst loading (0.1 mol% compared with 1 mol% when 
using 12). Rh(III) CNC pincer complex 13, with two NHC donor moieties, was also 
reported to be active for TH of cyclohexanone, acetophenone and benzophenone 
with low catalyst loadings (Scheme 1.9).
[34]
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Scheme 1.9: TH of ketones with Ir half-sandwich NHC complexes and Rh-CNC complex. 
Three main pathways have been proposed for the metal catalysed TH between 
alcohols (
i
PrOH) and ketones (Scheme 1.10);
[35]
  
 Pathway A involves direct hydrogen transfer where simultaneous hydride 
transfer takes place between the alkoxide and ketone, while both are coordinated 
to the metal centre. A typical example that follows such pathway is Meerwein-
Ponndorf-Verley reduction.  
 Pathway B is a typical example of metal-ligand bifunctional catalyst such as 7, 
where the metal hydride transfers one hydrogen atom to the carbon of C=O bond, 
while the acidic amine provides the second hydrogen atom to the oxygen, usually 
via six membered transition state.  
 Meanwhile in pathway C once the metal hydride species is formed the reaction 
proceeds by the coordination of ketone to the metal and then the hydride transfer 
takes place. Complex 9 follows this pathway as suggested by Crabtree and co-
workers.  
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Scheme 1.10: Reaction pathways proposed for the metal catalysed TH of ketones by 
i
PrOH. 
1.3 TH of ketones in aqueous media 
The TH of carbonyls can also be conducted in an aqueous media using formate salts 
as the hydride source as demonstrated by the seminal work of Sasson and Blum,
[36,37]
 
and later by Joo
[38,39]
 and co-workers in the 1980’s. A number of aromatic aldehydes 
were reduced in moderate to good yields by HCO2Na at 90 °C using RuCl2(PPh3)3 as 
the catalyst. In the case of ketone reduction analogous RhCl(PPh3)3 proved to have a 
higher activity, although a large excess of PPh3 was required for a sufficient 
reaction.
[36]
 Later studies by Joo revealed that the reactions in aqueous media are pH 
dependent.
[39]
 For example in a study using Ru and a water soluble (3-
sulfonatophenyl)diphenylphosphane (m-TPPMS) ligand in excess, TH of 
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cinnamaldehyde at pH 9 resulted in the formation of cinnamyl alcohol exclusively; 
however, at pH 3 the same reaction afforded 3-phenylpropanal as the major product 
(Scheme 1.11).
[39,40]
  
 
Scheme 1.11: Selectivity of the hydrogenation of cinnamaldehyde as a function of pH value. 
The in situ NMR experiments conducted revealed the formation of various Ru(II) 
hydrides; [HRuCl(m-TPPMS)3] and [RuH2(m-TPPMS)4] were the dominant species 
detected in acidic and basic solutions, respectively. [HRuCl(m-TPPMS)2], which is 
formed in acidic solution by the dissociation of phosphine from [HRuCl(m-
TPPMS)3] was reported to be the active species for the selective reduction of C=C 
bond. Conversely, [RuH2(m-TPPMS)4] formed under basic conditions is selective for 
C=O bond reduction (Scheme 1.12).
[39-41]
 The coordinative saturation of [RuH2(m-
TPPMS)4] probably prevents the coordination of C=C bond to the metal centre, but 
allows the reduction of C=O bond by intermolecular nucleophilic hydride transfer. 
 
Scheme 1.12: Formation of Ru-hydride species and their selectivity towards unsaturated bonds. 
Recently, water-soluble half-sandwich Ir(III),
[42]
 Rh(III)
[43]
 and Ru(II)
[44]
 complexes 
have shown to be active in carbonyl TH using HCO2Na or HCO2H (Scheme 1.13). 
For the reduction, the active hydride species is generated in situ from the 
decarboxylation of formate. Ogo and co-workers have reported that Ir complexes 14, 
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15 and 16 are effective for the TH of carbonyls under acidic conditions.
[42,45,46]
 The 
reaction is highly pH dependent and only works in a certain pH interval and is also 
dependent on the catalyst used. For example, in the case of 16 the optimum TOF is 
achieved when the reaction is conducted between pH 2.0-3.0 for both water soluble 
(cyclohexanone) and water insoluble (acetophenone) substrates using HCO2H. The 
reaction is faster because under these acidic conditions the carbonyl groups are 
activated by the protons; hence hydride transfer is easier.
[42,45]
 The formation of the 
active hydride catalyst 16a is also pH dependent, as high concentrations of it are 
only observed between the pH values of 2.0-6.0. Below pH 2.0, the protonation of 
16a occurs with H2 evolution. Above pH 6.0, 16 is predominantly deprotonated to 
form a hydroxo complex 16b that is inactive and hardly reacts with formic acid 
(Scheme 1.14).
[45]
 In comparison, complexes 14 and 15 were less active than 16.
[42,45]
 
The aqua complex 17, a Rh analogue of 14 was also less active.
[46,47]
 In contrast, 
Ru(II) catalyst 18 performed best at the pH of 4.0 with TOF up to 153 h
-1
 being 
achieved.
[44]
 
 
Scheme 1.13: Water-soluble half-sandwich complexes.   
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Scheme 1.14: Species observed at different pH values. 
Some of these complexes can also be used in conjunction with enzymes for the 
enantioselective reduction. Redox enzymes such as alcohol dehydrogenases require a 
cofactor such as nicotinamide adenine dinucleotide hydride (NADH) or nicotinamide 
adenine dinucleotide phosphate hydride (NADPH) as the hydride source. However, 
the in situ regeneration of these cofactors is expensive; thus efforts have been made 
to develop cheaper non-enzymatic regeneration systems. Steckhan and co-workers 
reported the use of half-sandwich [Cp*Rh(bpy)H]
+
 for the regioselective reduction 
of NAD
+
 to 1,4-NADH.
[48]
 The active hydride catalyst [Cp*Rh(bpy)H]
+
, which is an 
analogue of [Cp*Rh(bpy)OH2]
2+
 19, was generated in situ from the decarboxylation 
of HCO2Na. This system was successfully applied for the cofactor regeneration 
process in enzymatic reduction of ketones.
[49]
 Later, Fish and co-workers elucidated 
the mechanism of this important reaction.
[50]
 They proposed that once the hydride 
catalyst is formed, the amide functionality of the NAD
+
 coordinates to the Rh metal 
centre. This coordination site occurs by the ring slippage mechanism of the Cp* ring, 
where the coordination mode of the Cp* changes from 5 to 3. Next, the selective 
hydride transfer at C4 of the NAD
+
 occurs via six-membered transition state, which 
simultaneously includes the reversion of the coordination of Cp* from 3 to 5. 
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Finally, H2O displaces the NADH and gives the precursor catalyst 19 (Scheme 
1.15).
[50]
  
 
Scheme 1.15: Proposed mechanism for the regioselective, catalytic reduction of NAD
+
 model.   
Inspired by Ogo’s work,[42-44] Süss-Fink and co-workers reported a series of 
complexes containing chelating 1,10-phenanthroline ligands.
[51,52]
 However, the 
activity of these complexes was lower in comparison to bipyridine complexes.
[44]
 For 
example using 18, a TON of 196 was achieved after 4 h at 70 °C for the TH of 
acetophenone using HCO2H, whereas under the same condition a TON of 144 was 
achieved after 48 h when 1,10-phenanthroline ligand was used.
[44,51]
 Subsequently, 
the Rh cationic chlorido complex 20, which was reported by the same group, was 
found to be highly active in the TH of NAD
+
 in aqueous media. TOF of up to 2000 
h
-1
 was obtained using only 0.1 mol% catalyst. It was also compatible for the NADH 
regeneration for the stereoselective TH of ketones with alcohol dehydrogenase 
(Scheme 1.16).
[52]
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Scheme 1.16: Proposed mechanism for the chemoenzymatic ATH of ketones. 
1.4 TH of aldehydes 
Compared to ketones, the TH of aldehydes is less explored. Phosphine ligands have 
been traditionally used on transition metal catalysts for the TH of aldehydes. 
However, their conversions remained moderate.
[53,54]
 Catalytic TH of aldehydes is 
often challenging and several reasons may apply for the low conversion usually 
obtained; 
I. When reduction is carried out in iPrOH under basic conditions, the α-CH group 
to the carbonyl can be deprotonated and lead to the formation of aldol product. 
II. Substrate decarbonylation that may deactivate the catalyst through coordination 
of the resulting carbonyl.   
Crabtree and co-workers have recently reported that NHC ligands, being a stronger 
electron donors, can enhance the reactivity of the transition metal.
[55]
 The Ir-NHC 
complex 21, catalysed the TH of various aldehydes, achieving TOF’s of up to 3000 
h
-1
, in 
i
PrOH (Scheme 1.17). 
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Scheme 1.17: TH of aldehydes by Ir-NHC complex in 
i
PrOH. 
More recently, Baratta and co-workers reported the most efficient system for the TH 
of aldehydes using tridentate CNN ruthenium complex 22.
[56]
 
i
PrOH served as both 
the solvent and hydride donor and a TOF up to 5.0 x 10
5
 h
-1
 was achieved for the 
reduction of benzaldehyde using only a 0.05 mol% catalyst loading (Scheme 1.18). 
The association of a CNN ligand with the bulky diphosphane was considered to 
hinder the substrate decarbonylation. The system was also effective in reducing 
aliphatic aldehydes in high yield.  
 
Scheme 1.18: TH of aldehydes in 
i
PrOH by Ru-CNN complex. 
Xiao and co-workers demonstrated that the TH of aldehydes can be enhanced when 
conducted in aqueous media in an “on water” fashion.[57] The half-sandwich catalyst 
23 was prepared in situ using [Cp*IrCl2]2 and monotosylated ethylenediamine 
ligand. Although the catalyst was insoluble in water, it afforded a TOF of up to 1.3 x 
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10
5
 h
-1
 for the reduction of benzaldehdye in neat water (Scheme 1.19). Interestingly, 
when the same reaction was carried using F/T or 
i
PrOH, only a conversion up to 3% 
was achieved. This system was highly chemoselective towards aldehyde reduction 
when the TH of a substrate containing both an aldehyde and a ketone functionality 
was attempted. Moreover, the catalyst was also chemoselective towards the TH of 
α,β-unsaturated aldehydes giving allylic alcohols in high yields. An ample variety of 
functional groups were tolerated and reduction of aliphatic aldehydes was also 
viable. 
 
Scheme 1.19: TH benzaldehyde in water. 
1.5 ATH of ketones in organic media 
Asymmetric transfer hydrogenation (ATH) of ketones has also been developed in 
both organic and aqueous media. In early studies chiral monophosphine ligands were 
employed for the ATH of ketones, though the enantioselectivities achieved were 
generally low.
[2]
 Pfaltz and co-workers reported that Ir(I) complexes prepared in situ 
from [Ir(COD)Cl2] and tetrahydrobi(oxazoles) 24 can catalyse the reduction of 
ketones with 
i
PrOH under reflux conditions (Scheme 1.20).
[58]
 Alkyl aryl ketones 
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were smoothly reduced giving optically active alcohols in moderate to good 
enantioselectivities, whereas aliphatic substrates were found unreactive. Since then, 
several other chiral systems were developed by Genêt (Ru),
[59]
 Evans (Sm)
[60]
 and 
Lemaire (Rh),
[61]
 although the enantioselectivity was generally lower than 90%.  
 
Scheme 1.20: ATH using tetrahydrobi(oxazole) ligand. 
The pioneering work by Noyori, Ikariya and co-workers in 1995 led to a Ru(II) 
catalyst bearing a N-(p-toluenesulfonyl)-1,2-diphenylethylenediamine (Ts-DPEN) 
ligand, which was found to be highly efficient for the ATH of ketones.
[62]
 The 
enantioselectivities achieved were excellent (>95%), which was a significant 
breakthrough, as for the earlier reported systems the enantioselectivities were 
generally moderate. 
i
PrOH was used as the hydride source and the reaction was 
conducted at room temperature. It was important to run the reaction with a low 
substrate concentration (0.1 M) to achieve high enantioselectivity. At high 
concentration the enantiomeric purity of the chiral product deteriorated due to the 
occurrence of the reverse process originating from the structural similarity of the 
hydrogen donor (
i
PrOH) and product, both secondary alcohols. Subsequently, the 
same group reported that this problem could be avoided by substituting 
i
PrOH with 
F/T azeotrope as the hydrogen source.
[63]
 As a result, the reaction could be conducted 
with much higher substrate concentration (2-10 M) in comparison with the 
i
PrOH 
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reaction (<0.1 M), with almost quantitative yields and excellent enantioselectivities 
(Scheme 1.21).  
 
Scheme 1.21: ATH of acetophenone using Ru-TsDPEN. 
Since its discovery these Noyori-Ikariya type catalysts have found broad applications 
and inspired intense research into ATH. Many ligands have been developed that 
offer metal-ligand bifunctionality, such as bidentate,
[64]
 terdentate
[65]
 and tetradentate 
ligands.
[66]
 Some representative ligands are shown in Scheme 1.22, and their 
applications in the ATH of ketones have been summarised in many reviews.
[2,14,35,67]
   
 
Scheme 1.22: Representative ligands for ATH. 
Catalysts 25 and 34 are also efficient for the ATH of 1,2-diketones, giving the 
corresponding 1,2-diols in high yields and excellent enantioselectivities (up to 99%) 
in the presence of the F/T azeotrope.
[68,69] 
For unsymmetrically substituted 1,2-
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diketones the reduction took place at the less hindered carbonyl group first, and 
further reduction led to anti-1,2-diols. Under the same reaction conditions, racemic 
benzoin was also transformed into chiral diols via dynamic kinetic resolution 
(DKR).
[69]
 ATH of α,β-unsturated ketones to allylic alcohols, and methyl 2-
acylbenzoates to 3-alkylphtalides is also feasible with the same catalyst.
[70,71] 
Using 
the isoelectronic Rh(III) catalyst 35, a series of α-halo ketones, including heteroaryl 
ones, were reduced chemoselectively (Scheme 1.23).
[72]
 These catalysts are much 
more reactive compared with Ru-TsDPEN complexes. For example with an S/C of 
5000 the reduction of α-chloroacetophenone proceeded rapidly to give the 
corresponding chiral alcohol quantitatively with 96% ee (initial TOF, up to 2500h
-1
). 
In contrast, complex 34, which is highly effective for the ATH of simple ketones, 
exhibited no remarkable activity even at a lower S/C of 1000.  
 
Scheme 1.23: Half-sandwich Noyori-Ikariya type catalysts and their reactivity towards ATH of α-
chloroacetophenone. 
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An analogous Ir(III) complex 36 exhibited high reactivity but poor enantioselectivity 
(Scheme 1.23).
[72]
 This remarkable difference in the reactivity could be attributed to 
the electronic properties of the central metals. The chiral halo-hydrins are useful 
intermediates for the synthesis of optically active styrene oxides and aminoethanols 
that serve as building blocks for the synthesis of various pharmaceuticals. The ATH 
is an attractive way to these halo-hydrins and using Noyori-Ikariya type catalysts, the 
reaction has been demonstrated on relatively large scale at Pfizer and Eli Lilly.
[73]
 
Pfeffer and co-workers reported that ruthenacycles generated from [Ru(η6-
benzene)Cl2]2 and chiral amines (primary or secondary) are good catalyst precursors 
for the ATH of simple ketones.
[74]
 Enantioselectivities ranging from 38 to 89% were 
achieved for the TH of acetophenone with such catalysts (Scheme 1.24). The main 
advantage is the use of simple commercially available chiral amines that could easily 
be complexed in one step.  
 
Entry Ligand Product yield 
(%) 
ee(%) Configuration 
1 37 79 38 S 
2 38 86 54 S 
3 39 78 30 S 
4 40 96 69 S 
5 41 49 89 R 
Scheme 1.24: Primary and secondary amine ligands for ATH of acetophenone. 
Recently, the Ru(II)Pyme catalysts, which have previously shown good efficiency in 
the achiral TH of ketones, were also explored for asymmetric reduction (Scheme 
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1.25). Baratta and co-workers reported Ru(II) complex 42, bearing a chiral 
phosphine ligand and Pyme, which was found to be highly active for the reduction of 
ketones in 
i
PrOH, affording a TOF of up to 300000 h
-1
 and enantioselectivities 
ranging from 85 to 94%. The use of chiral CNN ligand was also feasible; good 
enantioselectivity was obtained with the high activity retained.
[75,76]
 Ru complexes 
44 and 45 bearing unsymmetrical NNN ligands have been reported recently by Yu 
and co-workers (Scheme 1.26).
[77]
 High yields with up to 97% ee are obtained for the 
corresponding alcohols in a few minutes at room temperature in 
i
PrOH with just 0.1 
mol% catalyst loading.  
 
Scheme 1.25: ATH of ketones with Ru(II)Pyme complexes. 
 
Scheme 1.26: ATH of ketones with Ru(II)-NNN complexes.  
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Wills and co-workers developed a series of structurally rigid, tethered complexes 
based on Rh and Ru (Scheme 1.27).
[78-82] 
These catalysts are highly active for the 
ATH of ketones and generally provide faster reaction rate than the non-tethered 
analogous using F/T as the hydrogen source. The rigid framework stabilises the 
catalyst making it moisture and air insensitive and also offers an additional element 
in controlling the reaction enantioselectivity. Of particular note is the oxo-tethered 
Ru amido complex 48 with a three-legged piano-stool configuration, recently 
developed independently by Ikariya and Wills.
[80,83] 
It exhibits excellent catalytic 
activity and selectivity for a wide range of ketones, affording up to >99% yield and 
99% ee for the corresponding alcohols (Scheme 1.28). The reaction was also 
performed at loadings as low as S/C = 30000 without the loss of catalytic activity or 
enantioselectivity, thus providing the highest activity among a series of Ru-TsDPEN 
complexes. In addition, the catalytic performance of oxo-tethered Ru complex is 
much higher than that of carbon chain tethered Ru complex reported earlier by 
Wills.
[83]
 Rh(III) complex 49, like its non-tethered analogous 35, is particularly good 
for  the ATH of -substituted aromatic ketones, affording the corresponding alcohols 
in quantitative yields and high enantioselectivities (up to 99.6%).
[81]
 Of further 
interest is the Rh(III) catalyst 50, which, containing a tethered monotosylated 1,2-
diaminocyclohexane (TsDAC) ligand, represents one of the best ATH systems for 
aliphatic ketones, providing 87% ee in the case of cyclohexylmethyl ketone.
[82] 
 
 
Scheme 1.27: Tethered complexes for ATH. 
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Scheme 1.28: ATH with oxo-tethered complex. 
1.6 ATH of ketones in aqueous media  
Transition metal catalysed ATH of ketones can be carried out efficiently in water. 
Significant advances have been made since the early 2000’s for the exploration of 
Noyori-Ikariya type catalysts in water. Williams, Blacker and co-workers reported 
TsDPEN and TsDAC containing a sulfonic acid or sulfonic acid sodium salt group, 
which made these ligands water soluble (51 and 52, Scheme 1.29).
[84] 
Subsequently, 
they tested these ligands for the ATH of simple ketones. The catalysts were prepared 
in situ by reacting the ligand with [Ru(p-cymene)Cl2]2 or [Cp*MCl2]2 (M = Rh, Ir). 
i
PrOH was used both as a co-solvent and as a hydrogen source and the reactions 
were carried out at room temperature. Although good to excellent 
enantioselectivities (up to 96%) were achieved, the activity was much lower 
compared with the reaction reported earlier in organic media.
[62,63] 
 
Chung and co-workers reported the first examples of ATH of ketones in neat water 
without any organic co-solvents. The active catalyst was formed by combining 
[Ru(p-cymene)Cl2]2 with a water soluble (s)-proline amide ligand, 53 (Scheme 
1.29).
[85]
 Sodium formate was used as the hydrogen source and the catalyst could be 
recycled up to 6 times without the loss of activity. A highly water soluble ligand 54 
has also been developed and found to have good activity in the presence of a 
surfactant sodium dodecyl sulfate (SDS).
[86]
 Remarkably, this system is also capable 
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of reducing α-bromo acetophenone in good yield and enantioselectivity. This is a 
challenging substrate, as under homogeneous condition using F/T azeotrope as the 
hydrogen source usually only formate displacement is observed.
[86]
  
 
Scheme 1.29: Water soluble ligands for ATH of ketones. 
A common focus in the research for the successful ATH of ketones in water has been 
the development of water soluble catalysts. However, Xiao and co-workers reported 
that water insoluble 34 and M-TsDAC (M = Ru, Rh, Ir) can also catalyse the 
reduction of ketones by HCO2Na. Water was found to accelerate the asymmetric 
reduction of unfunctionalised ketones. For example using 34 at S/C = 100 
acetophenone was fully reduced to its corresponding alcohol (95% ee) in 1 h at 40 
°C by HCO2Na in water. In comparison, the reaction run in F/T only afforded a 
conversion of 2% in 1 h (Scheme 1.30).
[87]
 Further investigation revealed that the 
ATH of ketones promoted by the Ru-TsDPEN catalyst in water is pH dependent, 
with higher pH favouring higher rates and enantioselectivities.
[88]
 The catalyst is 
partitioned in the substrate and water phase being more soluble in the former. Hence, 
it could be described as “on water” (biphasic) reaction. The tethered Rh-TsDAC 
complex 50 is also highly effective for the reduction of ketones in aqueous media 
including heterocyclic ketones.
[82] 
Thus, 2-acetylfuran was reduced to its 
corresponding alcohol using only a 0.01 mol% catalyst loading at room temperature 
Chapter 1 
26 
 
with an enantioselectivity of 98%. The ATH of aliphatic ketones was also feasible in 
water, albeit with slightly lower enantioselectivities.  
 
Scheme 1.30: Selected examples of alcohols obtained with Ru-TsDPEN in water. 
Li and co-workers demonstrated the ATH of α-keto esters to the highly useful chiral 
α-hydroxy esters in water using Ru(II) catalysts.[89] They found that a bulkier tosyl 
variant afforded greater conversions and enantioselectivities compared with less 
bulky ligands. The use of surfactant was necessary for higher activity with the best 
results obtained in the presence of dodecyltrimethylammonium bromide (DTAB) 
(Scheme 1.31). There appears to be, however, some effects from the substituents on 
the aryl ring of the substrates. Thus, high enantioselectivities were obtained with 
electron donating substrates compared with substrates containing electron 
withdrawing groups. Other metals tested such as Ir and Rh were less active, 
however. Wang and co-workers showed that complex 34 enables efficient ATH of α-
cyano aryl ketones, β-keto esters and β-keto amides when the reaction is performed 
in an emulsion of DCM and aqueous HCO2Na in the presence of 
tetrabutylammonium iodide (TBAI).
[90]
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Scheme 1.31: The effect of bulkier Ts-DPEN on the ATH of methyl 2-oxo-2-phenylacetate. 
Carreira and co-workers developed a series of chiral aqua complexes derived from 
Ir(III) trihydrate precatalysts (Scheme 1.32).
[91-93]
 Screening of a range of 
sulfonamides revealed that ligands bearing strong electron deficient sulfonamides 
provided the highest selectivity and reactivity. Thus, catalyst 57, bearing a 
perfluorinated sulfonamide reduced a range of α-cyano ketones using HCO2H in 
water (pH = 3.5) at a low catalyst loading (0.25-0.5 mol%).
[91]
 Substrates with 
electron donating and electron withdrawing groups did not adversely affect the 
selectivity or conversion, and substrates containg heteroaromatic ring were also 
viable (Scheme 1.33). Reduction of α-chloro and α-nitro ketones was also feasible 
albeit at lower pH of 2.0. Complex 58, containing a chiral diamine, which can be 
seen as a simplified alternative to commonly used Ts-DPEN, was also found to be 
highly efficient for the ATH of both α-nitro and α-cyano aryl ketones with generally 
>92% enantioselectivities achieved in most cases. It is particularly selective for the 
ortho-substituted aryl ketones, which have been known to give lower enantiomeric 
excess in the past, with up to 99% ee achieved with the current system.
[92]
 Further 
work revealed that the reaction is pH independent as it tolerates a wide pH range. For 
instance, the ATH of ethyl benzoylacetate proceeded with 100% conversion and 
94% ee to its corresponding alcohol at pH = 5.0. Remarkably exactly same result 
was obtained when the reaction was conducted at higher pH = 10.5.
[93]
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Scheme 1.32: Chiral aqua complexes. 
 
Scheme 1.33: Representative examples of ATH of various α-cyano ketones in water. 
1.7 TH of imines 
In contrast to the TH of ketones, the transition metal catalysed TH of imines is more 
challenging and a relatively underdeveloped transformation.
[94,95]
 One of the main 
reasons for that is the competitive coordination of the reduced products (ability to 
coordinate to a metal: amine>alcohol) to the metal centre that may lead to undesired 
catalyst poisoning. Despite that some significant advances have been achieved in the 
area of imine TH in the past two decades. Ru, Rh and Ir-based complexes are still 
usual catalysts choice. Imines are most commonly prepared from the condensation of 
amines and carbonyls. If the imine formation and its subsequent reduction are carried 
out in one pot, the reaction is known as direct reductive amination (DRA). 
Consequently, imine reduction is sometimes referred as indirect reductive amination 
(Scheme 1.34).  
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Scheme 1.34: Imine reduction and DRA. 
Grigg and co-workers reported the first example of TH of imine using the 
Wilkinson’s catalyst. A number of aldimines were reduced to their corresponding 
secondary amines in good yields in the presence of sodium carbonate in 
i
PrOH.
[96]
 In 
1992, Bäckvall and co-workers showed that the Ru complex [RuCl2(PPh3)3] can also 
catalyse the reduction of imines in 
i
PrOH.
[97]
 K2CO3 was essential for the reaction to 
proceed and aromatic imines gave better results than aliphatic ones. The reaction was 
sluggish when the monophosphine ligand was replaced by bidentate phosphine 
ligands such as 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) or 1,4-
bis(diphenylphosphino)butane (dppb), which could be attributed to the higher steric 
demand of the imines. Later studies revealed that the dihydride [RuH2(PPh3)3] was 
the active species and it catalysed the reduction of C=N bond in the absence of a 
base, indicating that this reaction proceeds through the hydride mechanism without 
ligand assistance (Scheme 1.35).
[98]
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Scheme 1.35: Proposed mechanism of [RuCl2(PPh3)3] catalysed TH of imine. 
Catalytic TH of imines can also be realised with the half-sandwich dimeric Shvo’s 
catalyst 60, which had earlier shown to be effective in ketone reduction.
[99]
 In 
solution, Shvo’s catalyst dissociates into interchangeable species 60a and 60b, with 
the former active in hydrogenation and the latter in dehydrogenation of 
i
PrOH 
(Scheme 1.36). The catalyst is highly active and reduces a range of N-aryl imines at 
very low catalyst loadings under mild conditions. The rate of imine reduction can be 
enhanced by carrying out the reaction under microwave irradiation.
[100]
 Interestingly, 
Shvo’s catalyst is also active for the racemisation of amines and alcohols.[101]  
 
Scheme 1.36: TH of imines with Shvo’s catalyst. 
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Casey and co-workers proposed an outer-sphere mechanism for the TH of imines 
with Shvo’s catalyst, where the hydride and the proton from the OH group of the 
cyclopentadienyl (Cp) ring were transferred simultaneously to the C=N bond, 
without it being coordinated to the metal centre.
[102]
 This mechanism is also 
consistent with ketone reduction. In contrast, Bäckvall and co-workers suggested an 
inner-sphere mechanism, where imine coordination is followed by the hydride 
transfer. A key step would involve the ring slippage of Cp from 5 to 3 to generate 
a coordinately unsaturated species, required for the imine to coordinate (Scheme 
1.37).
[103]
 
 
Scheme 1.37: Outer-sphere and inner-sphere mechanism proposed for imine reduction with Shvo’s 
catalyst. 
In recent years several reports have emerged describing the development of N-
heterocyclic carbene (NHC) complexes for the reduction of imines in 
i
PrOH.
[30,104-
108]
 Rh(III) complexes 10 and 61, bearing chelating bis-carbene ligands were found 
to catalyse the reduction of aldimines to the corresponding amines in good yield 
(Scheme 1.38).
[30]
 Interestingly, the analogous iridium catalyst 9c (see page 8), 
which was more active for promoting the TH of ketones (vide supra), was only 
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active for the TH of aromatic aldimines but rather ineffective in the case of aldimines 
prepared by the condensation of benzaldehyde and aliphatic amine, even at higher 
catalyst loadings.
[104]
 Both catalysts were sluggish, however, in the case of ketimine 
reduction. A Ru complex 62, with a pincer type bis NHC ligand has been 
demonstrated to be capable of TH of both ketones and aldimine at a very low loading 
(0.015 mol%); however only one example was presented in the case of the latter 
(Scheme 1.38).
[105]
 The high activity of the catalyst is probably due to the availability 
of two reactive sites and the stability provided by the chelating pincer type ligand.  
 
Scheme 1.38: Chelating bis-carbene complexes for TH of imines. 
A mono NHC Ru(II) complex 63 has recently been demonstrated to be capable of 
both the hydrogenation and TH of aldimine in 
i
PrOH, although higher catalyst 
loading was required for the latter (Scheme 1.39).
[106]
 The Ir(III) complex 64 was 
found to be active under base free conditions; however a silver salt is necessary for 
the removal of the chlorides to activate the catalyst (3 equiv. AgOTf relative to 64). 
Again only one example was described, where N-benzylideneaniline was reduced to 
its corresponding amine in 
i
PrOH at S/C = 1000 (Scheme 1.39).
[107]
 The combination 
of Ni(0) with NHC ligand also works effectively for the TH of imines, as 
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demonstrated by Schneider and co-workers.
[108]
 A range of imines, including 
ketimines were hydrogenated in the presence of Et2CHONa as the hydrogen source. 
Even though cyclic imines were also viable substrates, the reaction was not selective 
for the substrates containing halogen groups, and heteroaromatic substrates were 
found to poison the catalyst.   
 
Scheme 1.39: Mono-carbene complexes for TH of imines. 
1.8 ATH of imines 
The first ATH of imines was reported by Noyori and co-workers using the half-
sandwich complex 34 as catalyst and their analogues 65-67, some of which had been 
previously reported for the enantioselective TH of ketones.
[109]
 The reaction 
proceeded at room temperature using F/T azeotrope as the hydrogen source. The TH 
was found ineffective in 
i
PrOH or other alcoholic media, unlike the analogous ketone 
reductions. The use of aprotic polar co-solvents such as DMF, DMSO and MeCN 
was beneficial for the reaction, as in the neat F/T the reduction preceded slowly. 
Various imines, particularly the ones bearing alkyl and benzyl groups adjacent to the 
C=N bond, were reduced with high yields and enantioselectivities (Scheme 1.40). 
However, acyclic imines led to lower yields and enantioselectivities, possibly due to 
their configurational instability (easy interconversion between E and Z isomers in 
solution). Interestingly, under the conditions employed, the C=N bonds are reduced 
more than 1000 times faster than the C=O bonds. Thus the chemoselectivity of this 
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reaction is superior to that observed with NaBH3CN.
[109]
 Later, Vedejs and co-
workers applied this system for the reduction of aniline substituted 3,4-
dihydroisoquinolines.
[110]
 Even though moderate yields were obtained, the 
enantioselectivity was excellent.  
 
Scheme 1.40: ATH of imines using Ru(II) complexes. 
Complex 34 is also effective for the TH of N-sulfonylimines to their corresponding 
sultams.
[111]
 Ring-strained aziridines can be obtained from the ATH of arylazirines 
with the catalyst derived from the combination of [RuCl2(p-cymene)]2 and a chiral 
amino alcohol ligand, albeit with moderate enantioselectivities (Scheme 1.41).
[112]
 
The reaction was conducted in 
i
PrOH, whereas the use of F/T led to the 
decomposition of azirine.   
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Scheme 1.41: ATH of aziridines. 
Baker and co-workers demonstrated that complex 35, which is isoelectronic with and 
analogous in structure to 34, was more active for imine reduction with F/T 
azeotrope.
[113]
 However, the enantioselectivities obtained are generally slightly lower 
than those observed with 34, especially for acyclic imines derived from the 
condensation of acetophenone and benzylamine (Scheme 1.42). Blacker and co-
workers have recently described that the ATH of acyclic imines bearing a sterically 
bulky N-diphenylphosphinoyl group led to the corresponding amines with a high 
degree of enantioselectivity (Scheme 1.42).
[114]
 This superior enantiocontrol could be 
attributed to the bulkiness of the N-substituent, which may force the imine to exist 
predominantly in one geometrical isomer. In fact this transformation using 35 as 
catalyst has been accomplished on large scale too.
[114]
 Still of further interest is that 
catalyst 35 has recently been applied to the reduction of N-sulfonyl ketimines and 
cyclic sulfamate imines, affording the corresponding amines with enantioselectivities 
up to 99% ee (Scheme 1.42).
[115,116]
 The high selectivity observed could be attributed 
to the well defined E-geometry of N-sulfonyl imines.
[115]
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Scheme 1.42: ATH of imines using Rh(II) complex. 
Compared with ketones, the mechanism for TH of imines with Noyori’s Ru(II)-
TsDPEN has been less explored. However, a few reports have suggested that the 
reaction with imines may proceed through a different pathway to that proposed for 
carbonyl reductions. For instance in a stoichiometric reaction conducted by Bäckvall 
and co-workers, complex 69, derived from 34, did not react with ketimines under 
neutral condition. However, the reaction took place rapidly in the presence of an 
acid.
[117]
 Further studies conducted on 2-methylquinoline reduction also led to the 
same observations (Scheme 1.43).
[118]
 These evidences are consistent with an ionic 
pathway, where the imine is activated by protonation prior to the hydride transfer 
and no coordination of the substrate to the metal is involved. Such hypothetical 
mechanism clearly differs from the well established concerted pathway followed by 
34 for ketone reduction.
[14]
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Scheme 1.43: Stoichiometric reduction with Ru-H.  
ATH of imines can also be carried out in neat water. A range of cyclic imines were 
reduced with high yields and enantioselectivities with a catalyst prepared from 
[Ru(p-cymene)Cl2]2 and the water soluble diamine, 54.
[119]
 HCO2Na was used as the 
hydrogen source and the presence of a surfactant, cetyltrimethylammonium bromide 
(CTAB), was found to be beneficial to the reaction, probably because it increased the 
solubility of the substrate in water. Interestingly, in some cases the 
enantioselectivities achieved were higher than those obtained in F/T (Scheme 1.44). 
Discouragingly, attempts to reduce acyclic imines in water resulted in complete 
decomposition of the starting imine. A simpler method using Noyori’s catalyst 34 in 
the presence of CTAB and AgSbF6 was also reported for cyclic imines reduction.
[120]
 
The protocol also permitted the reduction of polycyclic iminium salts, allowing an 
easy access to alkaloids such as harmicine and crispine. In addition, 3,4-
dihydroisoquinolines bearing an aryl substituent at C1 position were also viable for 
reduction, albeit requiring a Lewis acid to activate the C=N bond towards the 
hydride attack (Scheme 1.45).    
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Scheme 1.44: ATH of imines in neat water. 
 
Scheme 1.45: ATH of cyclic and polycyclic iminium salts in water. 
1.9 Immobilised catalysts 
Catalyst separation is an important issue in homogeneous catalysis. Thus efforts 
have been made to immobilise these catalysts for recycling. Selected examples of 
immobilised ligands and catalysts are shown in Scheme 1.46. Besides being 
reusable, these ligands/catalysts have shown excellent activity and stereoinduction 
properties for ATH of ketones. The PEG-supported 70, represents one of the most 
efficient catalyst for the ATH of ketones in water. A wide range of aromatic ketones 
including heteroaromatic examples can be reduced using HCO2Na as the hydrogen 
source, with results comparable to those obtained with catalyst 34 (non-supported 
Ru-TsDPEN) under the same conditions. Remarkably, the catalyst could be recycled 
up to 14 times without compromising the enantioselectivity in the ATH of 
acetophenone in water (Scheme 1.47).
[121]
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Scheme 1.46: Immobilised catalyst and ligands for ATH. 
 
Scheme 1.47: ATH in water with supported Noyori-Ikariya catalyst. 
Li and co-workers have recently reported magnetically recoverable catalysts based 
on chiral ligands such as TsDPEN and TsDAC attached to SiO2 coated Fe3O4 
nanoparticles (71 and 72, Scheme 1.46).
[122]
 When such ligands were combined with 
[Cp*IrCl2]2 or [Cp*RhCl2]2, excellent activities and enantioselectivities (upto 99% 
ee) were obtained for the ATH of aromatic ketones in water. In addition to their high 
efficiency the main advantage of such catalysts is that they can be easily recovered 
by using a magnet. Thus neither filtration nor extraction is necessary. Moreover, the 
catalyst could be reused up to 10 times without losing its efficiency. 
The crosslinked polystyrene immobilised ligand 73, in combination with [Ru(p-
cymene)Cl2]2, was effective in the ATH of N-benzyl imines in DCM using F/T as the 
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hydride source to give the corresponding amines in high yields and good 
enantioselectivities. The role of the metal was essential for achieving high efficiency 
as longer reaction times were required and lower enantioselectivities were obtained 
when [Ru(p-cymene)Cl2]2 was replaced with the isoelectronic [Cp*IrCl2]2 and 
[Cp*RhCl2]2 (Scheme 1.48).
[123]
  
 
Scheme 1.48: ATH of N-benzyl imine with the crosslinked polystyrene immobilised catalysts. 
1.10 Cheap metal-catalysed TH of carbonyls and imines  
Parallel to the quest for more robust catalysts based on precious metals, chemists 
have also started to make progress with the use of cheaper metals, such as iron, 
cobalt and nickel.
[108,124-126]
 Fe is cheaper, abundant and environmentally benign 
compared with other metals. However, the development of Fe based catalysts, in 
particular for TH, lags far behind.
[2]
 Although, the potential of Fe in TH had been 
demonstrated as early as 1980’s, significant progress has only been achieved in the 
past few years. Beller and co-workers reported a Fe/porphyrin system for the TH of 
ketones, using 
i
PrOH as hydrogen source and Fe3(CO)12 as a  suitable metal 
precursor. Both aromatic and aliphatic ketones were reduced with excellent yields; 
however the reduction of -substituted aromatic ketones did not proceed under the 
reaction conditions (Scheme 1.49).
[127]
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Scheme 1.49: Fe-prophyrin catalysed TH of ketones in 
i
PrOH. 
Casey and co-workers reported a bifunctional Fe complex 75, which is analogous to 
the active Shvo’s Ru catalyst (Scheme 1.50).[128] This catalyst displays high 
selectivity towards carbonyls and is active under both hydrogenation and TH 
conditions. It has been proposed that the hydrogenation of carbonyls with complex 
75 proceeds by the concerted outer-sphere pathway in which both the hydride and 
the OH group contribute to the reduction (Scheme 1.50).
[125]
  
 
Scheme 1.50: Reduction of ketones with a bifunctional Fe complex and the proposed reaction 
pathway. 
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Morris and co-workers have developed a series of iron complexes with tetradentate 
PNNP ligands (Scheme 1.51).
[129-131]
 Complex 76 represents the first well defined 
iron catalyst capable of ATH of aromatic ketones. Using only 0.5 mol% catalyst 
most of the aromatic ketones were fully reduced within half hour, although the 
enantioselectivities obtained were relatively low.
[129]
 Complex 77, prepared with a 
chiral diphenylethylenediamine backbone significantly improved the activity and 
selectivity, affording a TOF up to 4900 h
-1
 and enantioselectivities up to 99% for the 
TH of ketones.
[130]
 The analogous 78 is highly enantioselective for the ATH of N-
(diphenylphosphinoyl) and N-(p-tolylsulphonyl) ketimines (Scheme 1.51).
[131]
 These 
iron complexes represent viable alternative to precious metal catalytic systems for 
TH; however they are still in their infancy. The catalytic activity and substrate scope 
have to be further improved in order to compete with the catalysts based on precious 
metals. In addition, their sensitivity to air and moisture makes them difficult for 
industrial applications.  
 
Scheme 1.51: Iron complexes for ATH. 
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1.11 Cyclometalated complexes 
A complex containing a metal-carbon  bond that is stabilised by at least one donor 
atom (such as N, O, C, P) is known as a cyclometalated complex (Scheme 1.52).
[132]
 
Cope and Siekman reported the first example of a cyclometalated reaction in 1965, 
when Pt and Pd dimer complexes were synthesised by reacting azobenzene with 
K2PtCl2 and PdCl2, respectively, at room temperature in dioxane/water mixture 
(Scheme 1.53).
[133]
  
 
Scheme 1.52: General scheme for cyclometalation reaction. 
 
Scheme 1.53: First example of synthesis of a cyclometalated reaction. 
Since then, a wide variety of organometallic complexes have been synthesised by 
cyclometalation. In particular, half-sandwich cyclometalated complexes based on Rh 
and Ir are probably two of the most popular classes of organometallic derivatives. 
Indeed, these metalacycles are particularly interesting because they are often 
encountered as intermediates in CH bond activation reactions promoted by 
[Cp*MCl2]2 (M = Rh, Ir) complexes.
[132,134]
 These complexes have garnered much 
attention since the seminal reports of Davies
[135]
 and Jones
[136]
 on their reactivity 
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towards unsaturated organic molecules. Depending on the donor atom, metalacycles 
can be divided into four different classes: [Cp*M(C
^
C)Cl], [Cp*M(C
^
P)Cl], 
[Cp*M(C
^
O)Cl] and [Cp*M(C
^
N)Cl]. 
Recently, many catalytic applications have been found for half-sandwich 
cyclometalated complexes, such as racemisation of alcohols and amines,
[137]
 
hydroamination
[138]
 and oxidation of water.
[139]
 [Cp*Ir(C
^
N)Cl] complex 79, reported 
by Feringa, de Vries and co-workers, is highly versatile for the racemisation of chiral 
alcohols, including aliphatic and -halo alcohols in the presence of a base. Its 
analogous 80 is active in the racemisation of chiral amines. In the absence of a base, 
the racemisation of secondary and tertiary chiral amines was completed within few 
hours (Scheme 1.54).
[137]
 The reaction was sluggish in the case of primary amines 
and led to the formation of dimers. Interestingly, complete racemisation of (S)-2-
methyl-1,2,3,4-tetrahydroquinoline was also viable.  
 
Scheme 1.54: Racemisation of alcohols and amines with complex 79 and 80. 
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Jin and co-workers reported a new type of cyclometalated half-sandwich Ir and Rh 
complexes containing carboranylamidinate ligands. These complexes were prepared 
in a one pot reaction by in situ formation of a C-lithio-carboranylamidinate ligand, 
followed by the addition of [Cp*MCl2]2 (M = Rh, Ir) in THF at room temperature. 
Precatalyst 81 showed high activity for the polymerisation of norbornene in the 
presence of methylaluminoxane (MAO) as cocatalyst (Scheme 1.55).
[140]
 Complexes 
82-84, synthesised by Crabtree and co-workers are active in number of reactions 
including N-alkylation of amines with alcohols and -alkylation of secondary 
alcohols with primary alcohols (Scheme 1.55).
[141]
 
 
Scheme 1.55: Cyclometalated half-sandwich complexes and their application in catalysis. 
Ikariya and co-workers have recently synthesised a new type of C-N chelate amido-
Ir bifunctional complexes derived from benzylic amines (Scheme 1.56).
[142]
 These 
complexes were subsequently explored as catalysts for the TH of acetophenone with 
i
PrOH as the hydrogen source. Surprisingly, the activity of 88 was found to be much 
higher than that of 36 under the same conditions, clearly demonstrating the 
electronic properties that the C-N ligands impart on the metal/NH bifunctional 
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system. The enantioselectivities obtained with 88 were however moderate, compared 
with 36 (Scheme 1.56).
[142]
  
 
Scheme 1.56: Amino-Ir complexes and their reactivity towards the reduction of acetophenone. 
Ikariya and co-workers also developed a -NH based bifunctional catalyst 89, 
bearing a C-N chelating protic pyrazole. Catalyst 89 promoted the intramolecular 
hydroamination of -alkenic primary amines to give the cyclisation product in the 
presence of KO
t
Bu. A metal-ligand cooperating mechanism was proposed, where the 
reaction would involve the nucleophilic attack of the amine to the coordinated olefin 
which is assisted by the secondary interaction with the basic pyrazolato ligand. 
Subsequent proton transfer from the pyrazole nitrogen would cleave the Ir-C bond, 
releasing the cyclisation product and regenerating the catalyst (Scheme 1.57).
[143]
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Scheme 1.57: Intramolecular hydroamination catalysed with 89. 
A recently reported Cr(CO)3-bound iridacycle 90 can readily promote the tandem 
transformation of terminal alkynes into racemic N-phenylamines by hydroamination 
and hydrosilation-protodesilation reactions under mild conditions (Scheme 1.58).
[144]
 
Rh and Ir complexes, prepared with a pyrazolyl-NHC donor ligand and a 
[Cp*MCl2]2 (M = Rh, Ir) precursor, also promoted the hydroamination of internal 
alkynes to give indolyl and pyrolyl heterocycles in good yields. The Ir catalyst 
showed higher efficiency than its Rh counterpart and in both cases addition of the 
silver salt AgBF4 was necessary to activate the catalysts (Scheme 1.59).
[145]
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Scheme 1.58: Hydroamination and hydrosilation-protodesilation reactions. 
 
Scheme 1.59: Hydroamination of internal alkynes. 
Recently Fujita, Yamaguchi and co-workers reported complex 93, prepared by the 
NaOAc promoted cyclometalation of 6-phenyl-2-pyridone with [Cp*IrCl2]2. This 
complex exhibited high activity for the dehydrogenation of secondary alcohols. 
Under base free conditions, only a 0.1-0.5 mol% catalyst loading was sufficient for 
fully converting alcohols to their corresponding ketones. In comparison, a loading of 
2 mol% was required for dehydrogenating primary alcohols. In the presence of a 
base moderate yields were achieved in most cases for their corresponding aldehydes. 
In both cases the reaction proceeded with the release of hydrogen gas (Scheme 
1.60).
[146]
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Scheme 1.60: Dehydrogenation of alcohols. 
[Cp*M(C
^
C)Cl] and their role in catalysis have been mainly reported by the groups 
of Peris, Crabtree and Albrecht, where the C donor is usually a carbene (Scheme 
1.61).
[147-149]
 Albrecht and co-workers reported complexes 94 and 95, prepared by 
the metalation of pyridinium functionalised triazolium salt with [Cp*IrCl2]2 in the 
presence of Ag2O. These complexes were found to exhibit excellent activity in 
electrochemically induced water oxidation.
[147]
 Later, Crabtree and co-workers 
synthesised Cp*Ir complex 96, bearing a cyclometalated N,N’-diphenylimidazolyl 
ligand. This catalyst was also competent to serve as a precursor for water oxidation 
in the presence of ceric ammonium nitrate (CAN).  The excellent activity observed 
with these catalysts may be due to the relative strong  donating ability of the NHC 
ligand which probably stabilises the high valent form of Ir during the reaction.
[148]
 
Peris and co-workers have recently reported the six-membered iridacycle 97 that 
shown catalytic activity for the diboration of olefins providing high conversions (60-
100%) for organodiboronate products.
[149]
 In contrast, phosphorous and oxygen 
containing cyclometalated complexes of the formula [Cp*M(C
^
P)Cl] or 
[Cp*M(C
^
O)Cl] have mainly been investigated in CH activation studies.
[132,150]
 It is 
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now evident that these half-sandwich cyclometalated complexes are emerging and 
beginning to realise their potential in catalysis. Although these catalysts have shown 
excellent activity in various reactions such as water oxidation and hydroamination, 
they are still relatively unexplored in TH or dehydrogenation reactions. 
 
Scheme 1.61: Cyclometalated half-sandwich complexes with C donor atom. 
1.12 Previous work within our group and the aim of this thesis  
During study of TH of imines, our group serendipitously discovered the 
cyclometalated Cp*Ir(III) complexes bearing ketimine ligands (Iridicycles). These 
complexes show excellent chemoselectivity and activity for the TH of imines, 
achieving an initial TOF up to 1.9 x 10
4
 h
-1
. They are active for both aldimines and 
ketimines reduction, including aromatic and aliphatic ones. Moreover, these catalysts 
are also versatile in transfer hydrogenative reductive amination, capable of 
chemoselectively reducing a wide range of aromatic and aliphatic derivatives of 
ketones and amines (Scheme 1.62).
[151]
 Analogous complexes bearing aldimine 
ligands have been reported by the groups of Davies and Jones; however they have 
not been reported for any catalytic reactions so far.  
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Scheme 1.62: Cyclometalated Cp*Ir(III) complexes bearing ketimine ligands. 
The main aim of this thesis is to understand and explore the scope of these new types 
of cyclometalated ketimine complexes. In particular, they are easy to synthesise and 
their modular structure framework allows for the detailed and rational development 
of more active catalysts (Scheme 1.63). Our main target was the development of a 
single versatile catalyst that would be capable of transfer-hydrogenating various 
unsaturated bonds such as ketones, imines and N-heterocycles. Catalysts capable of 
selectively reducing multiple bonds under relatively mild conditions are rare, and 
their development would be of significant interest to the industry. Although 
transition metal catalysed TH of ketones and imines has been widely studied during 
the last 20 years, there is a continuous demand in developing new versatile catalysts 
that can achieve such reactions under greener conditions and using simple 
methodologies that can be easily scaled up. In particular, catalysts capable of 
chemoselectively reducing functionalised acyclic ketimines, -substituted ketones 
and various N-heterocycles are highly desirable. Once a robust catalytic system has 
been established for hydrogenation, the next aim would be to explore such catalysts 
for dehydrogenation reactions. Catalytic acceptorless dehydrogenation (AD) of 
organic molecules has recently attracted great interest as it is clean, only liberating 
H2, which is viewed as high energy clean fuel for the future. Therefore a single 
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catalyst capable of hydrogenate/dehydrogenate of organic molecules would be 
attractive and on demand.   
 
Scheme 1.63: Modular structure of cyclometalated Cp*MCl complexes. 
During the course of my thesis, other members of our group have further expanded 
the scope of these cyclometalated Cp*Ir(III) complexes to numerous reactions. 
These include hydrogenation of imines
[152]
 and N-heterocycles with H2,
[153]
 
dehydrogenation of formic acid,
[154]
 the TH of simple ketones and the RA of 
aldehydes, ketones and levulinic acid with various amines in water, which 
demonstrate the versatility of these catalysts (Scheme 1.64).
[155-156]
 
 
Scheme 1.64: Scope of cyclometalated Cp*Ir(III) complexes reported by our group. 
 
 
 
Chapter 1 
53 
 
1.13 References  
[1] M. B. Smith, J. March, in March’s Advanced Organic Chemistry, 6th ed., 
Wiley-Interscience, New Jersey, 2007. 
[2] X. F. Wu, J. Xiao, in Comprehensive Organic synthesis (Eds.: P Knochel, G. 
A. Molander), 2
nd
 ed., Elsevier, Oxford, 2014, p. 198. 
[3] a) B. E. Hibbard, F. X. Webster, J. Chem. Ecol. 1993, 19, 2129-2141; b) G. 
Schening, O. Thomae, US2308232, 1943; c) T. S. Kaufman, Tetrahedron: 
Asymmetry 2004, 15, 1203-1237; d) J. J. Chen, D. M. Swope, K. Dashtipour, 
K. E. Lyons, Pharmacotherapy 2009, 29, 1452-1467. 
[4] H. U. Blaser, Adv. Synth. Catal. 2002, 344, 17-31. 
[5] N. Greeves, R. O. Hutchins, in Comprehensive Organic Synthesis: Reduction 
(Eds.: B. M. Trost, I. Fleming), Pergamon, Oxford, 1991. 
[6] J. Magano, J. R. Dunetz, Org. Process Res. Dev. 2012, 16, 1156-1184. 
[7] B. Küenburg, L. Czollner, J. Fröhlich, U, Jordis, Org. Process Res. Dev. 
1999, 3, 425-431. 
[8] E. W. Baxter, A. B. Reitz, in Organic Reactions (Eds.: L. E. Overman), 
Wiley, 2002, 59, 1. 
[9] A. F. Abdel-Magid, K. G. Carson, B. D. Harris, C. A. Maryanoff, R. D. Shah, 
J. Org. Chem. 1996, 61, 3849-3862. 
[10] R. A. Sheldon, J. Chem. Tech. Biotechnol. 1997, 68, 381-388. 
[11] a) R. A. Sheldon, I. Arends, U. Hanefeld, in Green Chemistry and Catalysis, 
Wiley-VCH, Weinheim, 2007; b) M. S. Simmons, in Green Chemistry: 
Designing Chemistry for the environment (Eds.: P. T. Anastas, T. C. 
Williamson), American Chemical Society, Washington DC, 1996, p. 116-
130. 
[12] a) J. B. Jones, Tetrahedron, 1986, 42, 3351-3403; b) S. M. A. D. Wildeman, 
T. Sonke, H. E. Schoemaker, O. May, Acc. Chem. Res. 2007, 40, 1260-1266; 
c) M. Höhne, U. T. Bornscheuer, ChemCatChem 2009, 1, 42-51; d) J. C. 
Moore, D. J. Pollard, B. Kosjek, P. N. Devines, Acc. Chem. Res. 2007, 40, 
1412-1419. 
[13] a) S. G. Ouellet, A. M. Walji, D. W. C. Macmillan, Acc. Chem. Res. 2007, 
40, 1327-1339; b) A. Berkessel, H. Gröger, in Asymmetric Organocatalysis, 
Wiley-VCH, Weinheim, 2005; c) T. Akiyama, Chem. Rev. 2007, 107, 5744-
Chapter 1 
54 
 
5758; d) M. Rueping, F. R. Schoepke, I. Atodiresei, E. Sugiono, in 
Biomimetic Organic Synthesis, Wiley-VCH 2010. 
[14] T. Ikariya, M. Shibasaki, Bifunctional Molecular Catalysis, Springer-Verlag, 
Berlin-Heidelberg, 2011. 
[15] a) R. A. W. Johnstone, A. H. Wilby, I. D. Entwistle, Chem. Rev. 1985, 85, 
129-170; b) H. Hattori, Chem. Rev. 1995, 95, 537-558. 
[16] K. S. Hayes, Applied Catalysis A: General 2001, 221, 187-195. 
[17] G. Brieger, T. J. Nestrick, Chem. Rev. 1974, 74, 567-580. 
[18] M. Watanabe, J. Hori, K. Murata, US20100234596A1, 2010. 
[19] a) H. Meerwein, R. Schmidt, Ann. 1925, 444, 221-238; b) J. M. Clay, in 
Named Reactions for Functional Group Transformations (Eds.: J. J. Li, E. J. 
Corey), John Wiley & sons: Hoboken, New Jersey, 2007, p. 123-128. 
[20] J. S. Cha, Org. Proc. Res. Dev. 2006, 10, 1032-1053. 
[21] R. L. Chowdhury, J. E. Bäckvall, J. Chem. Soc. Chem. Commun, 1991, 1063-
1064. 
[22] P. Dani, T. Karlen, R. A. Gossage, S. Gladiali, G. V. Koten, Angew. Chem. 
Int. Ed. 2000, 39, 743-744. 
[23] W. Baratta, P. D. Ros, A. D. Zotto, A. Sechi, E. Zangrando, P. Rigo, Angew. 
Chem. Int. Ed. 2004, 43, 3584-3588. 
[24] W. Baratta, J. Schütz, E. Herdtweck, W. A. Herrmann, P. Rigo, J. 
Organomet. Chem. 2005, 690, 5570-5575. 
[25] W. Baratta, G. Chelucci, S. Gladiali, K. Siega, M. Toniutti, M. Zanette, E. 
Zangrando, P. Rigo, Angew. Chem. Int. Ed. 2005, 44, 5214-5219. 
[26] a) C. Bianchini, E. Farnetti, M. Graziani, G. Nardin, A. Vacca, F. Zanobini, 
J. Am. Chem. Soc. 1990, 112, 9190-9197; b) C. Bianchini, E. Farnetti, L. 
Glendenning, M. Graziani, G. Nardin, M. Peruzzini, E. Rocchini, F. 
Zanobini, Organometallics, 1995, 14, 1489-1502. c) C. Bianchini, L. 
Glendenning, F. Zanobini, E. Farnetti, M. Graziani, E. Nagy, J. Mol. Catal. A 
1998, 132, 13-19. 
[27] Z. E. Clarke, P. T. Maragh, T. P. Dasgupta, D. G. Gusev, A. J. Lough, K. A. 
Rashid, Organometallics, 2006, 25, 4113-4117. 
[28] A. C. Hillier, H. M. Lee, E. D. Stevens, S. P. Nolan, Organometallics, 2001, 
20, 4246-4252. 
[29] J. M. Brown, Angew. Chem. Int. Ed. 1987, 26, 190-203.  
Chapter 1 
55 
 
[30] M. Albrecht, R. H. Crabtree, J. Mata, E. Peris, Chem. Commun. 2002, 32-33. 
[31] M. Albrecht, J. R. Miecznikowski, A. Samuel, J. W. Faller, R. H. Crabtree, 
Organometallics 2002, 21, 3596-3604. 
[32] A. P. D. Costa, M. Viciano, M. Sanau, S. Merino, J. Tejeda, E. Peris, B. 
Royo, Organometallics 2008, 27, 1305-1309. 
[33] R. Corberan, M. Sanau, E. peris, Organometallics 2007, 26, 3492-3498. 
[34] M. Poyatos, E. M. Marza, J. A. Mata. M. Sanau, E. Peris, Eur. J. Inorg. 
Chem. 2003, 1215-1221. 
[35] O. Saidi, J. M. J. Williams, Top. Organomet. Chem. 2011, 34, 77-106. 
[36] R. Bar, Y. Sasson, J. Blum, J. Mol. Catal. 1984, 26, 327-332. 
[37] R. Bar, L. K. Bar, Y. Sasson, J. Blum, J. Mol. Catal. 1985, 33, 161-177. 
[38] F. Joo, A. Benyei, J. Organomet. Chem. 1989, 363, C19-C21. 
[39] F. Joo, Acc. Chem. Res. 2002, 35, 738-745. 
[40] F. Joo, J. Kovacs, A. C. Benyei, A. Katho, Angew. Chem. Int. Ed. 1998, 37, 
969-970. 
[41] Z. Toth, F. Joo, M. T. Beck, Inorg. Chim. Acta. 1980, 42, 153-161. 
[42] S. Ogo, N. Makihara, Y. Kaneko, Y. Watanabe, Organometallics 2001, 20, 
4903-4910.  
[43] S. Ogo, H. Hayashi, K. Uehara, S. Fukuzumi, Appl. Organomet. Chem. 2005, 
19, 639-643. 
[44] S. Ogo, T. Abura, Y. Watanabe, Organometallics 2002, 21, 2964-2969. 
[45] T. Abura, S. Ogo, Y. Watanabe, S. Fukuzumi, J. Am. Chem. Soc. 2003, 125, 
4149-4154. 
[46] S. Ogo, N. Makihara, Y. Watanabe, Organometallics 1999, 18, 5470-5474. 
[47] M. S. Eisen, A. Haskel, H. Chen, M. M. Olmstead, D. P. Smith, M. F. 
Maestre, R. H. Fish, Organometallics 1995, 14, 2806-2812. 
[48] E. Steckhan, S. Herrmann, R. Ruppert, E. Dietz, M. Frede, E. Spika, 
Organometallics 1991, 10, 1568-1577. 
[49] a) V. D. Westerhausen, S. Herrmann, W. Hummel, E. Steckhan, Angew. 
Chem. Int. Ed. 1992, 31, 1529-1531; b) E. Steckhan, S. Herrmann, R. 
Ruppert, J. Thommes, C. Wandrey, Angew. Chem. Int. Ed. 1990, 29, 388-
390.  
[50] H. C. Lo, O. Buriez, J. B. Kerr, R. H. Fish, Angew. Chem. Int. Ed. 1999, 38, 
1429-1432. 
Chapter 1 
56 
 
[51] J. Canivet, L. K. Brelot, G. Süss-Fink, J. Organomet. Chem. 2005, 690, 
3202-3211. 
[52] J. Canivet, G. Süss-Fink, P. Štěpnička, Eur. J. Inorg. Chem. 2007, 4736-
4742. 
[53] D. J. Darensbourg, F. Joo, M. Kannisto, A. Katho, J. H. Reibenspies, 
Organometallic 1992, 11, 1990-1993. 
[54] H. Imai, T. Nishiguchi, K. Fukuzumi, Chem. Lett. 1975, 807-808. 
[55] J. R. Miecznikowski, R. H. Crabtree, Organometallics 2004, 23, 629-631. 
[56] W. Baratta, K. Siega, P. Rigo, Adv. Synth. Catal. 2007, 349, 1633-1636. 
[57] X. Wu, J. Liu, X. Li, A. Zanotti-Gerosa, F. Hancock, D. Vinci, J. Ruan, J. 
Xiao, Angew. Chem. Int. Ed. 2006, 45, 6718-6722. 
[58] D. Müller, G. Umbricht, B. Weber, A. Pfaltz, Helv. Chim. Acta 1991, 74, 
232-240. 
[59] J. P. Genêt, V. Ratovelomanana-Vidal, C. Pinel, Synlett 1993, 478-480. 
[60] D. A. Evans, S. G. Nelson, M. R. Gagné and A. R. Muci, J. Am. Chem. Soc. 
1993, 115, 9800-9801. 
[61] R. Gamez, F. Fache, M. Lemaire, Tetrahedron: Asymmetry 1995, 6, 705-718. 
[62] S. Hashiguchi, A. Fujii, J. Takehara, T. Ikariya, R. Noyori, J. Am. Chem. Soc. 
1995, 117, 7562-7563. 
[63] A. Fujii, S. Hashiguchi, N. Uematsu, T. Ikariya, R. Noyori, J. Am. Chem. 
Soc. 1996, 118, 2521-2522. 
[64] a) K. Püntener, L. Schwink, P. Knochel, Tetrahedron Lett. 1996, 37, 8165-
8168; b) S. I. Inoue, K. Nomura, S. Hashiguchi, R. Noyori, Y. Izawa, Chem. 
Lett. 1997, 957-958; c) M. J. Palmer, J. A. Kenny, T. Walsgrove, A. M. 
Kawamoto, M. Will, J. Chem. Soc., Perkin Trans. 1 2002, 416-427; d) D. G. 
I. Petra, P. C. J. Kamer, P. W. N. M. V. Leeuwen, K. Goubitz, A. M. V. 
Loon, J. G. de Vries, H. E. Schoemaker, Eur. J. Inorg. Chem. 1999, 2335-
2341; e) D. A. Alonso, S. J. M. Nordin, P. Roth, T. Tarnai, P. G. Andersson, 
J. Org. Chem. 2000, 65, 3116-3122. 
[65] a) Y. Jiang, Q. Jiang, X. Zhang, J. Am. Chem. Soc. 1998, 120, 3817-3818; b) 
H. Brunner, F. Henning, M. Webber, Tetrahedron: Asymmetry 2002, 13, 37-
42. 
[66] J.-X. Gao, T. Ikariya, R. Noyori, Organometallics 1996, 15, 1087-1089. 
Chapter 1 
57 
 
[67] a) Q.-L. Zhou, Privileged Chiral Ligands and Catalysts, Wiley-VCH, 2011; 
b) A. Bartoszewicz, N. Ahlsten, B. M. Matute, Chem. Eur. J. 2013, 19,  2  -
  0   c)  . Štefane, F. Po gan, in Asymmetric Hydrogenation and Transfer 
Hydrogenation of Ketones, Hydrogenation, (Ed. I. Karamé), 2012, ISBN: 
978-953-51-0785-9, InTech, DOI: 10.5772/47752. 
[68] T. Koike, K. Murata, T. Ikariya, Org. Lett. 2000, 2, 3833-3836. 
[69] K. Murata, K. Okano, M. Miyagi, H. Iwane, R. Noyori, T. Ikariya, Org. Lett. 
1999, 1, 1119-1121. 
[70] H. Ito, M. Hasegawa, Y. Takenaka, T. Kobayashi, K. Iguchi, J. Am. Chem. 
Soc. 2004, 126, 4520-4521. 
[71] K. Everaere, J. L. Scheffler, A. Mortreux, J. F. Carpentier, Tetrahedron Lett. 
2001, 42, 1899-1901. 
[72] T. Hamada, T. Torii, K. Izawa, R. Noyori, T. Ikariya, Org. Lett. 2002, 4, 
4373-4376. 
[73] S. P. Tanis, B. R. Evans, J. A. Nieman, T. T. Parker, W. D. Taylor, S. E. 
Heasley, P. M. Herrinton, W, R. Perrault, R. A. Hohler, L. A. Dolak, m. R. 
Hester, E. P. Seest, Tetrahedron: Asymmetry 2006, 17, 2154-2182. 
[74] a) J. B. Sortais, V. Ritleng, A. Voelklin, A. Holuigue, H. Smail, L. Barloy, C. 
Sirlin, G. K. M. Verzijl, J. A. F. Boogers, A. H. M. de Vries, J. G. de Vries, 
M. Pfeffer, Org. Lett. 2005, 7, 1247-1250; b) J. B. Sortais, L. Barloy, C. 
Sirlin, A. H. M. de Vries, J. G. de Vries, M. Pfeffer, Pure Appl. Chem. 2006, 
78, 457-462. 
[75] W. Baratta, E. Herdtweck, K. Siega, M. Toniutti, P. Rigo, Organometallics 
2005, 24, 1660-1669. 
[76] W. Baratta, M. Bosco, G. Chelucci, A. D. Zotto, K. Siega, M. Toniutti, E. 
Zangrando, P. Rigo, Organometallics 2006, 25, 4611-4620. 
[77] a) W. Ye, M. Zhao, W. Du, Q. Jiang, K. Wu, P. Wu, Z. Yu, Chem. Eur. J. 
2011, 17, 4737-4741; b) W. Ye, M. Zhao, Z. Yu, Chem. Eur. J. 2012, 18, 
10843-10846. 
[78] J. Hannedouche, G. J. Clarkson, M. Wills, J. Am. Chem. Soc. 2004, 126, 986-
987. 
[79] A. M. Hayes, D. J. Morris, G. J. Clarkson, M. Wills, J. Am. Chem. Soc. 2005, 
127, 7318-7319. 
[80] V. Parekh, J. A. Ramsden, M. Wills, Catal. Sci. Technol. 2012, 2, 406-414. 
Chapter 1 
58 
 
[81] D. S. Matharu, D. J. Morris, A. M. Kawamoto, G. J. Clarkson, M. Will, Org. 
Lett. 2005, 7, 5489-5491. 
[82] D. S. Matharu, D. J. Morris, G. J. Clarkson, M. Will, Chem. Commun. 2006, 
3232-3234. 
[83] T. Touge, T. Hakamata, H. Nara, T. Kobayashi, N. Sayo, T. Saito, Y. Kayaki, 
T. Ikariya, J. Am. Chem. Soc. 2011, 133, 14960-14963. 
[84] a) C. Bubert, J. Blacker, S. M. Brown, J. Crosby, S. Fitzjohn, J. P. 
Muxworthy, T. Thorpe, J. M. J. Williams, Tetrahedron Lett. 2001, 42, 4037-
4039; b) T. Thorpe, J. Blacker, S. M. Brown, C. Bubert, J. Crosby, S. 
Fitzjohn, J. P. Muxworthy, J. M. J. Williams, Tetrahedron Lett. 2001, 42, 
4041-4043. 
[85] H. Y. Rhyoo, H. J. Park, Y. K. Chung, Chem. Commun. 2001, 2064-2065. 
[86] Y. Ma, H. Liu, L. Chen, X. Cui, J. Zhu, J. Deng, Org. Lett. 2003, 5, 2103-
2106. 
[87] a) X. Wu, X. Li, W. Hems, F. King, J. Xiao, Org. Biomol. Chem. 2004, 2, 
1818-1821; b) X. Wu, D. Vinci, T. Ikariya, J. Xiao, Chem. Commun. 2005, 
4447-4449. 
[88] X. Wu, X. Li, F. King, J. Xiao, Angew. Chem. Int. Ed. 2005, 44, 3407-3411. 
[89] L. Yin, X. Jia, X. Li, A. S. C. Chan, Tetrahedron: Asymmetry 2009, 20, 
2033-2037. 
[90] W. Wang, Z. Li, W. Mu, L. Su, Q. Wang, Catal. Commun. 2010, 11, 480-
483. 
[91] O. Soltani, M. A. Ariger, H. V. Villa, E. M. Carreira, Org. Lett. 2010, 12, 
2893-2895. 
[92] H. V. Villa, S. Reber, M. A. Ariger, E. M. Carreira, Angew. Chem. Int. Ed. 
2011, 50, 8979-8981. 
[93] M. A. Ariger, E. M. Carreira, Org. Lett. 2012, 14, 4522-4524. 
[94] M. Wills, in Modern Reduction Methods, (Eds. P. G. Andersson, I. M. 
Munslow) Wiley-VCH, 2008, 271-296. 
[95] C. Wang, B. V. Marcos, J. Xiao, Chem. Commun. 2011, 47, 9773-9785. 
[96] R. Grigg, T. R. B. Mitchell, N. Tongpenyai, Synthesis 1981, 442-444. 
[97] G. Z. Wang, J. E. Bäckvall, J. Chem. Soc. Chem. Commun. 1992, 980-982. 
[98] A. Aranyos, G. Csjernyik, K. J. Szabo, J. E. Bäckvall, Chem. Commun. 1999, 
351-352. 
Chapter 1 
59 
 
[99] J. S. M. Samec, J. E. Bäckvall, Chem. Eur. J. 2002, 8, 2955-2961. 
[100] J. S. M. Samec, L. Mony, J. E. Bäckvall, Can. J. Chem. 2005, 83, 909-916. 
[101] M. C. Warner, C. P. Casey, J. E. Bäckvall, Top. Organomet. Chem. 2011, 37, 
85-125. 
[102] a) C. P. Casey, S. W. Singer, D. R. Powell, R. K. Hayashi, M. Kavana, J. Am. 
Chem. Soc. 2001, 123, 1090-1100; b) C. P. Casey, J. B. Johnson, J. Am. 
Chem. Soc. 2005, 127, 1883-1894; c) C. P. Casey, G. A. Bikzhanova, Q. Cui, 
I. A. Guzei, J. Am. Chem. Soc. 2005, 127, 14062-14071. 
[103] a) J. S. M. Samec, A. H. Ell, J. B. Aberg, T. Privalov, L. Eriksson, J. E. 
Bäckvall, J. Am. Chem. Soc. 2006, 128, 14293-14305; b) J. S. M. Samec, J. 
E. Bäckvall, P. G. Andersson, P. Brandt, Chem. Soc. Rev. 2006, 35, 237-248. 
[104] J. R. Miecznikowski, R. H. Crabtree, Polyhedron, 2004, 23, 2857-2872. 
[105] A. A. Danopoulos, S. Winston, W. B. Motherwell, Chem. Commun. 2002, 
1376-1377. 
[106] S. Burling, M. K. Whittlesey, J. M. J. Williams, Adv. Synth. Catal. 2005, 347, 
591-594. 
[107] R. Corberan, E. Peris, Organometallics 2008, 27, 1954-1958. 
[108] S. Kuhl, R. Schneider, Y. Fort, Organometallics 2003, 22, 4184-4186. 
[109] N. Uematsu, A. Fujii, S. Hashiguchi, T. Ikariya, R. Noyori, J. Am. Chem. 
Soc. 1996, 118, 4916-4917. 
[110] E. Vedejs, P. Trapencieris, E. Suna, J. Org. Chem. 1999, 64, 6724-6729. 
[111] K. H. Ahn, C. Ham, S. K. Kim, C. W. Cho, J. Org. Chem. 1997, 62, 7047-
7048. 
[112] P. Roth, P. G. Andersson, P. Somfai, Chem. Commun. 2002, 1752-1753. 
[113] J. Mao, D. C. Baker, Org. Lett. 1999, 1, 841-843. 
[114] A. J. Blacker, J. Martin, in Asymmetric Catalysis on Industrial Scale: 
Challenges, Approaches and Solutions (eds. H. U. Blaser and E. Schmidt), 
John Wiley & Sons, New York, 2004, 201-216. 
[115] S. H. Kwak, S. A. Lee, K. I. Lee, Tetrahedron: Asymmetry 2010, 21, 800-
804. 
[116] S. Kang, J. Han, E. S. Lee, E. B. Choi, H. K. Lee, Org. Lett. 2010, 12, 4184-
4187. 
[117] J. B. Aberg, J. S. M. Samec, J. E. Bäckvall, Chem. Commun. 2006, 2771-
2773. 
Chapter 1 
60 
 
[118] H. F. Zhou, Z. W. Li, Z. J. Wang, T. L. Wang, L. J. Xu, Y. He, Q. H. Fan, J. 
Pan, L. Q. Gu, A. S. C. Chan, Angew. Chem. Int. Ed. 2008, 47, 8464-8467. 
[119] J. Wu, F. Wang, Y. Ma, X. Cui, L. Cun, J. Zhu, J. Deng, B. Yu, Chem. 
Commun. 2006, 1766-1768. 
[120] L. Evanno, J. Ormala, P. M. Pihko, Chem. Eur. J. 2009, 15, 12963-12967. 
[121] X. Li, X. Wu, W. Chen, F. E. Hancock, F. King, J. Xiao, Org. Lett. 2004, 6, 
3321-3324. 
[122] a) Y. Sun, G. Liu, H. Gu, T. Huang, Y. Zhang, H. Li, Chem. Commun. 2011, 
47, 2583-2585; b) G. Liu, H. Gu, Y. Sun, J. Long, Y. Xu, H. Li, Adv. Synth. 
Catal. 2011, 353, 1317-1324. 
[123] N. Haraguchi, K. Tsuru, Y. Arakawa, S. Itsuno, Org. Biomol. Chem. 2009, 7, 
69-75. 
[124] K. Junge, K. Schroder, M. Beller, Chem. Commun. 2011, 47, 4849-4859. 
[125] A. Quintard, J. Rodriguez, Angew. Chem. Int. Ed. 2014, 53, 4044-4055. 
[126] G. Zhang, B. L. Scott, S. K. Hanson, Angew. Chem. Int. Ed. 2012, 51, 12102-
12106. 
[127] S. Enthaler, G. Erre, M. K. Tse, K. Junge, M. Beller, Tetrahedron Lett. 2006, 
47, 8095-8099. 
[128] C. P. Casey, H. Guan, J. Am. Chem. Soc. 2007, 129, 5816-5817. 
[129] C. S. Seng, F. Freutel, A. J. Lough, R. H. Morris, Angew. Chem. Int. Ed. 
2008, 47, 940-943. 
[130] A. Mikhailine, A. J. Lough, R. H. Morris, J. Am. Chem. Soc. 2009, 131, 
1394-1395. 
[131] A. Mikhailine, M. I. Maishan, R. H. Morris, Org. Lett. 2012, 14, 4638-4641. 
[132] Y.-F. Han, G.-X. Jin, Chem. Soc. Rev. 2014, 43, 2799-2823. 
[133] A. C. Cope, R. W. Siekman, J. Am. Chem. Soc. 1965, 87, 3272-3273. 
[134] G. Song, F. Wang, X. Li, Chem. Soc. Rev. 2012, 41, 3651-3678. 
[135] a) D. L. Davies, O. Al-Duaij, J. Fawcett, M. Giardiello, S. T. Hilton and D. 
R. Russell, Dalton Trans. 2003, 4132-4138; b) D. L. Davies, M. P. Lowe, K. 
S. Ryder, K. Singh and S. Singh, Dalton Trans. 2011, 40, 1028-1030; c) Y. 
Boutadla, D. L. Davies, R. C. Jones and K. Singh, Chem. Eur. J. 2011, 17, 
3438-3448; d) Y. Boutadla, D. L. Davies, O. Al-Duaij, J. Fawcett, R. C. 
Jones and K. Singh, Dalton Trans. 2010, 39, 10447-10457 
Chapter 1 
61 
 
[136] a) L. Li, W. W. Brennessel, W. D. Jones, Organometallics 2009, 28, 3492-
3500; b) L. Li, W. W. Brennessel, W. D. Jones, J. Am. Chem. Soc. 2008, 130, 
12414-12419. 
[137] T. Jerphagnon, A. J. A. Gayet, F. Berthiol, V. Ritleng, N. Mrsic, A. Meetsma, 
M. Pfeffer, A. J. Minnaard, B. L. Feringa, J. G. de Vries, Chem. Eur. J. 2009, 
15, 12780-12790. 
[138] S. Kuwata, T. Ikariya, Chem. Eur. J. 2011, 17, 3542-3556. 
[139] J. F. Hull, D. Balcells, J. D. Blakemore, C. D. Incarvito, O. Eisenstein, G. W. 
Brudvig, R. H. Crabtree, J. Am. Chem. Soc. 2009, 131, 8730-8731. 
[140] Z.-J. Yao, G. Su., G.-X. Jin, Chem. Eur. J. 2011, 17, 13298-13307. 
[141] D. Gnanamgari, E. L. O. Sauer, N. D. Schley, C. Butler, C. D. Incarvito, R. 
H. Crabtree, Organometallics 2009, 28, 321-325. 
[142] S. Arita, T. Koike, Y. Kayaki, T. Ikariya, Organometallics 2008, 27, 2795-
2802. 
[143] a) Y. Kashiwame, S. Kuwata, T. Ikariya, Chem. Eur. J. 2010, 16, 766-770; b) 
Y. Kashiwame, S. Kuwata, T. Ikariya, Organometallics 2012, 31, 8444-8455. 
[144] W. Iali, F. L. Paglia, X.-F. LeGoff, D. Sredojevic, M. Pfeffer, J.-P.Djukic, 
Chem. Commun. 2012, 48, 10310-10312. 
[145] K. Gray, M. J. Page, J. Wagler, B. A. Messerle, Organometallics 2012, 31, 
6270-6277. 
[146] K. Fujita, T. Yoshida, Y. Imori, R. Yamaguchi, Org. Lett. 2011, 13, 2278-
2281. 
[147] R. Lalrempuia, N. D. McDaniel, H. Muller-Bunz, S. Bernhard, M. Albrecht, 
Angew. Chem. Int. Ed. 2010, 49, 9765-9768. 
[148] T. P. Brewster, J. D. Blakemore, N. D. Schley, C. D. Incarvito, N. Hazari, G. 
W. Brudvig, R. H. Crabtree, Organometallics, 2011, 30, 965-973. 
[149] R. Corberan, V. Lillo, J. A. Mata, E. Fernandez, E. Peris, Organometallics 
2007, 26, 4350-4353. 
[150] a) L. E. E. Broeckx, M. Lutz, D. Vogt, C. Muller, Chem. Commun. 2011, 47, 
2003-2005; b) J. J. M. Weemers, W. N. P. van der Graaff, E. A. Pidko, M. 
Lutz, C. Muller, Chem. Eur. J. 2013, 19, 8991-9004; c) J. Campos, A. C. 
Esqueda, E. Carmona, Chem. Eur. J. 2010, 16, 419-422; d) J. Campos, E. 
Alvarez, E. Carmona, New. J. Chem. 2011, 35, 2122-2129. 
Chapter 1 
62 
 
[151] C. Wang, A. Pettman, J. Bacsa, J. L. Xiao, Angew. Chem. Int. Ed. 2010, 49, 
7548-7552. 
[152] a) W. J. Tang, C. H. Lau, X. F. Wu, J. L. Xiao, Synlett 2014, 25, 81-84; b) B. 
V. Marcos, W. J. Tang, F. Wu, J. L. Xiao, Org. Biomol. Chem. 2013, 11, 
6934-6939. 
[153] J. Wu, J. H. Barnard, Y. Zhang, D. Talwar, C. M. Robertson and J. L. Xiao, 
Chem. Commun. 2013, 49, 7052-7054. 
[154] J. H. Barnard, C. Wang, N. G. Berry and J. L. Xiao, Chem. Sci. 2013, 4, 
1234-1244. 
[155] Y. W. Wei, C. Wang, X. Jiang, D. Xue, J. Li and J. L. Xiao, Chem. Commun. 
2013, 49, 5408-5410. 
[156] a) Q. Lei, Y. W. Wei, D. Talwar, C. Wang, D. Xue and J. L. Xiao, Chem. 
Eur. J. 2013, 19, 4021-4029; b) Y. W. Wei, C. Wang, X. Jiang, D. Xue, J. Li 
and J. L. Xiao, Chem. Commun. 2013, 49, 5408-5410. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Chapter 2 
Highly Efficient and Chemoselective 
Transfer Hydrogenation of Carbonyl 
Compounds in Water 
 
 
 
 
 
 
 
 
Chapter 2  
63 
 
2.1 Introduction 
The reduction of α-substituted ketones to form β-functionalised secondary alcohols  
has drawn a lot of attention in the last two decades, due to the products being 
ubiquitous in naturally occurring and synthetic bioactive compounds.
[1]
 For example, 
β-hydroxyethers have been used as biological probes and synthetic intermediates for 
molecular switches.
[2,3]
 β-Aminoethers can be readily derived from β-hydroxyethers 
and are important precursors in the preparation of a wide variety of pharmaceutical 
compounds.
[4]
 A further example is found in β-hydroxyamines, which have been 
demonstrated as building blocks in many synthetic methodologies, leading to various 
bioactive compounds, including, for example, medicines that affect the central 
nervous and respiratory systems (Scheme 2.1).
[5]
 Of further interest are β-
hydroxyhalo compounds, which have found use in the preparation of numerous 
compounds for pharmaceuticals, fine chemicals and functional materials.
[2,6]
 
 
Scheme 2.1: Examples of drugs containing β-functionalised secondary alcohols. 
Given the versatility of the α-substituted ketones, a number of reagents and methods 
have been developed for their selective reduction, especially the asymmetric 
version.
[6-9]
 However, few catalysts are known that are capable of selective transfer 
hydrogenation (TH) of a wide range of α-substituted ketones.[7] In addition, most of 
the reactions are conducted in organic solvents, which generates unwanted waste. 
One way of minimising the environmental impact caused by the use of organic 
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solvents would be the use of water as the reaction medium. It is cheap, benign and 
readily available. However, the reduction of α-substituted ketones with TH in water 
is challenging, because the substrates are usually acid and/or base sensitive.
[6]
 Thus, 
there is a need for a catalyst that is versatile, active and chemoselective for the TH of 
α-substituted ketones with diverse properties to form the corresponding secondary 
alcohols. Herein, we report that the cyclometalated iridium complexes are also 
highly efficient and chemoselective for the TH of various α-substituted ketones, keto 
esters and α,β-unsaturated aldehydes in water (Scheme 2.2). 
 
Scheme 2.2: Transfer hydrogenation of α-substituted ketones and α,β-unsaturated carbonyls under 
aqueous conditions.
 
2.2 Results and discussion 
2.2.1 Optimisation of reaction conditions 
A series of cyclometalated iridium complexes, iridicycles C1-C6 (Scheme 2.3), were 
firstly synthesised according to the reported procedures.
[10]
 To investigate the 
efficacy of the iridicycles in reducing α-substituted ketones, the synthesised 
complexes C1-C6 were screened, by using 1-phenoxypropan-2-one as the 
benchmark substrate at a substrate/catalyst (S/C) ratio of 1000. As shown in Table 
2.1, all of these six precatalysts afforded good to excellent conversions for the TH in 
water at pH 4.5 in a short reaction time of 0.5 h (Table 2.1, Entries 3-8). Without the 
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imino ligand, the [Cp*IrCl2]2 is inactive (Table 2.1, entry 2). As expected, no 
reaction took place without a catalyst (Table 2.1, entry 1). It appears that the more 
electronic donation of the imino ligand to the iridium, the faster the reduction in 
water. This is seen by comparing the TH by using C2 with those by using C1 and 
C3. The highly conjugated C4 and C6 gave even higher conversions, although the 
anthracenyl-containing C5 was surprisingly less active. In particular, the 
phenanthrenyl-ligated C6 afforded almost full conversion in 0.5 h (Table 2.1, entry 
8), with higher S/C ratios being feasible. Thus, at an S/C of 10000, the TH was 
approximately complete in 2 h (Table 2.1, entry 9), and the catalyst delivered a 
conversion of 82% in 20 h at a much higher S/C of 50000 (Table 2.1, entry 11).  
 
Scheme 2.3: Iridicycle catalysts examined for TH in water. 
The TH reactions above were carried out at pH 4.5. Screening of the reaction 
conditions with C4 revealed that the solution pH value plays a critical role in the 
reduction. Thus, the TH occurred only within a certain window of acidic conditions 
(pH 3.0-5.0 for greater than 50% conversions), with the optimal pH value being 4.5 
(Figure 2.1), which was adopted for subsequent studies.  
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Table 2.1: Screening of catalysts for the TH of 1-phenoxypropan-2-one in water 
 
Entry
[a]
 Catalyst S/C
[b]
 Time (h) Conv. (%)
[c]
 
1 - - 0.5 n.r. 
2 [Cp*IrCl2]2 1000 0.5 <2 
3 C1 1000 0.5 88 
4 C2 1000 0.5 96 
5 C3 1000 0.5 59 
6 C4 1000 0.5 98 
7 C5 1000 0.5 75 
8 C6 1000 0.5 >99 
9 C6 10000 2 99 
10 C6 20000 6 96 
11 C6 50000 20 82 
[a] Reaction conditions: ketone (2.5 mmol), catalyst (0.01 mol%), HCO2H/HCO2Na aqueous solution 
(pH = 4.5; 3mL; 14.0 mmol of HCO2H and 29.4 mmol of HCO2Na in 2.8 mL of H2O), 80 °C, stirred 
in a carousel tube for 0.5 h. [b] S/C = substrate/catalyst molar ratio. [c] Conversion determined by 
1
H-
NMR spectroscopy; n.r. = no reaction. 
 
Figure 2.1: The effect of pH value on the TH of 1-phenoxypropan-2-one. 
This value is higher than that required for the TH of acetophenone using an 
analogous catalyst (pH 3.5),
[11]
 which presumably reflects the more electron-rich 
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ketone being reduced in this study. However, pH 4.5 is lower than that used with the 
Noyori-Ikariya M-TsDPEN catalysts (M = Ru, Rh or Ir), for which neutral to slightly 
basic reaction conditions were found to be optimal.
[12,13]
  As explained before,
[11,14]
 
the iridicycle catalyst is not capable of activating the ketone through its ligands, 
which renders activation through an acidic medium necessary, whereas the Noyori-
Ikariya type catalysts are able to readily hydrogenate a ketone by virtue of hydrogen 
bonding between the NH proton of the ligand and the substrate.
[12,15]
 
2.2.2 TH of β-keto ethers in water 
With the optimised reaction conditions in hand, the substrate scope of the reduction 
was explored. Firstly, a wide range of β-keto ethers were effectively and 
chemoselectively reduced to the desired β-hydroxy ethers. As shown in Table 2.2, 
the C6 catalyst is capable of reducing all type of β-keto ethers. Keto ethers featuring 
either aromatic or aliphatic units and aromatic, aliphatic, heterocyclic and 
fluoronated ethers were all viable and furnishing excellent yields at the S/C ratio of 
10000 and 2.5 mmol substrate scale. Furthermore, for β-aryl ketone aryl ethers, 
neither electron-withdrawing substituents nor electron-donating groups on the aryl 
ring of either ketones or ethers significantly affected the productivity and selectivity 
of the catalyst. Thus, TH of 1a and 1b afforded similar yields (Table 2.2, entry 1 
versus 2) and the reductions of 1f, 1g and 1h all provided excellent yields (Table 2.2, 
entries 6-8). The sterically bulky substituent on the aryl ether 1d also has little effect 
(Table 2.2, entry 4). More importantly, substrates containing a hexafluoroisopropyl 
group (1i) and a heptafluorobutoxy group (1j) can be reduced smoothly with 87% 
and 86% yields to afford highly demanding intermediates for pharmaceuticals and 
fine chemicals.
[16,17]
 To the best of our knowledge, there is no literature report for the 
TH of these substrates previously. The aliphatic substrates 1l-1o can also be 
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translated into the desired products smoothly with good to excellent yields (Table 
2.2, entries 12-15).  
Table 2.2: TH of β-keto ethers with C6 in water 
 
Entry
[a]
 Substrate Product Yield (%)
[b]
 
1 
  
2a 93 
2 
  
2b 91 
3 
  
2c 97 
4 
  
2d 95 
5 
  
2e 89 
6 
  
2f 97 
7 
  
2g 97 
8 
  
2h 93 
9 
  
2i 87 
 
10 
 
 
 
2j 
 
86 
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11 
  
 
2k 
 
98 
 
12 
  
 
2l 
 
97 
 
13 
  
 
2m 
 
91 
 
14
[c]
 
  
 
2n 
 
90 
 
15
[d]
   
 
2o 
 
87 
[a]
 
Reaction conditions: ketone (2.5 mmol), C6 (0.01 mol%), HCO2H/HCO2Na aqueous solution (pH 
= 4.5; 3 mL; 14.0 mmol of HCO2H and 29.4 mmol of HCO2Na in 2.8 mL of H2O), 80 °C, stirred in a 
carousel tube for 14 h. [b] Yield of isolated product. [c] 42:58 (trans:cis). [d] 52:48 (trans:cis)  
2.2.3 TH of α-substituted ketones 
α-Halo, hydroxy, nitrile-substituted ketones are more challenging to reduce due to 
the ease of dissociation of these α-functional groups under acidic and/or basic 
conditions.
[18]
 However, the current reduction system overcomes these challenges. 
By modification of the reaction conditions, the desired products were obtained with 
excellent isolated yields for almost all of these problematic ketones. As shown in 
Table 2.3, with the cyclometalated complex C4, which is slightly more active than 
C6, α-hydroxyacetophenone (3a) was converted to a 1,3-diol with 93% yield at an 
S/C ratio of 1000 (Table 2.3, entry 1), and α-chloroacetophenone (3b) was reduced 
to the α-chlorophenylethanol with 94% isolated yield (Table 2.3, entry 2). For the 
substrates 3c and 3d, which bear an electron-donating and -withdrawing group, 
respectively, the reduction afforded almost identical yields (Table 2.3, entries 3 and 
4). Moreover, α,α-dichloroacetophenone (3e) was successfully reduced to α,α-
dichlorophenylethanol with 87% yield (Table 2.3, entry 5), albeit at a lower S/C ratio 
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of 200. The reduction of α-chloroketones is often problematic because they are 
vulnerable to dechlorination under TH conditions.
[18,19]
 The α-fluoroketones were 
also viable for this reduction system. Thus, excellent yields were obtained for the TH 
of α-fluoro- and α,α,α-trifluoroacetophenone (3f and 3g, respectively; Table 2.3, 
entries 6 and 7). Equally, the α-nitrile ketones (3h-3l) were converted into the 
corresponding secondary alcohols with excellent yields, including examples of 
heterocyclic ketones (Table 2.3, entries 8-12). Still further, the catalytic system was 
successfully applied to α-acyloxy, α-morpholino, and α-semialdehyde ketones (3m-
3p; Table 2.3, entries 13-16), with the α-functional groups tolerated and high yields 
obtained for all of the desired products. Selective reduction of analogues of 3m by 
TH is difficult, because the acyl group is prone to migration by hydrolysis.
[20]
 
Indeed, there are only a few literature reports describing the TH of this class of 
substrates; however, the catalyst loadings are high and the yields are relatively low 
due to the aforementioned problem.
[21]
 To the best of our knowledge, this is the first 
time that a homogeneous catalyst has been reported for the TH of α-piperidyl and α-
semialdehyde ketones. 
Unfortunately, the TH of α-bromoacetophenone is not selective under the present 
condition. The liability of α-bromo group meant that a range of products were 
obtained (Scheme 2.4). 3q underwent debromonation to give 3r, which in turn is 
further reduced to 4r. Displacement of α-bromo group by formate ion gave 3s, which 
was also further reduced to 4s to some degree. However, despite the unwanted by-
products, the desired 4q was obtained in a moderate yield.  
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Table 2.3: TH of α-substituted ketones with C4 in water 
 
Entry
[a]
 Substrate Product  Yield (%)
[b]
 
1 
  
4a 93 
2 
  
4b 94 
3 
  
4c 92 
4 
  
4d 93 
5
[c]
 
  
4e 87 
6 
  
4f 95 
7 
  
4g 96 
8 
  
4h 90 
9 
  
4i 92 
10 
  
4j 91 
11 
  
4k 89 
12 
  
4l 90 
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13 
  
4m 96 
14 
  
4n 88 
15
[d]
 
  
4o 86 
16 
  
4p 94 
[a] Reaction conditions: ketone (2.5 mmol), C4 (0.1 mol%), HCO2H/HCO2Na aqueous solution (pH = 
4.5; 3 mL; 14.0 mmol of HCO2H and 29.4 mmol of HCO2Na in 2.8 mL of H2O, 80 °C, stirred in a 
carousel tube for 18 h. [b] Yield of isolated product.
 
[c] S/C = 200.
 
[d] Yield determined by 
1
H-NMR 
spectroscopy. 
 
Scheme 2.4: TH of α-bromoacetophenone under present conditions. 
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2.2.4 TH of α- and β-keto esters 
To showcase the broader utility of the catalytic system, C4 was also applied to the 
reduction of keto esters.
[22]
 Both aromatic and aliphatic β-keto esters were reduced to 
afford the corresponding alcohols with excellent yields under the catalysis of 0.1 
mol% of C4 (Table 2.4). Likewise, the analogous α-keto esters were also reduced 
with ease, which demonstrates the versatility of the cyclometalated iridium catalyst. 
Products 6e and 8c are known to be important intermediates for medicines and fine 
chemicals.
[17,23]
 Again, there appears to be no correlation between the electron 
properties of the substituents on the phenyl ring and the yield obtained under the 
conditions employed (Table 2.4, entries 1-4). 
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Table 2.4: TH of α- and β-keto esters with C4 in water 
 
Entry
[a]
 Substrate Product  Yield (%)
[b]
 
1 
  
6a 94 
2 
  
6b 91 
3 
  
6c 94 
4 
  
6d 92 
5 
  
6e 95 
6 
  
8a 96 
7
[c]
 
  
8b 91 
8 
  
8c 92 
[a] Reaction conditions: keto ester (2.5 mmol), C4 (0.1 mol%), HCO2H/HCO2Na aqueous solution 
(pH = 4.5; 3 mL; 14.0 mmol of HCO2H and 29.4 mmol of HCO2Na in 2.8 mL of H2O), 80 °C, stirred 
in a carousel tube for 14 h. [b] Yield of isolated product.
 
[c] Yield determined by 
1
H-NMR 
spectroscopy. 
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2.2.5 TH of α,β-unsaturated aldehydes 
The highly efficient and chemoselective reduction of α,β-unsaturated ketones and 
aldehydes has been a research topic in the last several decades.
[24,25]
 Mixtures of 
products are frequently obtained, because many catalysts reduce both C=O and C=C 
bonds rather than exclusively either the C=O or C=C bond. Hence, selectivity is still 
an issue.
[25] 
Therefore, we subsequently examined these substrates with the current 
reduction system. Disappointedly, C4 was not chemoselective for the reduction of 
α,β-unsaturated ketones and catalysed the reduction of both the C=C and C=O bonds 
(Scheme 2.5). 
 
Scheme 2.5: Attempted chemoselective TH of α,β-unsaturated ketones in water. 
Catalyst C4 is, however, highly chemoselective in the reduction of α,β-unsaturated 
aldehydes to afford only unsaturated alcohols (Table 2.5). In the case of the aromatic 
α,β-unsaturated aldehydes, almost identical yields of allylic alcohols were obtained 
for those substrates that are relatively sterically demanding (9b, 9c and 9f; Table 2.5, 
entries 2, 3 and 6), or that bear electron-withdrawing or -donating groups substituted 
on the phenyl ring (9d versus 9e; Table 2.5, entry 4 versus 5). Good yields were also 
achieved for the TH of aliphatic α,β-unsaturated aldehydes (Table 2.5, entries, 7-9). 
The chemoselectivity observed with the α,β-unsaturated aldehydes  may stem from 
the aldehyde group being easier to reduce than a ketone. Once reduced, the C=C 
bond can no longer be hydrogenated by the catalyst. 
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Table 2.5: TH of α,β-unsaturated aldehydes with C4 in water 
 
Entry
[a]
 Substrate Product  Yield (%)
[b]
 
1 
  
10a 95 
2 
  
10b 91 
3 
  
10c 90 
4 
  
10d 88 
5 
  
10e 96 
6 
  
10f 94 
7
[c]
 
  
10g 92 
8   10h 78 
9 
  
10i 85 
[a] Reaction conditions: aldehyde (2.5 mmol), C4 (0.1 mol%), HCO2H/HCO2Na aqueous solution 
(pH = 4.5; 3 mL; 14.0 mmol of HCO2H and 29.4 mmol of HCO2Na in 2.8 mL of H2O), stirred in a 
carousel tube for 6 h. [b] Yield of isolated product.
 
[c] E/Z = 52:48. 
2.2.6 Mechanistic considerations 
A plausible mechanism is proposed for the TH in question in Scheme 2.6. Catalyst C 
is first converted into the formate complex I in the presence of formate.
[26]
 
Decarboxylation of I leads to the active, but coordinatively saturated, hydride 
species II.
[27]
 The ketone substrate, activated by the hydroxonium ion under the 
acidic conditions employed,
[11]
 is then reduced through direct hydride transfer from 
II without ketone coordination to the metal centre, that is, by the ionic or outer-
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sphere mechanism.
[28]
 In previous studies, our group have shown that hydride can be 
easily generated from an iridicycle and formate and transferred to protonated 
imines.
[27]
 
 
Scheme 2.6: Proposed mechanism for the TH by an iridicycle. 
2.3 Conclusion 
In summary, this chapter has demonstrated that cyclometalated iridium complexes, 
iridicycles, catalyse the highly efficient and chemoselective TH of a wide variety of 
carbonyl groups, including a series of α-substituted ketones, α- and β-ketoesters, and 
α,β-unsaturated aldehydes. With the reduction feasible in water at S/C ratios of 
1000-50000, the current protocol provides a practical, easy and efficient synthesis of 
β-functionalised secondary alcohols, especially β-hydroxyethers, β-hydroxyamines 
and β-hydroxyhalo compounds, which are bioactive and/or of value for the synthesis 
of pharmaceuticals, fine chemicals, perfumes and agrochemicals. 
2.4 Experimental 
2.4.1 General information 
Unless otherwise specified, all reagents were commercially purchased and used 
without further purification. Deionised water was used for the reactions. NMR 
spectra were recorded on a Bruker 400 MHz or 250 MHz NMR spectrometer with 
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TMS as the internal standard. HRMS were obtained by chemical ionisation (CI) at 
the Department of Chemistry, University of Liverpool or by (FAB) at the EPSRC 
National Mass Spectrometry Service Centre at Swansea University. Elemental 
analyses were performed by the Elemental Analysis Service of Department of 
Chemistry. β-keto ethers (1a-j and 1l-m) were prepared according to the 
literature.
[29]
 Pentamethylcyclopentadienyliridium(III) chloride, dimer [Cp*IrCl2]2 
was purchased from Strem Chemicals Inc. Solution of various pH value was 
prepared by a reported method and measured using a pH meter at 20 
ᵒ
C.
[11]
 
1
H-NMR, 
13
C-NMR and HRMS were collected for all the products, and the NMR data are 
consistent with the reported literature. 
2.4.2 General procedure for the preparation of imine ligands 
Ketone (5.0 mmol) and amine (5.5 mmol) were dissolved in toluene (80 mL). 
NaHCO3 (420 mg, 5 mmol) and 4Å MS (1.2 g) were then added. The mixture was 
stirred under reflux for 24 h, then cooled to room temperature and filtered through 
celite. The solvent was removed under vacuum and the resulting crude mixture was 
crystallised using hexane/DCM to give the corresponding imine.
[30]
 
2.4.3 General procedure for the preparation of cyclometalated iridium 
complexes 
[Cp*IrCl2]2 (200 mg, 0.25 mmol), imine ligand (0.55 mmol), NaOAc (206 mg, 2.5 
mmol) were placed in a carousel reaction tube. DCM (10 mL) was introduced and 
the resulting mixture was stirred for 24 h at room temperature. The reaction mixture 
was then filtered through celite and dried over Na2SO4. The solvent was evaporated 
under vacuum and the resulting solid was washed with a hexane/diethyl ether (2:1) 
mixture.
[10]
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2.4.4 Typical procedure for the TH of β-keto ethers in water 
β-Keto ether (2.5 mmol) and C6 (0.17 mg, 2.5 x 10-4 mmol) were placed in a 
carousel reaction tube. The tube was degassed and charged with nitrogen. 
HCO2H/HCO2Na aqueous solution of pH 4.5 (3 mL) was then introduced and the 
mixture was stirred at 80 °C for 14 h under nitrogen. The reaction mixture was 
cooled to room temperature and quenched with saturated sodium bicarbonate 
solution. The aqueous layer was extracted with ethyl acetate (3 x 25 mL) and the 
combined organic layers were washed with brine (25 mL). The organic layer was 
collected and dried over anhydrous sodium sulphate. Filtration, followed by 
evaporation of the solvent under reduced pressure, gave the crude mixture. Flash 
column chromatography of the crude mixture afforded the desired β-hydroxy ether 
product. 
2.4.5 Typical procedure for the TH of α-functionalised aromatic ketones in 
water 
Ketone (2.5 mmol) and C4 (1.6 mg, 2.5 x 10
-3
 mmol) were placed in a carousel 
reaction tube. The tube was degassed and charged with nitrogen. HCO2Na/HCO2H 
aqueous solution of pH 4.5 (3 mL) was then introduced and the mixture was stirred 
at 80 °C for 18 h under nitrogen. The reaction mixture was cooled to room 
temperature, quenched with saturated NaCl solution (20 mL) and extracted with 
ethyl acetate (3 x 25 mL). The combined organic layer was dried over anhydrous 
sodium sulphate. Filtration, followed by evaporation of the solvent under reduced 
pressure, gave the crude mixture. Flash column chromatography of the crude mixture 
afforded the desired product. 
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2.4.6 Typical procedure for the TH of α-keto and β-keto esters in water 
Keto ester (2.5 mmol) and C4 (1.6 mg, 2.5 x 10
-3
 mmol) were placed in a carousel 
reaction tube. The tube was degassed and charged with nitrogen. HCO2Na/HCO2H 
aqueous solution of pH 4.5 (3 mL) was then introduced and the mixture was stirred 
at 80 °C for 14 h under nitrogen. The reaction mixture was cooled to room 
temperature, quenched with saturated NaCl solution (20 mL) and extracted with 
ethyl acetate (3 x 25 mL). The combined organic layer was dried over anhydrous 
sodium sulphate. Filtration, followed by evaporation of the solvent under reduced 
pressure, gave the crude mixture. Flash column chromatography of the crude mixture 
afforded the desired hydroxy ester product. 
2.4.7 Typical procedure for the TH of α,β-unsaturated aldehydes in water 
α,β-Unsaturated aldehyde (2.5 mmol) and C4 (1.6 mg, 2.5 x 10-3 mmol) were placed 
in a carousel reaction tube. The tube was degassed and charged with nitrogen. 
HCO2Na/HCO2H aqueous solution of pH 4.5 (3 mL) was then introduced and the 
mixture was stirred at 80 °C for 6 h under nitrogen. The reaction mixture was cooled 
to room temperature, quenched with saturated NaCl solution (20 mL) and extracted 
with ethyl acetate (3 x 25 mL). The combined organic layer was dried over 
anhydrous sodium sulphate. Filtration, followed by evaporation of the solvent under 
reduced pressure, gave the crude mixture. Flash column chromatography of the 
crude mixture afforded the desired alcohol product. 
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2.4.8 Data of the cyclometalated iridium complexes 
 
Complex C1:
[14]
 Black solid; m.p. 170-174 °C: 
1
H NMR (CDCl3, 400 MHz, 253 K) 
δ (ppm): 8.62 (d, J = 2.3 Hz, 1H), 7.89 (dd, J = 8.4, 2.3 Hz, 1H), 7.78 (d, J = 8.3 Hz, 
1H), 7.64 (d, J = 8.5 Hz, 1H), 7.03 (d, J = 8.4 Hz, 1H), 6.94 (d, J = 8.1 Hz, 1H), 6.84 
(d, J = 8.6 Hz, 1H), 3.89 (s, 3H), 2.51 (s, 3H), 1.46 (s, 15H). 
13
C NMR (CDCl3, 100 
MHz, 253 K) δ (ppm): 180.5, 168.4, 157.9, 153.6, 148.8, 143.6, 129.2, 128.7, 124.4, 
123.1, 117.1, 115.1, 112.5, 90.1, 55.7, 17.8, 8.8. Anal. calc. for C25H28ClIrN2O3 (%): 
C, 47.50; H, 4.46; N, 4.43. Found: C, 47.56; H, 4.43; N, 4.42. HRMS (FAB) for 
C25H28Cl
191
IrN2O3 [M]
+
: m/z calc., 630.1389; found, 630.1383. 
 
Complex C2: Yellow solid; m.p. 271-275 °C:
 1
H NMR (CDCl3, 400 MHz, 253 K) δ 
(ppm): 7.78 (d, J = 8.3 Hz, 1H), 7.21 (d, J = 8.1 Hz, 1H), 7.00-6.78 (m, 3H), 6.59 (d, 
J = 8.1 Hz, 1H), 6.12 (d, J = 1.2 Hz, 1H), 6.03 (d, J = 1.2 Hz, 1H), 3.87 (s, 3H), 2.38 
(s, 3H), 1.49 (s, 15H). 
13
C NMR (CDCl3, 100 MHz, 253 K) δ (ppm): 180.5, 157.4, 
150.5, 148.5, 144.3, 143.1, 142.2, 125.3, 125.1, 123.7, 114.9, 112.2, 102.9, 99.6, 
89.6, 55.6, 17.6, 9.1. HRMS (FAB) for C26H29O3N
191
Ir [M-Cl]
+
: m/z calc., 594.1748; 
found, 594.1747. 
 
Complex C3: Yellow solid; m.p. 278-282 °C:
 1
H NMR (CDCl3, 400 MHz, 253 K) δ 
(ppm): 7.86 (d, J = 7.6 Hz, 1H), 7.47-7.41 (m, 2H), 7.35-7.05 (m, 7H), 7.04-6.99 (m, 
1H), 6.96-6.89 (m, 1H), 6.84 (d, J = 7.7 Hz, 1H), 1.44 (s, 15H). 
13
C NMR (CDCl3, 
100 MHz, 253 K) δ (ppm): 184.0, 169.9, 151.0, 148.3, 135.3, 134.3, 131.7, 131.3, 
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129.8, 129.7, 128.6, 128.1, 127.6, 125.6, 124.0 (br), 121.2, 89.7, 8.27. HRMS 
(ASAP) for C29H30ClIrN [M+H]
+
: m/z calc., 620.1696; found, 620.1699. 
 
Complex C4:
[14]
 Red solid; m.p. 276-280 °C: 
1
H NMR (CDCl3, 400 MHz, 293 K) δ 
(ppm): 8.16 (s, 1H), 8.05 (s, 1H), 7.88 (d, J = 7.9 Hz, 1H), 7.80 (dd, J = 8.3, 2.9 Hz, 
2H), 7.48 (dd, J = 8.4, 7.4, 1H), 7.32 (dd, J = 8.4, 7.6 Hz, 1H), 7.08-6.82 (m, 3H), 
3.90 (s, 3H), 2.58 (s, 3H), 1.47 (s, 15H).
 13
C NMR (CDCl3, 100 MHz, 253 K) δ 
(ppm): 181.3, 159.5, 157.6, 148.1, 144.2, 136.9, 132.2, 129.6, 129.2, 129.1, 127.4, 
126.5, 125.1, 123.5, 123.4, 114.9, 112.3, 89.0, 55.7, 17.3, 8.8. Anal. calc. for 
C29H31ClIrNO (%): C, 54.66; H, 4.90; N, 2.20. Found: C, 54.33; H, 4.90; N, 2.06. 
HRMS (FAB) for C29H31Cl
191
IrNO [M]
+
: m/z calc., 635.1695; found, 635.1692.  
 
Complex C5: Deep Red solid; m.p. >300 °C: 
1
H NMR (CDCl3, 400 MHz, 253 K) δ 
(ppm): 8.42 (s, 1H), 8.35 (s, 1H), 8.27 (d, J = 13.1 Hz, 2H), 7.99 (dd, J = 16.4, 8.4 
Hz, 2H), 7.94-7.87 (m, 1H), 7.48-7.36 (m, 2H), 7.09-6.84 (m, 3H), 3.90 (s, 3H), 2.59 
(s, 3H), 1.49 (s, 15H).
 13
C NMR (CDCl3, 100 MHz, 253 K) δ (ppm): 180.8, 157.7, 
156.9, 148.8, 144.2, 135.0, 133.0, 131.2, 130.1, 129.9, 129.0, 128.6, 128.4, 128.3, 
128.2, 125.9, 125.3, 124.2, 123.4, 114.9, 112.3, 89.0, 55.7, 17.3, 8.8. HRMS (FAB) 
for C33H33NO
191
Ir [M-Cl]
+
: m/z calc., 650.2163; found, 650.2156. 
 
Complex C6: Deep Red solid; m.p. >300 °C: 
1
H NMR (CDCl3, 400 MHz, 253 K) δ 
(ppm): 9.10 (s, 1H), 8.84 (d, J = 8.1 Hz, 1H), 8.05 (s, 1H), 7.96-7.84 (m, 2H), 7.76-
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7.57 (m, 4H), 7.12-6.84 (m, 3H), 3.90 (s, 3H), 2.62 (s, 3H), 1.52 (s, 15H).
 13
C NMR 
(CDCl3, 100 MHz, 253 K) δ (ppm): 181.4, 162.9, 157.6, 147.8, 144.1, 133.5, 133.2, 
129.4, 129.0, 128.6, 128.5, 128.0, 127.5, 127.0, 126.1, 125.0, 124.6, 123.6, 123.5, 
115.0, 112.3, 89.2, 55.7, 17.3, 9.0. Anal. calc. for C33H33ClIrNO (%):C, 57.67; H, 
4.84; N, 2.04. Found: C, 57.88; H, 4.80; N, 1.91. HRMS (FAB) for C33H33NO
191
Ir 
[M-Cl]
+
: m/z calc., 650.2163; found, 650.2160. 
2.4.9 Data of the β-hydroxy ethers 
 
2-(4-Chlorophenoxy)-1-phenylethanol, 2a:
[31]
 
1
H NMR (CDCl3, 250 MHz, 300 K) δ 
(ppm): 7.48-7.33 (m, 5H), 7.27-7.20 (m, 2H), 6.90-6.82 (m, 2H), 5.12 (dt, J = 8.5, 
2.7 Hz, 1H), 4.13-3.93 (m, 2H), 2.73 (bs, OH). 
13
C NMR (CDCl3, 63 MHz, 300 K) δ 
(ppm): 157.0, 139.4, 129.4, 128.6, 128.3, 126.2 (2), 115.9, 73.6, 72.5. HRMS for 
C14H12ClO [(M-H2O) + H]
+
: m/z calc., 231.0571; found, 231.0579. 
 
2-(4-Methoxyphenoxy)-1-phenylethanol, 2b:
[32]
 
1
H NMR (CDCl3, 250 MHz, 300 K) 
δ (ppm): 7.47-7.28 (m, 5H), 6.88-6.79 (m, 4H), 5.09 (dd, J = 8.8, 3.2 Hz, 1H), 4.05 
(dd, J = 9.6, 3.2 Hz, 1H), 3.94 (dd, J = 9.7, 8.8 Hz, 1H), 3.76 (s, 3H), 2.87 (bs, OH). 
13
C NMR (CDCl3, 63 MHz, 300 K) δ (ppm): 154.2, 152.5, 139.7, 128.5, 128.1, 
126.3, 115.7, 114.7, 74.1, 72.6, 55.7. HRMS for C15H20NO3 [M+NH4]
+
: m/z calc., 
262.1443; found, 262.1435. 
 
2-(Naphthalen-2-yloxy)-1-phenylethanol, 2c:
[33]
 
1
H NMR (CDCl3, 250 MHz, 300 
K) δ (ppm): 7.75-7.56 (m, 3H), 7.43-7.24 (m, 7H), 7.13 (dd, J = 9.0, 2.5 Hz, 1H), 
7.03 (d, J = 2.4 Hz, 1H), 5.09 (dd, J = 8.4, 3.4 Hz, 1H), 4.14-4.01 (m, 2H), 3.13 (bs, 
OH). 
13
C NMR (CDCl3, 63 MHz, 300 K) δ (ppm): 156.4, 139.9, 134.6, 129.7, 129.3, 
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128.7, 128.3, 127.8, 126.9, 126.6, 126.5, 124.0, 118.8, 107.2, 73.4, 72.6. HRMS for 
C18H15O [(M-H2O) + H]
+
: m/z calc., 247.1123; found, 247.1117. 
 
2-(2,6-Dimethylphenoxy)-1-phenylethanol, 2d:
[4]
 
1
H NMR (CDCl3, 400 MHz, 300 
K) δ (ppm): 7.45-7.40 (m, 2H), 7.38-7.32 (m, 2H), 7.32-7.26 (m, 1H), 6.99 (d, J = 
7.5 Hz, 2H), 6.91 (dd, J = 8.3, 6.5 Hz, 1H), 5.16-5.09 (m, 1H), 3.89-3.84 (m, 2H), 
3.06 (bs, OH), 2.27 (s, 6H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 155.6, 
140.2, 131.1, 129.4, 128.9, 128.5, 126.7, 124.6, 77.3, 73.8, 16.8. HRMS for 
C16H22NO2 [M+NH4]
+
: m/z calc., 260.1651; found, 260.1646. 
 
1-Phenyl-2-(pyridin-3-yloxy)ethanol, 2e:
[4]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 8.18 (t, J = 1.7 Hz, 1H), 8.14-8.10 (m, 1H), 7.48-7.42 (m, 2H), 7.40-7.34 (m, 
2H), 7.32-7.28 (m, 1H), 7.19-7.14 (m, 2H), 5.11 (dd, J = 6.8, 5.5 Hz, 1H), 4.50 (bs, 
OH), 4.08-4.03 (m, 2H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 154.9, 142.1, 
140.1, 137.7, 128.6, 128.2, 126.3, 124.0, 121.5, 73.7, 72.3. HRMS for C13H14NO2 
[M+H]
+
: m/z calc., 216.1025; found, 216.1029. 
 
1-(4-Chlorophenyl)-2-phenoxyethanol, 2f:
[33]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.41-7.35 (m, 4H), 7.31-7.27 (m, 2H), 7.00-6.97 (m, 1H), 6.92-6.89 (m, 2H), 
5.10 (dd, J = 8.7, 3.2 Hz, 1H), 4.08 (dd, J = 9.6, 3.3 Hz, 1H), 3.96 (dd, J = 9.6, 8.7 
Hz, 1H), 2.83 (bs, OH). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 158.2, 138.1, 
133.9, 129.6, 128.8, 127.7, 121.5, 114.6, 73.1, 72.0. HRMS for C14H17ClNO2 
[M+NH4]
+
: m/z calc., 266.0942; found, 266.0932.  
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4-(1-Hydroxy-2-phenoxyethyl)benzonitrile, 2g:
[31]
 
1
H NMR (CDCl3, 400 MHz, 300 
K) δ (ppm): 7.60-7.56 (m, 2H), 7.47-7.36 (m, 5H), 6.99-6.96 (m, 2H), 5.16 (dd, J = 
8.4, 3.4 Hz, 1H), 4.15-4.06 (m, 2H), 2.42 (bs, OH). 
13
C NMR (CDCl3, 100 MHz, 300 
K) δ (ppm): 161.7, 139.2, 134.1, 128.7, 128.5, 126.2, 119.0, 115.3, 104.6, 73.4, 72.4. 
HRMS for C15H17N2O2 [M+NH4]
+
: m/z calc., 257.1285; found, 257.1283. 
 
1-(4-Methoxyphenyl)-2-phenoxyethanol, 2h:
[33]
 
1
H NMR (CDCl3, 400 MHz, 300 
K) δ (ppm): 7.40-7.35 (m, 2H), 7.31-7.24 (m, 2H), 6.99-6.89 (m, 5H), 5.08-5.04 (m, 
1H), 4.06 (dd, J = 9.6, 3.3 Hz, 1H), 3.99 (dd, J = 9.6, 8.8 Hz, 1H), 3.81 (s, 3H), 2.79 
(d, J = 2.1 Hz, OH). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 160.0, 158.8, 
132.2, 130.0, 128.0, 121.7, 115.1, 114.4, 73.7, 72.6, 55.7. HRMS for C15H15O2 [(M-
H2O) + H]
+
: m/z calc., 227.1072; found, 227.1066. 
 
2-((1,1,1,3,3,3-Hexafluoropropan-2-yl)oxy)-1-phenylethanol, 2i: 
1
H NMR (CDCl3, 
400 MHz, 300 K) δ (ppm): 7.40-7.32 (m, 5H), 5.01 (dt, J = 8.8, 2.8 Hz, 1H), 4.32 
(sep, J = 5.9 Hz, 1H), 4.00 (dd, J = 10.3, 2.8 Hz, 1H), 3.86 (dd, J = 10.3, 9.1 Hz, 1H), 
2.53 (d, J = 2.7 Hz, OH). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 138.8, 128.7, 
128.4, 126.1, 121.4 (ddq, J = 3.1, 14.3, 285.7 Hz), 79.7, 76.5 (sep, J = 32.4 Hz), 73.2.
 
19
F NMR (CDCl3, 375 MHz, 300 K) δ (ppm): -73.9. HRMS for C11H14F6NO2 
[M+NH4]
+
: m/z calc., 306.0923; found, 306.0927. 
 
2-(2,2,3,3,3-Pentafluoropropoxy)-1-phenylethanol, 2j: 
1
H NMR (CDCl3, 400 MHz, 
300 K) δ (ppm): 7.40-7.28 (m, 5H), 4.92 (dt, J = 8.7, 2.8 Hz, 1H), 4.14-3.94 (m, 2H), 
3.78 (dd, J = 9.9, 3.1 Hz, 1H), 3.64 (dd, J = 9.9, 9.0 Hz, 1H), 2.69 (d, J = 2.6 Hz, 
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OH). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 139.4, 128.6, 128.2, 126.2, 
116.2 (qt, J = 288.3, 33.7 Hz), 114.8 (tq, J = 257.1, 31.9 Hz), 109.0 (tq, J = 264.8, 
38.7 Hz), 78.3, 72.9, 68.0 (t, J = 25.6 Hz).
 19
F NMR (CDCl3, 375 MHz, 300 K) δ 
(ppm): -137.9 (m), -131.1 (m), -91.2 (m). HRMS for C12H15F7NO2 [M+NH4]
+
: m/z 
calc., 338.0986; found, 338.0987. 
 
1-Phenoxypropan-2-ol, 2k:
[34]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 7.26 
(dd, J = 8.8, 7.4 Hz, 2H), 6.94 (t, J = 7.4 Hz, 1H), 6.89 (dd, J = 8.8, 0.91 Hz, 2H), 
4.21-4.13 (m, 1H), 3.88 (dd, J = 9.4, 3.3 Hz, 1H), 3.77 (dd, J = 9.4, 7.6 Hz, 1H), 2.83 
(d, J = 3.4 Hz, OH), 1.26 (d, J = 6.5 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ 
(ppm): 158.6, 129.6, 121.1, 114.6, 73.2, 66.3, 18.9. HRMS for C9H16NO2 
[M+NH4]
+
: m/z calc., 170.1176; found, 170.1171. 
 
1-(2,6-Dimethylphenoxy)propan-2-ol, 2l:
[35]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.01 (d, J = 7.5 Hz, 2H), 6.92 (dd, J = 8.4, 6.6 Hz, 1H), 4.26-4.20 (m, 1H), 
3.72 (dd, J = 9.4, 3.3 Hz, 1H), 3.64 (dd, J = 9.4, 7.7 Hz, 1H), 2.65 (bs, OH), 2.28 (s, 
6H), 1.26 (d, J = 6.4 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 155.6, 
131.2, 129.4, 124.5, 77.4, 67.5, 19.0, 16.7. HRMS for C11H20NO2 [M+NH4]
+
: m/z 
calc., 198.1494; found, 198.1490. 
 
1-(Pyridin-3-yloxy)propan-2-ol, 2m:
[36]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 8.19 (t, J = 1.8 Hz, 1H), 8.11 (t, J = 3.0 Hz, 1H), 7.15-7.11 (m, 2H), 4.18-4.09 
(m, 1H), 3.86 (dd, J = 9.4, 3.7 Hz, 1H), 3.80 (dd, J = 9.4, 7.1 Hz, 1H), 1.22 (d, J = 
6.4 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 154.0, 140.9, 136.8, 
123.0, 120.3, 72.7, 64.8, 18.2. HRMS for C8H12NO2 [M+H]
+
: m/z calc., 154.0868; 
found, 154.0863. 
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2-Ethoxycyclohexanol, 2n:
[37]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): (42:58, 
trans:cis): trans isomer: 3.83-3.81 (m, 1H), 3.62-3.35 (m, 3H), 2.76 (bs, OH), 2.09-
1.99 (m, 1H), 1.79-1.68 (m, 2H), 1.63-1.49 (m, 2H), 1.29-1.19 (m, 6H). 
13
C NMR 
(CDCl3, 100 MHz, 300 K) δ (ppm): 83.4, 73.5, 63.9, 32.0, 29.2, 24.2, 22.2, 15.6.; cis 
isomer: 3.75-3.67 (m, 1H), 3.62-3.35 (m, 2H), 3.05-2.99 (m, 1H), 2.70 (bs, OH), 
2.09-1.99 (m, 1H), 1.79-1.68 (m, 2H), 1.63-1.49 (m, 3H), 1.29-1.19 (m, 5H). 
13
C 
NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 78.3, 68.4, 63.5, 30.4, 26.6, 23.9, 21.1, 
15.5. HRMS for C8H17O2 [M+H]
+
: m/z calc., 145.1223; found, 145.1228. 
 
2-Methyltetrahydrofuran-3-ol, 2o:
[38]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 
(52:48, trans:cis): trans isomer: 4.13-4.05 (m, 1H), 4.00-3.81 (m, 2H), 3.72-3.62 (m, 
1H), 2.28 (bs, OH), 2.20-2.05 (m, 1H), 1.83-1.71 (m, 1H), 1.13 (d, J = 6.4 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 77.6, 72.1, 64.6, 33.6, 12.9; cis 
isomer: 4.00-3.81 (m, 2H), 3.77 (qd, J = 6.4, 3.3 Hz, 1H), 3.72-3.62 (m, 1H), 2.70 
(bs, OH), 2.20-2.05 (m, 1H), 1.93-1.83 (m, 1H), 1.20 (d, J = 6.4 Hz, 3H). 
13
C NMR 
(CDCl3, 100 MHz, 300 K) δ (ppm): 81.0, 76.2, 65.1, 34.7, 17.9. HRMS for 
C5H14NO2 [M+NH4]
+
: m/z calc., 120.1019; found, 120.1020. 
2.4.10 Data of the α-functionalised alcohols 
 
1-Phenylethane-1,2-diol, 4a:
[39]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 7.38-
7.28 (m, 5H), 4.78 (dd, J = 8.4, 3.4 Hz, 1H), 3.71 (dd, J = 11.5, 3.4 Hz, 1H), 3.62 
(dd, J = 11.5, 8.4 Hz, 1H), 3.30 (bs, 2 OH’s). 13C NMR (CDCl3, 100 MHz, 300 K) δ 
(ppm): 140.5, 128.6, 128.0, 126.1, 74.7, 68.1. HRMS for C8H14NO2 [M+NH4]
+
: m/z 
calc., 156.1019; found, 156.1020. 
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2-Chloro-1-phenylethanol, 4b:
[40]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 
7.37-7.29 (m, 5H), 4.86 (dt, J = 8.7, 3.3 Hz, 1H), 3.71 (dd, J = 11.3, 3.5 Hz, 1H), 
3.62 (dd, J = 11.4, 8.7 Hz, 1H), 2.87 (d, J = 3.0 Hz, OH). 
13
C NMR (CDCl3, 100 
MHz, 300 K) δ (ppm): 140.0, 128.7, 128.5, 126.1, 74.1, 50.9. HRMS for C8H13ClNO 
[M+NH4]
+
: m/z calc., 174.0686; found, 174.0681. 
 
2-Chloro-1-(4-methoxyphenyl)ethanol, 4c:
[41]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.30 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 8.6 Hz, 2H), 4.84 (dd, J = 8.6, 3.3 Hz, 
1H), 3.80 (s, 3H), 3.71-3.60 (m, 2H), 2.69 (bs, OH). 
13
C NMR (CDCl3, 100 MHz, 
300 K) δ (ppm): 159.7, 132.1, 127.3, 114.1, 73.7, 55.3, 50.9. HRMS for C9H12ClO2 
[M+H]
+
: m/z calc., 187.0520; found, 187.0522. 
 
2-Chloro-1-(4-fluorophenyl)ethanol, 4d:
[41]
 
1
H NMR (CDCl3, 250 MHz, 300 K) δ 
(ppm): 7.40-7.29 (m, 2H), 7.11-7.00 (m, 2H), 4.86 (dt, J = 8.4, 3.8 Hz, 1H), 3.72-
3.55 (m, 2H), 2.93 (d, J = 3.2 Hz, OH). 
13
C NMR (CDCl3, 63 MHz, 300 K) δ (ppm): 
162.6 (d, J = 246.7 Hz), 135.7 (d, J = 3.2 Hz), 127.8 (d, J = 8.2 Hz), 115.5 (d, J = 
21.6 Hz), 73.4, 50.7 (d, J = 1.1 Hz). 
19
F NMR (CDCl3, 235 MHz, 300 K) δ (ppm): -
113.5. HRMS for C8H7ClF [(M-H2O) + H]
+
: m/z calc., 157.0215; found, 157.0214. 
 
2,2-Dichloro-1-phenylethanol, 4e:
[42]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 
7.45-7.35 (m, 5H), 5.82 (d, J = 5.4 Hz, 1H), 4.98 (dd, J = 5.5, 4.2 Hz, 1H), 2.90 (d, J 
= 4.0 Hz, OH). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 137.3, 129.1, 128.5, 
127.1, 78.9, 76.4. HRMS for C8H7Cl2 [(M-H2O) + H]
+
: m/z calc., 172.9919; found, 
172.9923. 
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2-Fluoro-1-phenylethanol, 4f:
[43]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 
7.40-7.29 (m, 5H), 5.01-4.94 (m, 1H), 4.55-4.31 (m, 2H), 2.83 (d, J = 2.0 Hz, OH). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 139.1 (d, J = 8.2 Hz), 129.5, 129.3, 
127.2, 88.0 (d, J = 174.7 Hz), 73.8 (d, J = 19.8 Hz). HRMS for C8H8F [(M-H2O) + 
H]
+
: m/z calc., 123.0605; found, 123.0606. 
 
2,2,2-Trifluoro-1-phenylethanol, 4g:
[44]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.46-7.32 (m, 5H), 4.94 (q, J = 6.7 Hz, 1H), 3.02 (bs, OH). 
13
C NMR (CDCl3, 
100 MHz, 300 K) δ (ppm): 133.9, 129.6, 128.7, 127.5, 124.3 (q, J = 281.5 Hz), 72.8 
(q, J = 31.8 Hz). 
19
F NMR (CDCl3, 375 MHz, 300 K) δ (ppm): -78.3 (d, J = 6.7 Hz). 
HRMS for C8H6F3 [(M-H2O) + H]
+
: m/z calc., 159.0416; found, 159.0414. 
 
3-Hydroxy-3-phenylpropanenitrile, 4h:
[45]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.41-7.28 (m, 5H), 4.95 (t, J = 6.1 Hz, 1H), 3.26 (bs, OH), 2.68 (d, J = 6.2 
Hz, 2H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 141.1, 128.9, 128.7, 125.6, 
117.6, 69.8, 27.9. HRMS for C9H10NO [M+H]
+
: m/z calc., 148.0757; found, 
148.0758. 
 
3-Hydroxy-3-(p-tolyl)propanenitrile, 4i:
[46]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.27 (d, J = 8.2 Hz, 2H), 7.19 (d, J = 8.2 Hz, 2H), 4.99-4.95 (m, 1H), 2.74-
2.70, 3.26 (m, 2H), 2.60 (d, J = 3.4 Hz, OH), 2.35 (s, 3H). 
13
C NMR (CDCl3, 100 
MHz, 300 K) δ (ppm): 138.7, 138.1, 129.6, 125.5, 117.4, 70.0, 27.9, 21.1. HRMS for 
C10H15N2O [M+NH4]
+
: m/z calc., 179.1179; found, 179.1183. 
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3-(4-Fluorophenyl)-3-hydroxypropanenitrile, 4j:
[47]
 
1
H NMR (CDCl3, 250 MHz, 
300 K) δ (ppm): 7.42-7.29 (m, 2H), 7.14-7.01 (m, 2H), 5.08-4.92 (m, 1H), 3.32 (d, J 
= 3.9 Hz, OH), 2.71 (d, J = 6.1 Hz, 2H). 
13
C NMR (CDCl3, 63 MHz, 300 K) δ 
(ppm): 162.6 (d, J = 247.2 Hz), 136.9 (d, J = 3.2 Hz), 127.4 (d, J = 8.3 Hz), 117.4, 
115.7 (d, J = 21.7 Hz), 69.2, 28.0. 
19
F NMR (CDCl3, 235 MHz, 300 K) δ (ppm): -
113.1. HRMS for C9H9FNO [M+H]
+
: m/z calc., 166.0663; found, 166.0666. 
 
3-Hydroxy-3-(thiophen-2-yl)propanenitrile, 4k:
[47]
 
1
H NMR (CDCl3, 400 MHz, 300 
K) δ (ppm): 7.31 (dd, J = 5.1, 1.0 Hz, 1H), 7.08 (d, J = 3.5 Hz, 1H), 7.03 (dd, J = 5.1, 
3.7, 1H), 5.32-5.24 (m, 1H), 2.93 (d, J = 3.2 Hz, OH), 2.89-2.83 (m, 2H). 
13
C NMR 
(CDCl3, 100 MHz, 300 K) δ (ppm): 144.4, 127.1, 125.8, 124.8, 117.0, 66.3, 28.2. 
HRMS for C7H8NOS [M+H]
+
: m/z calc., 154.0321; found, 154.0326. 
 
3-(Furan-2-yl)-3-hydroxypropanenitrile, 4l:
[47]
 
1
H NMR (CDCl3, 400 MHz, 300 K) 
δ (ppm): 7.43-7.39 (m, 1H), 6.42-6.35 (m, 2H), 5.07-5.00 (m, 1H), 2.90 (d, J = 6.3 
Hz, 2H), 2.87 (d, J = 5.0 Hz, OH). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 
152.9, 142.9, 116.9, 110.6, 107.5, 63.8, 24.9. HRMS for C7H11N2O2 [M+NH4]
+
: m/z 
calc. 155.0815; found, 155.0817. 
 
2-Hydroxy-2-phenylethyl benzoate, 4m:
[48]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 8.06 (d, J = 7.7 Hz, 2H), 7.58 (t, J = 7.4 Hz, 1H), 7.50-7.30 (m, 7H), 5.16-
5.07 (m, 1H), 4.53 (dd, J = 11.6, 3.4 Hz, 1H), 4.43 (dd, J = 11.6, 8.2 Hz, 1H), 2.66 
(bs, OH). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 166.8, 139.9, 133.3, 129.8, 
129.7, 128.7, 128.5, 128.3, 126.2, 72.6, 69.8. HRMS for C15H13O2 [(M-H2O) + H]
+
: 
m/z calc., 225.0910; found, 225.0910. 
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2-Morpholino-1-phenylethanol, 4n:
[49]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.41-7.28 (m, 5H), 4.75 (dd, J = 10.4, 3.6 Hz, 1H), 3.80-3.69 (m, 4H), 2.80-
2.69 (m, 2H), 2.58-2.40 (m, 4H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 
141.9, 128.4, 127.6, 125.9, 68.6, 67.1, 66.7, 53.5. HRMS for C12H18NO2 [M+H]
+
: 
m/z calc., 208.1332; found, 208.1334. 
 
3,3-Dimethoxy-1-phenylpropan-1-ol, 4p:
[50]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.37-7.31 (m, 4H), 7.28-7.23 (m, 1H), 4.86 (dd, J = 9.1, 3.4 Hz, 1H), 4.55 (t, 
J = 5.6 Hz, 1H), 3.37 (s, 3H), 3.34 (s, 3H), 2.10-2.02 (m, 1H), 1.99-1.94 (m, 1H). 
13
C 
NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 144.2, 128.4, 127.4, 125.7, 103.4, 70.8, 
53.7, 53.0, 41.6. HRMS for C11H20NO3 [M+NH4]
+
: m/z calc., 214.1438; found, 
214.1442. 
2.4.11 Data of the α-hydroxy and β-hydroxy esters 
 
Ethyl 3-hydroxy-3-phenylpropanoate, 6a:
[51]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.40-7.25 (m, 5H), 5.11 (dt, J = 8.9, 4.1 Hz, 1H), 4.15 (q, J = 7.2 Hz, 2H), 
3.45 (d, J = 3.6 Hz, OH), 2.77-2.64 (m, 2H), 1.24 (t, J = 7.2 Hz, 3H). 
13
C NMR 
(CDCl3, 100 MHz, 300 K) δ (ppm): 172.4, 142.6, 128.5, 127.8, 125.7, 70.3, 60.9, 
43.4, 14.2. HRMS for C11H16NO2 [(M-H2O) + NH4]
+
: m/z calc., 194.1176; found, 
194.1169. 
 
Ethyl 3-hydroxy-3-(3-nitrophenyl)propanoate, 6b:
[51]
 
1
H NMR (CDCl3, 400 MHz, 
300 K) δ (ppm): 8.27 (s, 1H), 8.15 (dd, J = 8.1, 1.3 Hz, 1H), 7.74 (d, J = 7.7 Hz, 1H), 
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7.54 (t, J = 8.1 Hz, 1H), 5.28-5.18 (m, 1H), 4.20 (q, J = 7.2 Hz, 2H), 3.78 (d, J = 3.5 
Hz, OH), 2.80-2.72 (m, 2H), 1.28 (t, J = 7.2 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 
300 K) δ (ppm): 172.0, 148.4, 144.7, 131.9, 129.5, 122.7, 120.8, 69.3, 61.2, 43.0, 
14.1. HRMS for C11H17N2O5 [M+NH4]
+
: m/z calc., 257.1132; found, 257.1126. 
 
Ethyl 3-hydroxy-3-(m-tolyl)propanoate, 6c:
[52]
 
1
H NMR (CDCl3, 400 MHz, 300 K) 
δ (ppm): 7.24 (dd, J = 7.5, 6.9 Hz, 1H), 7.20 (s, 1H), 7.16 (d, J = 7.7 Hz, 1H), 7.10 
(d, J = 7.4 Hz, 1H), 5.11 (dt, J = 8.9, 3.8 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 3.27 (d, J 
= 3.4 Hz, OH), 2.78-2.66 (m, 2H), 2.35 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H). 
13
C NMR 
(CDCl3, 100 MHz, 300 K) δ (ppm): 172.5, 142.5, 138.2, 128.6, 128.5, 126.4, 122.7, 
70.3, 60.9, 43.3, 21.5, 14.2. HRMS for C12H15O2 [(M-H2O) + H]
+
: m/z calc., 
191.1067; found, 191.1070. 
 
Ethyl 3-hydroxy-3-(3,4,5-trimethoxyphenyl)propanoate, 6d:
[53]
 
1
H NMR (CDCl3, 
400 MHz, 300 K) δ (ppm): 6.60 (s, 2H), 5.06 (dt, J = 9.0, 3.4 Hz, 1H), 4.19 (q, J = 
7.1 Hz, 2H), 3.85 (s, 6H), 3.82 (s, 3H), 3.50 (d, J = 3.3 Hz, OH), 2.78-2.65 (m, 2H), 
1.27 (t, J = 7.1 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 172.3, 153.2, 
138.5, 137.2, 102.5, 70.5, 60.9, 60.8, 56.0, 43.6, 14.2. HRMS for C14H19O5 [(M-
H2O) + H]
+
: m/z calc., 267.1227; found, 267.1230. 
 
Ethyl 4,4,4-trifluoro-3-hydroxybutanoate, 6e:
[54]
 
1
H NMR (CDCl3, 400 MHz, 300 
K) δ (ppm): 4.51-4.41 (m, 1H), 4.36 (bs, OH), 4.21 (q, J = 7.2 Hz, 2H), 2.75-2.63 
(m, 2H), 1.29 (t, J = 7.2 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 
170.8, 124.5 (q, J = 281.2 Hz), 67.0 (q, J = 32.4 Hz), 61.6, 34.9, 13.9. 
19
F NMR 
(CDCl3, 375 MHz, 300 K) δ (ppm): -80.0. HRMS for C6H13F3NO3 [M+NH4]
+
: m/z 
calc., 204.0842; found, 204.0843. 
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Ethyl 2-hydroxy-2-phenylacetate, 8a:
[55]
 
1
H NMR (CDCl3, 250 MHz, 300 K) δ 
(ppm): 7.45-7.25 (m, 5H), 5.15 (d, J = 5.7 Hz, 1H), 4.30-4.10 (m, 2H), 3.51 (d, J = 
5.7 Hz, OH), 1.22 (t, J = 7.1 Hz, 3H). 
13
C NMR (CDCl3, 63 MHz, 300 K) δ (ppm): 
173.7, 138.4, 128.5, 128.4, 126.5, 72.9, 62.2, 14.0. HRMS for C10H11O2 [(M-H2O) + 
H]
+
: m/z calc., 163.0754; found, 163.0751. 
 
Ethyl 3,3,3-trifluoro-2-hydroxypropanoate, 8c:
[56]
 
1
H NMR (CDCl3, 400 MHz, 300 
K) δ (ppm): 4.42-4.38 (m, 1H), 4.36-4.25 (m, 2H), 3.43 (bs, OH), 1.29 (t, J = 7.2 Hz, 
3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 167.9 (d, J = 2.2 Hz), 122.6 (q, J 
= 283.2 Hz), 70.3 (q, J = 33.1 Hz), 64.1, 14.3. 
19
F NMR (CDCl3, 375 MHz, 300 K) δ 
(ppm): -76.6. HRMS for C5H8F3O3 [M+H]
+
: m/z calc., 173.0420; found, 173.0418. 
2.4.12 Data of the α,β-unsaturated alcohols 
 
3-Phenylprop-2-en-1-ol, 10a:
[57]
 
1
H NMR (CDCl3, 250 MHz, 300 K) δ (ppm): 7.39-
7.20 (m, 5H), 6.59 (d, J = 15.9 Hz, 1H), 6.34 (dt, J = 15.9, 5.6 Hz, 1H), 4.29 (dd, J = 
5.6, 1.3 Hz, 2H), 2.07 (bs, OH). 
13
C NMR (CDCl3, 63 MHz, 300 K) δ (ppm): 136.7, 
131.1, 128.6, 128.5, 127.7, 126.5, 63.6. HRMS for C9H9 [(M-H2O) + H]
+
: m/z calc., 
117.0699; found, 117.0695. 
 
3-(2-Nitrophenyl)prop-2-en-1-ol, 10b:
[58]
 
1
H NMR (CDCl3, 250 MHz, 300 K) δ 
(ppm): 8.00-7.85 (m, 1H), 7.65-7.52 (m, 2H), 7.46-7.33 (m, 1H), 7.09 (dt, J = 15.7, 
1.6 Hz, 1H), 6.35 (dt, J = 15.7, 5.3 Hz, 1H), 4.49-4.30 (m, 2H), 2.10 (bs, OH). 
13
C 
NMR (CDCl3, 63 MHz, 300 K) δ (ppm): 147.8, 134.1, 133.1, 132.5, 128.8, 128.1, 
125.8, 124.5, 63.3. HRMS for C9H13N2O3 [M+NH4]
+
: m/z calc., 197.0921; found, 
197.0919. 
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3-(2-Methoxyphenyl)prop-2-en-1-ol, 10c:
[59]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.41 (d, J = 7.5 Hz, 1H), 7.21 (t, J = 7.9 Hz, 1H), 6.93-6.84 (m, 3H), 6.35 (dt, 
J = 16.1, 5.9 Hz, 1H), 4.29 (d, J = 5.5 Hz, 2H), 3.81 (s, 3H), 2.12 (bs, OH). 
13
C NMR 
(CDCl3, 100 MHz, 300 K) δ (ppm): 156.7, 129.4, 128.8, 127.0, 126.1, 125.8, 120.7, 
110.9, 64.1, 55.4. HRMS for C10H13O2 [M+H]
+
: m/z calc., 165.0916; found, 
165.0913. 
 
3-(4-Nitrophenyl)prop-2-en-1-ol, 10d:
[60]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 8.18 (d, J = 8.8 Hz, 2H), 7.51 (d, J = 8.8 Hz, 2H), 6.72 (d, J = 16.0 Hz, 1H), 
6.55 (dt, J = 15.9, 5.0 Hz, 1H), 4.41 (td, J = 5.4, 1.5 Hz, 2H), 1.87 (t, J = 5.7 Hz, 
OH). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 146.9, 143.3, 133.6, 128.2, 
126.9, 124.0, 63.1. HRMS for C9H13N2O3 [M+NH4]
+
: m/z calc., 197.0921; found, 
197.0918. 
 
3-(4-Methoxyphenyl)prop-2-en-1-ol, 10e:
[61]
 
1
H NMR (CDCl3, 250 MHz, 300 K) δ 
(ppm): 7.25 (d, J = 8.7 Hz, 2H), 6.81 (d, J = 8.7 Hz, 2H), 6.49 (d, J = 15.9 Hz, 1H), 
6.17 (dt, J = 15.9, 5.8 Hz, 1H), 4.23 (d, J = 5.8 Hz, 2H), 3.76 (s, 3H), 2.97 (bs, OH). 
13
C NMR (CDCl3, 63 MHz, 300 K) δ (ppm): 159.2, 130.6, 129.5, 127.7, 126.4, 
114.0, 63.6, 55.2. HRMS for C10H13O2 [M+H]
+
: m/z calc., 165.0916; found, 
165.0915. 
 
2-Methyl-3-phenylprop-2-en-1-ol, 10f:
[57]
 
1
H NMR (CDCl3, 250 MHz, 300 K) δ 
(ppm): 7.36-7.18 (m, 5H), 6.52 (s, 1H), 4.17 (s, 2H), 1.96 (bs, OH), 1.89 (s, 3H). 
13
C 
NMR (CDCl3, 63 MHz, 300 K) δ (ppm): 137.7, 137.6, 128.9, 128.1, 126.4, 125.0, 
68.9, 15.3. HRMS for C10H11 [(M-H2O) + H]
+
: m/z calc., 131.0855; found, 
131.0858. 
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3,7-Dimethylocta-2,6-dien-1-ol, 10g:
[57]
 mixture of E/Z isomers (52:48): 
1
H NMR 
(CDCl3, 400 MHz, 300 K) δ (ppm): 5.49-5.37 (m, 1H), 5.14-5.04 (m, 1H), 4.15-4.08 
((m, 2H): 4.14 (d, J = 6.9 Hz, 1H, CH2OH, E isomer), 4.09 (d, J = 7.2 Hz, 1H, 
CH2OH, Z isomer)), 2.12-2.01 (m, 4H), 1.75-1.60 (m, 10H). 
13
C NMR (CDCl3, 100 
MHz, 300 K) δ (ppm): Z isomer: 139.8, 132.4, 124.5, 123.8, 58.9, 32.0, 26.5, 26.66, 
23.4, 17.7. E isomer: 139.6, 131.7, 123.9, 123.4, 59.3, 39.5, 26.4, 26.65, 17.6, 16.2. 
HRMS for C10H17 [(M-H2O) + H]
+
: m/z calc., 137.1325; found, 137.1322. 
 
Oct-2-en-1-ol, 10h:
[62]
 
1
H NMR (CDCl3, 250 MHz, 300 K) δ (ppm): 5.76-5.57 (m, 
2H), 4.08 (d, J = 4.7 Hz, 2H), 2.12-1.95 (m, 2H), 1.56 (bs, OH), 1.44-1.21 (m, 6H), 
0.89 (t, J = 6.8 Hz, 3H). 
13
C NMR (CDCl3, 63 MHz, 300 K) δ (ppm): 133.5, 128.8, 
63.8, 32.2, 31.4, 28.8, 22.5, 14.0. HRMS for C8H15 [(M-H2O) + H]
+
: m/z calc., 
111.1168; found, 111.1169. 
 
Cyclohex-1-en-1-ylmethanol, 10i:
[63]
 
1
H NMR (CDCl3, 250 MHz, 300 K) δ (ppm): 
5.79-5.57 (m, 1H), 3.96 (s, 2H), 2.14-1.92 (m, 5H), 1.75-1.50 (m, 4H). 
13
C NMR 
(CDCl3, 63 MHz, 300 K) δ (ppm): 137.5, 122.9, 67.5, 25.5, 24.9, 22.5, 22.4. HRMS 
for C7H11 [(M-H2O) + H]
+
: m/z calc., 95.0855; found, 95.0855. 
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Chapter 3 
A Simple and Environmentally 
Friendly Approach for the Transfer 
Hydrogenation of N-Heterocycles in 
Water  
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3.1 Introduction 
Saturated nitrogen heterocycles are frequently found in drug and biologically active 
molecules, such as oxamniquine, a schistosomicide,
[1]
 paroxetine, a CCRI type anti-
depressant,
[2]
 salsolinol, an endogenous monoamine oxidase inhibitor,
[3]
 and CEPC a 
serotonin 5-HT2C antagonist,
[4]
 (Scheme 3.1). The most obvious route to access these 
types of molecules is via the reduction of the corresponding unsaturated parent 
heterocycles, which can be efficiently synthesised by cross-coupling and classic 
heterocyclic chemistry. Nonetheless, this method only has 0.8% occurrence rate 
among the medical chemist’s toolbox, despite the fact that 42.9% of the total 
pharmaceutical compounds contain aliphatic amines.
[5]
 This must be a reflection of 
either limited supply of the building blocks from commercial sources or significant 
challenges at the late stage reduction step. 
 
Scheme 3.1: Bioactive molecules that contain a saturated nitrogen heterocycle core. 
Reduction of nitrogen heterocycles has traditionally been done by heterogeneous 
hydrogenation (i.e. Pd/C, Rh/C, Adams's catalyst, Raney nickel),
[6]
 electrolytic 
reduction,
[7]
 Birch reduction
[8]
 and more recently with homogenous hydrogenation.
[9]
 
Despite the fact that there are many examples in the literature, one or more 
significant limitations are always found under those reaction conditions. For 
example, Birch and metal hydride reduction require stoichiometric amount of 
Chapter 3 
101 
 
metallic reductants and have very limited functional group compatibility. Whilst 
heterogeneous catalysts containing Pd, Pt, Ni or Rh on supported materials can 
reduce a range of heterocycles even under atmospheric pressure of hydrogen, they 
often have limited selectivity and the potential of over reduction. Homogeneous 
catalysis has attracted much attention, due to the easily controllable selectivities and 
reactivities through ligand modification. Nevertheless, there are still significant 
challenges in this area, including the improvement in turnover number (TON) and 
turnover frequency (TOF), reduction in cost, and the expansion of the reaction scope.  
Transfer hydrogenation (TH) of heterocycles is a reaction of great interest due to its 
operational simplicity. In contrast to ketones, the TH of heterocycles has been much 
less explored. Yamaguchi demonstrated that by using [IrCp*Cl2]2 in a mixture of 
i
PrOH and H2O under refluxing conditions, a series of quinolines can be fully 
reduced to tetrahydroquinolines (Scheme 3.2).
[10]
 The presence of an acid 
considerably enhanced the reduction, presumably by activating the quinoline through 
the protonation to form a quinolinium salt, which is easier to reduce.  
 
Scheme 3.2: Ir catalysed TH of quinolines with 
i
PrOH. 
Frediani and co-workers reported a Rh-bipyridine catalyst that can reduce quinoline 
and pyridines with a moderate conversion by using 
i
PrOH as the hydride source 
(Scheme 3.3).
[11]
 The same catalyst could also be applied to the reduction of other 
unsaturated bonds, including C=C and C=O bonds in reasonable conversions. 
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Crabtree identified a cationic Ir(I)-NHC catalyst (1a) that can reduce quinolines to 
tetrahydroquinolines in 
i
PrOH with moderate yields. Pyrazine showed complete 
conversion to piperazine under the reaction condition (Scheme 3.4).
[12]
 Other N-
heterocycles, for instance, isoquinolines, pyridines and indoles, were found to be 
inactive in this system.  
 
Scheme 3.3: Rh catalysed TH of quinolines with 
i
PrOH. 
 
Scheme 3.4: 1a catalysed TH of N-heterocycles. 
The most versatile, simple and yet highly active system was recently reported by 
Xiao and co-workers. By using [Cp*RhCl2]2 with KI as an additive, a range of N-
heterocycles, including quinolines, isoquinolines, quinoxalines and pyridinium salts, 
can be reduced in the HCO2H-NEt3 azeotrope.
[13,14]
 As shown in Scheme 3.5, N-
heterocycles were reduced in high yields using just 0.01-0.2 mol% catalyst under 
mild condition. TH of indoles did not proceed under the protocol, however, and the 
reduction of 4-subtituted quinoline was rather sluggish. For example at higher 
catalyst loading of 2 mol% and 50% KI, only 23% conversion of 4-methyl quinoline 
was obtained after 24 h.
[13]
 Interestingly, the TH of pyridinium salts affords two 
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different products, depending on the substitution pattern at the pyridinium ring. For 
instance, 2- or 3-substitued pyridines are fully reduced to piperdines, while 4-
substitued pyridines exclusively gives 1,2,3,6-tetrahydropyridines (Scheme 3.6). 
This is because the hydride addition preferentially takes place at the 4 position for 2- 
or 3-substituted pyridines (i.e. 1,4-addition), whereas in the case of 4-substituted 
pyridines 1,4-addition is disfavoured possibly due to the steric reasons and instead 
1,2-addition takes place (Scheme 3.7).
[14]
 
 
Scheme 3.5: [Cp*RhCl2]2 catalysed TH of N-heterocycles. 
 
Scheme 3.6: [Cp*RhCl2]2 catalysed TH of pyridinium salts. 
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Scheme 3.7: 1,4-Addition versus 1,2-addition. 
Asymmetric transfer hydrogenation (ATH) of N-heterocycles has also been 
investigated, mainly with organocatalysts
[15]
 and to a lesser degree with 
homogeneous catalysts.
[16]
 However, Hantzsch esters are predominantly used, which 
are expensive hydrogen donors compared with others that are commercially 
available (
t
Bu-HEH - £70.5/gram versus HCO2H - £30/L).  
The conditions for both TH and ATH of N-heterocycles reactions are not yet ideal, 
as high catalyst loadings, high reaction temperature and/or a limited substrate scope 
are limitations often encountered. Moreover, organic solvents are normally used that 
impose an environmental impact. In addition, an active, versatile catalyst capable of 
either hydrogenation or TH of various N-heterocycles, for example quinolines, 
isoquinolines, quinoxalines, indoles and pyridines, remain to be seen. Following the 
success of iridicycles in the TH of a range of -substituted ketones in water 
described in Chapter 2, we report in this chapter our efforts to test whether the same 
catalysts are capable of reducing these more inert N-heterocycles in water.  
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3.2 Results and discussion 
3.2.1 Optimisation of the reaction conditions 
In Chapter 2 it was discussed that the complex C4 exhibits the highest activity at pH 
4.5 for the TH of -substituted ketones in water; hence the same conditions were 
adopted for the optimisation study. 2-Methylquinoline (2a) was chosen as a model 
substrate. TH of 2a gave full conversion within 3 h with only 0.1 mol% loading of 
C4 at both 80 °C and 60 °C, in an aqueous formate solution of pH 4.5 (Table 3.1, 
entries 1 and 2). Gratifyingly, lowering the temperature to 30 °C also led to a 70% 
conversion within 3 h (Table 3.1, entry 3). Screening of the solution pH with C4 
revealed that the reaction occurs only within a certain window of acidic condition. 
pH 4.5 was adopted for subsequent studies. This finding is also consistent with the 
TH of -substituted ketones (vide supra). In contrast, the analogous Rh complex D4 
only gave a 12% conversion (Table 3.1, entry 6). Other catalysts, which are known 
to be active for the TH of quinolines (Scheme 3.8), showed much lower activities 
under the reaction conditions employed (Table 3.1, entries 7-11). Although the 
dimeric [Cp*IrCl2]2 also led to a moderate conversion (38% in 3 h, Table 3.1, entry 
11), further testing showed that it exhibited very limited substrate scope (Table 3.2). 
For instance, TH of 3-methylquinoline led to its tetrahydro variant only in 4% 
conversion after 20 h (Table 3.2, entry 2).  
 
Scheme 3.8: List of TH catalysts examined for quinoline reduction. 
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Table 3.1: Screening of catalysts for the TH of 2-methylquinoline in water 
 
Entry
[a]
 Catalyst pH Temp. (°C) Conv. (%)
[b]
 
1 C4 4.5 80 >99 
2 C4 4.5 60 >99 
3 C4 4.5 30 70 
4 C4 2.5 30 20 
5 C4 6.5 30 <5 
6 D4 4.5 30 12 
7 1a 4.5 30 n.r. 
8 1b 4.5 30 8 
9 [Cp*RhCl2]2 4.5 30 5 
10
[c]
 [Cp*RhCl2]2 4.5 30 4 
11 [Cp*IrCl2]2 4.5 30 38 
[a] Reaction conditions: 2-methylquinoline (2.5 mmol), catalyst (0.1 mol%), HCO2H/HCO2Na 
aqueous solution (pH = 4.5; 3mL; 14.0 mmol of HCO2H and 29.4 mmol of HCO2Na in 2.8 mL of 
H2O), stirred in a carousel tube for the time indicated. [b] Conversion determined by 
1
H-NMR 
spectroscopy [c] With 10 mol% KI; n.r. = no reaction. 
Table 3.2: Substrate scope with [Cp*IrCl2]2 
Entry
[a]
 Substrate Time (h) Temp. (°C) Conv. (%)
[b]
 
1 Quinoline 20 30 8 
2 3-Methylquinoline 20 30 4 
3 6-Bromoquinoline 3 30 n.r. 
4 Indole 20 30 n.r. 
[a] Reaction conditions: substrate (0.5 mmol), [Cp*IrCl2]2 (1 mol%), HCO2H/HCO2Na aqueous 
solution (pH = 4.5; 3mL; 14.0 mmol of HCO2H and 29.4 mmol of HCO2Na in 2.8 mL of H2O), stirred 
in a carousel tube for the time indicated. [b] Conversion determined by 
1
H-NMR spectroscopy; n.r. = 
no reaction. 
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In order to establish that aqueous conditions are the optimum, other hydride sources 
and solvents were also tested using C4 for the TH of 2-methylquinoline. As seen in 
Table 3.3, apart from water, the TH also worked in MeOH and TFE with F/T as the 
hydrogen source, but with lower conversions (65% and 68%, respectively). Much 
lower conversions were recorded in non-protic solvents, such as THF or DMF (<5% 
conversion in 3 h). Other commonly used hydride sources such as 
i
PrOH and Et3SiH 
were sluggish under the reaction conditions (Table 3.3, entries 7 and 8).  
Table 3.3: Screening of hydride sources and solvents 
 
Entry
[a]
 Hydride source Solvent Conv. (%)
[b]
 
1 F/T MeOH 64 
2 F/T TFE 68 
3 F/T THF 1 
4 F/T toluene 3 
5 F/T DCM 13 
6 F/T DMF 4 
7 0.1M KOH/
 i
PrOH iPrOH 15 
8 Et3SiH H2O n.r. 
[a] Reaction conditions: 2-methylquinoline (2.5 mmol), C4 (0.1 mol%), hydride source (20 equiv.), 
solvent, stirred in a carousel tube for the 3 h. [b] Conversion determined by 
1
H-NMR spectroscopy; 
n.r. = no reaction. 
3.2.2 TH of quinolines 
Once the optimal TH condition for 2-methylquinoline had been established, an array 
of 26 diversely substituted quinolines (2a-2z) was hydrogenated in the aqueous 
formate solution of pH 4.5, as summarised in Table 3.4. The iridium based catalyst 
C4 exhibited high reactivity for all of the quinoline substrates examined. Thus, 
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unsubstituted quinoline 2d, 2-substituted quinoline 2a and 3-substitued quinoline 2b 
were all effectively reduced at 30 °C with excellent yields (Table 3.4, entries 1, 2 
and 4). Increasing the steric bulkiness at the 2-postion led to a decrease in 
conversion, which could be compensated by increasing the reaction temperature to 
reflux (3e, 84% yield; Table 3.4, entry 5). Challenging 4-substitued quinolines 2c 
and 2z were also reduced in high yields, albeit with high temperature (Table 3.4, 
entries 3 and 26). Other functional groups, including halogen (2g-2k), ether (2m-2o), 
protected amine (2q), amide (2r), ester (2s), carboxylic acid (2t), heterocycles (2v-
2x) and a trifluoromethyl group (2p) were all tolerated under the reaction condition, 
exhibiting insignificant effect on the yields with products isolated in average yield of 
>90% (Table 3.4, entries 7-20 and 22-24). Even with a highly sensitive functional 
group, such as boronic acid pinacol ester, 3u was isolated in 62% (Table 3.4, entry 
21), together with 30% of the deboronated product 3a. 
Table 3.4: TH of quinolines 
 
Entry
[a]
 Substrate Product Yield (%)
[b]
 
1 
  
3a 96 
2 
  
3b 93 
3
[c]
 
  
3c 90 
4 
  
3d 90 
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5
[c]
 
  
3e 84 
6 
  
3f 94 
7 
  
3g 97 
8 
  
3h 97 
9 
  
3i 95 
10 
  
3j 98 
11 
  
3k 92 
12 
  
3l 95 
13 
  
3m 96 
14 
  
3n 94 
15 
  
3o 93 
16 
  
3p 98 
17
[c,d]
 
  
3q 90 
18
[c]
 
  
3r 91 
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19 
  
3s 92 
20 
  
3t 82 
21
[c]
 
  
3u 62 
22 
  
3v 95 
23 
  
3w 96 
24
[c]
 
  
3x 82 
25 
  
3y 95 
26
[c,e]
 
  
3z 84 
[a] Reaction conditions: quinoline (2.5 mmol), C4 (0.1 mol%), HCO2H/HCO2Na aqueous solution 
(pH = 4.5; 3mL; 14.0 mmol of HCO2H and 29.4 mmol of HCO2Na in 2.8 mL of H2O), 30 °C stirred 
in a carousel tube for 14 h. [b] Yield of isolated product. [c] Reaction was carried out at reflux. [d] 
Yield determined by 
1
H-NMR spectroscopy. [e] 0.5 mol% C4 used. 
In order to demonstrate the potential usefulness of this method in process chemistry, 
2a was used as the model substrate for a larger scale reduction. As shown in Scheme 
3.9, 35.8g (0.25 mol) of 2a was effectively reduced with just 0.01 mol% C4 at 30 °C 
(75% conversion in 24 h; TON = 7500). The product was separated from the reaction 
mixture by a simple phase separation and purified by fractional distillation. 
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Moreover, the aqueous layer could be reused by adjusting the pH back to 4.5 by the 
addition of fresh formic acid. No special equipment was required for this reaction, 
nor was an inert atmosphere necessary. In addition, no organic solvent was required 
for the entire operation, and only minimum waste was generated, showing the 
protocol to be greener than the traditional methods, which often involves the use of 
NaBH3CN in acetic acid or Pd/C or Pd/Al2O3 under high pressure of H2.
[17,18]
 
 
Scheme 3.9: Large scale TH of 2-methylquinoline. 
3.2.3 TH of isoquinolines and pyridines  
Based on the successful results obtained for the TH of quinolines with C4, the 
substrate scope was expanded to more challenging isoquinolines and pyridines. 
Reduction of isoquinoline and 2-phenylpyridine led to the recovery of the starting 
material under the reaction conditions used in Table 3.4, presumably due to their 
high aromatic stability. It was thought that activating the substrate by quaternizing 
the nitrogen atom would lead to a higher activity.
[14]
 This is indeed the case, and the 
optimisation results for isoquinoline and pyridine are shown in Table 3.5 and 3.6, 
respectively. 
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Table 3.5: Reaction optimisation for the TH of isoquinoline 
 
Entry
[a]
 R X
-
 Temp. (°C) Conv. (%)
[b]
 
1 - - 30 n.r. 
2 - - reflux n.r. 
3 H OTf reflux 47 
4 Me I reflux n.r. 
5 Et I reflux 89 
6 Bn Br reflux 90 
7 Bn Br 30 n.r. 
[a] Reaction conditions: isoquinoline (0.5 mmol), C4 (1 mol%), HCO2H/HCO2Na aqueous solution 
(pH = 4.5; 3mL; 14.0 mmol of HCO2H and 29.4 mmol of HCO2Na in 2.8 mL of H2O), stirred in a 
carousel tube for 24 h. [b] Conversion determined by 
1
H-NMR spectroscopy; n.r. = no reaction. 
Table 3.6: Reaction optimisation for the TH of pyridine 
 
Entry
[a]
 R X
-
 Temp. (°C) Time (h) Conv. (%)
[b]
 
1 - - 30 24 n.r. 
2 - - reflux 24 n.r. 
3 H OTf reflux 24 n.r. 
4 Me I reflux 24 n.r. 
5 Et I reflux 24 63 
6 Et I reflux 36 93 
7 Bn Br reflux 36 92 
[a] Reaction conditions: pyridine (0.5 mmol), C4 (1 mol%), HCO2H/HCO2Na aqueous solution (pH = 
4.5; 3mL; 14.0 mmol of HCO2H and 29.4 mmol of HCO2Na in 2.8 mL of H2O), stirred in a carousel 
tube for the time indicated. [b] Conversion determined by 
1
H-NMR spectroscopy; n.r. = no reaction. 
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After the optimised conditions had been established, an array of 6 isoquinolinium 
(4a-4f) and 10 pyridinium (6a-6j) salts were reduced (Table 3.7). Unsubstitued 
isoquinolinium, 1-methyl, 3-methyl and 6-methyl isoquinolinium salts gave the 
highest yields (>95%; Table 3.7, entries 2-5). Increasing the steric bulk at the 1-
position by replacing the methyl group with a phenyl did not affect the yield (Table 
3.7, entry 1). A functional group, such as bromine, was well tolerated under the 
reaction condition (Table 3.7, entry 6). Likewise, 2-substituted pyridinium salts (6a-
6e) were all reduced with good yields, regardless of the nature of the functional 
groups (Table 3.7, entries 7-11). Interestingly, substrates bearing an electron 
withdrawing group at the 4-position gave exclusively the fully reduced piperidines, 
whilst those having an electron donating group led to the partially reduced 3,4-
unsaturated piperidines (Table 3.7, entries 13 and 14 versus 15 and 16). This 
phenomenon could be explained by a competitive 1,2-hydride addition versus 1,4-
hydride addition (vide supra). Having an electron withdrawing substituent probably 
renders the 4-position more electrophilic, favouring the 1,4-addition. 
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Table 3.7: TH of isoquinolinium and pyridinium salts 
 
Entry
[a]
 Substrate Product Yield (%)
[b]
 
1 
  
5a 90 
2 
  
5b 95 
3
[c]
 
  
5c 98 
4
[c]
 
  
5d 97 
5 
  
5e 99 
6 
  
5f 91 
7 
  
7a 90 
8
[d]
 
  
7b 72 
9 
  
7c 90 
10 
  
7d 94 
11 
  
7e 81 
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12
[c]
 
  
7f 82 
13
[c]
 
  
7g 95 
14 
  
7h 92 
15 
  
7i 82 
16 
  
7j 80 
[a] Reaction conditions: isoquinolinium or pyridinium salts (2.5 mmol), C4 (1 mol%), 
HCO2H/HCO2Na aqueous solution (pH = 4.5; 3mL; 14.0 mmol of HCO2H and 29.4 mmol of 
HCO2Na in 2.8 mL of H2O), reflux, stirred in a carousel tube for 24 h (isoquinolinium) or 36 h 
(pyridinium). [b] Yield of isolated product. [c] Yield determined by 
1
H-NMR spectroscopy. [d] 
Isolated as debenzylated product after the column. 
3.2.4 TH of indoles 
Substrate scope of indoles was examined next with C4 under the condition of Table 
3.4. A range of indoles with both electron-donating and electron-withdrawing groups 
were reduced to the corresponding indolines in good yields (Table 3.8). However, 
TH of 5-bromoindole gave a lower yield (Table 3.8, entry 3). For 5-bromoindole 8c, 
a thick layer of coating was always observed on the reaction vessel above the solvent 
level, even at reflux and with the addition of MeOH as a co-solvent. This reflects 
that the solubility of 8c was an issue under the reaction conditions employed and this 
may have led to the lower conversion. Disappointedly, TH of sterically hindered 2-
phenylindole failed to proceed under the present reaction conditions, and 3-
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methylindole gave a low yield (Table 3.8, entries 6 and 7). One of the explanations 
could be the unfavourable tautomerization of 8f or difficulty in its protonation at the 
3-position due to sterics, following which 1,2-hydride addition can occur. 
Table 3.8: TH of indoles 
 
Entry
[a]
 Substrate Product Yield (%)
[b]
 
1 
  
9a 96 
2 
  
9b 94 
3
[c,d]
 
  
9c 30 
4 
  
9d 92 
5
[c]
 
  
9e 78 
6
[c,d]
 
  
9f 33 
7 
  
9g n.r. 
[a] Reaction conditions: indole (2.5 mmol), C4 (0.1 mol%), HCO2H/HCO2Na aqueous solution (pH = 
4.5; 3mL; 14.0 mmol of HCO2H and 29.4 mmol of HCO2Na in 2.8 mL of H2O), 30 °C, stirred in a 
carousel tube for 16 h. [b] Yield of isolated product. [c] Using 0.5 mol% C4, at reflux and with the 
addition of MeOH (1 mL). [d] Yield determined by 
1
H-NMR spectroscopy; n.r. = no reaction. 
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3.2.5 TH of other N-heterocycles and imines 
In order to further demonstrate the potential of C4 as a versatile catalyst for the TH 
of a range of heterocycles, rather than a specialised catalyst for a particular class of 
substrates, a range of diverse substrates, including cyclic and acyclic imines and 
other fused heterocycles, were examined. Acridine (10b), neocuproine (10c) and 
quinoxaline (10a) were all reduced to their corresponding products in excellent 
yields, although the latter was exclusively isolated as a mono N-formyl derivative 
(Table 3.9, entries 1-3). Interestingly, 1H-cyclopenta[b]pyridine 10d was reduced at 
the carbocycle ring to give the pyridine 11d (Table 3.9, entry 4). Both the cyclic and 
acyclic imines were fully reduced to give the corresponding amines 11f and 11g, 
respectively, with good yields (Table 3.9, entries 6 and 7). Salsolidine (11f) is 
naturally isolated from the plants of the genus salsola and is a stereoselective 
competitive inhibitor of the enzyme monoamine oxidase.
[19]
 Under the present 
reaction condition pyrazine also resisted the TH with C4 (Table 3.9, entry 5).  
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Table 3.9: TH of other N-heterocycles and imines  
 
Entry
[a]
 Substrate Product Yield (%)
[b]
 
1 
 
 
11a 90 
2 
  
11b 82 
3 
  
11c 96 
4 
  
11d 99 
5 
 
 
11e n.r. 
6
[c]
 
  
11f 98 
7
[d,e]
 
  
11g 90 
[a] Reaction conditions: N-heterocycle or imine (2.5 mmol), C4 (0.1 mol%), HCO2H/HCO2Na 
aqueous solution (pH = 4.5; 3mL; 14.0 mmol of HCO2H and 29.4 mmol of HCO2Na in 2.8 mL of 
H2O), reflux, stirred in a carousel tube for 16 h. [b] Yield of isolated product. [c] Reaction conducted 
at 30 
°
C. [d] Yield determined by 
1
H-NMR spectroscopy. [e] Obtained as a mixture of 60% and 30% 
11g and its N-formyl derivative, respectively; n.r. = no reaction 
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3.2.6 Mechanistic investigations 
The TH of quinolines in an acidic medium has been suggested to proceed by an ionic 
pathway.
[13]
 The initial hydride delivery to the protonated quinoline may occur via 
the 1,4-addition fashion; isomerisation and further reduction via 1,2-addition would 
afford the product (Scheme 3.10). If the reaction is initiated by 1,2-hydride addition, 
the resulting 1,2-dihydroquinoline may not be further reduced; but it may undergo 
dehydrogenation to go back to the starting material or disproportionate.
[20]
 In order to 
gain more insight into the reaction mechanism, a combination of intermediate 
reactions, isotope labelling and stoichiometric reactions were explored. 
 
Scheme 3.10: Suggested possible reaction pathways for the TH of quinolines. 
3.2.6.1 Deuterium labelling 
Deuterium labelling reactions were carried out on the model substrate 2a with C4 at 
30 
°
C in water. Using fully deuterated reagents and solvent, 87%, 94% and 100% 
deuterium incorporation onto the 2, 3 and 4-position of the product was observed, 
respectively (Scheme 3.11, eq. 1). When HCO2Na and HCO2H were used together 
with D2O, 52%, 49%, and 55% deuterium were incorporated onto the 2, 3 and 4-
position of the product, respectively (Scheme 3.11, eq. 2). On the other hand, when 
DCO2D, DCO2Na were used in H2O, only 18%, 0%, and 14% deuterium were 
incorporated onto these positions, respectively (Scheme 3.11, eq. 3). One possible 
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explanation for deuterium (Eq. 2) and hydrogen (Eq. 3) incorporation is that 
following the formation of the iridium hydride/deuteride takes place, the transfer of 
the hydride/deuteride to the substrate is the rate limiting step. This would allow the 
iridium hydride/deuteride to be scrambled with the solvent (Scheme 3.11, eq. 4 and 
5), producing a mixture of iridium hydride and deuteride and consequently the 
partial incorporation of deuterium into the product.
[21]
 The reaction shown in Eq. 3 
also reveals that when H2O was used as the solvent, no deuterium was incorporated 
onto the 3-position. This is consistent with the assumption that there is an acid-
mediated isomerisation reaction between the hydride addition steps (Scheme 3.10). 
 
Scheme 3.11: Deuterium labelling experiments. 
3.2.6.2 Monitoring the reaction by 
1
H-NMR in situ  
Further support to the hydride transfer being the rate limiting was gained by 
monitoring the reduction of the protonated 2a with C4 in situ using 
1
H-NMR 
spectroscopy (Figure 3.1). As noted before, neutral 2a was not reduced with an 
isolated closely-related Ir-H.
[22]
 The reaction was carried out in a NMR tube 
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equipped with a Young’s tap, containing 1 equiv. of C4 and 5 equiv. of 2a.HBF4 in 
d
4
-MeCN (Figure 3.1, spectrum 1). After the addition of 5 equiv. of the F/T, a 
hydride signal was immediately observed at  -15.8 (Spectrum 2). While the signal 
of the product tetrahydroquinoline gradually increased in intensity over time (Spectra 
3 and 4), signals corresponding to the potential intermediates 2a1, 2a2 and 2a3 
(Scheme 3.10) were not observed. Nonetheless the hydride signal remained, which, 
together with the rapid hydride formation, is consistent with the assumption that the 
transfer hydrogenation in question is turnover-limited by the step of hydride transfer. 
 
Figure 3.1: In situ 
1
H-NMR; spectrum 1: C4 and 2a
.
HBF4 (5 equiv.) in d
4
-MeCN; spectrum 2: after 
the addition of F/T (5 equiv.); spectrum 3: after 5 min; spectrum 4: after 30 min. 
3.2.6.3 Reactions of proposed intermediates  
The TH of 2a may yield two distinct intermediates, namely 1,2-dihydroquinoline 
(via 1,2-addition) and 3,4-dihydroquinoline (via 1,4-addition) (Scheme 3.10). To 
gain evidence into their possible involvement in the reduction, a 1:1 mixture of 
dihydroquinoline 2l1 and quinoline 2l was subjected to the standard reaction 
conditions (Scheme 3.12, eq 6). In the presence of C4, only the fully reduced 
4 
3 
2 
1 
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tetrahydroquinoline 3l (100%) was obtained after the reaction. However, in the 
absence of C4, 23% of 3l and 77% of 2l were obtained. And in both cases, no 
starting dihydroquinoline 2l1 was observed after the reaction. These results supports 
the hypothesis that the 1,2-addition product (e.g. 2l1) is consumed via a 
disproportionation mechanism instead of being reduced by the catalysis of C4. 
Further evidence to this hypothesis comes from the observation that when 2l2 was 
used as a substrate, no reaction occurred (Scheme 3.12, eq 7). 
 
Scheme 3.12: Control experiments. 
To probe whether the 1,4-addition  precedes the 1,2-addition in the TH or vice versa, 
a model substrate N-cinnamylidene aniline 12a was subjected to the C4 catalysed 
reduction. Under the standard reaction conditions, a mixture of 13a and 13b (43:57) 
was obtained (Scheme 3.13), indicating that both 1,2- and 1,4-hydride additions are 
likely to happen for quinoline type substrates. 
 
Scheme 3.13: Reaction of N-cinnamylidene aniline with C4 in water. 
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3.2.6.4 Proposed reaction mechanism 
On the basis of the experimental results presented above, a plausible mechanism is 
proposed for the TH of quinolines (Scheme 3.14). C4 reacts with formate to generate 
the active Ir-H species that can react with the 2ax (2-methylquinoline, pKa 5.4) in 
two different pathways. In Pathway 1, 2ax undergoes 1,4-addition to give the 1,4-
dihydroquinoline 2a2, which then isomerises to 2a3. Protonation of 2a3 followed by 
1,2-addition then yields 3a. Pathway 2 involves the 1,2-hydride addition as the first 
step to give 1,2-dihydroquinoline 2a1, which then reduces 2ax to 2a2. Isomerisation 
of the latter affords 2a3, which is finally reduced by 1,2-addition after protonation to 
yield 3a. Whilst the pathway 1 and 2 are both competitive, the rate of each is likely 
to be affected by both steric and electronic effects. 
 
Scheme 3.14: Plausible reaction mechanism for the TH of quinolines catalysed by C4. 
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3.3 Conclusion 
In summary, this chapter demonstrates that a wide variety of N-heterocycles, 
including but not limited to quinolines, isoquinolines, indoles, quinoxalines and 
pyridinium salts, can be effectively reduced using an iridicycle in water. This 
reaction is applicable to large scale synthesis with no need for specialised equipment. 
The use of environmentally benign solvent, renewable hydride donor and easy work-
up and purification provides a significant advantage for industrial applications. To 
the best of our knowledge, this work constitutes the first example of a highly 
versatile homogenous catalyst that can reduce a range of N-heterocycles in water 
under the TH conditions. In addition, iridicycle exhibits great functional group 
tolerance, including highly sensitive boronic acid pinacol ester. 
3.4 Experimental 
3.4.1 General information 
Unless otherwise specified, all reagents were commercially purchased and used 
without further purification. Deionised water was used for the reactions. NMR 
spectra were recorded on a Bruker 400 MHz or 250 MHz NMR spectrometer with 
TMS as the internal standard. Elemental Analysis and Mass Spectrometry Analysis 
were carried out at the Microanalysis Centre of the University of Liverpool. 
Quinolines 2n-t, 2v-x and 2z were prepared according to the reported literature 
procedures.
[23]
 All the data collected for the products were consistent with the 
literature. Compounds 3f, 3n, 3o, 3r-y, 5e, 5f, 7e, 7i and 11a are unknown.  
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3.4.2 Typical reaction procedure for the TH of quinolines 
Quinoline (2.5 mmol) and C4 (1.6 mg, 2.5 x 10
-3
 mmol) were placed in a carousel 
reaction tube. HCO2H/HCO2Na aqueous solution of pH 4.5 (3 mL) was then 
introduced and the mixture was stirred at 30 °C for 14 h. The reaction mixture was 
quenched with saturated sodium bicarbonate solution. The aqueous layer was 
extracted with ethyl acetate (3 x 10 mL) and the combined organic layers were 
washed with brine (20 mL). The organic layer was collected and dried over 
anhydrous sodium sulphate. Filtration, followed by evaporation of the solvent under 
reduced pressure, gave the crude mixture that was purified with flash column 
chromatography to afford the desired 1,2,3,4-tetrahydroquinoline. 
3.4.3 Typical reaction procedure for the TH of isoquinolinium and pyridinium 
salts 
Isoquinolinium or pyridinium (2.5 mmol) and C4 (16 mg, 2.5 x 10
-2
 mmol) were 
placed in a carousel reaction tube. HCO2H/HCO2Na aqueous solution of pH 4.5 (3 
mL) was then introduced and the mixture was stirred at reflux temperature for 24 h 
(36 h for pyridinium). The reaction mixture was quenched with saturated sodium 
bicarbonate solution. The aqueous layer was extracted with ethyl acetate (3 x 10 mL) 
and the combined organic layers were washed with brine (20 mL). The organic layer 
was collected and dried over anhydrous sodium sulphate. Filtration, followed by 
evaporation of the solvent under reduced pressure, gave the crude mixture that was 
purified with flash column chromatography to afford the desired 1,2,3,4-
tetrahydroisoquinoline or piperidine. 
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3.4.4 Typical reaction procedure for the TH of indoles, imines and other N-
heterocycles 
Imine/N-heterocycle (2.5 mmol) and C4 (1.6 mg, 2.5 x 10
-3
 mmol) were placed in a 
carousel reaction tube. HCO2H/HCO2Na aqueous solution of pH 4.5 (3 mL) was 
then introduced (for substrate 8c, 8e and 8f, 1 mL of MeOH was added) and the 
mixture was stirred at 30 °C (or at reflux, refer to the Tables 3.8 and 3.9 for the 
reaction temperature) for 16 h. The reaction mixture was quenched with saturated 
sodium bicarbonate solution. The aqueous layer was extracted with ethyl acetate (3 x 
10 mL) and the combined organic layers were washed with brine (20 mL). The 
organic layer was collected and dried over anhydrous sodium sulphate. Filtration, 
followed by evaporation of the solvent under reduced pressure, gave the crude 
mixture that was purified with flash column chromatography to afford the desired 
product. 
3.4.5 Data of the cyclometalated rhodium complex D4 
 
Complex D4: Red solid; 
1
H NMR (CD2Cl2, 400 MHz, 293 K) δ (ppm): 8.11 (s, 1H), 
8.02 (s, 1H), 7.83 (d, J = 8.3 Hz, 2H), 7.52-7.33 (m, 4H), 7.00 (d, J = 8.5 Hz, 2H), 
3.86 (s, 3H), 2.43 (s, 3H), 1.40 (s, 15H).
 13
C NMR (CD2Cl2, 100 MHz, 293 K) δ 
(ppm): 178.8, 175.5, 175.2, 157.9, 147.5, 143.5, 135.7, 133.5, 130.1, 128.9, 127.6, 
127.2, 126.1, 124.0, 123.8, 113.8, 96.2, 96.1, 55.5, 16.9, 8.5. Anal. calc. for 
C29H31ClRhNO + H2O (%): C, 61.55; H, 5.88; N, 2.47. Found: C, 61.70; H, 5.46; N, 
2.37. 
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3.4.6 Data of 1,2,3,4-tetrahydroquinolines (3a-z) 
 
2-Methyl-1,2,3,4-tetrahydroquinoline, 3a:
[13]
 
1
H NMR (CDCl3, 400 MHz, 298 K) δ 
(ppm): 6.95-6.94 (m, 2H), 6.61-6.58 (m, 1H), 6.47-6.45 (m, 1H), 3.66 (bs, 1H), 3.42-
3.35 (m, 1H), 2.87-2.70 (m, 2H), 1.95-1.88 (m, 1H), 1.63-1.53 (m, 1H), 1.20 (d, J = 
6.3 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 144.8, 129.3, 126.7, 
121.1, 117.0, 114.0, 47.2, 30.2, 26.6, 22.6. HRMS for C10H14N [M+H]
+
: m/z calc., 
148.1121; found, 148.1124. 
 
3-Methyl-1,2,3,4-tetrahydroquinoline, 3b:
[13]
 
1
H NMR (CDCl3, 400 MHz, 298 K) δ 
(ppm): 6.98-6.92 (m, 2H), 6.60 (td, J = 7.3, 1.1 Hz, 1H), 6.47 (d, J = 7.9 Hz, 1H), 
3.82 (bs, 1H), 3.28-3.24 (m, 1H), 2.89 (dd, J = 10.6, 9.7 Hz, 1H), 2.77 (ddd, J = 16.0, 
4.8, 1.8 Hz, 1H), 2.42 (dd, J = 16.0, 10.3 Hz, 1H), 2.11-1.99 (m, 1H), 1.04 (d, J = 6.7 
Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 144.2, 129.5, 126.7, 121.2, 
117.0, 113.9, 48.9, 35.5, 27.2, 19.0. HRMS for C10H14N [M+H]
+
: m/z calc., 
148.1121; found, 148.1125. 
 
4-Methyl-1,2,3,4-tetrahydroquinoline, 3c:
[22]
 
1
H NMR (CDCl3, 400 MHz, 298 K) δ 
(ppm): 7.05 (d, J = 7.5 Hz, 1H), 6.97-6.93 (m, 1H), 6.62 (td, J = 7.4, 1.0 Hz, 1H), 
6.46 (dd, J = 8.0, 0.9 Hz, 1H), 3.79 (bs, 1H), 3.35-3.23 (m, 2H), 2.95-2.86 (m, 1H), 
2.01-1.94 (m, 1H), 1.71-1.63 (m, 1H), 1.28 (d, J = 7.0 Hz, 3H). 
13
C NMR (CDCl3, 
100 MHz, 298 K) δ (ppm): 144.3, 128.5, 126.7, 126.6, 117.0, 114.2, 39.0, 30.3, 29.9, 
22.7. HRMS for C10H14N [M+H]
+
: m/z calc., 148.1121; found, 148.1126. 
 
1,2,3,4-Tetrahydroquinoline, 3d:
[22]
 
1
H NMR (CDCl3, 400 MHz, 298 K) δ (ppm): 
6.97-6.93 (m, 2H), 6.59 (t, J = 7.4 Hz, 1H), 6.46 (d, J = 7.8 Hz, 1H), 3.79 (bs, 1H), 
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3.29 (t, J = 5.4 Hz, 2H), 2.75 (t, J = 6.4 Hz, 2H), 1.96-1.90 (m, 2H). 
13
C NMR 
(CDCl3, 100 MHz, 298 K) δ (ppm): 144.8, 129.5, 126.7, 121.5, 116.9, 114.2, 42.0, 
27.0, 22.2. HRMS for C9H12N [M+H]
+
: m/z calc., 134.0970; found, 134.0974. 
 
2-Phenyl-1,2,3,4-tetrahydroquinoline, 3e:
[13]
 
1
H NMR (CDCl3, 400 MHz, 298 K) δ 
(ppm): 7.40-7.33 (m, 4H), 7.30-7.26 (m, 1H), 7.02-6.99 (m, 2H), 6.65 (td, J = 7.4, 
0.8 Hz, 1H), 6.54 (d, J = 7.7 Hz, 1H), 4.44 (dd, J = 9.4, 3.3 Hz, 1H), 4.05 (bs, 1H), 
2.96-2.88 (m, 1H), 2.73 (dt, J = 16.3, 4.7 Hz, 1H), 2.15-2.09 (m, 1H), 2.04-1.94 (m, 
1H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 144.8, 144.7, 129.3, 128.6, 
127.4, 126.9, 126.6, 120.9, 117.2, 114.0, 56.3, 31.0, 26.4. 
 
3-Methyl-1,2,3,4-tetrahydrobenzo[f]quinoline, 3f: 
1
H NMR (CDCl3, 400 MHz, 298 
K) δ (ppm): 7.72 (d, J = 8.5 Hz, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.49 (d, J = 8.7 Hz, 
1H), 7.43-7.38 (m, 1H), 7.22-7.18 (m, 1H), 6.76 (d, J = 8.8 Hz, 1H), 3.86 (bs, 1H), 
3.48-3.40 (m, 1H), 3.15-3.08 (m, 1H), 3.02-2.94 (m, 1H), 2.15-2.08 (m, 1H), 1.77-
1.67 (m, 1H), 1.27 (d, J = 6.3 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 
141.9, 133.4, 128.4, 127.8, 127.2, 126.3, 121.6, 121.3, 118.2, 111.5, 46.9, 30.1, 22.6, 
22.2. HRMS for C14H16N [M+H]
+
: m/z calc., 198.1280; found, 198.1283. 
 
6-Fluoro-2-methyl-1,2,3,4-tetrahydroquinoline, 3g:
[13]
 
1
H NMR (CDCl3, 400 MHz, 
298 K) δ (ppm): 6.69-6.64 (m, 2H), 6.41-6.37 (m, 1H), 3.57 (bs, 1H), 3.38-3.30 (m, 
1H), 2.86-2.77 (m, 1H), 2.72-2.66 (m, 1H), 1.94-1.88 (m, 1H), 1.60-1.50 (m, 1H), 
1.20 (d, J = 6.2 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 155.5 (d, J = 
234.7 Hz), 141.0 (d, J = 1.7 Hz), 122.5 (d, J = 6.8 Hz), 115.4 (d, J = 21.5 Hz), 114.7 
(d, J = 7.7 Hz), 113.2 (d, J = 22.4 Hz), 47.3, 29.9, 26.7, 22.5. HRMS for C10H13FN 
[M+H]
+
: m/z calc., 166.1027; found, 166.1031. 
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6-Chloro-2-methyl-1,2,3,4-tetrahydroquinoline, 3h:
[13]
 
1
H NMR (CDCl3, 400 MHz, 
298 K) δ (ppm): 6.92-6.88 (m, 2H), 6.38 (d, J = 8.3 Hz, 1H), 3.69 (bs, 1H), 3.41-3.33 
(m, 1H), 2.83-2.65 (m, 2H), 1.94-1.88 (m, 1H), 1.60-1.50 (m, 1H), 1.20 (d, J = 6.3 
Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 143.3, 128.8, 126.5, 122.6, 
121.3, 114.9, 47.1, 29.7, 26.5, 22.5. 
 
6-Bromo-2-methyl-1,2,3,4-tetrahydroquinoline, 3i:
[13]
 
1
H NMR (CDCl3, 400 MHz, 
298 K) δ (ppm): 7.06-7.01 (m, 2H), 6.33 (d, J = 8.5 Hz, 1H), 3.72 (bs, 1H), 3.41-3.33 
(m, 1H), 2.83-2.65 (m, 2H), 1.94-1.88 (m, 1H), 1.59-1.49 (m, 1H), 1.20 (d, J = 6.3 
Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 143.7, 131.7, 129.3, 123.1, 
115.4, 108.3, 47.1, 29.6, 26.4, 22.5. HRMS for C10H13BrN [M+H]
+
: m/z calc., 
226.0226; found, 226.0230. 
 
7-Fluoro-2-methyl-1,2,3,4-tetrahydroquinoline, 3j:
[13]
 
1
H NMR (CDCl3, 400 MHz, 
298 K) δ (ppm): 6.85 (t, J = 7.4 Hz, 1H), 6.27 (td, J = 8.5, 2.5 Hz, 1H), 6.15 (dd, J = 
10.8, 2.5 Hz, 1H), 3.76 (bs, 1H), 3.43-3.35 (m, 1H), 2.80-2.64 (m, 2H), 1.95-1.88 
(m, 1H), 1.60-1.50 (m, 1H), 1.20 (d, J = 6.3 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 
298 K) δ (ppm): 162.1 (d, J = 240.3 Hz), 145.9 (d, J = 10.5 Hz), 130.0 (d, J = 9.9 
Hz), 116.4 (d, J = 2.4 Hz), 103.3 (d, J = 21.5 Hz), 100.1 (d, J = 24.4 Hz), 47.0, 30.0, 
26.0, 22.5. HRMS for C10H13FN [M+H]
+
: m/z calc., 166.1027; found, 166.1030. 
 
8-Chloro-2-methyl-1,2,3,4-tetrahydroquinoline, 3k:
[24]
 
1
H NMR (CDCl3, 250 MHz, 
298 K) δ (ppm): 7.06 (d, J = 7.9 Hz, 1H), 6.86 (d, J = 7.4 Hz, 1H), 6.51 (t, J = 7.7 
Hz, 1H), 4.26 (bs, 1H), 3.53-3.40 (m, 1H), 2.91-2.69 (m, 2H), 1.99-1.89 (m, 1H), 
1.66-1.50 (m, 1H), 1.27 (d, J = 6.3 Hz, 3H). 
13
C NMR (CDCl3, 63 MHz, 298 K) δ 
(ppm): 140.7, 127.4, 126.7, 122.4, 117.8, 116.3, 47.2, 29.6, 26.7, 22.5. 
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2,6-Dimethyl-1,2,3,4-tetrahydroquinoline, 3l:
[13]
 
1
H NMR (CDCl3, 400 MHz, 298 
K) δ (ppm): 6.78-6.76 (m, 2H), 6.40 (d, J = 8.3 Hz, 1H), 3.52 (bs, 1H), 3.39-3.31 (m, 
1H), 2.85-2.76 (m, 1H), 2.71-2.65 (m, 1H), 2.20 (s, 3H), 1.94-1.87 (m, 1H), 1.62-
1.52 (m, 1H), 1.19 (d, J = 6.2 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 
142.4, 129.8, 127.2, 126.3, 121.2, 114.3, 47.3, 30.4, 26.6, 22.6, 20.4. HRMS for 
C11H16N [M+H]
+
: m/z calc., 162.1277; found, 162.1279. 
 
6-Methoxy-2-methyl-1,2,3,4-tetrahydroquinoline, 3m:
[13]
 
1
H NMR (CDCl3, 400 
MHz, 298 K) δ (ppm): 6.60-6.57 (m, 2H), 6.44 (d, J = 8.4 Hz, 1H), 3.72 (s, 3H), 3.47 
(bs, 1H), 3.36-3.29 (m, 1H), 2.88-2.80 (m, 1H), 2.73-2.67 (m, 1H), 1.94-1.88 (m, 
1H), 1.62-1.52 (m, 1H), 1.19 (d, J = 6.3 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 298 
K) δ (ppm): 151.9, 138.9, 122.5, 115.3, 114.7, 112.9, 55.8, 47.5, 30.3, 26.9, 22.6. 
HRMS for C11H16NO [M+H]
+
: m/z calc., 178.1226; found, 178.1229. 
 
6-(Benzyloxy)-2-methyl-1,2,3,4-tetrahydroquinoline, 3n: 
1
H NMR (CDCl3, 400 
MHz, 298 K) δ (ppm): 7.42-7.27 (m, 5H), 6.65-6.63 (m, 2H), 6.43-6.41 (m, 1H), 
4.95 (s, 2H), 3.47 (bs, 1H), 3.35-3.28 (m, 1H), 2.86-2.78 (m, 1H), 2.71-2.65 (m, 1H), 
1.92-1.86 (m, 1H), 1.61-1.51 (m, 1H), 1.18 (d, J = 6.2 Hz, 3H). 
13
C NMR (CDCl3, 
100 MHz, 298 K) δ (ppm): 151.1, 139.2, 137.8, 128.5, 127.7, 127.5, 122.5, 116.0, 
115.2, 114.0, 70.9, 47.5, 30.3, 26.9, 22.6. HRMS for C17H20NO [M+H]
+
: m/z calc., 
254.1545; found, 254.1541. 
 
6-(Allyloxy)-2-methyl-1,2,3,4-tetrahydroquinoline, 3o: 
1
H NMR (CDCl3, 400 MHz, 
298 K) δ (ppm): 6.62-6.59 (m, 2H), 6.43 (d, J = 8.1 Hz, 1H), 6.09-5.99 (m, 1H), 5.38 
(dd, J = 17.3, 1.6 Hz, 1H), 5.24 (dd, J = 10.5, 1.4 Hz, 1H), 4.44 (dt, J = 5.3, 1.4 Hz, 
2H), 3.44 (bs, 1H), 3.37-3.29 (m, 1H), 2.87-2.79 (m, 1H), 2.72-2.66 (m, 1H), 1.94-
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1.88 (m, 1H), 1.62-1.52 (m, 1H), 1.19 (d, J = 6.3 Hz, 3H). 
13
C NMR (CDCl3, 100 
MHz, 298 K) δ (ppm): 150.8, 139.1, 134.0, 122.5, 117.2, 115.9, 115.2, 113.9, 69.7, 
47.5, 30.3, 26.9, 22.6. HRMS for C13H18NO [M+H]
+
: m/z calc., 204.1383; found, 
204.1391. 
 
2-Methyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline, 3p:
[25]
 
1
H NMR (CDCl3, 
400 MHz, 298 K) δ (ppm): 7.18-7.17 (m, 2H), 6.44 (d, J = 8.9 Hz, 1H), 4.03 (bs, 
1H), 3.49-3.41 (m, 1H), 2.86-2.71 (m, 2H), 1.98-1.92 (m, 1H), 1.61-1.52 (m, 1H), 
1.23 (d, J = 6.3 Hz, 3H). 
19
F NMR (CDCl3, 376 MHz, 298 K) δ (ppm): -60.8. 
13
C 
NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 147.3, 126.3 (q, J = 3.7 Hz), 125.0 (q, J = 
270.3 Hz), 124.0 (q, J = 3.8 Hz), 120.3, 118.1 (q, J = 32.3 Hz), 112.9, 47.1, 29.4, 
26.4, 22.4. HRMS for C11H13F3N [M+H]
+
: m/z calc., 216.0995; found, 216.1000. 
 
N,N-Diethyl-2-methyl-1,2,3,4-tetrahydroquinoline-6-carboxamide, 3r: 
1
H NMR 
(CDCl3, 400 MHz, 298 K) δ (ppm): 7.05 (s, 1H), 7.01 (d, J = 8.2 Hz, 1H), 6.41 (d, J 
= 8.2 Hz, 1H), 3.97 (bs, 1H), 3.45-3.40 (m, 5H), 2.86-2.69 (m, 2H), 1.97-1.91 (m, 
1H), 1.62-1.53 (m, 1H), 1.22 (d, J = 6.3 Hz, 3H), 1.17 (d, J = 7.0 Hz, 6H). 
13
C NMR 
(CDCl3, 100 MHz, 298 K) δ (ppm): 172.0, 145.7, 128.4, 125.6, 125.3, 120.5, 112.9, 
47.2, 29.8, 26.4, 22.5, 13.6 (br), one carbon signal is not observed. HRMS for 
C15H23N2O [M+H]
+
: m/z calc., 247.1805; found, 247.1812. 
 
Methyl 2-methyl-1,2,3,4-tetrahydroquinoline-6-carboxylate, 3s: 
1
H NMR (CDCl3, 
400 MHz, 298 K) δ (ppm): 7.66-7.64 (m, 2H), 6.40 (d, J = 8.9 Hz, 1H), 4.26 (bs, 
1H), 3.83 (s, 3H), 3.52-3.44 (m, 1H), 2.86-2.74 (m, 2H), 1.99-1.93 (m, 1H), 1.62-
1.52 (m, 1H), 1.24 (d, J = 6.3 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 
167.5, 148.6, 131.1, 129.1, 119.8, 117.7, 112.6, 51.5, 47.2, 29.4, 26.3, 22.4. HRMS 
for C12H16NO2 [M+H]
+
: m/z calc., 206.1176; found, 206.1182. 
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2-Methyl-1,2,3,4-tetrahydroquinoline-6-carboxylic acid, 3t: 
1
H NMR (CDCl3, 400 
MHz, 298 K) δ (ppm): 7.72-7.69 (m, 2H), 6.40 (d, J = 9.0 Hz, 1H), 3.54-3.46 (m, 
1H), 2.86-2.75 (m, 2H), 2.00-1.93 (m, 1H), 1.62-1.52 (m, 1H), 1.24 (d, J = 6.3 Hz, 
3H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 172.1, 149.4, 131.8, 129.9, 
119.7, 116.5, 112.5, 47.2, 29.4, 26.3, 22.4. HRMS for C11H14NO2 [M+H]
+
: m/z calc., 
192.1019; found, 192.1024. 
 
2-Methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,4-
tetrahydroquinoline, 3u: 
1
H NMR (CDCl3, 400 MHz, 298 K) δ (ppm): 7.43-7.41 (m, 
2H), 6.43 (d, J = 7.7 Hz, 1H), 3.92 (bs, 1H), 3.47-3.39 (m, 1H), 2.85-2.70 (m, 2H), 
1.95-1.89 (m, 1H), 1.61-1.51 (m, 1H), 1.31 (s, 12H), 1.20 (d, J = 6.3 Hz, 3H). 
13
C 
NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 147.5, 136.1, 133.8, 119.9, 113.0, 83.1, 
47.1, 29.9, 26.3, 24.8, 22.6, one carbon signal is not observed. HRMS for 
C16H24BNO2 [M]
+
: m/z calc., 273.2009; found, 273.2005. 
 
6-(Furan-2-yl)-2-methyl-1,2,3,4-tetrahydroquinoline, 3v: 
1
H NMR (CDCl3, 400 
MHz, 298 K) δ (ppm): 7.37-7.36 (m, 1H), 7.29-7.27 (m, 2H), 6.48 (d, J = 8.9 Hz, 
1H), 6.41-6.38 (m, 2H), 3.90 (bs, 1H), 3.47-3.39 (m, 1H), 2.90-2.73 (m, 2H), 1.98-
1.92 (m, 1H), 1.65-1.55 (m, 1H), 1.23 (d, J = 6.3 Hz, 3H). 
13
C NMR (CDCl3, 100 
MHz, 298 K) δ (ppm): 155.0, 144.2, 140.6, 125.0, 122.9, 121.1, 120.4, 114.0, 111.4, 
101.8, 47.3, 30.0, 26.6, 22.5. HRMS for C14H16NO [M+H]
+
: m/z calc., 214.1226; 
found, 214.1230. 
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2-Methyl-6-(thiophen-2-yl)-1,2,3,4-tetrahydroquinoline, 3w: 
1
H NMR (CDCl3, 400 
MHz, 298 K) δ (ppm): 7.24-7.21 (m, 2H), 7.13-7.10 (m, 2H), 7.01-6.99 (m, 1H), 
6.45 (d, J = 8.9 Hz, 1H), 3.80 (bs, 1H), 3.46-3.38 (m, 1H), 2.89-2.72 (m, 2H), 1.97-
1.91 (m, 1H), 1.64-1.54 (m, 1H), 1.21 (d, J = 6.3 Hz, 3H). 
13
C NMR (CDCl3, 100 
MHz, 298 K) δ (ppm): 145.6, 144.4, 127.8, 127.1, 124.8, 123.5, 122.6, 121.2, 120.7, 
114.1, 47.3, 30.0, 26.6, 22.6. HRMS for C14H16NS [M+H]
+
: m/z calc., 230.0998; 
found, 230.1005. 
 
2-Methyl-6-(pyridin-4-yl)-1,2,3,4-tetrahydroquinoline, 3x: 
1
H NMR (CDCl3, 400 
MHz, 298 K) δ (ppm): 8.53 (d, J = 6.0 Hz, 2H), 7.42 (d, J = 6.2 Hz, 2H), 7.33-7.27 
(m, 2H), 6.53 (d, J = 8.8 Hz, 1H), 3.99 (bs, 1H), 3.48-3.46 (m, 1H), 2.88-2.84 (m, 
1H), 2.83-2.84 (m, 1H), 1.97-1.93 (m, 1 H), 1.63-1.60 (m, 1H), 1.24 (d, J = 6.4 Hz, 
3H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 150.0, 148.4, 145.9, 127.8, 
125.8, 125.4, 121.2, 120.3, 114.1, 47.2, 29.8, 26.6, 22.5. HRMS for C15H17N2 
[M+H]
+
: m/z calc., 225.1392; found, 225.1397. 
 
2,5,7-Trimethyl-1,2,3,4-tetrahydroquinoline, 3y: 
1
H NMR (CDCl3, 250 MHz, 298 
K) δ (ppm): 6.35 (s, 1H), 6.20 (s, 1H), 3.61 (bs, 1H), 3.38-3.25 (m, 1H), 2.72-2.49 
(m, 2H), 2.18 (s, 3H), 2.13 (s, 3H), 2.05-1.92 (m, 1H), 1.65-1.49 (m, 1H), 1.19 (d, J 
= 6.3 Hz, 3H). 
13
C NMR (CDCl3, 63 MHz, 298 K) δ (ppm): 144.8, 136.9, 135.8, 
120.0, 116.9, 112.7, 46.7, 30.6, 23.6, 22.5, 21.0, 19.3. 
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2-Methyl-4-phenyl-1,2,3,4-tetrahydroquinoline, 3z:
[26]
 
1
H NMR (CDCl3, 400 MHz, 
298 K) δ (ppm): 7.33-7.30 (m, 2H), 7.25-7.20 (m, 3H), 6.98-6.95 (m, 1H), 6.59-6.57 
(m, 1H), 6.53-6.49 (m, 2H), 4.14 (dd, J = 12.5, 5.5 Hz, 1H), 3.84 (bs, 1H), 3.64-3.56 
(m, 1H), 2.13 (ddd, J = 12.9, 5.5, 2.3 Hz, 1H), 1.88-1.79 (m, 1H), 1.23 (d, J = 6.2 Hz, 
3H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 145.9, 145.2, 129.7, 128.7, 
128.5, 127.1, 126.4, 124.9, 117.4, 114.1, 47.7, 44.6, 41.2, 22.6. HRMS for C16H18N 
[M+H]
+
: m/z calc., 224.1434; found, 224.1443. 
3.4.7 Data of 1,2,3,4-tetrahydroisoquinolines (5a-5f) and piperidines (7a-7j) 
 
2-Ethyl-1-phenyl-1,2,3,4-tetrahydroisoquinoline, 5a:
[27]
 
1
H NMR (CDCl3, 400 
MHz, 298 K) δ (ppm): 7.31-7.22 (m, 5H), 7.12-7.06 (m, 2H), 6.99-6.96 (m, 1H), 
6.68 (d, J = 7.8 Hz, 1H), 4.58 (s, 1H), 3.21-3.16 (m, 1H), 3.14-3.08 (m, 1H), 2.88-
2.82 (m, 1H), 2.66-2.57 (m, 2H), 2.40-2.31 (m, 1H), 1.04 (t, J = 7.1 Hz, 3H). 
13
C 
NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 144.3, 138.7, 134.8, 129.7, 128.9, 128.4, 
128.2, 127.1, 125.8, 125.6, 68.0, 48.2, 46.7, 29.1, 11.5. HRMS for C17H20N [M+H]
+
: 
m/z calc., 238.1596; found, 238.1599. 
 
2-Ethyl-1,2,3,4-tetrahydroisoquinoline, 5b:
[28]
 
1
H NMR (CDCl3, 400 MHz, 298 K) 
δ (ppm): 7.14-6.99 (m, 4H), 3.62 (s, 2H), 2.92 (t, J = 5.9 Hz, 2H), 2.73 (t, J = 5.9 Hz, 
2H), 2.58 (q, J = 7.1 Hz, 2H), 1.19 (t, J = 7.2 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz, 
298 K) δ (ppm): 134.8, 134.3, 128.6, 126.6, 126.1, 125.6, 55.8, 52.2, 50.6, 29.1, 
12.4. 
 
2-Ethyl-6-methyl-1,2,3,4-tetrahydroisoquinoline, 5e: 
1
H NMR (CDCl3, 250 MHz, 
298 K) δ (ppm): 6.91 (bs, 3H), 3.52 (s, 2H), 2.87 (t, J = 5.9 Hz, 2H), 2.71 (t, J = 5.9 
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Hz, 2H), 2.56 (q, J = 7.2 Hz, 2H), 2.28 (s, 3H), 1.18 (t, J = 7.2 Hz, 3H). 
13
C NMR 
(CDCl3, 100 MHz, 298 K) δ (ppm): 135.5, 134.1, 131.8, 129.1, 126.5, 126.4, 55.6, 
52.2, 50.8, 29.1, 21.0, 12.4. HRMS for C12H18N [M+H]
+
: m/z calc., 176.1439; 
found, 176.1442. 
 
6-Bromo-2-ethyl-1,2,3,4-tetrahydroisoquinoline, 5f: 
1
H NMR (CDCl3, 400 MHz, 
298 K) δ (ppm): 7.38 (t, J = 4.6 Hz, 1H), 6.99 (d, J = 4.9 Hz, 2H), 3.61 (s, 2H), 2.87 
(t, J = 6.0 Hz, 2H), 2.75 (t, J = 6.0 Hz, 2H), 2.58 (q, J = 7.2 Hz, 2H), 1.19 (t, J = 7.1 
Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 137.4, 134.2, 130.1, 126.9, 
125.8, 125.2, 55.9, 51.9, 50.7, 30.3, 12.4. 
 
1-Benzyl-2-phenylpiperidine, 7a:
[14]
 
1
H NMR (CDCl3, 400 MHz, 298 K) δ (ppm): 7.47-
7.20 (m, 10H), 3.78 (d, J = 13.5 Hz, 1H), 3.12 (d, J = 9.4 Hz, 1H), 3.00-2.81 (m, 
2H), 2.03-1.87 (m, 1H), 1.78 (d, J = 12.5 Hz, 2H), 1.71-1.52 (m, 3H), 1.37 (td, J = 
8.4, 3.8 Hz, 1H). 13C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 128.8, 128.5, 128.0, 
127.5, 126.9, 126.6, 69.2, 59.7, 53.3, 36.9, 25.9, 25.2. (2 C signals not observed due 
to low intensity). HRMS for C18H22N [M+H]
+
: m/z calc., 252.1752; found, 252.1753. 
 
Diphenyl(piperidin-2-yl)methanol, 7b:
[29]
 
1
H NMR (CDCl3, 400 MHz, 298 K) δ (ppm): 
7.36-7.32 (m, 11 H), 4.87 (bs, 1H), 2.58 (t, J = 7.3 Hz, 2H), 2.44 (q, J = 6.6 Hz, 1H), 
2.30 (t, J = 7.3 Hz, 2H), 1.45 (quin, J = 7.5 Hz, 2H), 1.32-1.25 (m, 2H). 13C NMR 
(CDCl3, 100 MHz, 298 K) δ (ppm): 141.6, 128.5, 128.2, 128.1, 85.6, 52.6, 47.1, 38.1, 
25.6, 22.2. 
 
Benzyl ((1-benzylpiperidin-2-yl)methyl)carbamate, 7c:
[14]
 
1
H NMR (CDCl3, 400 MHz, 298 
K) δ (ppm): 7.33-7.15 (m, 10H), 5.33 (bs, 1H), 5.09 (s, 2H), 3.98 (d, J = 13.5 Hz, 1H), 
3.54-3.42 (m, 1H), 3.37-3.26 (m, 1 H), 3.20 (d, J = 13.5 Hz, 1H), 2.88-2.73 (m, 1H), 
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2.47-2.31 (m, 1H), 2.12-1.94 (m, 1H), 1.77-1.59 (m, 2H), 1.56-1.45 (m, 2H), 1.45-
1.22 (m, 2H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 161.1, 156.8, 139.0, 
136.8, 128.8, 128.5, 128.3, 127.8, 126.9, 66.6, 59.3, 57.7, 51.8, 42.7, 28.8, 24.8, 
23.7. HRMS for C21H27N2O2 [M+H]
+
: m/z calc., 339.2073; found, 339.2066. 
 
Tert-butyl ((1-benzylpiperidin-2-yl)methyl)carbamate, 7d:
[14]
 
1
H NMR (CDCl3, 400 
MHz, 298 K) δ (ppm): 7.33-7.24 (m, 5H), 5.05 (bs, 1H), 4.00 (d, J = 13.5 Hz, 1H), 
3.44-3.41 (m, 1H), 3.28-3.20 (m, 2H), 2.83-2.80 (m, 1H), 2.41-2.40 (m, 1H), 2.06-
2.01 (m, 1H), 1.72-1.63 (m, 2H), 1.54-1.26 (m, 13H). 
13
C NMR (CDCl3, 100 MHz, 
298 K) δ (ppm): 156.4, 139.1, 128.9, 128.3, 126.9, 79.0, 59.5, 57.6, 51.8, 42.2, 28.9, 
28.5, 24.7, 23.7. HRMS for C18H29N2O2 [M+H]
+
: m/z calc., 305.2229; found, 
305.2231. 
 
1-Benzyl-2-(4-methoxyphenyl)piperidine, 7e: 
1
H NMR (CDCl3, 400 MHz, 298 K) δ 
(ppm): 7.43-7.33 (m, J = 8.2 Hz, 2H), 7.32-7.13 (m, 5H), 6.92-6.79 (m, J = 8.4 Hz, 
2H), 3.85-3.66 (m, 4H), 3.05 (dd, J = 2.4, 11.0 Hz, 1H), 2.95 (d, J = 11.5 Hz, 1H), 
2.78 (d, J = 13.7 Hz, 1H), 1.97-1.86 (m, 1H), 1.81-1.71 (m, 2H), 1.66-1.52 (m, 3H), 
1.42-1.28 (m, 1H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 158.5, 139.9, 
137.8, 128.7, 128.4, 128.0, 126.5, 113.9, 68.5, 59.7, 55.3, 53.5, 37.1, 26.1, 25.3. 
 
1,4-Dibenzyl-1,2,3,6-tetrahydropyridine, 7h:
[14]
 
1
H NMR (CDCl3, 400 MHz, 298 K) 
δ (ppm): 7.35-7.15 (m, 10 H), 5.39-5.34 (m, 1H), 3.57 (s, 2H), 3.28 (s, 2H), 3.00-
2.98 (m, 2H), 2.53 (t, J = 5.8 Hz, 2H), 2.08-2.02 (m, 2H). 
13
C NMR (CDCl3, 100 
MHz, 298 K) δ (ppm): 139.5, 135.9, 129.3, 129.1, 128.7, 128.3, 128.2, 127.1, 126.0, 
124.2, 62.7, 52.8, 49.8, 43.5, 30.9. HRMS for C19H22N [M+H]
+
: m/z calc., 264.1747; 
found, 264.1753. 
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Isolated as 9:1 mixture; 1-Benzyl-4-(trifluoromethyl)piperidine, 7i: 
1
H NMR 
(CDCl3, 400 MHz, 298 K) δ (ppm): 7.33-7.23 (m, 5H), 3.50 (s, 2H), 2.97-2.94 (m, 
2H), 2.02-1.90 (m, 3H), 1.82-1.79 (m, 2H), 1.68-1.58 (m, 2H). 
13
C NMR (CDCl3, 
100 MHz, 298 K) δ (ppm): 138.2, 129.0, 128.3, 127.8 (q, J = 278.0 Hz), 127.1, 63.1, 
52.4, 40.4 (q, J = 27.2 Hz), 24.7 (q, J = 2.6 Hz). HRMS for C13H17F3N [M+H]
+
: m/z 
calc., 244.1313; found, 244.1311. 1-Benzyl-4-(trifluoromethyl)-1,2,3,6-
tetrahydropyridine, 7i-1:
[14]
 
1
H NMR (CDCl3, 400 MHz, 298 K) δ (ppm): 7.33-7.23 
(m, 5H), 6.27-6.23 (m, 1H), 3.61 (s, 2H), 3.09-3.06 (m, 2H), 2.62 (t, J = 5.7 Hz, 2H), 
2.30-2.27 (m, 2H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 137.8, 128.6 (q, J 
= 44.3 Hz), 128.4, 128.3, 127.3, 127.2 (q, J = 28.1 Hz), 123.5 (q, J = 272.0 Hz), 62.3, 
51.5, 48.5, 23.2. HRMS for C13H15F3N [M+H]
+
: m/z calc., 242.1157; found, 
242.1154. 
 
Ethyl 1-benzylpiperidine-4-carboxylate, 7j:
[30]
 
1
H NMR (CDCl3, 400 MHz, 298 K) δ 
(ppm): 7.32-7.22 (m, 5H), 4.12 (q, J = 7.1 Hz, 2H), 3.49 (s, 2H), 2.89-2.81 (m, 2H), 
2.33-2.21 (m, 1H), 2.07-1.97 (m, 2H), 1.90-1.72 (m, 4H), 1.24 (t, J = 7.1 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 175.2, 138.4, 129.0, 128.2, 126.9, 
63.2, 60.2, 52.9, 41.2, 28.3, 14.2. HRMS for C15H22NO2 [M+H]
+
: m/z calc., 
248.1651; found, 248.1647. 
3.4.8 Data of indolines and other saturated N-heterocycles 
 
Indoline, 9a:
[22]
 
1
H NMR (CDCl3, 400 MHz, 298 K) δ (ppm): 7.11 (d, J = 7.2 Hz, 1H), 7.01 
(t, J = 7.6 Hz, 1H), 6.70 (t, J = 7.4 Hz, 1H), 6.64 (d, J = 7.7 Hz, 1H), 3.73 (bs, 1H), 3.54 (t, J 
= 8.4 Hz, 2H), 3.02 (t, J = 8.4 Hz, 2H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 151.6, 
129.3, 127.2, 124.6, 118.7, 109.4, 47.3, 29.9. HRMS for C8H10N [M+H]
+
: m/z calc., 
120.0813; found, 120.0817. 
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5-Methoxyindoline, 9b:
[22]
 
1
H NMR (CDCl3, 400 MHz, 298 K) δ (ppm): 6.75 (s, 1H), 6.59 
(d, J = 1.4 Hz, 2H), 3.74 (s, 3H), 3.53 (t, J = 8.3 Hz, 2H), 3.35 (bs, 1H), 3.01 (t, J = 8.3 Hz, 
2H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 153.6, 145.3, 131.2, 112.2, 111.6, 110.1, 
56.0, 47.8, 30.5. HRMS for C9H12NO [M+H]
+
: m/z calc., 150.0919; found, 150.0926. 
 
2-Methylindoline, 9d:
[22]
 
1
H NMR (CDCl3, 400 MHz, 298 K) δ (ppm): 7.07 (d, J = 7.3 Hz, 
1H), 7.00 (t, J = 7.6 Hz, 1H), 6.68 (t, J = 7.4 Hz, 1H), 6.59 (d, J = 7.7 Hz, 1H), 4.02-3.94 (m, 
1H), 3.67 (bs, 1H), 3.13 (dd, J = 15.4, 8.5 Hz, 1H), 2.63 (dd, J = 15.4, 7.8 Hz, 1H), 1.28 (d, J 
= 6.2 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 151.0, 128.9, 127.2, 124.7, 
118.5, 109.2, 55.2, 37.8, 22.3. HRMS for C9H12N [M+H]
+
: m/z calc., 134.0970; found, 
134.0972. 
 
5-Chloro-2-methylindoline, 9e:
[31]
 
1
H NMR (CDCl3, 400 MHz, 298 K) δ (ppm): 7.01 (s, 
1H), 6.95 (dd, J = 8.2, 2.0 Hz, 1H), 6.49 (d, J = 8.2 Hz, 1H), 4.04-3.96 (m, 1H), 3.69 (bs, 
1H), 3.12 (dd, J = 15.6, 8.6 Hz, 1H), 2.61 (dd, J = 15.7, 7.7 Hz, 1H), 1.27 (d, J = 6.3 Hz, 
3H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 149.5, 130.8, 127.0, 124.9, 123.0, 109.8, 
55.6, 37.6, 22.2. HRMS for C9H11ClN [M+H]
+
: m/z calc., 168.0580; found, 168.0581. 
 
3,4-Dihydroquinoxaline-1(2H)-carbaldehyde, 11a: 
1
H NMR (CDCl3, 400 MHz, 298 K) δ 
(ppm): 8.73 (s, 1H), 7.06 (dd, J = 8.0, 1.2 Hz, 1H), 7.00 (td, J = 7.7, 1.4 Hz, 1H), 6.74-6.67 
(m, 1H), 6.64 (dd, J = 8.0, 1.4 Hz, 1H), 4.05 (bs, 1H), 3.92-3.86 (m, 2H), 3.41 (t, J = 4.8 Hz, 
2H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 160.1, 136.5, 125.9, 123.7, 117.9, 
117.7, 115.1, 41.2, 37.3.  
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9,10-Dihydroacridine, 11b:
[13]
 
1
H NMR (CDCl3, 400 MHz, 298 K) δ (ppm): 7.15-6.99 (m, 
4H), 6.85 (td, J = 7.4, 1.0 Hz, 2H), 6.66 (d, J = 7.8 Hz, 2H), 5.94 (bs, 1H), 4.05 (s, 2H). 
13
C 
NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 140.1, 128.6, 127.0, 120.7, 120.1, 113.4, 31.4. 
 
2,9-Dimethyl-1,2,3,4-tetrahydro-1,10-phenanthroline, 11c:
[32]
 
1
H NMR (CDCl3, 400 MHz, 
298 K) δ (ppm): 7.88 (d, J = 8.3 Hz, 1H), 7.16 (d, J = 8.3 Hz, 1H), 7.09 (d, J = 8.1 Hz, 1H), 
6.94 (d, J = 8.1 Hz, 1H), 5.84 (bs, 1H), 3.60-3.55 (m, 1H), 3.03-2.95 (m, 1H), 2.89-2.82 (m, 
1H), 2.68 (s, 3H), 2.06-2.02 (m, 1H), 1.77-1.67 (m, 1H), 1.37 (d, J = 6.3 Hz, 3H). 
13
C NMR 
(CDCl3, 100 MHz, 298 K) δ (ppm): 155.8, 140.1, 136.8, 136.0, 127.8, 125.3, 121.3, 116.6, 
113.3, 46.6, 30.0, 26.7, 25.2, 22.5. HRMS for C14H17N2 [M+H]
+
: m/z calc., 213.1386; found, 
213.1393. 
 
6,7-Dihydro-5H-cyclopenta[b]pyridine, 11d:
[33]
 
1
H NMR (CDCl3, 250 MHz, 298 K) δ 
(ppm): 8.32 (d, J = 4.8 Hz, 1H), 7.48 (dd, J = 7.5, 0.9 Hz, 1H), 7.01 (dd, J = 7.5, 5.0 Hz, 1H), 
3.04-2.90 (m, 4H), 2.12 (pen, J = 7.5 Hz, 2H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 
165.6, 147.4, 136.8, 132.0, 120.9, 34.2, 30.7, 23.0. HRMS for C8H10N [M+H]
+
: m/z calc., 
120.0813; found, 120.0811. 
 
6,7-Dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline, 11f:
[34]
 
1
H NMR (CDCl3, 400 
MHz, 298 K) δ (ppm): 6.63 (s, 1H), 6.57 (s, 1H), 4.05 (m, 1H), 3.86 (s, 3H), 3.85 (s, 3H), 
3.28-3.23 (m, 1H), 3.03-2.97 (m, 1H), 2.83-2.73 (m, 1H), 2.68-2.62 (m, 1H), 1.84 (bs, 1H), 
1.44 (d, J = 6.6 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): 147.3, 147.2, 132.4, 
126.8, 111.7, 109.0, 56.0, 55.9, 51.2, 41.8, 29.6, 22.9. HRMS for C12H18NO2 [M+H]
+
: m/z 
calc., 208.1332; found, 208.1336. 
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4.1 Introduction 
Primary amines are important motifs in organic compounds because of the presence 
of this functional group in numerous bioactive molecules and their widespread 
pharmaceutical applications (Scheme 4.1).
[1]
 Hence, the efficient and economical 
production of primary amines is of high priority.
[2]
  
 
Scheme 4.1: Examples of drugs containing primary amines. 
There are several methods with which these amines can be synthesised. Typical 
examples include the reduction of nitriles, amides and nitro compounds,
[3]
 alkylation 
of ammonia with organic halides,
[4]
  and hydroamination of alkenes.
[5]
 However, one 
of the most desired and convenient ways of synthesising primary amines is by direct 
reductive amination (DRA),
[6-8]
 in which a carbonyl group is condensed with an 
ammonia source and subsequently reduced in situ without the need of isolating the 
often unstable imine intermediate (Scheme 4.2). A well-known example is the 
classic Leuckart-Wallach reaction.
[9]
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Scheme 4.2: General scheme of direct reductive amination (DRA). 
Reducing agents such as pyridine borane, NaBH3CN and NaBH(OAc)3 are 
commonly employed in the DRA process.
[10]
 However, for successful, complete 
DRA, excess amount of these boron reducing agents is often required. NaBH3CN is 
highly toxic and the final product is usually contaminated with cyanide. 
NaBH(OAc)3 is poorly soluble in most commonly used organic solvents and 
pyridine borane, on the other hand, can be unsafe to use on industrial scales due to its 
propensity to violently decompose.
[11]
 Heterogeneous catalysts have also been 
widely used in DRA;
[12]
 however poor chemoselectivity limits their performance. In 
this context, a homogeneously catalysed DRA would be of great interest. Indeed, a 
lot of efforts have been made in developing homogeneous organocatalytic,
[13]
 
hydrogenative
[14]
 and transfer hydrogenative
[8,15]
 catalytic systems for DRA in the 
past few years. However, they are mainly directed to the production of secondary 
and tertiary amines. In terms of primary amines, DRA reactions have been much less 
explored.
[16-18]
 
The first successful hydrogenative homogeneous metal catalysed DRA with 
ammonia was reported by Beller and co-workers.
[16]
 Although high selectivity was 
achieved towards primary amines formation, high temperatures and pressures were 
required (135 °C, 65 bar H2). Most of the reported reactions were conducted with 
aromatic aldehydes and poor yields were obtained when aliphatic amines were used. 
Kadyrov and co-workers also described the use of hydrogenative DRA with 
ammonia. However, the selectivity towards primary amine formation (versus 
Chapter 4  
145 
 
alcohol) and the yields obtained were relatively poor.
[17]
 Subsequently, 
enantioselective DRA of β-keto amides and β-keto esters were also reported, albeit 
requiring high pressures of H2.
[18] 
One way of overcoming these problems would be the transfer-hydrogenative DRA, 
by using a hydrogen source other than hydrogen gas. This is an operationally simple 
and versatile method for reduction, avoiding the need for high-pressure reactors that 
are typically required for hydrogenation.
[11,19]
 The Leuckart-Wallach reaction uses 
formic acid as the reductant and no catalyst. However, it requires high temperatures 
and is poorly chemoselective.
[9]
 Despite the huge potential of catalytic DRA, only a 
few examples have been reported for the synthesis of primary amines by 
homogeneous metal-catalysed transfer hydrogenative DRA.
[20-23]
  
The first successful example of such a DRA with HCO2NH4 was reported by 
Kitamura and co-workers (Scheme 4.3).
[20]
 The reaction conditions were milder (low 
temperature) than those used in the hydrogenative DRA and the catalyst was also 
effective in the DRA of α-keto acids. The substrate scope was, however, not 
satisfactory, and the selectivity towards primary amines (versus ketone reduction and 
N-alkylation) was still an issue. Subsequently, Kadyrov and co-workers reported the 
enantioselective DRA with HCO2NH4 (Scheme 4.4).
[21]
 The use of additional NH3 
was found to be crucial to enhance the enantioselectivity. High yields and 
enantioselectivities were only achieved in the case of aromatic ketones and inferior 
results were obtained when examples of aliphatic ketones were attempted. In 
addition, the selectivity towards primary amines was low, as N-formyl derivatives 
were obtained as the major products, which subsequently had to be hydrolysed. Ogo 
and co-workers reported a water-soluble catalyst that enabled DRA of α-keto acids 
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under aqueous conditions (Scheme 4.5).
[23]
 Optimal pH of 5 was critical for the 
selective synthesis of α-amino acids. 
 
Scheme 4.3: Rhodium catalysed transfer hydrogenative DRA. 
 
Scheme 4.4: Ruthenium catalysed transfer hydrogenative DRA. 
 
Scheme 4.5: Iridium catalysed transfer hydrogenative DRA under aqueous condition. 
Although the few reports above have described the synthesis of primary amines by 
DRA, the results are still far from satisfactory. From the literature, we can highlight 
some major issues for both hydrogenative and transfer-hydrogenative DRA:  
1) Substrate scope is limited, especially for ketones with additional functional 
groups. 
2) Selectivity towards primary amine is still a major challenge. 
3) Catalysts capable of the DRA of aliphatic ketones are highly desirable.  
4) In terms of economy, a robust, versatile catalyst for the synthesis of primary 
amines by DRA is of high priority.  
Thus, developing a catalyst that overcomes these issues would be of great interest. 
Following the successful exploration of cyclometalated Ir(III) complexes in the 
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transfer hydrogenation of -substituted ketones and N-Heterocycles in water, we 
report in this chapter that such complexes are also highly versatile and 
chemoselective for the synthesis of primary amines by direct reductive amination.
[24]
 
4.2 Results and discussion 
4.2.1 Optimisation of reaction conditions 
Aiming to find a robust catalyst for the DRA concerned, a range of complexes C1-
C12 (Scheme 4.6) were firstly prepared. These complexes are diverse in both the 
conjugation and electronic property of the aromatic rings coordinated to the iridium 
metal.  
 
Scheme 4.6: Cyclometalated iridium complexes examined in this chapter. 
In this study, 2-acetonaphthone was chosen as a model substrate for the optimisation 
of reaction conditions. Initial reduction experiments were carried out at an S/C ratio 
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of 1000:1, by using 10 equivalents of HCO2NH4 and temperature of 80 °C. The 
results are summarised in Table 4.1. Only 6% conversion was obtained when the 
reductive amination was carried out in the presence of the iridium dimer [Cp*IrCl2]2. 
Catalyst C8, bearing no substituents on the phenyl rings afforded 36% conversion 
with a high selectivity towards the primary amine 2a (28% relative to the starting 
1a); however, the byproducts alcohol (3a), secondary amine (4a) and N-formyl (5a) 
were also observed in 5, 1 and 2% yields, respectively. These byproducts are 
common in metal-catalysed DRA reactions, although the later N-formyl derivative 
could be converted into the desired primary amine by one additional step of 
hydrolysis. Catalysts or reaction conditions disfavouring the production of these 
byproducts, especially alcohol and secondary amine, would be highly beneficial. 
Catalyst C9 and C1, with a meta-NO2 and para-NO2 group (with respect to imine) 
on the ligand did not improve the activity (Table 4.1, entries 3 and 4). When the 
OMe group was replaced with a more electron-donating –NMe2 group, the activity 
decreased (C10; Table 4.1, entry 5). Since the amino group might get protonated, the 
electron donating ability of the NMe2 probably decreases. Interestingly, catalyst 
C11, with an electron-rich OMe group at the meta-position significantly improved 
the catalytic activity, giving a 70% conversion (64% primary amine) in 4 h (Table 
4.1, entry 6). The result was slightly improved by introducing another methoxy 
group at the para-position also (C12; Table 4.1, entry 7). Gratifyingly, 98% 
conversion (90% primary amine) was achieved when catalyst C2, which contained a 
1,3-dioxol group on the phenyl ring was used (Table 4.1, entry 8). Other aromatic 
rings, such as naphthyl, phenanthrenyl and anthracenyl were also targeted. To our 
delight, catalyst C4 which contains a naphthyl ring gave excellent results, with 99% 
conversion and a very high selectivity towards primary amines (Table 4.1, entry 10). 
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Table 4.1: Optimising reaction conditions of DRA 
 
Entry
[a]
 Catalyst Solvent Conv. (%)
[b]
 2a
[b]
 3
[b]
 4
[b]
 5
[b]
 
1 [Cp*IrCl2]2 MeOH 6 - 1 - 5 
2 C8 MeOH 36 28 5 1 2 
3 C9 MeOH 9 5 1 1 2 
4 C1 MeOH  38 35 - 1 2 
5 C10 MeOH 12 7 3 1 1 
6 C11 MeOH 70 64 2 2 2 
7 C12 MeOH 86 79 2 2 3 
8 C2 MeOH 98 90 3 2 3 
9 C7 MeOH 42 34 4 1 3 
10 C4 MeOH 99 94 1 2 2 
11
[c]
 C4 MeOH 54 53 - - 1 
12
[d] 
C4 MeOH 82 65 9 3 5 
13 C5 MeOH 93 84 1 2 6 
14 C6 MeOH 65 53 4 3 5 
15 C3 MeOH 62 47 5 4 6 
16 C4 H2O 99 1 98 - - 
17 C4 toluene 15 4 3 1 7 
18 C4 DMF 18 3 - 2 13 
19 C4 EtOAc 35 1 13 2 19 
20 C4 TFE 96 81 4 3 8 
[a] Reaction conditions: 2-acetonaphthone (0.5 mmol), HCO2NH4 (5 mmol), catalyst (5x10
-4
 mmol), 
HCO2H/Et3N (5:2) azeotrope (0.5 mL) and solvent (3 mL), stirred at 80 °C in a carousel tube for 4 h. 
[b] Determined by 
1
H NMR spectroscopy (%). [c] In the absence of F/T azeoptrope. [d] Five 
equivalents of ammonium formate used. 
Addition of the formic acid-triethyl amine (F/T) azeotrope was found to promote the 
reaction. In its absence, the C4-catalysed reaction proceeded in only 54% conversion 
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in 4 h (Table 4.1, entry 11). The F/T azeotrope increases the acidity of the reaction 
medium, and indeed it is known that the imine formation and its subsequent 
reduction benefits from the acidic conditions.
[25]
 When the reaction was conducted 
with five equivalents of ammonium formate, the conversion decreased and formation 
of more byproducts was observed (Table 4.1, entry 12). In contrast, the catalysts C5 
and C6, bearing an anthracene and phenanthrene ring, respectively, gave lower 
conversions (Table 4.1, entries 13 and 14). This is at least partly due to their low 
solubility in the reaction medium. It was confirmed that the reaction did not proceed 
in the absence of a catalyst. 
The reaction in various solvents was investigated next. MeOH was found to be the 
best medium, giving high selectivity towards the primary amine relative to other 
solvents (Table 4.1, entries 17-20). Interestingly, when the reaction was conducted in 
water, the reduction of ketone dominated, with the alcohol product observed in 98% 
ratio (Table 4.1, entry 16). Our group have recently shown that aqueous media of 
lower pH favour the ketone reduction over the imine formation.
[26]
 
4.2.2 DRA of aromatic ketones with HCO2NH4 
The substrate scope was examined with catalyst C4 under the optimised conditions 
(0.1 mol% C4, 80 °C in MeOH). The results of DRA of aromatic ketones are 
summarised in Table 4.2. All the phenyl derivatives, regardless of the nature of the 
substituents and their positions, gave excellent yields (Table 4.2, entries 3-16). The 
naphthyl derivatives also reacted well giving high yields (Table 4.2, entries 1 and 2). 
Disubstituted aromatic ketones and those with increasing chain length at the α-
position did not affect the yields of the product (Table 4.2, entries 17-19). When an 
α,β-unsaturated ketone was subjected to the DRA under the present conditions, 
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reduction of the carbon double bond was observed as well (Table 4.2, entry 20). This 
suggests that when a double bond is present next to a carbonyl, 1,4-reduction 
pathway is favoured over 1,2-reduction, and it is not surprising, as 1,4-reduction is 
frequently observed in transfer hydrogenation.
[27]
   The cyclic substrates, 1-indanone 
and 1-tetralone, both gave their corresponding amines in excellent yields (Table 4.2, 
entries 21 and 22). In contrast to the α,β-unsaturated ketone, when 2-
acetylbenzofuran was used, the double bond was retained, with 1-(benzofuran-2-
yl)ethanamine obtained in 91% yield (Table 4.2, entry 23), a result that reflects the 
aromaticity of the substrate. A thiophene ring was also tolerated well, affording 1-
(2,5-dimethylthiophen-3-yl)ethanamine in an excellent yield (Table 4.2, entry 24). It 
was found that a prolonged reaction time increases the concentration of N-formyl 
derivatives in these reactions. In fact, reaction times of 4-12 h were sufficient for the 
completion of the DRA. 
Table 4.2: DRA of aromatic ketones with HCO2NH4 
 
Entry
[a]
 Ketones Amines  Yields (%)
[b]
 
 
1 
  
 
2a 
 
93 
 
2 
  
 
2b 
 
94 
 
3 
  
 
2c 
 
84 
 
4 
  
 
2d 
 
91 
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5 
  
 
2e 
 
88 
 
6 
  
 
2f 
 
89 
 
7 
  
 
2g 
 
91 
 
8 
  
 
2h 
 
85 
 
9 
  
 
2i 
 
90 
 
10 
  
 
2j 
 
89 
 
11 
  
 
2k 
 
90 
 
12 
  
 
2l 
 
87 
 
13 
  
 
2m 
 
82 
 
14 
  
 
2n 
 
88 
 
15 
  
 
2o 
 
84 
 
16 
  
 
2p 
 
86 
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17 
  
 
2q 
 
90 
 
18 
  
 
2r 
 
92 
 
19 
  
 
2s 
 
88 
 
20 
  
 
2t 
 
82 
 
21 
  
 
2u 
 
90 
 
22 
  
 
2v 
 
87 
23 
  
2w 91 
 
24 
  
 
2x 
 
92 
[a] Reaction conditions: ketone (0.5 mmol), HCO2NH4 (5 mmol), catalyst (5x10
-4
 mmol), 
HCO2H/Et3N (5:2) azeotrope (0.5 mL) and MeOH (3 mL), stirred at 80 °C in a carousel tube for 12 h. 
[b] Yield of  isolated product. 
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4.2.3 DRA of aliphatic ketones with HCO2NH4 
Reactions of aliphatic ketones with HCO2NH4 are summarised in Table 4.3. As can 
be seen, 4-phenylbutan-2-one and its variant 4-(3,4-methylenedioxy)phenyl-2-
butanone both were converted to their corresponding amines in excellent yields 
(Table 4.3, entries 1 and 2). Cyclohexanamine and 1-cyclohexylethanamine were 
also obtained in good yields (Table 4.3, entries 3 and 4). Interestingly, a bulkier 
substrate, cyclododecanone, was also aminated in a high yield without any 
predicament (Table 4.3, entry 5). Long-chain aliphatic substrates worked well, 
furnishing good yields regardless of the position of the carbonyl unit (Table 4.3, 
entries 6 and 7). Still interestingly, 6-methylhept-5-en-2-one gave its corresponding 
amine in a very good yield, leaving its C=C double bond intact. This shows the 
selectivity of the catalyst towards C=N bond reduction over a C=C bond. Indeed, the 
reduction of C=C double bond is only observed when it is present at a position α to 
the C=O group. 3,3-Dimethyl-1,5-dioxaspiro[5.5]undecan-9-one, a useful 
monoprotected form of the dione, was selectively aminated in excellent yield without 
the hydrolysis of its 1,3-dioxane being observed (Table 4.3, entry 9). Thus, the 
catalytic system offers a simple and efficient way of obtaining 
aminocyclohexanones, which are useful intermediates, especially for the synthesis of 
Pramipexole, a dopamine agonist of the non-ergoline class used for the treatment of 
signs and symptoms of idiopathic Parkinson’s disease.[28] 2-Aminotetralin, another 
key precursor, was also obtained in a very good yield from its corresponding β-
tetralone (Table 4.3, entry 10). 2-Aminotetralins are used in the synthesis of many 
therapeutic agents and have also been known to possess other pharmacological 
activities, including dopamine receptor activity.
[29]
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Table 4.3: DRA of aliphatic ketones with HCO2NH4 
 
Entry
[a]
 Ketones Amines  Yield (%)
[b]
 
1 
  
7a 91 
2 
  
7b 93 
3 
  
7c 80 
4 
  
7d 83 
5 
  
7e 90 
6 
  
7f 80 
7 
  
7g 81 
8 
  
7h 83 
9 
  
7i 90 
10 
  
7j 87 
[a] Reaction conditions: ketone (0.5 mmol), HCO2NH4 (5 mmol), catalyst (5x10
-4
 mmol), 
HCO2H/Et3N (5:2) azeotrope (0.5 mL) and MeOH (3 mL), stirred at 80 °C for 8 h. [b] Yield of 
isolated product. 
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4.2.4 DRA of β-keto ethers with HCO2NH4 
Next, the substrate scope was expanded to β-keto ethers. The product β-amino 
ethers, generated from the DRA, are of biological interest as the analogues are 
effective sodium channel blockers.
[30]
 To the best of our knowledge, the 
homogeneous metal-catalysed transfer-hydrogenative DRA of β-keto ethers has 
previously never been reported. Our protocol is mild and efficient, allowing direct 
access to β-amino ethers in a one-pot fashion. The results are presented in Table 4.4. 
As can be seen, 1-phenoxypropan-2-one, containing an aliphatic ketone and a 
phenoxy group, was aminated to give 9a in a high yield (Table 4.4, entry 1). The 
amino ether product offers a valuable building block for the synthesis of various 
antiepileptic agents.
[31]
 Aromatic β-keto ethers, regardless of the substituent nature, 
all reacted well under the present conditions (Table 4.4, entries 2-4). Interestingly, 
unusual β-keto ethers bearing an aromatic ketone and fluoro-alkoxy group were also 
tolerated, leading to their corresponding amines in a good yield (Table 4.4, entries 5-
6). 2-Ethoxycyclohexanamine was also obtained in a good yield, showing again the 
excellent activity of C4 towards the DRA of β-keto ethers (Table 4.4, entry 7).   
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Table 4.4: DRA of β-keto ethers with HCO2NH4 
 
Entry
[a]
 Ketones Amines  Yield (%)
[b]
 
1 
  
9a 87 
2 
  
9b 93 
3 
  
9c 90 
4 
  
9d 91 
5 
  
9e 74 
6 
  
9f 77 
7
[c]
 
  
9g 81 
[a] Reaction conditions: ketone (0.5 mmol), HCO2NH4 (5 mmol), catalyst (5x10
-4
 mmol), 
HCO2H/Et3N (5:2) azeotrope (0.5 mL) and MeOH (3 mL), stirred at 80 °C for 12 h. [b] Yield of 
isolated product. [c] Syn/anti ratio = 6:1. 
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4.2.5 DRA of α-keto acids with HCO2NH4 
To further demonstrate the versatility of C4, the DRA of α-keto acids was targeted 
next and the results are summarised in Table 4.5. Non-natural α-amino acids are in 
the focus of interest, as they are widely used as building blocks in drug synthesis, 
especially in the synthesis of semi-synthetic broad-spectrum antibiotics like 
Ampicillin and Amoxicillin.
[32]
 Transfer hydrogenative DRA of α-keto acids offers 
an easy way of generating these non-natural α-amino acids, in particular, as they are 
generally difficult to be synthesised through enzymatic methods.
[20,33]
 Electron 
neutral substrates, 2-oxo-2-phenylacetic acid and 2-(naphthalen-2-yl)-2-oxoacetic 
acid, were successfully aminated to their corresponding amines in near quantitative 
yields (Table 4.5, entries 1 and 5). Both electron-poor and -rich substrates gave 
excellent yields of their amines (Table 4.5, entries 2-4). Interestingly, α-keto acids 
containing a heteroatom posed no poisoning effect on the catalyst, giving excellent 
yields (Table 4.5, entries 6-7). The protocol is attractive not only because high yields 
are obtained, but also because the α-amino acid products precipitate from the 
reaction mixture and can be obtained by a simple filtration. 
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Table 4.5: DRA of α-keto acids with HCO2NH4 
 
Entry
[a]
 Ketones Amines  Yield (%)
[b]
 
1 
  
11a 95 
2 
  
11b 91 
3 
  
11c 90 
4 
  
11d 88 
5 
  
11e 96 
6 
  
11f 94 
7 
  
11g 92 
[a] Reaction conditions: ketone (0.5 mmol), HCO2NH4 (5 mmol), catalyst (5x10
-4
 mmol), 
HCO2H/Et3N (5:2) azeotrope (0.5 mL) and MeOH (3 mL), stirred at 80 °C for 12 h. [b] Yield of 
isolated product. 
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4.2.6 Synthesis of Mexiletine 
To showcase the synthetic utility of the DRA, the protocol was applied to a synthesis 
of Mexiletine, a class Ib antiarrhythmic agent that interferes with the sodium channel 
(Scheme 4.7).
[34]
 1-(2,6-Dimethylphenoxy)propan-2-one was synthesised by reacting 
2,6-dimethylphenol with chloroacetone.
[35]
 Transfer-hydrogenative DRA of the 
resulting β-keto ether by C4 afforded the target Mexiletine with an overall yield of 
77% (Scheme 4.7). This two-step synthesis is economical and high-yielding under 
mild reaction conditions. A conventional three-step method, by using Raney nickel 
under hydrogenative conditions,
[36,37]
 
 
is shown in Scheme 4.8.  
 
Scheme 4.7: Synthesis of Mexiletine by transfer hydrogenative DRA. 
 
Scheme 4.8: A conventional three-step synthesis of Mexiletine. 
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4.2.7 Mechanistic considerations 
A reaction mechanism for the DRA is proposed in Scheme 4.9. Reduction by the 
catalyst C4 most likely proceeds by the ionic mechanism,
[38]
 as the catalyst does not 
offer metal-ligand bifunctionality.
[39]
 Complex C4 is first converted into I in the 
presence of formic acid. The decarboxylation of formate by iridium leads to the 
iridium hydride species II.
[40,41]
 Simultaneously, an imine is generated through the 
condensation of a ketone with ammonia. This imine is protonated under the acidic 
conditions and enters the catalytic cycle as the iminium ion, where it is reduced to 
the product by direct hydride transfer to the protonated C=N bond.
[38, 42]
  
 
Scheme 4.9: Proposed DRA mechanism under the present conditions. 
In the preliminary studies, the DRA reaction of acetonaphthone 1a was monitored in 
situ by 
1
H-NMR spectroscopy under the normal catalytic conditions but at room 
temperature. Formation of hydride II was confirmed and shown to be instantaneous. 
However, no other new species were observed at this temperature, which indicated 
that hydride transfer or imine generation may be more difficult than the hydride 
formation in the overall DRA. Condensation of 1a with ammonia was not observed 
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even after heating the sample at 50 
°
C for 10 min. Complex II was isolated and 
characterised by X-ray diffraction (Figure 4.1). Our previous study suggests that the 
imine is reduced by the cyclometalated iridium hydride at room temperature only 
when it is present in its protonated but not neutral form.
[40]
 These results are in 
agreement with the proposed ionic mechanism. 
 
Figure 4.1: Molecular structure of the hydride II determined by X-ray diffraction. Thermal ellipsoids 
are displayed at 50% probability 
4.3 Conclusion 
This chapter demonstrates that primary amines can be readily accessed by the DRA 
of various ketones by using economic, safe and easy-to-handle ammonium formate. 
Cyclometalated iridium complexes hold the key, allowing the DRA to proceed with 
high productivity and excellent chemoselectivity toward primary amines under mild 
transfer-hydrogenative conditions. Aromatic ketones, aliphatic ones, α-keto acids 
and β-keto ethers are all viable substrates under the current conditions, showing the 
versatility of the iridicycle catalyst identified. 
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4.4 Experimental 
4.4.1 General information 
Unless otherwise specified, all reagents were commercially purchased and used 
without further purification. Dichloromethane (DCM) was dried over CaH2 and 
distilled prior to use. MeOH was dried over magnesium and distilled prior to use. 
NMR spectra were recorded on a Bruker 400 MHz NMR spectrometer unless 
otherwise specified. HRMS analyses were carried out by the EPSRC National Mass 
Spectrometry Service Centre at Swansea University. Cyclometalated iridium hydride 
was in situ formed and was also prepared according to the literature procedure.
[40]
 β-
Keto ethers (8a-g) were prepared according to the literature.
[35]
 8e, 8f and 9f are 
unknown compounds. 
1
H-NMR, 
13
C-NMR and HRMS were collected for all the 
products. 
1
H-NMR and 
13
C-NMR are consistent with the reported literature (see 
below). 
4.4.2 Typical procedure for the DRA of ketones 
Ketone (0.5 mmol), C4 (0.32 mg, 5x10
-4
 mmol) and ammonium formate (315 mg, 5 
mmol) were placed in a carousel reaction tube. MeOH (3 mL) was introduced with a 
syringe and the resulting mixture was bubbled with nitrogen for 2 min. The F/T 
azeotrope (0.5 mL) was then added and the mixture was stirred at 80 °C for 8-12 h. 
The reaction mixture was cooled to room temperature and the solvent evaporated 
under vacuum. 1M HCl solution was added to the resulting residue and the mixture 
was washed with diethyl ether (2 x 15 mL) to remove neutral compounds. The 
aqueous layer was basified with dilute KOH solution and was bought to a pH of 10-
12. It was than extracted with DCM (3 x 30 mL) and the combined organic layers 
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were dried over anhydrous sodium sulphate. Filtration, followed by evaporation of 
solvent under reduced pressure gave the desired product. 
4.4.3 Representative procedure for the DRA of α-keto acids 
2-Oxo-2-phenylacetic acid (75.1 mg, 0.50 mmol), C4 (0.32 mg, 5x10
-4
 mmol) and 
ammonium formate (315 mg, 5.00 mmol) were placed in a carousel reaction tube. 
MeOH (3 mL) was introduced with a syringe and the resulting mixture was bubbled 
with nitrogen for 2 min. The F/T azeotrope (0.5 mL) was then added and the mixture 
was stirred at 80 °C for 12 h. The reaction mixture was cooled to room temperature 
and the resultant precipitate filtered off and washed with MeOH to give 2-amino-2-
phenylacetic acid as a white solid (71.8 mg, 95% yield).  
4.4.4 Data of the cyclometalated iridium complexes 
 
Complex C7: Yellow solid: 
1
H NMR (CDCl3, 400 MHz, 253 K) δ (ppm): 8.17 (s, 
1H), 8.08 (s, 1H), 7.91 (d, J = 7.8 Hz, 1H), 7.81 (dd, J = 8.2, 2.8 Hz, 2H), 7.57-7.41 
(m, 3H), 7.35-7.29 (m, 2H), 6.93 (d, J = 7.6 Hz, 1H), 2.58 (s, 3H), 1.45 (s, 15H).
 13
C 
NMR (CDCl3, 100 M Hz, 253 K) δ (ppm): 181.2, 159.6, 150.7, 148.0, 137.0, 132.3, 
130.2, 129.6, 129.3, 129.2, 127.7, 127.5, 126.6, 126.5, 123.8, 123.6, 122.3, 89.0, 
17.4, 8.7. HRMS for C28H29ClIrN [M]
+
: m/z calc., 607.1605; found, 607.1603. 
 
Complex C8: Orange solid; 
1
H NMR (CDCl3, 400 MHz, 253 K) δ (ppm): 7.85 (d, J 
= 7.3 Hz, 2H), 7.56 (d, J = 7.6 Hz, 1H), 7.49 (t, J = 7.7 Hz, 1H), 7.42 (t, J = 7.4 Hz, 
1H), 7.32-7.21 (m, 2H), 7.06 (t, J = 7.4 Hz, 1H), 6.87 (d, J = 7.5 Hz, 1H), 2.47 (s, 
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3H), 1.41 (s, 15H). 
13
C NMR (CDCl3, 100 MHz, 253 K) δ (ppm): 181.5, 168.2, 
150.7, 147.7, 135.1, 132.3, 130.1, 128.7, 127.7, 126.4, 123.6, 122.5, 121.6, 89.2, 
17.2, 8.7. Anal. calc. for C24H27ClIrN (%): C, 51.74; H, 4.88; N, 2.51. Found: C, 
51.31; H, 4.79; N, 2.35. HRMS (FAB) for C24H27ClIrN [M]
+
: m/z calc., 557.1448; 
found, 557.1442. 
 
Complex C9: Red solid: 
1
H NMR (CDCl3, 400 MHz, 253 K) δ (ppm): 8.36 (d, J = 
2.3 Hz, 1H), 8.07 (dd, J = 8.4, 2.3 Hz, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.76 (dd, J = 
8.8, 2.0 Hz, 1H), 7.02 (dd, J = 8.9, 2.4 Hz, 1H), 6.95 (dd, J = 8.4, 2.4 Hz, 1H), 6.85 
(dd, J = 8.4, 2.1 Hz, 1H), 3.89 (s, 3H), 2.56 (s, 3H), 1.45 (s, 15H). 
13
C NMR (CDCl3, 
100 MHz, 253 K) δ (ppm): 181.9, 180.8, 157.9, 148.6, 143.3, 142.7, 135.7, 126.0, 
124.5, 123.3, 123.2, 115.2, 112.5, 90.6, 55.7, 17.4, 8.8. Anal. calc. for 
C25H28ClIrN2O3 (%): C, 47.50; H, 4.46; N, 4.43. Found: C, 47.70; H, 4.26; N, 4.20. 
HRMS (FAB) for C25H28Cl
191
IrN2O3 [M]
+
: m/z calc., 630.1389; found, 630.1390. 
 
Complex C10: Black solid: 
1
H NMR (CDCl3, 400 MHz, 253 K) δ (ppm): 8.62 (d, J = 
2.2 Hz, 1H), 7.88 (dd, J = 8.6, 2.2 Hz, 1H), 7.78-7.65 (m, 1H), 7.60 (d, J = 8.6 Hz, 
1H), 6.89-6.61 (m, 3H), 3.03 (s, 6H), 2.51 (s, 3H), 1.47 (s, 15H). 
13
C NMR (CDCl3, 
100 MHz, 253 K) δ (ppm): 179.6, 168.1, 154.0, 149.0, 148.7, 140.1, 129.2, 128.4, 
124.1, 123.0, 117.0, 113.3, 110.3, 90.0, 40.9, 17.8, 8.8. HRMS (FAB) for 
C26H31Cl
191
IrN3O2 [M]
+
: m/z calc., 643.1705; found, 643.1698. 
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Complex C11: Red solid: 
1
H NMR (CDCl3, 400 MHz, 253 K) δ (ppm): 7.79 (d, J = 
8.8 Hz, 1H), 7.72 (d, J = 8.2 Hz, 1H), 7.07 (d, J = 2.5 Hz, 1H), 7.02-6.95 (m, 2H), 
6.91 (d, J = 8.1 Hz, 1H), 6.81 (d, J = 8.3 Hz, 1H), 3.88 (s, 3H), 3.83 (s, 3H), 2.44 (s, 
3H), 1.44 (s, 15H). 
13
C NMR (CDCl3, 100 MHz, 253 K) δ (ppm): 181.4, 157.8, 
157.5, 154.9, 148.0, 144.2, 135.3, 124.9, 123.4, 119.5, 114.9, 113.0, 112.3, 88.9, 
55.6, 55.4, 17.3, 8.8. Anal. calc. for C26H31ClIrNO2 (%): C, 50.60; H, 5.06; N, 2.27. 
Found: C, 50.53; H, 5.08; N, 2.16. HRMS (FAB) for C26H31IrNO2 [M-Cl]
+
: m/z 
calc., 582.1984; found, 582.1980. 
 
Complex C12: Red solid: 
1
H NMR (CDCl3, 400 MHz, 253 K) δ (ppm): 7.80 (d, J = 
8.1 Hz, 1H), 7.31 (s, 1H), 7.03 (s, 1H), 6.98 (d, J = 8.3 Hz, 1H), 6.90 (d, J = 8.3 Hz, 
1H), 6.81 (d, J = 8.1 Hz, 1H), 4.06 (s, 3H), 3.88 (s, 3H), 3.87 (s, 3H), 2.44 (s, 3H), 
1.44 (s, 15H). 
13
C NMR (CDCl3, 100 MHz, 253 K) δ (ppm): 180.3, 161.7, 157.3, 
151.8, 144.3, 144.1, 139.3, 125.1, 123.8, 115.9, 114.9, 112.2, 110.8, 88.9, 55.9, 55.7, 
55.6, 17.4, 8.9. Anal. calc. for C27H33ClIrNO3 (%):C, 50.10; H, 5.14; N, 2.16. Found: 
C, 50.07; H, 5.10; N, 2.10. HRMS (FAB) for C27H33Cl
191
IrNO3 [M]
+
: m/z calc., 
645.1749; found, 645.1758. 
 
Complex II: Purple solid: 
1
H NMR (Benzene-d6, 400 MHz, 300 K) δ (ppm): 8.59 (s, 
1H), 7.98 (d, J = 8.3 Hz, 1H), 7.88 (s, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.43 (t, J = 7.5 
Hz, 1H), 7.31 (t, J = 7.5 Hz, 1H), 6.93-6.55 (m, 2H), 3.35 (s, 3H), 2.00 (s, 3H), 1.72 
(s, 15H), -15.23 (s, 1H). Anal. calc. for C29H32IrNO (%):C, 57.78; H, 5.35; N, 2.32. 
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Found: C, 57.48; H, 5.68; N, 2.34. HRMS (APCI) for C29H31NO
191
Ir [M-H]
+
: m/z 
calc., 600.2006; found, 600.2002. 
4.4.5 Data of the β-keto ethers 
 
1-Phenyl-2-(2,2,2-trifluoroethoxy)ethanone, 8f: 
1
H NMR (CDCl3, 400 MHz, 300 
K) δ (ppm): 7.92 (d, J = 7.7 Hz, 2H), 7.64 (t, J = 7.6 Hz, 1H), 7.51 (t, J = 7.8 Hz, 
2H), 4.99 (s, 2H), 4.08 (q, J = 8.7 Hz, 2H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ 
(ppm): 195.3, 134.6, 134.4, 129.3, 128.2, 124.2 (q, J = 278.9, CF3), 74.6, 68.9 (q, J = 
34.4 Hz, CH2CF3). 
19
F NMR (CDCl3, 376 MHz, 300 K) δ (ppm): -74.6. HRMS for 
C10H10O2F3 [M+H]
+
: m/z calc., 219.0627; found, 219.0626. 
 
2-(1,1,1,3,3,3-Hexafluoropropan-2-yloxy)-1-phenylethanone, 8g: 
1
H NMR (CDCl3, 
400 MHz, 300 K) δ (ppm): 7.92 (d, J = 7.8 Hz, 2H), 7.66 (t, J = 7.5 Hz, 1H), 7.52 (t, 
J = 7.8 Hz, 2H), 5.14 (s, 2H), 4.55 (sep, J = 5.8 Hz, 1H). 
13
C NMR (CDCl3, 100 
MHz, 300 K) δ (ppm): 193.7, 134.7, 134.4, 129.4, 128.3, 123.2 (q, J = 283.4, 2CF3), 
75.8 (sep, J = 32.7 Hz, OCH(CF3)2), 74.3. 
19
F NMR (CDCl3, 376 MHz, 300 K) δ 
(ppm): -73.5. HRMS for C11H8O2F6Na [M+Na]
+
: m/z calc., 309.0326; found, 
309.0318. 
4.4.6 Data of the aromatic primary amines 
 
1-(Naphthalen-2-yl)ethanamine, 2a:
[8]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.88-7.77 (m, 4H), 7.55-7.43 (m, 3H), 4.30 (q, J = 6.5 Hz, 1H), 2.56 (bs, 2H), 
1.51 (d, J = 6.6 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 144.7, 133.9, 
133.1, 128.7, 128.3, 128.0, 126.5, 126.0, 124.9, 124.4, 51.8, 25.6. HRMS for 
C12H14N [M+H]
+
: m/z calc., 172.1121; found, 172.1119. 
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1-(6-Methoxynaphthalen-2-yl)ethanamine, 2b:
[43]
 
1
H NMR (CDCl3, 400 MHz, 300 
K) δ (ppm): 7.73-7.67 (m, 3H), 7.44 (dd, J = 8.4, 1.8 Hz, 1H), 7.16-7.09 (m, 2H), 
4.24 (q, J = 6.6 Hz, 1H), 3.90 (s, 3H), 1.55 (bs, 2H), 1.45 (d, J = 6.6 Hz, 3H). 
13
C 
NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 157.9, 143.4, 134.1, 129.6, 129.3, 127.4, 
125.4, 124.1, 119.2, 106.1, 55.7, 51.7, 26.1. HRMS for C13H15NO [M]
+
: m/z calc., 
201.1148; found, 201.1146. 
 
1-Phenylethanamine, 2c:
[8]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 7.36-7.29 
(m, 4H), 7.26-7.19 (m, 1H), 4.11 (q, J = 6.6 Hz, 1H), 1.53 (bs, 2H), 1.38 (d, J = 6.6 
Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 148.2, 128.9, 127.2, 126.1, 
51.7, 26.1. HRMS for C8H12N [M+H]
+
: m/z calc., 122.0964; found, 122.0964. 
 
1-(Biphenyl-4-yl)ethanamine, 2d:
[44]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 
7.68-7.60 (m, 4H), 7.52-7.44 (m, 4H), 7.42-7.36 (m, 1H), 4.21 (q, J = 6.6 Hz, 1H), 
1.70 (bs, 2H), 1.49 (d, J = 6.6 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ 
(ppm): 147.3, 141.4, 140.2, 129.2, 127.7, 127.6, 127.5, 126.6, 51.5, 26.1. HRMS for 
C14H16N [M+H]
+
: m/z calc., 198.1277; found, 198.1277. 
 
1-(4-Methoxyphenyl)ethanamine, 2e:
[8]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.26 (d, J = 8.4 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 4.07 (q, J = 6.6 Hz, 1H), 
3.78 (s, 3H), 1.51 (bs, 2H), 1.36 (d, J = 6.6 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 
300 K) δ (ppm): 158.9, 140.4, 127.1, 114.2, 55.7, 51.1, 26.2. HRMS for C9H14NO 
[M+H]
+
: m/z calc., 152.1070; found, 152.1069. 
Chapter 4  
169 
 
 
1-(4-Fluorophenyl)ethanamine, 2f: 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 
7.27-7.21 (m, 2H),  6.97-6.90 (m, 2H), 4.05 (q, J = 6.6 Hz, 1H), 1.59 (bs, 2H), 1.29 
(d, J = 6.6 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 162.1 (d, J = 
244.3 Hz), 143.7 (d, J = 3.1 Hz), 127.6 (d, J = 7.9 Hz), 115.6 (d, J = 21.1 Hz), 51.1, 
26.2. HRMS for C8H11NF [M+H]
+
: m/z calc., 140.0870; found, 140.0867. 
 
1-(4-Bromophenyl)ethanamine, 2g:
[45]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.37 (d, J = 8.4 Hz, 2H),  7.16 (d, J = 8.4 Hz, 2H), 4.02 (q, J = 6.6 Hz, 1H), 
1.60 (bs, 2H), 1.29 (d, J = 6.6 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ 
(ppm): 147.0, 131.9, 128.0, 120.8, 51.2, 26.1. HRMS for C8H11NBr [M+H]
+
: m/z 
calc., 200.0069; found, 200.0068. 
 
1-(4-(Trifluoromethyl)phenyl)ethanamine, 2h:
[46]
 
1
H NMR (CDCl3, 400 MHz, 300 
K) δ (ppm): 7.61 (d, J = 8.2 Hz, 2H),  7.50 (d, J = 8.2 Hz, 2H), 4.22 (q, J = 6.6 Hz, 
1H), 1.70 (bs, 2H), 1.42 (d, J = 6.6 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ 
(ppm): 152.0, 129.5 (d, J = 32.4 Hz), 127.5, 126.5 (2C), 125.8 (q, J = 3.7 Hz), 123.3 
(d, J = 272.1 Hz, CF3), 51.4, 26.1. HRMS for C9H11NF3 [M+H]
+
: m/z calc., 
190.0838; found, 190.0834. 
 
1-(4-Nitrophenyl)ethanamine, 2i:
[11]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 
8.09 (d, J = 8.8 Hz, 2H),  7.46 (d, J = 8.7 Hz, 2H), 4.18 (q, J = 6.6 Hz, 1H), 1.60 (bs, 
2H), 1.33 (d, J = 6.7 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 155.6, 
147.2, 127.1, 124.2, 51.3, 26.2. HRMS for C8H11N2O2 [M+H]
+
: m/z calc., 167.0815; 
found, 167.0815. 
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1-(3-Methoxyphenyl)ethanamine, 2j:
[47]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.25 (d, J = 7.5 Hz, 1H),  6.95-6.89 (m, 2H), 6.80-6.75 (m, 1H), 4.09 (q, J = 
6.6 Hz, 1H), 3.81 (s, 3H), 1.62 (bs, 2H), 1.38 (d, J = 6.6 Hz, 3H). 
13
C NMR (CDCl3, 
100 MHz, 300 K) δ (ppm): 160.2, 150.0, 129.9, 118.5, 112.5, 111.8, 55.6, 51.7, 26.0. 
HRMS for C9H14NO [M+H]
+
: m/z calc., 152.1070; found, 152.1071. 
 
1-(3-Fluorophenyl)ethanamine, 2k:
[47]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.34-7.28 (m, 1H),  7.16-7.05 (m, 2H), 6.94 (td, J = 8.5, 2.6 Hz, 1H), 4.14 (q, 
J = 6.6 Hz, 1H), 1.61 (bs, 2H), 1.39 (d, J = 6.6 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 
300 K) δ (ppm): 163.4 (d, J = 245.6 Hz), 150.9 (d, J = 6.5 Hz), 130.3 (d, J = 8.2 Hz), 
121.8 (d, J = 2.7 Hz), 114.0 (d, J = 21.2 Hz), 113.0 (d, J = 21.4 Hz), 51.4 (d, J = 1.7 
Hz), 26.1. HRMS for C8H11FN [M+H]
+
: m/z calc., 140.0870; found, 140.0867. 
 
1-(3-Bromophenyl)ethanamine, 2l:
[48]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 
7.43 (t, J = 1.7 Hz, 1H),  7.28 (d, J = 7.8 Hz, 1H), 7.19 (d, J = 6.8 Hz, 1H), 7.11 (t, J 
= 7.7 Hz, 1H), 4.01 (q, J = 6.6 Hz, 1H), 2.02 (bs, 2H), 1.29 (d, J = 6.6 Hz, 3H). 
13
C 
NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 150.1, 130.5, 130.4, 129.4, 124.9, 123.0, 
51.3, 25.8. HRMS for C8H11BrN [M+H]
+
: m/z calc., 200.0069; found, 200.0069.  
 
1-(3-(Trifluoromethyl)phenyl)ethanamine, 2m:
[47]
 
1
H NMR (CDCl3, 400 MHz, 300 
K) δ (ppm): 7.63 (s, 1H), 7.55 (d, J = 7.5 Hz, 1H),  7.50 (d, J = 7.3 Hz, 1H), 7.44 (dd, 
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J = 7.5, 7.3 Hz, 1H), 4.20 (q, J = 6.6 Hz, 1H), 1.94 (bs, 2H), 1.41 (d, J = 6.6 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 148.7, 131.2 (q, J = 32.2 Hz), 129.7, 
129.3, 124.7 (q, J = 272.4 Hz, CF3), 124.1 (q, J = 3.9 Hz), 123.0 (q, J = 3.6 Hz), 
51.4, 26.0. HRMS for C9H11F3N [M+H]
+
: m/z calc., 190.0838; found, 190.0837.  
 
1-(3-Nitrophenyl)ethanamine, 2n:
[49]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 
8.25 (s, 1H), 8.09 (d, J = 8.2 Hz, 1H),  7.72 (d, J = 7.7 Hz, 1H), 7.49 (dd, J = 8.2, 7.7 
Hz, 1H), 4.27 (q, J = 6.6 Hz, 1H), 1.58 (bs, 2H), 1.42 (d, J = 6.6 Hz, 3H). 
13
C NMR 
(CDCl3, 100 MHz, 300 K) δ (ppm): 150.2, 148.8, 132.6, 129.7, 122.3, 121.3, 51.2, 
26.2. HRMS for C8H11O2N2 [M+H]
+
: m/z calc., 167.0815; found, 167.0812. 
 
1-(2-Methoxyphenyl)ethanamine, 2o:
[50]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.33 (dd, J = 7.5, 1.6 Hz, 1H), 7.20 (ddd, J = 8.3, 7.3, 1.7 Hz, 1H),  6.94 (td, J 
= 7.4, 1.1 Hz, 1H), 6.86 (d, J = 8.2 Hz, 1H), 4.35 (q, J = 6.7 Hz, 1H), 3.84 (s, 3H), 
1.65 (bs, 2H), 1.39 (d, J = 6.7 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ 
(ppm): 157.2, 136.2, 128.0, 126.1, 121.0, 110.9, 55.6, 46.4, 23.7. HRMS for 
C9H14ON [M+H]
+
: m/z calc., 152.1070; found, 152.1068. 
 
1-(2-Fluorophenyl)ethanamine, 2p:
[51]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.43 (td, J = 7.6, 1.7 Hz, 1H), 7.26-7.19 (m, 1H), 7.14 (td, J = 7.5, 1.1 Hz, 
1H), 7.06-7.00 (m, 1H), 4.40 (q, J = 6.7 Hz, 1H), 1.75 (bs, 2H), 1.44 (d, J = 6.7 Hz, 
3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 160.8 (d, J = 244.6 Hz), 134.8 (d, 
J = 13.6 Hz), 128.5 (d, J = 8.4 Hz), 127.1 (d, J = 5.0 Hz), 124.6 (d, J = 3.5 Hz), 115.8 
(d, J = 22.2 Hz), 45.8 (d, J = 2.8 Hz), 24.4. HRMS for C8H11FN [M+H]
+
: m/z calc., 
140.0870; found, 140.0867. 
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1-(3,4-Dimethoxyphenyl)ethanamine, 2q:
[47]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 6.83 (s, 1H),  6.81-6.71 (m, 2H), 4.00 (q, J = 6.6 Hz, 1H), 3.81 (s, 3H), 3.77 
(s, 3H), 1.41 (bs, 2H), 1.28 (d, J = 6.6 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) 
δ (ppm): 149.4, 148.2, 140.9, 118.0, 111.5, 109.5, 56.3, 56.2, 51.4, 26.2. HRMS for 
C10H15NO2Na [M+Na]
+
: m/z calc., 204.0995; found, 204.0994. 
 
1-(Benzo[d][1,3]dioxol-5-yl)ethanamine, 2r:
[52]
 
1
H NMR (CDCl3, 400 MHz, 300 K) 
δ (ppm): 6.87 (d, J = 1.6 Hz, 1H),  6.81-6.73 (m, 2H), 5.93 (s, 2H), 4.05 (q, J = 6.5 
Hz, 1H), 1.56 (bs, 2H), 1.35 (d, J = 6.6 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 
K) δ (ppm): 148.1, 146.7, 142.4, 119.1, 108.5, 106.7, 101.3, 51.5, 26.2. HRMS for 
C9H12NO2 [M+H]
+
: m/z calc., 166.0863; found, 166.0860. 
 
1-Phenylpropan-1-amine, 2s:
[47]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 7.38-
7.31 (m, 4H), 7.28-7.23 (m, 1H), 3.82 (t, J = 6.8 Hz, 1H), 1.77-1.67 (m, 4H, 
including NH2), 0.89 (t, J = 7.4 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ 
(ppm): 146.8, 128.8, 127.3, 126.8, 58.2, 32.8, 11.4. HRMS for C9H14N [M+H]
+
: m/z 
calc., 136.1121; found, 136.1118. 
 
1,3-Diphenylpropan-1-amine, 2t:
[53]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 
7.27-7.22 (m, 4H), 7.21-7.15 (m, 3H), 7.12-7.04 (m, 3H), 3.84 (t, J = 7.0 Hz, 1H), 
3.01 (bs, 2H), 2.58-2.41 (m, 2H), 2.06-1.90 (m, 2H). 
13
C NMR (CDCl3, 100 MHz, 
300 K) δ (ppm): 145.0, 142.0, 129.1, 128.8 (2C), 127.8, 127.0, 126.3, 56.2, 40.6, 
33.0. HRMS for C15H18N [M+H]
+
: m/z calc., 212.1434; found, 212.1432. 
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2,3-Dihydro-1H-inden-1-amine, 2u:
[54]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.38-7.33 (m, 1H), 7.28-7.21 (m, 3H), 4.39 (t, J = 7.5 Hz, 1H), 3.04-2.94 (m, 
1H), 2.89-2.78 (m, 1H), 2.58-2.48 (m, 1H), 1.75-1.68 (m, 3H, including NH2). 
13
C 
NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 147.8, 143.5, 127.6, 126.9, 125.1, 123.7, 
57.7, 37.8, 30.5. HRMS for C9H12N [M+H]
+
: m/z calc., 134.0964; found, 134.0962. 
 
1,2,3,4-Tetrahydronaphthalen-1-amine, 2v:
[8]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.42 (d, J = 7.2 Hz, 1H), 7.24-7.14 (m, 2H), 7.10 (d, J = 7.2 Hz, 1H), 4.00 (t, 
J = 5.7 Hz, 1H), 2.90-2.71 (m, 2H), 2.11-1.91 (m, 2H), 1.85-1.68 (m, 2H), 1.62 (bs, 
2H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 141.5, 137.1, 129.4, 128.4, 
127.0, 126.4, 49.8, 33.9, 30.0, 20.0. HRMS for C10H14N [M+H]
+
: m/z calc., 
148.1121; found, 148.1118. 
 
1-(Benzofuran-2-yl)ethanamine, 2w:
[55]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.43 (ddd, J = 7.5, 1.6, 0.9 Hz, 1H), 7.37-7.33 (m, 1H), 7.18-7.08 (m, 2H), 
6.41 (t, J = 0.9 Hz, 1H), 4.13 (q, J = 6.7 Hz, 1H), 2.04 (bs, 2H), 1.44 (d, J = 6.7 Hz, 
3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 163.2, 155.1, 128.9, 124.1, 
123.0, 121.2, 111.4, 100.8, 45.9, 22.3. HRMS for C10H12NO [M+H]
+
: m/z calc., 
162.0913; found, 162.0912. 
 
1-(2,5-Dimethylthiophen-3-yl)ethanamine, 2x:
[56]
 
1
H NMR (CDCl3, 400 MHz, 300 
K) δ (ppm): 6.69 (s, 1H), 4.14 (q, J = 6.6 Hz, 1H), 2.41 (s, 3H), 2.35 (s, 3H), 1.75 
(bs, 2H), 1.34 (d, J = 6.6 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 
143.4, 136.3, 130.3, 123.7, 45.3, 24.9, 15.6, 13.0. HRMS for C8H13NSNa [M+Na]
+
: 
m/z calc., 178.0661; found, 178.0657. 
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4.4.7 Data of the aliphatic primary amines 
 
4-Phenylbutan-2-amine, 7a: 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 7.33-7.27 
(m, 2H), 7.24-7.19 (m, 3H), 2.95 (sex, J = 6.4 Hz, 1H), 2.75-2.63 (m, 2H), 1.73-1.62 
(m, 2H), 1.27 (bs, 2H), 1.13 (d, J = 6.3 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 
K) δ (ppm): 142.7, 128.8, 128.7, 126.1, 47.0, 42.3, 33.3, 24.5. HRMS for C10H16N 
[M+H]
+
: m/z calc., 150.1277; found, 150.1275. 
 
4-(Benzo[d][1,3]dioxol-5-yl)butan-2-amine, 7b:
[8]
 
1
H NMR (CDCl3, 400 MHz, 300 
K) δ (ppm): 6.65 (d, J = 7.8 Hz, 1H), 6.62 (d, J = 1.2 Hz, 1H), 6.57 (dd, J = 7.8, 1.2 
Hz, 1H), 5.84 (s, 2H), 2.86 (sex, J = 6.4 Hz, 1H), 2.59-2.44 (m, 2H), 1.75 (bs, 2H), 
1.60-1.51 (m, 2H), 1.05 (d, J = 6.4 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ 
(ppm): 147.9, 145.9, 136.5, 121.4, 109.2, 108.5, 101.1, 46.8, 42.3, 32.9, 24.3. HRMS 
for C11H16NO2 [M+H]
+
: m/z calc., 194.1176; found, 194.1175. 
 
Cyclohexanamine, 7c:
[57]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 2.69-2.51 
(m, 1H), 1.87-1.52 (m, 5H), 1.32-0.95 (m, 7H). 
13
C NMR (CDCl3, 100 MHz, 300 K) 
δ (ppm): 50.9, 37.3, 26.1, 25.5. HRMS for C6H14N [M+H]
+
: m/z calc., 100.1121; 
found, 100.23. 
 
1-Cyclohexylethanamine, 7d:
[20]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 2.67 
(quin, J = 6.4 Hz, 1H), 1.82-1.63 (m, 5H), 1.46 (bs, 2H), 1.30-1.10 (m, 4H), 1.04 (d, 
J = 6.5 Hz, 3H), 1.02-0.91 (m, 2H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 
52.0, 45.8, 29.5, 29.3, 27.0, 26.8, 26.7, 21.2. HRMS for C8H18N [M+H]
+
: m/z calc., 
128.1434; found, 128.1432. 
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Cyclododecanamine, 7e:
[58]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 2.97-2.88 
(m, 1H), 1.82 (bs, 2H), 1.63-1.52 (m, 2H), 1.45-1.25 (m, 20H). 
13
C NMR (CDCl3, 
100 MHz, 300 K) δ (ppm): 48.1, 33.4, 24.6, 24.2, 23.8, 23.7, 21.7. HRMS for 
C12H26N [M+H]
+
: m/z calc., 184.2060; found, 184.2060. 
 
Octan-2-amine, 7f:
[20]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 2.90-2.77 (m, 
1H), 1.93 (bs, 2H), 1.34-1.13 (m, 10H), 1.00 (d, J = 6.3 Hz, 3H), 0.81 (d, J = 6.8 Hz, 
3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 47.3, 40.5, 32.2, 29.8, 26.8, 24.2, 
23.0, 14.4. HRMS for C8H20N [M+H]
+
: m/z calc., 130.1590; found, 130.1589. 
 
Nonan-3-amine, 7g: 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 2.63-2.51 (m, 
1H), 2.07 (bs, 2H), 1.37-1.14 (m, 12H), 0.88-0.79 (m, 6H). 
13
C NMR (CDCl3, 100 
MHz, 300 K) δ (ppm): 53.1, 37.6, 32.3, 30.7, 29.9, 26.5, 23.0, 14.5, 10.7. HRMS for 
C9H22N [M+H]
+
: m/z calc., 144.1747; found, 144.1746. 
 
6-Methylhept-5-en-2-amine, 7h:
[59]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 
5.04 (td, J = 7.1, 1.1 Hz, 1H), 2.90-2.76 (m, 1H), 2.04-1.86 (m, 2H), 1.62 (s, 3H), 
1.54 (s, 3H), 1.48 (bs, 2H), 1.35-1.24 (m, 2H), 1.00 (d, J = 6.3 Hz, 3H). 
13
C NMR 
(CDCl3, 100 MHz, 300 K) δ (ppm): 132.0, 124.6, 47.1, 40.5, 26.1, 25.4, 24.2, 18.1. 
HRMS for C8H18N [M+H]
+
: m/z calc., 128.1434; found, 128.1432. 
 
3,3-Dimethyl-1,5-dioxaspiro[5.5]undecan-9-amine, 7i: 
1
H NMR (CDCl3, 400 MHz, 
300 K) δ (ppm): 3.48 (s, 2H), 3.45 (s, 2H), 2.79-2.65 (m, 1H), 2.23-2.11 (m, 2H), 
1.76-1.64 (m, 2H), 1.55-1.25 (m, 6H, including NH2), 0.93 (s, 6H). 
13
C NMR 
Chapter 4  
176 
 
(CDCl3, 100 MHz, 300 K) δ (ppm): 98.9, 72.0, 71.6, 51.5, 34.0, 32.3, 31.9, 24.5. 
HRMS for C11H22NO2 [M+H]
+
: m/z calc., 200.1645; found, 200.1648. 
 
1,2,3,4-Tetrahydronaphthalen-2-amine, 7j:
[60]
 
1
H NMR (CDCl3, 400 MHz, 300 K) 
δ (ppm): 7.06-6.96 (m, 4H), 3.18-3.04 (m, 1H), 2.97-2.88 (m, 1H), 2.85-2.74 (m, 
2H), 2.55-2.44 (m, 1H), 1.99-1.88 (m, 1H), 1.78 (bs, 2H), 1.59-1.46 (m, 1H). 
13
C 
NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 135.5, 134.9, 129.0, 128.4, 125.5, 125.4, 
47.1, 39.0, 32.5, 27.8. HRMS for C10H14N [M+H]
+
: m/z calc., 148.1121; found, 
148.1120. 
4.4.8 Data of the β-amino ethers 
 
1-Phenoxypropan-2-amine, 9a:
[61]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 
7.34-7.27 (m, 2H), 7.00-6.91 (m, 3H), 3.89 (dd, J = 8.9, 1.1 Hz, 1H), 3.70 (dd, J = 
8.9, 1.1 Hz, 1H), 3.41-3.32 (m, 1H), 1.69 (bs, 2H), 1.19 (d, J = 6.5 Hz, 3H). 
13
C 
NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 159.3, 129.9, 121.2, 114.9, 74.8, 46.7, 
20.2. HRMS for C9H14NO [M+H]
+
: m/z calc., 152.1070; found, 152.1069. 
 
2-(2,6-Dimethylphenoxy)-1-phenylethanamine, 9b:
[62]
 
1
H NMR (CDCl3, 400 MHz, 
300 K) δ (ppm): 7.47 (d, J = 7.2 Hz, 2H), 7.38 (dt, J = 7.4, 1.7 Hz, 2H), 7.31 (dt, J = 
7.2, 1.9 Hz, 1H), 7.01 (d, J = 7.4 Hz, 2H), 6.95 (dd, J = 8.2, 6.6 Hz, 1H), 4.48 (dd, J 
= 8.0, 4.3 Hz, 1H), 3.87 (m, 2H), 2.34 (bs, 2H), 2.28 (s, 6H). 
13
C NMR (CDCl3, 100 
MHz, 300 K) δ (ppm): 155.8, 142.2, 131.2, 129.3, 128.9, 128.0, 127.3, 124.3, 77.6, 
56.7, 16.7. HRMS for C16H20NO [M+H]
+
: m/z calc., 242.1539; found, 242.1542. 
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2-(4-Chlorophenoxy)-1-phenylethanamine, 9c:
[62]
 
1
H NMR (CDCl3, 400 MHz, 300 
K) δ (ppm): 7.47 (d, J = 7.2 Hz, 2H), 7.40 (t, J = 7.4 Hz, 2H), 7.35 (dt, J = 7.2, 2.5 
Hz, 1H), 7.24 (dt, J = 9.0, 2.8 Hz, 2H), 6.85 (dt, J = 9.0, 2.8 Hz, 2H), 4.44 (dd, J = 
8.8, 3.6 Hz, 1H), 4.07 (dd, J = 9.0, 3.7 Hz, 1H), 3.92 (t, J = 9.1 Hz, 1H), 2.13 (bs, 
2H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 157.7, 141.8, 129.8, 129.1, 
128.3, 127.3, 126.2, 116.3, 74.5, 55.6. HRMS for C14H15NOCl [M+H]
+
: m/z calc., 
248.0837; found, 248.0840. 
 
2-(4-Methoxyphenoxy)-1-phenylethanamine, 9d: 
1
H NMR (CDCl3, 400 MHz, 300 
K) δ (ppm): 7.48 (d, J = 7.2 Hz, 2H), 7.42-7.37 (m, 2H), 7.33 (dt, J = 7.2, 1.8 Hz, 
1H), 6.89-6.82 (m, 4H), 4.43 (dd, J = 9.0, 3.6 Hz, 1H), 4.06 (dd, J = 9.0, 3.6 Hz, 1H), 
3.90 (t, J = 9.1 Hz, 1H), 3.79 (s, 3H), 2.20 (bs, 2H). 
13
C NMR (CDCl3, 100 MHz, 
300 K) δ (ppm): 154.4, 153.2, 142.1, 129.0, 128.1, 127.4, 116.0, 115.0, 75.0, 56.1, 
55.7. HRMS for C15H18NO2 [M+H]
+
: m/z calc., 244.1332; found, 244.1335.  
 
1-Phenyl-2-(2,2,2-trifluoroethoxy)ethanamine, 9e:
[63]
 
1
H NMR (CDCl3, 400 MHz, 
300 K) δ (ppm): 7.41-7.27 (m, 5H), 4.24 (dd, J = 9.0, 3.6 Hz, 1H), 3.91-3.80 (m, 
2H), 3.75 (dd, J = 9.0, 3.6 Hz, 1H), 3.57 (t, J = 9.0 Hz, 1H), 2.25 (bs, 2H). 
13
C NMR 
(CDCl3, 100 MHz, 300 K) δ (ppm): 141.7, 129.0, 128.2, 127.3, 125.7 (q, J = 279.6, 
CF3), 79.0, 69.2 (q, J = 34.2 Hz, OCH2CF3), 55.8. 
19
F NMR (CDCl3, 376 MHz, 300 
K) δ (ppm): -74.5. HRMS for C10H13NOF3 [M+H]
+
: m/z calc., 220.0944; found, 
220.0946. 
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2-(1,1,1,3,3,3-Hexafluoropropan-2-yloxy)-1-phenylethanamine, 9f: 
1
H NMR 
(CDCl3, 400 MHz, 300 K) δ (ppm): 7.33-7.23 (m, 5H), 4.23 (dd, J = 9.1, 3.4 Hz, 
1H), 4.05 (sep, J = 5.9 Hz, 1H), 3.90 (dd, J = 9.1, 3.4 Hz, 1H), 3.70 (t, J = 9.1 Hz, 
1H), 1.99 (bs, 2H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 140.9, 129.1, 
128.4, 127.3, 123.3 (q, J = 283.7, 2CF3), 81.6, 76.8 (sep, J = 32.1 Hz, OCH(CF3)2), 
55.8. 
19
F NMR (CDCl3, 376 MHz, 300 K) δ (ppm): -74.3. HRMS for C11H12NOF6 
[M+H]
+
: m/z calc., 288.0823; found, 288.0812. 
 
2-Ethoxycyclohexanamine, 9g:
[64]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 
syn:anti = 6:1; for Syn isomer: 3.58 (dq, J = 9.3, 7.0 Hz, 1H), 3.44 (dq, J = 9.3, 7.0 
Hz, 1H), 3.37 (dddd, J = 3.6, 3.4, 3.4, 3.0 Hz, 1H), 2.88 (ddd, J = 7.7, 4.2, 3.6 Hz, 
1H), 1.86-1.77 (m, 1H), 1.77-1.65 (bs, 2H), 1.63-1.51 (m, 4H), 1.44-1.35 (m, 1H), 
1.34-1.24 (m, 2H), 1.21 (t, J = 7.0 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ 
(ppm): 79.0, 64.0, 51.3, 31.7, 27.7, 23.1, 21.8, 16.1. HRMS for C8H18NO [M+H]
+
: 
m/z calc., 144.1383; found, 144.1382.  
4.4.9 Data of the α-amino acids 
 
2-Amino-2-phenylacetic acid, 11a:
[65]
 
1
H NMR (DMSO-d6 + HCl, 400 MHz, 300 
K) δ (ppm): 8.96 (bs, 3H), 7.53-7.47 (m, 2H), 7.47-7.40 (m, 3H), 5.05 (s, 1H). 13C 
NMR (DMSO-d6 + HCl, 100 MHz, 300 K) δ (ppm): 169.9, 133.5, 129.6, 129.2, 
128.5, 55.9. HRMS for C8H10NO2 [M+H]
+
: m/z calc., 152.0706; found, 152.0706. 
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2-Amino-2-(4-chlorophenyl)acetic acid, 11b:
[66]
 
1
H NMR (DMSO-d6 + HCl, 400 
MHz, 300 K) δ (ppm): 9.04 (bs, 3H), 7.57-7.48 (m, 4H), 5.11 (s, 1H). 13C NMR 
(DMSO-d6 + HCl, 100 MHz, 300 K) δ (ppm): 169.6, 134.4, 132.5, 130.5, 129.2, 
55.1. HRMS for C8H9NO2Cl [M+H]
+
: m/z calc., 186.0316; found, 186.0316. 
 
2-Amino-2-(4-(trifluoromethyl)phenyl)acetic acid, 11c:
[67]
 
1
H NMR (DMSO-d6 + 
HCl, 400 MHz, 300 K) δ (ppm): 9.14 (bs, 3H), 7.82 (d, J = 8.0 Hz, 2H), 7.74 (d, J = 
8.0 Hz, 2H), 5.24 (s, 1H). 
13
C NMR (DMSO-d6 + HCl, 100 MHz, 300 K) δ (ppm): 
169.3, 137.9, 130.0 (q, J = 31.9), 129.5, 126.1 (q, J = 3.5 Hz), 124.3 (q, J = 272.9 
Hz), 55.4. 
19
F NMR (CDCl3, 376 MHz, 300 K) δ (ppm): -61.7. HRMS for 
C9H9NO2F3 [M+H]
+
: m/z calc., 220.0580; found, 220.0581. 
 
2-Amino-2-(4-methoxyphenyl)acetic acid, 11d:
[68]
 
1
H NMR (DMSO-d6 + HCl, 400 
MHz, 300 K) δ (ppm): 8.88 (bs, 3H), 7.43 (d, J = 8.7 Hz, 2H), 7.00 (d, J = 8.7 Hz, 
2H), 4.99 (s, 1H), 3.76 (s, 3H). 
13
C NMR (DMSO-d6 + HCl, 100 MHz, 300 K) δ 
(ppm): 170.2, 160.2, 129.9, 125.4, 114.6, 55.7, 55.3. HRMS for C9H11NO3Na 
[M+Na]
+
: m/z calc., 204.0631; found, 204.0633. 
 
2-Amino-2-(naphthalen-2-yl)acetic acid, 11e:
[69]
 
1
H NMR (DMSO-d6 + HCl, 400 
MHz, 300 K) δ (ppm): 9.10 (bs, 3H), 8.08 (s, 1H), 8.03-7.89 (m, 3H), 7.66-7.52 (m, 
3H). 
13
C NMR (DMSO-d6 + HCl, 100 MHz, 300 K) δ (ppm): 169.9, 133.2, 132.8, 
131.0, 129.0, 128.3, 128.2, 128.1, 127.4, 127.3, 125.5, 56.0. HRMS for 
C12H11NO2Na [M+Na]
+
: m/z calc., 224.0682; found, 224.0683. 
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2-Amino-2-(1H-indol-3-yl)acetic acid, 11f:
[70]
 
1
H NMR (DMSO-d6 + HCl, 400 
MHz, 300 K) δ (ppm): 11.6 (bs, 1H), 8.77 (bs, 3H), 7.67 (d, J = 7.9 Hz, 1H), 7.56 (d, 
J = 1.9 Hz, 1H), 7.44 (d, J = 8.0 Hz, 1H) 7.15 (t, J = 7.4 Hz, 1H), 7.07 (t, J = 7.3 Hz, 
1H), 5.29 (s, 1H). 
13
C NMR (DMSO-d6 + HCl, 100 MHz, 300 K) δ (ppm): 170.6, 
136.4, 126.3, 125.5, 122.2, 119.7, 119.2, 112.3, 106.8, 49.2.  
 
2-Amino-2-(thiophen-2-yl)acetic acid, 11g:
[71]
 
1
H NMR (DMSO-d6 + HCl, 400 
MHz, 300 K) δ (ppm): 9.03 (bs, 3H), 7.64 (d, J = 5.1 Hz, 1H), 7.32 (d, J = 3.2 Hz, 
1H), 7.10 (dd, J = 5.1, 3.6 Hz, 1H) 5.40 (s, 1H). 
13
C NMR (DMSO-d6 + HCl, 100 
MHz, 300 K) δ (ppm): 169.2, 134.4, 129.2, 128.4, 127.6, 51.3. HRMS for 
C6H7NO2SNa [M+Na]
+
: m/z calc., 180.0090; found, 180.0089. 
4.4.10 Data of the Mexiletine 
 
1-(2,6-Dimethylphenoxy)propan-2-amine:
[72] 1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.03 (d, J = 7.3 Hz, 2H), 6.94 (dd, J = 8.2, 6.8 Hz, 1H), 3.68 (dd, J = 9.0, 4.2 
Hz, 1H), 3.57 (dd, J = 9.0, 7.6 Hz, 1H), 3.45-3.36 (m, 1H), 2.31 (s, 6H), 1.92 (bs, 
2H), 1.20 (d, J = 6.5 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 155.9, 
131.2, 129.3, 124.2, 78.6, 47.7, 20.1, 16.7. HRMS for C11H18NO [M+H]
+
: m/z calc., 
180.1383; found, 180.1383. 
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4.4.11 Crystallographic data of complex II 
 
 
 
CCDC 942737 
Table 1 Crystal data and structure refinement for complex II 
Identification code 942737 
Empirical formula C29H32IrNO 
Formula weight 602.76 
Temperature/K 100.15 
Crystal system monoclinic 
Space group I2/a 
a/Å 17.6600(18) 
b/Å 8.7325(9) 
c/Å 30.881(4) 
α/° 90.00 
β/° 92.0600(10) 
γ/° 90.00 
Volume/Å
3
 4759.3(9) 
Z 8 
ρcalcmg/mm
3
 1.682 
m/mm
-1
 5.632 
F(000) 2384.0 
Crystal size/mm
3
 0.25 × 0.25 × 0.1 
2Θ range for data collection 2.64 to 52.76° 
Index ranges -22 ≤ h ≤ 22, -10 ≤ k ≤ 10, -38 ≤ l ≤ 38 
Reflections collected 23179 
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Independent reflections 4860[R(int) = 0.0456] 
Data/restraints/parameters 4860/48/300 
Goodness-of-fit on F
2
 1.113 
Final R indexes [I>=2σ (I)] R1 = 0.0545, wR2 = 0.1189 
Final R indexes [all data] R1 = 0.0626, wR2 = 0.1248 
Largest diff. peak/hole / e Å
-3
 8.45/-3.51 
μ(MoKα)    5.632 mm-1 
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Chapter 5 
Acceptorless Dehydrogenation of N-
Heterocycles  
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5.1 Introduction  
Catalytic dehydrogenation (CDH) is one of the most important reactions in the 
manufacturing of commodity chemicals.
[1]
 For instance, annually approximately 17 
million tons of styrene are produced by CDH of ethyl benzene over oxide catalysts. 
However, CDH has been much less used in the synthesis of fine chemicals, 
pharmaceuticals and agrochemicals, although it offers considerable benefits with 
respect to atom economy and environmental impact due to the avoidance of using 
stoichiometric oxidants. In recent years, CDH of alkanes,
 
alcohols and amines has 
been realized with transition-metal complexes, although sacrificial hydrogen 
acceptors and additives are frequently used.
[2,3]
 However, homogeneous catalysts 
capable of dehydrogenating heterocycles are very rare, and those catalysts that are 
active are mostly heterogeneous ones, which usually show poor functionality 
tolerance and require harsh reaction conditions.
[4,5]
  
Fujita and Yamaguchi reported the first example of homogeneous dehydrogenation 
of tetrahydroquinolines using a Cp*Ir(2-hydroxypyridine) catalyst.
[6]
 A limitation is 
that only a few examples of 1,2,3,4-tetrahydroquinolines were demonstrated and the 
reaction conditions were relatively forcing [2 mol% catalyst for 20 h in refluxing p-
xylene (bp 138 °C) or 5 h in mesitylene (bp 165 °C)]. A significant advantage is that 
the same catalyst is capable of the reverse reaction, i.e. hydrogenation of quinolines 
to tetrahydroquinolines under H2 (1 atm) in quantitative yield (Scheme 5.1). 
Recently, the same group demonstrated the first homogeneous perdehydrogenation 
of fused bicyclic N-heterocycles using a Cp*Ir catalyst bearing a 1,10-
phenanthroline-2,9-dione ligand (Scheme 5.2).
[7]
 The reverse, perhydrogenation was 
also viable, albeit with high pressures of H2 (70 atm). 
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Scheme 5.1: Dehydrogenation and hydrogenation of 2-methyl tetrahydroquinoline. 
 
Scheme 5.2: Perdehydrogenation and perhydrogenation of 2,6-dimethyldecahydro-1,5-naphthyridine. 
Ru hydride complexes (1c-1e) are also efficient for acceptorless dehydrogenation of 
N-heterocycles.
[8]
 Among them, Shvo’s complex shows the best activity with almost 
quantitative yield of the desired products. Relatively high temperature and catalyst 
loadings are required for the reaction to proceed and again, only a few examples of 
N-heterocycles were demonstrated which are shown in Scheme 5.3.  
 
Scheme 5.3: Representative examples of dehydrogenation with Ru-H complexes. 
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More recently, Jones reported a well defined Fe complex 1f, bearing a 
bis(phosphino)amine pincer ligand that promoted the acceptorless dehydrogenation 
of a range of N-heterocycles (Scheme 5.4).
[9]
 Remarkably, a challenging piperidine 
substrate was also fully dehydrogenated to its corresponding pyridine. In addition, 
catalyst 1f is also active in the hydrogenation of unsaturated N-heterocycles. 
 
Scheme 5.4: Representative examples of dehydrogenation with a Fe complex. 
Given the importance of nitrogen-containing aromatics in numerous naturally 
occurring alkaloids and synthetic pharmaceuticals, and as potential hydrogen storage 
materials,
[10] 
developing a single catalytic system with higher CDH activity and 
wider scope would be of significant interest. 
As shown in earlier chapters, the cyclometalated Cp*Ir(III) imino complexes are 
excellent catalysts for reductive amination and for ketones and N-heterocycles 
reduction.
[11] 
They readily form hydrides under H2 pressure or when treated with 
formate, and can release H2 with the aid of an acid. Inspired by the work of Fujita 
and Yamaguchi, we envisioned that when reacted with an amine, complex C could 
undergo β-hydrogen elimination, thus generating an imino bond and H2 upon 
protonation (Scheme 5.5). However, C differs from Fujita-Yamaguchi catalyst (1a) 
not only structurally but also probably mechanistically if it catalyses the 
dehydrogenation. Containing no bifunctional ligand, the hydride generated from C 
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can only be protonated intermolecularly. In contrast, 1a operates by ligand-promoted 
dehydrogenation.
[12,13]
  
 
Scheme 5.5: Cyclometalated Cp*Ir(III) imino complexes and hypothesised dehydrogenation of N-
-heterocycles. 
Following the success of Cp*Ir(III) imino complexes in hydrogenation reactions as 
demonstrated in earlier chapters, it would be interesting to test if the same complexes 
could be exploited for the CDH (Scheme 5.5). This chapter reports that such 
complexes are indeed capable of dehydrogenating not only tetrahydroquinolines but 
other N-heterocycles as well.
[14]
 These results further demonstrate the versatility of 
Cp*Ir(III) imino complexes in both hydrogenation and dehydrogenation reactions. 
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5.2 Results and discussion 
5.2.1 Optimisation of reaction conditions 
2-Methyl-1,2,3,4-tetrahydroquinoline (2a) was chosen as a model substrate for the 
optimisation. As expected, in the absence of a catalyst, formation of 2-methyl-
quinoline (3a) was not detected in 2,2,2-trifluoro-ethanol (TFE; bp 78 °C) after 2 h 
at reflux (Table 5.1, entry 1). After screening a variety of precatalysts and solvents 
(Table 5.1, entries 2-19), we were pleased to observe that complex C11, which bears 
electron-donating OMe groups efficiently catalysed the CDH of 2a in TFE 
furnishing 88% conversion in 2 h. Full conversion, along with release of H2, was 
reached with 0.1 mol% catalyst overnight (Table 5.1, entry 7). Formation of H2 was 
confirmed by GC analysis and quantified with the water displacement method (vide 
infra). Other complexes and solvents were less effective.  
TFE appears to play multiple roles in the CDH. It may promote the dissociation of 
chlorine from the catalyst and hence the coordination of 2a to C11 before CDH takes 
place (Scheme 5.6). In support of this view, addition of a chloride salt inhibits the 
CDH (Table 5.1, entry 20). However, adding a silver or sodium salt did not improve 
the reactivity of C11 when the reaction was carried out in toluene (Table 5.1, entries 
21-22). It was noted that strong reflux is necessary for higher conversions, and 
remarkably, when nitrogen was bubbled through the solution, the CDH occurred 
even at room temperature, thus affording 52% conversion overnight. These 
observations indicate that the CDH is rate-limited by the step of dihydrogen 
formation,
[12]
 which is probably facilitated by TFE through protonation of the 
intermediate hydride (Scheme 5.7).
[15]
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Scheme 5.6: TFE promoted dissociation of chlorine from the catalyst.  
 
Scheme 5.7: TFE facilitated dihydrogen formation. 
Consistent with this, the CDH became progressively slower when alcohols of lower 
acidity were used, for example, TFE (pKa 12.5) versus 2,2-difluoro-ethanol (DFE; 
pKa 13.1), and ethanol (pKa 15.8; Table 5.1, entries 7, 10 and 11). Thus, CDH by 
C11 appears mechanistically distinct from that by the Fujita-Yamaguchi catalyst 
(1a). To further demonstrate that the high activity of this CDH results from the 
combination of C11 and TFE, that is, a solvent-assisted CDH, C11 was compared 
with 1a. Under the conditions of Table 5.1, the later afforded less than 2% 
conversion (Table 5.1, entry 23). In contrast, the conversion was less than 1% with 
the former but 77% with the latter under Fujita’s conditions (2 mol%, p-xylene, 
reflux, 20 h). 
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Table 5.1: Optimising reaction conditions for the CDH 
 
Entry
[a]
 Catalyst Additive Solvent Conv. (%)
[b]
 
1
[c]
 none - TFE n.r. 
2 [Cp*IrCl2]2 - TFE 3 
3 IrCl3.3H2O - TFE <1 
4 C8 - TFE 42 
5 C13 - TFE 74 
6 C1 - TFE 25 
7
[d]
 C11 - TFE 88 
8 C9 - TFE 29 
9 C12 - TFE 72 
10 C11 - DFE 23 
11 C11 - EtOH 4 
12 C11 - 
i
PrOH <1 
13 C11 - MeOH 14 
14 C11 - H2O 3 
15
[c]
 C11 - THF n.r. 
16
[c]
 C11 - DMF n.r. 
17 C11 - MeCN <1 
18
[c]
 C11 - toluene n.r. 
19
[e]
 C11 - p-xylene <1 
20
[f]
 C11 TBAC TFE 56 
21 C11 AgBF4 toluene 6 
22
[c]
 C11 NaBF4 toluene n.r. 
23 1a - TFE 2 
24
 [g]
 1a - p-xylene 77 
[a] Reaction conditions: 2a (0.5 mmol) and catalyst (1 mol%) in solvent (3 mL) stirred at reflux under 
nitrogen for 2 h; 1 mol% additive when used. [b] Determined by 
1
H-NMR spectroscopy. [c]
 
No 
reaction observed. [d] Full conversion with 0.1 mol% C11 overnight. [e] 2a (1.0 mmol) and catalyst 
(2 mol%), reflux, 20h. [f] 20 mol% TBAC used. [g] 2 mol% 1a used. Cp* = C5Me5, DFE = 
difluoroethanol, n.r. = no reaction, TBAC = tetrabutylammonium chloride.  
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5.2.2 CDH of tetrahydroquinolines 
With the C11/TFE catalytic system in hand, a variety of tetrahydroquinolines (2) 
were subjected to the CDH (Table 5.2). These were dehydrogenated to give 
quinolines in good to excellent yields with 0.1 mol% of C11. Slightly lower yields 
were obtained with the nonsubstituted 1,2,3,4-tetrahydroquinoline (2b) and 3-
methyl-1,2,3,4-tetrahydroquinoline (2c), even at a higher catalyst loading of 1 mol% 
(Table 5.2, entries 2 and 3).
[16]
 All the 6-substituted substrates afforded the 
corresponding products in high yields (Table 5.2, entries 5-8), regardless of the 
nature of the substituent. The less basic 2j was also dehydrogenated in excellent 
yield (Table 5.2, entry 10). The acridine 3k and the 1,2,3,4-tetrahydro variant 3l, 
used as antitumor drugs and an analogue of acetylcholinesterase inhibitor,
[17]
 were 
obtained from 2k and 2l, respectively, in excellent yields (Table 5.2, entries 11 and 
12). Notably, the 2,2’-biquinoline 3m, a well-known diamine ligand, was generated 
along with liberation of 4 equivalents of H2 from the octahydro form 2m (Table 5.2, 
entry 13). The catalyst is chemoselective, as seen in the CDH of 2i bearing a primary 
alcohol group, affording 3i with exclusive dehydrogenation selectivity towards the 
N-heterocyclic ring (Table 5.2, entry 9). 
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Table 5.2: CDH of tetrahydroquinolines 
 
Entry
[a]
 Substrate  Product  yield (%)
[b]
 
1 
 
2a 
 
3a 95 
2
[c]
 
 
2b 
 
3b 87 
3
[c]
 
 
2c 
 
3c 72 
4 
 
2d 
 
3d 87 
5 
 
2e 
 
3e 94 
6 
 
2f 
 
3f 97 
7 
 
2g 
 
3g 93 
8 
 
2h 
 
3h 94 
9 
 
2i 
 
3i 81 
10 
 
2j 
 
3j 92 
11 
 
2k 
 
3k 92 
12 
 
2l 
 
3l 88 
13
[c]
 
 
2m 
 
3m 81 
[a] Reaction conditions: 2 (0.5 mmol) and C11 (0.1 mol%) in TFE (3 mL) stirred at reflux under 
nitrogen for 20 h. [b] Yield of isolated product. [c] Used 1 mol% C11. 
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5.2.3 CDH of tetrahydroisoquinolines and tetrahydro-β-carbolines  
Isoquinolines and β-carbolines have broad pharmaceutical applications.[18] They can 
be obtained by traditional oxidation of the easily accessible tetrahydro or 3,4-dihydro 
analogs.
[19]
 Following the CDH of 2, tetrahydroisoquinolines and 
tetrahydro-β-carbolines (4) were examined. These substrates are challenging to fully 
dehydrogenate, because of their tendency to form stable imine intermediates.
[20] 
Table 5.3 shows that 4 can be dehydrogenated to isoquinolines (5) in good to 
excellent yields in general at a 0.1 mol% catalyst loading (entries 1-8). Among the 
substrates examined, only the nonsubstituted 4a and sterically demanding 4e 
necessitated a higher catalyst loading of 1 mol%. In the case of the former, 5a was 
obtained in only 30% yield. Worth noting is that the tetrahydroharman 4i was fully 
dehydrogenated to give the aribine 5i, an important β-carboline alkaloid (Table 5.3, 
entry 9), and 4j was converted into 5j in high yield (Table 5.3, entry 10). 
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Table 5.3: CDH of tetrahydroisoquinolines and tetrahydro-β-carbolines 
 
Entry
[a]
 Substrate  Product  yield (%)
[b]
 
1
[c,d]
 
 
4a 
 
5a 30 
2 
 
4b 
 
5b 90 
3 
 
4c 
 
5c 92 
4 
 
4d 
 
5d 93 
5
[c]
 
 
4e 
 
5e 82 
6 
 
4f 
 
5f 95 
7 
 
4g 
 
5g 93 
8 
 
4h 
 
5h 96 
9
[c]
 
 
4i 
 
5i 93 
10 
 
4j 
 
5j 95 
[a] Reaction conditions: 4 (0.5 mmol) and C11 (0.1 mol%) in TFE (3 mL) stirred at reflux under 
nitrogen for 20 h. [b] Yield of isolated product. [c] Used 1 mol% C11. [d] Yield as determined by 
1
H-
NMR spectroscopy. 
 
Chapter 5 
199 
 
5.2.4 CDH of 3,4-dihydroisoquinolines 
The CDH of 3,4-dihydroisoquinolines (6), which can be produced by the classical 
Bischler-Napieralski reaction, were targeted next (Table 5.4).
[21]
 Although high 
yields were achieved, surprisingly a high catalyst loading (1 mol%) was required 
(Table 5.4, entries 1-6). Under the reaction conditions used for 1,2,3,4-
tetrahydroisoquinolines 4 (Table 5.3), CDH of 6 was hardly detectable, thus 
suggesting that the CDH of 4 does not proceed via the intermediacy of 6. 
Table 5.4: CDH of 3,4-dihydroisoquinolines 
 
Entry
[a]
 Substrate  Product  yield (%)
[b]
 
1 
 
6a 
 
5b 89 
2 
 
6b 
 
5c 92 
3 
 
6c 
 
5f 93 
4 
 
6d 
 
5g 94 
5 
 
6e 
 
5h 95 
6 
 
6f 
 
5i 81 
[a] Reaction conditions: 6 (0.5 mmol) and C11 (1 mol%) in TFE (3 mL) stirred at reflux under 
nitrogen for 20 h. [b] Yield of isolated product. 
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Apart from CDH, C11 also catalyses the hydrogenation of 6a into 4b with excellent 
conversion at 20 °C and 1 atm H2 pressure (Scheme 5.8). The highly stable 5b was 
hydrogenated as well, although more forcing reaction conditions were needed. 
Together with the results in Tables 5.3 and 5.4, these results weave a unique network 
which links the three forms of isoquinoline by hydrogenation and dehydrogenation 
using a single catalyst (C11; Scheme 5.8). 
 
Scheme 5.8: Hydrogenation/dehydrogenation-linked interchangeable transformations between 
isoquinoline and derivatives. 
5.2.5 CDH of indoline derivatives and tetrahydroquinoxalines 
Bearing in mind that there are diverse ways for the preparation of indolines,
[22] 
direct 
CDH adds a valuable alternative to the strategies of indole synthesis. Using C11, 
various indoline derivatives were dehydrogenated, affording indoles in excellent 
yields (Table 5.5). In particular, sterically demanding 2,3-dimethyl and 2-
phenylindolines were dehydrogenated to indoles in 96% yield (Table 5.5, entries 5 
and 7). However, as with 4a, the nonsubstituted 7a was more difficult to 
dehydrogenate (Table 5.5, entry 1). 
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Table 5.5: CDH of indoline derivatives 
 
Entry
[a]
 Substrate  Product  yield (%)
[b]
 
1
[c]
 
 
7a 
 
8a 91 
2 
 
7b 
 
8b 95 
3
[d]
 
 
7c 
 
8c 93 
4 
 
7d 
 
8d 90 
5 
 
7e 
 
8e 96 
6 
 
7f 
 
8f 98 
7 
 
7g 
 
8g 96 
[a] Reaction conditions: 7 (0.5 mmol) and C11 (0.1 mol%) in TFE (3 mL) stirred at reflux under 
nitrogen for 20 h. [b] Yield of isolated product. [c] Used 1 mol% C11. [d] Used 0.5 mol% C11. 
Traditional synthesis of quinoxalines makes use of reactions such as condensation 
and oxidative cyclisation.
[23]
 To the best of our knowledge CDH has not been 
employed for the synthesis of quinoxalines. We therefore investigated the 
dehydrogenation of tetrahydroquinoxalines (9; Table 5.6). The CDH worked, giving 
rise to good to excellent yields of the quinoxalines 10 with 0.1 mol% of C11. 
However, a higher catalyst loading was necessary for the sterically bulky 9d and 9e 
(Table 5.6, entries 4 and 5). 
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Table 5.6: CDH of tetrahydroquinoxalines 
 
Entry
[a]
 Substrate  Product  yield (%)
[b]
 
1 
 
9a 
 
10a 92 
2 
 
9b 
 
10b 79 
3 
 
9c 
 
10c 93 
4
[c]
 
 
9d 
 
10d 85 
5
[c]
 
 
9e 
 
10e 82 
6 
 
9f 
 
10f 62 
7 
 
9g 
 
10g 64 
[a] Reaction conditions: 9 (0.5 mmol) and C11 (0.1 mol%) in TFE (3 mL) stirred at reflux under 
nitrogen for 20 h. [b] Yield of isolated product. [c] Used 1 mol% C11. 
5.2.6 CDH in total synthesis of alkaloids 
To showcase the synthetic utility of the CDH, the protocol was applied to a rapid 
total synthesis of two well-known, naturally occurring alkaloids, papaverine and 
harmine. Papaverine is an opium alkaloid antispasmodic drug, clinically used for the 
treatment of vasospasm and occasionally for erectile dysfunction.
[24]
 Harmine is a 
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major β-carboline alkaloid found in pegunam harmala extract. It is an inhibitor of 
monoamine reuptake system and has also shown cytotoxic activities against a series 
of tumor cell lines.
[25]
 Our synthesis of papaverine started with the condensation of 
commercially available homoveratric acid and homoveratrylamine under 
microwave-assisted, neat conditions, thus generating the corresponding amide in 
almost quantitative yield (Scheme 5.9). The amide was then treated with POCl3 to 
furnish a cyclic imine by the Bischler-Napieralski reaction.
[21] 
The last step of the 
synthesis was accomplished by C11 catalysed CDH of the 3,4-dihydroisoquinoline. 
The three-step synthesis, employing commercially available materials with an 
overall yield of 78%, appears to offer a most efficient and economically sound 
method for this significant alkaloid.
[26]
 
 
Scheme 5.9: Synthesis of papaverine. 
Scheme 5.10 shows the synthesis of harmine starting with a Pictet-Spengler 
reaction
[21]
 of acetaldehyde with 6-methoxytryptamine. CDH of the resulting 
tetrahydroharmine by C11 afforded the target alkaloid, with an overall yield of 57%. 
In comparison with other known methods,
[27] 
this concise synthesis of harmine using 
commercially available materials is high-yielding and less wasteful under mild 
reaction conditions. 
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Scheme 5.10: Synthesis of harmine. 
5.2.7 Mechanistic considerations 
Preliminary mechanistic studies of CDH of 2-methyl-1,2,3,4-tetrahydroquinoline 
(2a) and 1-methyl-1,2,3,4-tetrahydroisoquinoline (4b) shed light on how these CDH 
reactions may take place. In the presence of C11 in TFE-d3, 2a undergoes rapid H-D 
exchange at the C2-position at room temperature. However, no other species were 
observed apart from 2a and trace amounts of 3a in the 
1
H NMR spectrum (Figure 
5.1). This suggests again that dehydrogenation, without releasing H2, is a fast 
process.
  
Figure 5.1: 
1
H NMR spectra recorded at 298 K: a) 2a (0.25 mmol, 37 mg) in TFE-d3 (0.8 mL); b) a) 
+ C11 (0.05 mmol), 3.5 min after addition; c) 20 min after addition of C11. c = catalyst, s = solvent, p 
= product. 
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Under the normal reflux conditions (Table 5.2), 3a was obtained with deuterium 
incorporation at the C3 and methyl position. To further confirm the deuteration, the 
dehydrogenation of 2f was carried out using TFE-d3 under reflux conditions for 20 h 
(whereby the Me of OMe at C6 could be used as an internal standard). 2f was 
converted to 3fd with partial deuteration (60%) at C3 and multiple deuterations (61% 
in total) at the R group (Scheme 5.11).  
 
Scheme 5.11: Dehydrogenation of 2f in TFE-d3. 
On this basis, CDH of 2a is suggested to proceed by the pathway shown in Scheme 
5.12. At low temperature, 2a is in equilibrium with 2a1, which is probably 
protonated by or hydrogen-bonded with the medium, and 2a2, with the equilibrium 
strongly favouring 2a. At high temperature 2a1 isomerises to 2a4 by acid catalysis, 
which hydrogenates 2a3, thus resulting in the formation of 3a and 2a. 
 
Scheme 5.12: Proposed pathway for the CDH of tetrahydroquinolines. 
When 4b was subjected to CDH with 0.1 mol% of C11 in refluxing TFE for a short 
time, both 6a and 5b were observed (Scheme 5.13, Eq. 1). However, 6a showed no 
observable CDH under these conditions (Eq. 2), although it gave 4b and 5b at 1 
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mol% of C11 (Eq. 3). In contrast, using of 0.1 mol% of C11 but in the presence of 
4c, 6a was converted into 4b and 5b (Eq. 4), thus showing that 6a can readily 
undergo CDH, probably by 4b, if a hydride donor such as 4c, is present.  
 
 
Scheme 5.13: Control experiments. 
These observations suggest that the CDH of 4b involves a pathway as shown in 
Scheme 5.14, where 4b can be dehydrogenated into either 6a or 4b1. But it is 4b1 
that gives rise to the product 5b. The formation of 5b from 6a proceeds by its first 
reduction to 4b. When 6a alone is dehydrogenated, it is likely to be reduced to 4b in 
the first place by TFE, a solvent of well-known to resistance to oxidation.
 
This 
explains why 6 is more difficult to dehydrogenate than 4.  
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Scheme 5.14: Proposed pathway for the CDH of tetrahydro- and dihydroisoquinolines. 
The hypothesis on TFE acting as a hydride donor finds support in the observation of 
Ir-H hydride resonance at δ -10.10 ppm in the 1H NMR spectrum when C11 was 
dissolved in TFE and heated to 60 °C for 1 h in a high pressure sapphire NMR tube. 
The formation of 2,2,2-trifluoroacetaldehyde was also observable at δ 9.66 ppm as a 
quartet (Figure 5.2). 
  
 
Figure 5.2: 
1
H NMR spectrum of TFE + C11 recorded at 60 °C after 1 h, showing the hydride and 
aldehydes region. Conditions: TFE (1 mL) + C11 (10 mg, 0.017 mmol). 
5.3 Conclusion 
In summary, this chapter demonstrates the development of a versatile catalytic 
system for the oxidant-free, acceptorless CDH of various benzo-fused 
N-heterocycles.
[14]
 The high activity and broad substrate scope of the catalytic 
system make the protocol a promising alternative for laboratory as well as industrial 
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applications, and this is reinforced by the ease of operation, atom economy and 
environmental benefits offered by CDH. 
5.4 Experimental 
5.4.1 General information 
Unless otherwise specified, reagents and solvents were purchased commercially and 
used as received. Substrates 2a, 2c, 2e, 2f, 2g, 2h, 2i, 2j, and 2l were prepared by the 
reduction of corresponding quinolines, and 9a, 9b, 9c, 9f, and 9g  by reduction of the 
corresponding quinoxalines.
[28]
 Substrate 2m was prepared by the hydrogenation of 
2,2’-biquinoline according to the literature method using Adam’s catalyst.[29] 
Substrates 7b and 7e were prepared by the hydrogenation of the corresponding 
indoles according to the literature method.
[30]
 7f was obtained from reduction by 
using sodium borocyanohydride,
[31]
 while 7g was synthesised through tin-mediated 
reduction of the corresponding indoles.
[32]
 9d and 9e were prepared by the reduction 
with sodium borohydride of the corresponding quinoxalines, which were prepared by 
the condensation of diamines with diketones or dialdehydes according to the 
literature methods.
[33,34]
 Dihydroisoquinolines were prepared by the Bischler-
Napieralski synthesis and were subsequently reduced to give their tetrahydro 
variants.
[28,34]
 NMR spectra were recorded on a Bruker 400 MHz NMR spectrometer 
unless otherwise specified. Elemental analysis and mass spectrometry analysis were 
carried out at the Microanalysis Centre of University of Liverpool and the EPSRC 
National Mass Spectrometry Service Centre at Swansea University. 
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5.4.2 General procedure for the dehydrogenation of N-heterocyclic amines 
N-Heterocyclic amine (0.50 mmol) and C11 (0.31 mg, 5x10
-4
 mmol, measured using 
a stock TFE solution) were dissolved in TFE (3 mL) in a carousel reaction tube. The 
tube was then degassed and the reaction mixture was refluxed under N2 for 20 h.  It 
was then cooled to room temperature and the solvent was evaporated under vacuum. 
The resulting crude solid was purified using flash chromatography to give the 
corresponding product. All the dehydrogenation products are known, except 5g, and 
their NMR spectra were consistent with the literature.  
5.4.3 Typical procedure for the hydrogen evolution experiment 
A solution of 2-methyl-1,2,3,4-tetrahydroquinoline (0.5 mmol) in TFE (2 mL) was 
added to a thick walled glass vessel fitted with a side arm and a rubber septum which 
had been preheated to the appropriate temperature by means of an oil bath. The 
vessel was previously degassed three times and placed under an N2 atmosphere. The 
vessel was connected to the gas collection apparatus (standard water displacement 
apparatus, using a graduated cylinder to determine volume) and the entire system 
was flushed with N2 for 5 minutes and allowed to equilibrate for 5 minutes. A 
solution of the catalyst C11 (18.6 mg, 6 mol%) in TFE (1 mL) was added via syringe 
through the septum. Any small volume of gas collected resulting from addition of 
the catalyst solution was noted and subtracted from the values for gas collected. The 
reaction was stirred vigorously at a constant temperature until gas evolution ceased 
(2.5 h). The volume of collected gas was noted, supposing that all the gas consisted 
of hydrogen. The presence of hydrogen in the collected gas was confirmed by GC. 
After the reaction was complete, the solution was evaporated to give a crude product 
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which was analysed by 
1
H NMR, which confirmed full conversion of the 2-
methylquinoline product. 
The calculation of the volume of 1 mole of H2 at 25 °C was carried out using Van 
der Waals equation, as shown below: 
   
   
  
           
Where; 
R: 8.3145 m³ Pa mol
-1
 K
-1  
T: 298.15 K  p: 101,325 Pa (1 atm) 
a: 0.002476 m
6
·Pa·mol
-2
   b: 0.02661x10
-3
 m
3
·mol
-1 
  Thus, V (H2, 25 °C, 1 atm) = 24.49 L·mol
-1 
  
The collected volume of gas in the experiment above was 24.2 mL, which 
corresponds to 0.98 mmol of H2. Since the dehydrogenation is 0.5 mmol in scale, 
this is consistent with the release of 2 equivalents of H2 per mole of 2-methyl-
1,2,3,4-tetrahydroquinoline. 
5.4.4 Data for the quinolines  
 
2-Methylquinoline (3a):
[35]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 8.02 (d, J = 
8.4 Hz, 2H), 7.75 (dd, J = 8.2, 1.0 Hz, 1H), 7.67 (ddd, J = 8.6, 6.8, 1.6 Hz, 1H), 7.46 
(ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.26 (d, J = 8.4 Hz, 1H), 2.74 (s, 3H). 
13
C NMR 
(CDCl3, 100 MHz, 300 K) δ (ppm): 159.4, 148.3, 136.6, 129.8, 129.0, 127.9, 126.9, 
126.1, 122.4, 25.8. MS (CI) for C10H10N [M+H]
+
: m/z 144.2. 
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Quinoline (3b):
[36]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 8.92 (dd, J = 4.2, 
1.7 Hz, 1H), 8.13 (t, J = 9.3 Hz, 2H), 7.81 (d, J = 8.1 Hz, 1H), 7.71 (ddd, J = 8.4, 7.0, 
1.4 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 7.38 (dd, J = 8.1, 4.2 Hz, 1H). 
13
C NMR 
(CDCl3, 100 MHz, 300 K) δ (ppm): 150.8, 148.7, 136.4, 129.9, 129.8, 128.7, 128.2, 
126.9, 121.5. Anal. calc. for C9H7N (%): C, 83.69; H, 5.46; N, 10.84. Found: C, 
83.60; H, 5.42; N, 10.77. MS (CI) for C9H8N [M+H]
+
: m/z 130.2. 
 
3-Methylquinoline (3c):
[36]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 8.78 (d, J = 
2.1 Hz, 1H), 8.07 (d, J = 8.5 Hz, 1H), 7.93 (s, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.65 
(ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.54-7.50 (m, 1H), 2.53 (s, 3H). 
13
C NMR (CDCl3, 
100 MHz, 300 K) δ (ppm): 152.3, 146.9, 135.1, 130.9, 129.5, 128.9, 128.5, 127.5, 
127.0, 19.2. Anal. calc. for C10H9N (%): C, 83.88; H, 6.34; N, 9.78. Found: C, 83.74; 
H, 6.58; N, 9.91. MS (CI) for C10H10N [M+H]
+
: m/z 144.0. 
 
4-Methylquinoline (3d):
[37]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 8.76 (d, J = 
4.4 Hz, 1H), 8.11 (d, J = 8.4 Hz, 1H), 7.96 (dd, J = 8.4, 1.6 Hz, 1H), 7.69 (ddd, J = 
8.4, 6.8, 1.6 Hz, 1H), 7.54 (ddd, J = 8.4, 6.8, 1.3 Hz, 1H),  7.19 (dd, J = 4.4, 0.8 Hz, 
1H), 2.67 (J = 0.8 Hz, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 150.6, 
148.4, 144.6, 130.4, 129.5, 128.7, 126.7, 124.2, 122.2, 19.0. Anal. calc. for C10H9N 
(%): C, 83.88; H, 6.34; N, 9.78. Found: C, 84.28; H, 6.57; N, 9.89. MS (CI) for 
C10H10N [M+H]
+
: m/z 144.2. 
 
2,6-Dimethylquinoline (3e):
[38]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 7.94 
(d, J = 8.6 Hz, 1H), 7.91 (d, J = 8.3 Hz, 1H), 7.55-7.47 (m, 2H), 7.24 (d, J = 8.3 Hz, 
1H), 2.72 (s, 3H), 2.51 (s, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 158.4, 
146.9, 135.9, 135.8, 132.0, 128.7, 126.9, 126.8, 122.3, 25.7, 21.9. Anal. calc. for 
Chapter 5 
212 
 
C11H11N (%): C, 84.04; H, 7.05; N, 8.91. Found: C, 83.81; H, 7.08; N, 8.87. MS (CI) 
for C11H12N [M+H]
+
: m/z 158.1. 
 
6-Methoxy-2-methylquinoline (3f):
[36]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 
7.92 (t, J = 8.2 Hz, 2H), 7.33 (dd, J = 9.2, 2.8 Hz, 1H), 7.23 (d, J = 8.5 Hz, 1H), 7.04 
(d, J = 2.8 Hz, 1H), 3.91 (s, 3H), 2.70 (s, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ 
(ppm): 157.6, 156.7, 144.3, 135.4, 130.4, 127.7, 122.6, 122.2, 105.6, 55.9, 25.4. 
Anal. calc. for C11H11NO (%): C, 76.28; H, 6.40; N, 8.09. Found: C, 76.23; H, 6.46; 
N, 8.12. MS (CI) for C11H12NO [M+H]
+
: m/z 174.2. 
 
6-Fluoro-2-methylquinoline (3g):
[39]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 
8.02-7.98 (m, 2H), 7.45 (td, J = 8.8, 2.8 Hz, 1H), 7.38 (dd, J = 8.9, 2.8 Hz, 1H), 7.30 
(d, J = 8.3 Hz, 1H), 2.73 (s, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 
160.1 (d, JCF = 246.7), 158.7 (d, JCF = 2.7 Hz), 145.3, 135.9 (d, JCF = 5.2 Hz), 131.4 
(d, JCF = 9.5 Hz), 127.4 (d, JCF = 9.8 Hz), 123.1, 119.9 (d, JCF = 26.1 Hz) 110.9 (d, 
JCF = 22.1 Hz), 25.6. MS (CI) for C10H8FN [M+H]
+
: m/z 162.1. HRMS for C10H9FN 
[M+H]
+
: m/z calc., 162.0714; found, 162.0713. 
 
6-Chloro-2-methylquinoline (3h):
[40]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 
7.96 (dd, J = 8.6, 4.0 Hz, 2H), 7.75 (d, J = 2.3 Hz, 1H), 7.61 (dd, J = 9.0, 2.3 Hz, 
1H), 7.31 (d, J = 8.4 Hz, 1H), 2.74 (s, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ 
(ppm): 159.8, 146.7, 135.6, 131.7, 130.7, 130.6, 127.5, 126.6, 123.3, 25.7. Anal. 
calc. for C10H8ClN (%): C, 67.62; H, 4.54; N, 7.89. Found: C, 67.40; H, 4.25; N, 
7.91. MS (CI) for C10H9ClN [M+H]
+
: m/z 178.2. 
 
Quinolin-2-ylmethanol (3i):
[41]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 8.15 
(d, J = 8.8 Hz, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.74 (ddd, J = 
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8.0, 6.8, 1.2 Hz, 1H), 7.55 (t, J = 7.4 Hz, 1H), 7.29 (d, J = 8.4 Hz, 1H), 4.93 (s, 2H), 
4.57 (br, 1H),. 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 159.3, 147.1, 137.3, 
130.2, 129.0, 128.1, 128.0, 126.8, 118.7, 64.5. Anal. calc. for C10H9NO (%): C, 
75.45; H, 5.70; N, 8.80. Found: C, 74.99; H, 5.71; N, 8.60. MS (CI) for C10H10NO 
[M+H]
+
: m/z 160.2. 
 
2-Phenylquinoline (3j):
[42]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 8.29-8.12 
(m, 4H), 7.88 (d, J = 8.5 Hz, 1H), 7.83 (d, J = 8.2 Hz, 1H) 7.78-7.69 (m, 1H), 7.58-
7.44 (m, 4H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 157.8, 148.7, 140.1, 
137.2, 130.2, 130.1, 129.7, 129.3, 128.0, 127.9, 127.6, 126.7, 119.4. Anal. calc. for 
C15H11N (%): C, 87.77; H, 5.40; N, 6.82. Found: C, 87.56; H, 5.26; N, 6.62. MS (CI) 
for C15H12N [M+H]
+
: m/z 206.1.  
 
Acridine (3k):
[43]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 8.79 (s, 1H), 8.25 (d, 
J = 8.8 Hz, 2H), 8.02 (d, J = 8.4 Hz, 2H), 7.80 (ddd, J = 8.4, 6.8, 1.6 Hz, 2H), 7.55 (t, 
J = 7.2 Hz, 2H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 149.5, 136.3, 130.8, 
129.8, 128.6, 127.0, 126.1. Anal. calc. for C13H9N (%): C, 87.12; H, 5.06; N, 7.82. 
Found: C, 86.24; H, 4.97; N, 7.72. MS (CI) for C13H10N [M+H]
+
: m/z 180.2. 
 
1,2,3,4-Tetrahydroacridine (3l):
[44]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 
7.98 (d, J = 8.4 Hz, 1H), 7.81 (s, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.61 (ddd, J = 8.4, 
7.0, 1.2 Hz, 1H), 7.44 (t, J = 7.2 Hz, 1H), 3.14 (t, J = 6.4 Hz, 2H), 2.98 (t, J = 6.4 Hz, 
2H), 2.03-1.96 (m, 2H), 1.95-1.87 (m, 2H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ 
(ppm): 159.7, 147.0, 135.4, 131.4, 128.9, 128.7, 127.6, 127.3, 126.0, 34.0, 29.7, 
23.7, 23.3. Anal. calc. for C13H13N (%): C, 85.21; H, 7.15; N, 7.64. Found: C, 84.84; 
H, 7.18; N, 7.51. MS (CI) for C13H14N [M+H]
+
: m/z 184.2. 
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2,2'-Biquinoline (3m):
[45]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 8.85 (d, J = 
8.6 Hz, 2H), 8.32 (d, J = 8.6 Hz, 2H), 8.23 (d, J = 8.5 Hz, 2H), 7.88 (dd, J = 8.1, 1.2 
Hz, 2H), 7.75 (ddd, J = 8.5, 6.9, 1.5 Hz, 2H), 7.57 (ddd, J = 8.1, 6.9, 1.2 Hz, 2H). 
13
C 
NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 156.7, 148.4, 137.1, 130.4, 129.9, 128.9, 
128.1, 127.4, 119.9. Anal. calc. for C18H12N2 (%): C, 84.35; H, 4.72; N, 10.93. 
Found: C, 84.16; H, 4.61; N, 10.89. MS (CI) for C18H13N2 [M+H]
+
: m/z 257.2. 
5.4.5 Data for the isoquinolines 
 
1-Methylisoquinoline (5b):
[46]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 8.39 (d, 
J = 5.7 Hz, 1H), 8.12 (d, J = 8.3 Hz, 1H), 7.80 (d, J = 8.3 Hz, 1H), 7.67 (ddd, J = 8.1, 
6.9, 1.2 Hz, 1H), 7.59 (ddd, J = 8.3, 7.0, 1.2 Hz, 1H), 7.51 (d, J = 5.8 Hz, 1H), 2.97 
(s, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 159.0, 142.2, 136.3, 130.3, 
127.9, 127.6, 127.4, 126.0, 119.7, 22.8. Anal. calc. for C10H9N (%): C, 83.88; H, 
6.34; N, 9.78. Found: C, 83.46; H, 6.52; N, 9.54. MS (CI) for C10H10N [M+H]
+
: m/z 
144.2. 
 
1-Isopropylisoquinoline (5c):
[47]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 8.49 
(d, J = 5.6 Hz, 1H), 8.22 (d, J = 8.4 Hz, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.65 (ddd, J = 
8.0, 6.8, 1.2 Hz, 1H), 7.58 (ddd, J = 8.4, 6.8, 1.2 Hz, 1H), 7.48 (d, J = 5.6 Hz, 1H), 
3.96 (septet, J = 6.8 Hz, 1H), 1.45 (d, J = 6.4 Hz, 6H). 
13
C NMR (CDCl3, 100 MHz, 
300 K) δ (ppm): 166.7, 142.3, 136.8, 129.9, 127.9, 127.2, 126.7, 125.2, 119.4, 31.4, 
22.6. Anal. calc. for C12H13N (%): C, 84.17; H, 7.65; N, 8.18. Found: C, 84.41; H, 
7.84; N, 8.10. MS (CI) for C12H14N [M+H]
+
: m/z 172.2. 
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3-Methylisoquinoline (5d):
[48]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 9.19 (s, 
1H), 7.93 (d, J = 8.1 Hz, 1H), 7.73 (d, J = 8.2 Hz, 1H), 7.66-7.62 (m, 1H), 7.54-7.48 
(m, 2H), 2.71 (s, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 152.4, 152.0, 
137.0, 130.7, 127.9, 127.2, 126.7, 126.3, 118.9, 24.6. Anal. calc. for C10H9N (%): C, 
83.88; H, 6.34; N, 9.78. Found: C, 84.00; H, 6.33; N, 9.70. MS (CI) for C10H10N 
[M+H]
+
: m/z 144.0. 
 
1-(tert-Butyl)isoquinoline (5e):
[49]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 
8.53 (d, J = 8.8 Hz, 1H), 8.44 (d, J = 5.6 Hz, 1H), 7.82 (d, J = 8.4 Hz, 1H), 7.62 (ddd, 
J = 8.0, 6.8, 1.2 Hz, 1H), 7.54 (ddd, J = 8.4, 6.8, 1.6 Hz, 1H), 7.50 (d, J = 5.6 Hz, 
1H), 1.67 (s, 9H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 167.8, 141.0, 137.8, 
129.2, 128.7, 127.7, 126.6, 126.1, 120.2, 40.3, 31.6. Anal. calc. for C13H15N (%): C, 
84.28; H, 8.16; N, 7.56. Found: C, 84.87; H, 8.14; N, 7.29. MS (CI) for C13H16N 
[M+H]
+
: m/z 186.2. 
 
1-Cyclohexylisoquinoline (5f):
[50]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 8.47 
(d, J = 5.6 Hz, 1H), 8.22 (d, J = 8.4 Hz, 1H), 7.80 (d, J = 8.4 Hz, 1H), 7.64 (ddd, J = 
8.0, 6.8, 1.2 Hz, 1H), 7.58 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.47 (d, J = 5.6 Hz, 1H), 
3.56 (tt, J = 11.6, 3.2 Hz, 1H), 2.01-1.76 (m, 7H), 1.60-1.34 (m, 3H). 
13
C NMR 
(CDCl3, 100 MHz, 300 K) δ (ppm): 166.1, 142.4, 136.8, 129.9, 127.9, 127.2, 126.7, 
125.1, 119.3, 42.0, 33.0, 27.3, 26.7. Anal. calc. for C15H17N (%): C, 85.26; H, 8.11; 
N, 6.63. Found: C, 85.94; H, 8.37; N, 6.63. MS (CI) for C15H18N [M+H]
+
: m/z 
212.4. 
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1-Cyclohexyl-6,7-dimethoxyisoquinoline (5g): 
1
H NMR (CDCl3, 400 MHz, 300 K) 
δ (ppm): 8.36 (d, J = 5.6 Hz, 1H), 7.40 (s, 1H), 7.34 (d, J = 5.6 Hz, 1H), 7.06 (s, 1H), 
4.05 (s, 3H), 4.02 (s, 3H), 3.39 (tt, J = 11.4, 3.1 Hz, 1H), 2.10-1.22 (m, 10H). 
13
C 
NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 163.6, 152.7, 150.2, 141.5, 133.6, 122.3, 
118.1, 106.0, 103.6, 56.4, 42.2, 32.8, 27.3, 26.7. Anal. calc. for C17H21NO2 (%): C, 
75.25; H, 7.80; N, 5.16. Found: C, 75.00; H, 7.98; N, 5.06. MS (CI) for C17H22NO2 
[M+H]
+
: m/z 272.4. 
 
6,7-Dimethoxy-1-phenylisoquinoline (5h):
[51]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 8.48 (d, J = 5.6 Hz, 1H), 7.71 (dd, J = 6.8, 1.6 Hz, 2H), 7.55-7.46 (m, 4H), 
7.38 (s, 1H), 7.13 (s, 1H), 4.05 (s, 3H), 3.86 (s, 3H). 
13
C NMR (CDCl3, 100 MHz, 
300 K) δ (ppm): 158.7, 153.1, 150.4, 141.8, 140.5, 134.2, 130.0, 128.8, 122.9, 119.1, 
106.0, 105.4, 56.5, 56.3. Anal. calc. for C17H15NO2 (%): C, 76.96; H, 5.70; N, 5.28. 
Found: C, 76.28; H, 5.72; N, 5.18. MS (CI) for C17H16NO2 [M+H]
+
: m/z 266.3. 
 
1-Methyl-9H-pyrido[3,4-b]indole (5i):
[52]
 
1
H NMR (d
6
-Acetone, 400 MHz, 300 K) δ 
(ppm): 10.69 (bs, 1H), 8.27 (d, J = 5.2 Hz, 1H), 8.19 (d, J = 8.0 Hz, 1H), 7.90 (d, J = 
5.2 Hz, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.52 (ddd, J = 8.2, 7.2, 1.0 Hz, 1H), 7.25 (ddd, 
J = 8.0, 7.0, 1.0 Hz, 1H), 2.79 (s, 3H). 
13
C NMR (d
6
-Acetone, 400 MHz, 300 K) δ 
(ppm): 143.5, 141.9, 139.4, 136.1, 129.1, 128.8, 123.1, 122.8, 120.7, 113.7, 113.1, 
21.0. MS (CI) for C12H11N2 [M+H]
+
: m/z 183.3. 
 
1-Phenyl-9H-pyrido[3,4-b]indole (5j):
[52]
 
1
H NMR (d
6
-DMSO, 400 MHz, 300 K) δ 
(ppm): 11.60 (s, 1H), 8.47 (d, J = 5.2 Hz, 1H), 8.27 (d, J = 8.0 Hz, 1H), 8.13 (d, J = 
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5.2 Hz, 1H), 8.06-8.03 (m, 2H), 7.67-7.51 (m, 5H),  7.27 (ddd, J = 8.0, 7.0, 1.0 Hz, 
1H). 
13
C NMR (d
6
-DMSO, 400 MHz, 300 K) δ (ppm): 142.5, 141.5, 138.8, 133.4, 
129.5, 129.1, 128.9, 128.7, 128.5, 122.0, 121.2, 119.9, 114.3, 112.8. MS (CI) for 
C17H13N2 [M+H]
+
: m/z 245.3. 
5.4.5 Data for the indoles 
 
1H-indole (8a):
[53]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 8.1(bs, 1H), 7.65 
(dd, J = 7.9, 0.7 Hz, 1H), 7.40 (dd, J = 8.1, 0.8 Hz, 1H), 7.23-7.17 (m, 2H), 7.15-7.09 
(m, 1H), 6.58-6.54 (m, 1H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 136.2, 
128.3, 124.6, 122.4, 121.2, 120.3, 111.5, 103.0. Anal. calc. for C8H7N (%): C, 82.02; 
H, 6.02; N, 11.96. Found: C, 81.82; H, 6.00; N, 11.91. MS (CI) for C8H8N [M+H]
+
: 
m/z 118.0. 
 
5-Methoxy-1H-indole (8b):
[53]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 8.09 
(bs, 1H), 7.31 (d, J = 8.8 Hz, 1H), 7.20 (t, J = 2.8 Hz, 1H), 7.16 (d, J = 2.4 Hz, 1H), 
6.92 (dd, J = 8.8, 2.5 Hz, 1H), 6.54-6.51 (m, 1H), 3.90 (s, 3H). 
13
C NMR (CDCl3, 
100 MHz, 300 K) δ (ppm): 154.6, 131.4, 128.7, 125.3, 112.8, 112.2, 102.8, 102.7, 
56.3. Anal. calc. for C9H9NO (%): C, 73.45; H, 6.16; N, 9.52. Found: C, 73.35; H, 
6.17; N, 9.57. MS (CI) for C9H10NO [M+H]
+
: m/z 148.2. 
 
5-Chloro-1H-indole (8c):
[54]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 8.15 (bs, 
1H), 7.61 (d, J = 2.1 Hz, 1H), 7.30 (d, J = 8.7 Hz, 1H), 7.22 (t, J = 2.8 Hz, 1H), 7.14 
(dd, J = 8.6, 2.0 Hz, 1H), 6.51-6.48 (m, 1H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ 
(ppm): 134.5, 129.4, 125.9, 125.8, 122.7, 120.5, 112.4, 102.9. Anal. calc. for 
C8H6ClN (%): C, 63.38; H, 3.99; N, 9.24. Found: C, 63.55; H, 3.89; N, 9.24. MS 
(CI) for C8H7ClN [M+H]
+
: m/z 151.9. 
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2-Methyl-1H-indole (8d):
[55]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 7.61(bs, 
1H), 7.50 (d, J = 7.5 Hz, 1H), 7.22-7.17 (m, 1H), 7.12-7.03 (m, 2H), 6.19 (s, 1H), 
2.35 (s, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 136.5, 135.6, 129.5, 
121.4, 120.1, 110.7, 100.8, 14.1. Anal. calc. for C9H9N (%): C, 82.41; H, 6.92; N, 
10.68. Found: C, 82.10; H, 6.73; N, 10.49. MS (CI) for C9H10N [M+H]
+
: m/z 132.1. 
 
2,3-Dimethyl-1H-indole (8e):
[56]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 7.62 
(bs, 1H), 7.55 (d, J = 6.9 Hz, 1H), 7.28 (dd, J = 6.7, 1.8 Hz, 1H), 7.22-7.13 (m, 2H), 
2.39 (s, 3H), 2.30 (s, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 135.6, 
131.1, 129.9, 121.3, 119.4, 118.4, 110.5, 107.5, 11.9, 8.9. Anal. calc. for C10H11N 
(%): C, 82.72; H, 7.64; N, 9.65. Found: C, 82.58; H, 7.63; N, 9.64. MS (CI) for 
C10H12N [M+H]
+
: m/z 146.2.  
 
3-Methyl-1H-indole (8f):
[57]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 7.72 (bs, 
1H), 7.58 (d, J = 6.8 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 7.18 (t, J = 7.0 Hz, 1H), 7.12 
(t, J = 6.8 Hz, 1H), 6.90 (s, 1H), 2.32 (s, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ 
(ppm): 136.7, 128.7, 122.3, 122.1, 119.6, 119.3, 112.1, 111.4, 10.1. Anal. calc. for 
C9H9N (%): C, 82.41; H, 6.92; N, 10.68. Found: C, 82.45; H, 6.91; N, 10.64. MS 
(CI) for C9H10N [M+H]
+
: m/z 132.1. 
 
2-Phenyl-1H-indole (8g):
[58]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 8.36 (bs, 
1H), 7.68 (dd, J = 8.2, 1.0 Hz, 3H), 7.47 (t, J = 7.6 Hz, 2H), 7.42 (d, J = 8.0 Hz, 1H), 
7.35 (t, J = 8.0 Hz, 1H), 7.24 (td, J = 7.2, 1.2 Hz, 1H), 7.18 (td, J = 7.4, 0.8 Hz, 1H), 
6.87 (d, J = 1.2 Hz, 1H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 138.3, 137.2, 
132.8, 129.7, 129.5, 128.2, 125.6, 122.8, 121.1, 120.7, 111.4, 100.4. Anal. calc. for 
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C14H11N (%): C, 87.01; H, 5.74; N, 7.25. Found: C, 86.90; H, 5.73; N, 7.21. MS (CI) 
for C14H12N [M+H]
+
: m/z 194.3. 
5.4.6 Data for the quinoxalines 
 
2-Methylquinoxaline (10a):
[59]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 8.73 (s, 
1H), 8.06 (dd, J = 8.1, 1.5 Hz, 1H), 8.00 (dd, J = 8.2, 1.4 Hz, 1H), 7.75-7.67 (m, 2H), 
2.77 (s, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 156.2, 148.5, 144.5, 
143.4, 132.5, 131.6, 131.4, 131.1, 25.1. Anal. calc. for C9H8N2 (%): C, 74.98; H, 
5.59; N, 19.43. Found: C, 75.04; H, 5.58; N, 19.29. MS (CI) for C9H9N2 [M+H]
+
: 
m/z 145.0. 
 
2-Phenylquinoxaline (10b):
[60]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 9.35 (s, 
1H), 8.22-8.13 (m, 4H), 7.83-7.75 (m, 2H), 7.61-7.52 (m, 3H). 
13
C NMR (CDCl3, 
100 MHz, 300 K) δ (ppm): 152.3, 143.8, 142.7, 142.0, 137.2, 130.8, 130.6, 130.05, 
130.01, 129.6, 129.5, 128.0. Anal. calc. for C14H10N2 (%): C, 81.53; H, 4.89; N, 
13.58. Found: C, 80.88; H, 4.98; N, 13.24. MS (CI) for C14H11N2 [M+H]
+
: m/z 
207.2. 
 
2,3-Dimethylquinoxaline (10c):
[61]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 
7.99 (dd, J = 6.3, 3.5 Hz, 2H), 7.67 (dd, J = 6.4, 3.5 Hz, 2H), 2.74 (s, 6H). 
13
C NMR 
(CDCl3, 100 MHz, 300 K) δ (ppm): 153.9, 141.5, 129.2, 128.7, 23.6. Anal. calc. for 
C10H10N2 (%): C, 75.92; H, 6.37; N, 17.71. Found: C, 75.97; H, 6.25; N, 17.77. MS 
(CI) for C10H11N2 [M+H]
+
: m/z 159.1. 
 
2-Methyl-3-phenylquinoxaline (10d):
[61]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 8.15-8.12 (m, 1H), 8.09-8.06 (m, 1H), 7.78-7.71 (m, 2H), 7.69-7.66 (m, 2H), 
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7.57-7.48 (m, 3H), 2.80 (s, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 
155.3, 152.9, 141.6, 141.4, 139.4, 130.2, 129.7, 129.6, 129.4, 129.3, 129.0, 128.7, 
24.8. Anal. calc. for C15H12N2 (%): C, 81.79; H, 5.49; N, 12.72. Found: C, 81.42; H, 
5.68; N, 12.62. MS (CI) for C15H13N2 [M+H]
+
: m/z 221.1. 
 
2,3-Diphenylquinoxaline (10e):
[62]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 
8.23-8.20 (m, 2H), 7.82-7.78 (m, 2H), 7.57-7.54 (m, 4H), 7.41-7.34 (m, 6H), 2.62 (s, 
3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 153.9, 141.6, 139.5, 130.4, 
130.3, 129.6, 129.2, 128.7. Anal. calc. for C20H14N2 (%): C, 85.08; H, 5.00; N, 9.92. 
Found: C, 84.68; H, 5.00; N, 9.83. MS (CI) for C20H15N2 [M+H]
+
: m/z 283.1. 
 
5-Methylquinoxaline (10f):
[63]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 8.87 
(dd, J = 6.7, 1.7 Hz, 2H), 7.98 (d, J = 8.4 Hz, 1H), 7.71-7.63 (m, 2H), 2.83 (s, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 145.0, 144.1, 143.6, 142.7, 138.1, 
130.5, 130.3, 127.8, 17.8. Anal. calc. for C9H8N2 (%): C, 74.98; H, 5.59; N, 19.43. 
Found: C, 74.49; H, 5.68; N, 19.13. MS (CI) for C9H9N2 [M+H]
+
: m/z 145.2. 
 
6-Methylquinoxaline (10g):
[64]
 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 8.81 
(d, J = 8.3 Hz, 2H), 8.01 (d, J = 8.6 Hz, 1H), 7.89 (s, 1H), 7.63 (dd, J = 8.6, 1.6 Hz, 
1H), 2.62 (s, 3H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 145.3, 144.5, 143.5, 
141.9, 141.1, 132.8, 129.4, 128.7, 22.3. Anal. calc. for C9H8N2 (%): C, 74.98; H, 
5.59; N, 19.43. Found: C, 74.51; H, 5.72; N, 19.10. MS (CI) for C9H9N2 [M+H]
+
: 
m/z 145.2. 
5.4.7 Synthesis of papaverine 
N-(3,4-Dimethoxyphenethyl)-2-(3,4-dimethoxyphenyl)acetamide. The amide was 
prepared from the corresponding amine and acid according to the literature method 
Chapter 5 
221 
 
with some modification.
[65]
 A mixture of 3,4-dimethoxyphenylacetic acid (2.5 mmol, 
500 mg) and 3,4-dimethoxyphenethylamine (2.5 mmol, 477 mg) in a test vial was 
heated at 150 
o
C for 30 min under microwave irradiation. After cooling to ambient 
temperature, the solidified mixture was dissolved in DCM (100 mL) followed by 
washing sequentially with 10% KOH aq (10 ml), 5% HCl aq (10 mL) and brine (10 
mL). The organic layer was dried over MgSO4, filtered and concentrated under 
reduced pressure to give a pale-yellow solid (880 mg, 98% yield). 
1
H NMR (CDCl3, 
400 MHz, 300 K) δ (ppm): 6.80 (d, J = 8.0 Hz, 1H), 6.72-6.68 (m, 3H), 6.62 (d, J = 
1.6 Hz, 1H), 6.52 (dd, J = 8.0, 2.0 Hz, 1H),   5.44 (bs, 1H), 3.88 (s, 3H), 3.86 (s, 3H), 
3.83 (s, 6H), 3.48 (s, 2H), 3.44 (q, J = 6.8 Hz, 2H), 2.68 (t, J = 7.0 Hz, 2H). 
13
C 
NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 171.6, 149.7, 149.4, 148.7, 148.0, 131.4, 
127.6, 122.0, 121.0, 112.8, 112.1, 111.8, 111.5, 56.30, 56.26, 56.24, 56.22, 43.9, 
41.1, 35.4. MS (CI) for C20H26NO5 [M+H]
+
: m/z 360.4. 
1-(3,4-Dimethoxybenzyl)-6,7-dimethoxy-3,4-dihydroisoquinoline (3,4-
dihydropapaverine). The cyclic imine was prepared from the corresponding amide 
according to the literature.
[66] 
To a solution of N-(3,4-dimethoxyphenethyl)-2-(3,4-
dimethoxyphenyl)acetamide (2.0 mmol, 701 mg) in toluene (40 mL), POCl3 (4.0 
mmol, 0.4 mL) was introduced dropwise at room temperature. The mixture was 
refluxed for 5 h and evaporated to remove toluene after cooling. The resulting 
residue was basified with an aqueous solution of Na2CO3 followed by extraction 
with DCM (5×30 mL). The combined organic extracts were evaporated to dryness 
before running a short column (silica gel, EtOAc/MeOH) to obtain the desired imine 
(slightly yellow solid, 614 mg, 90% yield). 
1
H NMR (CDCl3, 400 MHz, 300 K) δ 
(ppm): 7.00 (s, 1H), 6.87-6.84 (m, 2H), 6.79-6.77 (m, 1H), 6.66 (s, 1H), 3.98 (s, 2H), 
3.88 (s, 3H), 3.83 (s, 3H), 3.82 (s, 3H), 3.75 (s, 3H),  3.73 (t, J = 7.6 Hz, 2H), 2.65 (t, 
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J = 7.6 Hz, 2H). 
13
C NMR (CDCl3, 100 MHz, 300 K) δ (ppm): 166.0, 151.1, 149.5, 
148.1, 147.6, 132.2, 131.0, 122.0, 121.1, 112.1, 111.7, 110.87, 110.1, 56.4, 56.32, 
56.27, 56.22, 47.6, 43.5, 26.2. MS (CI) for C20H24NO4 [M+H]
+
: m/z 342.4. 
1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline (Papaverine):
[67]
 The reaction 
conditions were the same as for the general dehydrogenation except for using 1 
mol% catalyst under 12 h. The product was obtained in 88% yield as a slightly 
yellow solid. 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 8.37 (d, J = 5.6 Hz, 1H), 
7.43 (d, J = 5.6 Hz, 1H), 7.35 (s, 1H), 7.05 (s, 1H),  6.83-6.81 (m, 2H), 6.77-6.75 (m, 
1H), 4.53 (s, 2H), 4.00 (s, 3H), 3.91 (s, 3H), 3.82 (s, 3H), 3.77 (s, 3H). 
13
C NMR 
(CDCl3, 100 MHz, 300 K) δ (ppm): 158.2, 152.8, 150.2, 149.4, 147.9, 141.5, 133.9, 
132.7, 123.4, 120.9, 119.1, 112.3, 111.6, 105.7, 104.6, 56.4, 56.27, 56.26, 56.21, 
42.7. MS (CI) for C20H22NO4 [M+H]
+
: m/z 340.2. 
5.4.8 Synthesis of harmine 
7-Methoxy-1-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole 
(Tetrahydroharmine). The tetrahydroharmine was prepared by Pictect-Spengler 
reaction according to a modified literature method.
[68]
 6-Methoxytryptamine (2.0 
mmol, 381 mg) was added to an aqueous solution (25 mL) of H2SO4 (conc., 2.4 
mmol, 240 mg). After introducing acetaldehyde (16.0 mmol, 0.9 mL), the mixture 
was heated for 20 min at 110 
o
C and then cooled to room temperature.  The mixture 
was extracted with DCM (4×20 mL) after being basified with an aqueous solution of 
KOH. The combined organic extracts were evaporated to dryness before passing a 
short column (silica gel, DCM/MeOH) to afford the desired product (pale-yellow 
solid, 272 mg, 63% yield). 
1
H NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 7.76 (bs, 
1H), 7.35 (d, J = 8.4 Hz, 1H), 6.83 (d, J = 1.2 Hz, 1H), 6.77 (dd, J = 8.4, 1.6 Hz, 1H), 
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4.15 (q, J = 6.6 Hz, 1H), 3.83 (s, 3H), 3.36 (dt, J = 12.8, 4.2 Hz, 1H), 3.04 (ddd, J = 
13.1, 8.5, 4.9 Hz, 1H), 2.78-2.66 (m, 2H), 1.88 (bs, 1H), 1.44 (d, J = 6.4 Hz, 3H). 
13
C 
NMR (CDCl3, 400 MHz, 300 K) δ (ppm): 156.6, 136.8, 136.2, 122.4, 119.0, 109.2, 
108.7, 95.4, 56.2, 48.6, 43.2, 23.1, 21.2. MS (CI) for C13H17N2O [M+H]
+
: m/z 217.2. 
7-Methoxy-1-methyl-9H-pyrido[3,4-b]indole (Harmine):
[69]
 The reaction conditions 
were the same as for the general dehydrogenation except for using 1 mol% catalyst 
under 30 h. The product was obtained in 91% yield as a slightly yellow solid. 
1
H 
NMR (d6-DMSO, 400 MHz, 300 K) δ (ppm): 11.40 (bs, 1H), 8.15 (d, J = 5.2 Hz, 
1H), 8.06 (d, J = 8.8 Hz, 1H), 7.81 (d, J = 5.2 Hz, 1H), 7.01 (d, J = 2.4 Hz, 1H), 6.84 
(dd, J = 8.6, 2.2 Hz, 1H), 3.87 (s, 3H), 2.72 (s, 3H). 
13
C NMR (d6-DMSO, 400 MHz, 
300 K) δ (ppm): 160.4, 142.3, 141.6, 138.1, 134.9, 127.6, 123.0, 115.2, 112.3, 109.4, 
94.9, 55.7, 20.7. MS (CI) for C13H13N2O [M+H]
+
: m/z 213.3. 
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Regioselective Acceptorless 
Dehydrogenative Coupling of N-
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6.1 Introduction 
Circumventing the use of stoichiometric oxidants, acceptorless dehydrogenation 
reactions have recently become a rapidly growing area of research.
[1]
 These reactions 
can be performed under mild conditions, with the only byproduct being H2, which is 
a valuable feedstock itself and energy carrier.
[2]
 Not only can such reactions be 
applied to the synthesis of unsaturated compounds, they also allow for easy bond 
formation, giving rise to novel coupling reactions, which require no 
prefunctionalisation of the coupling partners. Indeed, the last few years have 
witnessed the application of this acceptorless dehydrogenative coupling (ADC) 
strategy to the synthesis of many value-added compounds in a manner that is more 
straightforward and economic and greener than the conventional methods.
[1,3]
 In the 
vast majority of the reported cases, an alcohol is first dehydrogenated, generating an 
electrophilic carbonyl species that can react with a common nucleophile (Scheme 
6.1). Examples are seen in the ADC of alcohols with amines to form amides,
[4]
 
imines,
[5]
 and N-heterocycles,
[6]
 and of alcohols to form esters,
[7]
 polyesters,
[8]
 or 
lactones.
[9]
 
 
Scheme 6.1: General modes of ADC reactions reported in the literature. 
Dehydrogenation of alcohols has also been harnessed to make C-C bonds. Thus, an 
alcohol is dehydrogenated to an electrophilic carbonyl, or a nucleophilic enolate in 
the presence of a base, which subsequently reacts with a carbon nucleophile or an 
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electrophile to generate an unsaturated bond that is reduced in situ by the H2 
borrowed from the initial dehydrogenation step (Scheme 6.1).
[10,11]
  
Acceptorless dehydrogenation of N-heterocycles is rare in the literature, however, 
and ADC of N-heterocycles is even rarer. To the best of our knowledge, there 
appears to be only one report where an N-phenyl tetrahydroisoquinoline was 
alklylated with carbon nucleophiles at the 1-position,
[12]
 whilst the simultaneous 
activation of an amine to generate an enamine to allow for C-C coupling remains 
unknown in the context of ADC.
[13]
 Although a number of excellent examples have 
been demonstrated in the cross dehydrogenative coupling of N-heterocycles with 
various nucleophiles, these reactions generally necessitate the use of stoichiometric 
oxidants, such as 
t
BuOOH, rather than releasing the hydrogen as H2.
[14]
 
It was successfully demonstrated in Chapter 5 that when the dehydrogenation of 2-
methyl tetrahydroquinoline was carried out using cyclometalated iridium complex in 
TFE-d3, the reaction led to extensive H-D exchange at the α and  positions. This 
suggested that the dehydrogenation leads to the generation of an imine, which 
isomerises to an enamine at these positions (Scheme 6.2). Therefore, it was 
envisioned that this nucleophilic intermediate might be intercepted by a carbon-
based electrophile, thus affording C-C bond formation at -methyl and consequently 
functionalisation of quinolines.
[15,16]
 This chapter will cover our efforts in showing 
that the same cyclometalated iridium complexes can be exploited for this new 
strategy. Not only does the ADC enables the coupling of the sp
3
 carbon with a range 
of electrophiles, but it can also be cascaded with Friedel-Crafts addition at sp
2
 
carbons and with reduction to generate novel saturated N-heterocycles (Scheme 6.2).  
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Scheme 6.2: ADC, Friedel-Crafts-ADC, and ADC-reduction reactions. 
6.2 Results and discussion 
6.2.1 Optimisation of reaction conditions 
The study was initiated by testing various cyclometalated iridium complexes 
(Iridicycles C; Scheme 6.3) for the ADC of 2-methyl-1,2,3,4-tetrahydroquinoline 
(1a) with ethyl 3,3,3-trifluoropyruvate (TFP) as an electrophile.  
 
Scheme 6.3: Cyclometalated iridium complexes. 
As expected, in the absence of a catalyst, formation of 2a was not detected in 2,2,2-
trifluoroethanol (TFE) after 2 h stirring at 30  C, although 2a2 was obtained in a high 
yield (Table 6.1, entry 1). [Cp*IrCl2]2 without the ligand was also ineffective (Table 
6.1, entry 2).  
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Table 6.1: Optimisation of reaction conditions   
 
Entry
[a]
 Catalyst Solvent 2a
[b]
 2a1
[b]
 2a2
[b]
 10a
[b]
 
1 none TFE - - <95 - 
2 [Cp*IrCl2]2 TFE <2 <1 <90 - 
3 C8 TFE 61 28 <3 <1 
4 C9 TFE 38 16 5 <2 
5 C10 TFE 46 14 4 <2 
6 C11 TFE 64 31 <1 <2 
7 C2 TFE 63 30 <1 <2 
8 C4 TFE 58 20 <1 <2 
9 C11 H2O 8 6 - - 
10 C11 MeOH - 18 10 4 
11 C11 
i
PrOH - - 11 - 
12 C11 Toluene - - 62 - 
13 C11 EtOAc - 6 48 - 
14
[c]
 C11 TFE 40 56 <1 <2 
15
[d]
 C11 TFE 71 24 <1 <2 
16
[e]
 C11 TFE 78 16 <1 4 
17
[f]
 C11 TFE 77 12 <1 8 
18
[g,h]
 C11 TFE 60 2 <1 24 
19
[e,i]
 C11 TFE 78 16 <1 4 
20
[e,j]
 C11 TFE 76 15 <1 4 
[a] See experimental section for details. [b] Conversion (%) determined by 
1
H-NMR spectroscopy. [c]
 
1.0 equivalent of 3,3,3-trifluoropyruvate (TFP) used. [d] 2.5 equiv. of TFP used. [e] 2.8 equiv. of TFP 
used. [f] 3.0 equiv. of TFP used. [g] 4.0 equiv. of TFP used. [h] Some other unidentified byproducts 
observed by 
1
H-NMR spectroscopy. [i] Under N2. [j] Under Air. 
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After screening a variety of iridicycles (Table 6.1, entries 3-8), electron-rich 
complexes were found to give a higher activity compared with electron-poor, with 
C11 furnishing the desired product 2a in 64% yield in just 2 h (Table 6.1, entries 6). 
ADC proceeds best in TFE, compared to other solvents that were screened (Table 
6.1, entries 9-13). Variation of electrophile ratio revealed that the optimal yield was 
achieved when 2.8 equivalents of electrophile was used in the reaction (Table 6.1, 
entries 6 and 14-20). The excess amount of electrophile was necessary to inhibit the 
dehydrogenation of 1a to 2a1. Formation of H2 was confirmed by GC-MS analysis. 
The hydrogenation of TFP by C11 was not observed. 
6.2.2 ADC of 2-methyl tetrahydroquinolines 
Using the optimal conditions established, the ADC of various tetrahydroquinolines 
1a-v with TFP was explored. In each case, the corresponding products 2a-v was 
obtained in good to excellent isolated yields, with the C-C coupling taking place 
almost exclusively at the β position (Table 6.2). These quaternary trifluoromethyl 
hydroxyl compounds are highly valuable in pharmaceuticals due to their biological 
activities.
[16,17]
 A variety of functionalities were tolerated, demonstrating the utility 
of the protocol in practice. Thus, substrates bearing either electron-donating or -
withdrawing groups all gave excellent yields regardless of their positions (Table 6.2, 
entries 2-5 and 11-12). Hydrogenation-labile aromatic halides, with the substituent at 
different positions, afforded the coupling products 2f-j in more than 70% yield 
(Table 6.2, entries 6-10). Whilst ester and amide moieties are typically employed in 
ortho-directing C-H functionalisation, regioselective ADC took place when 1m-p 
were coupled with TFP, furnishing excellent yields for the expected 2m-p (Table 
6.2, entries 13-16). Delightfully, thiophene- and pyridine-containing substrates 
underwent the ADC without poisoning the catalyst (Table 6.2, entries 18 and 19). 
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However, when the furan derivative 1t was subjected to the ADC, competitive 
Friedel-Crafts alkylation was observed at the furan ring, leading to a highly 
functionalised product 2t (Table 6.2, entry 20). It is known that furan can undergo 
electrophilic aromatic substitution at the 2-position in acidic media.
[18] 
Further to our 
delight, substrates containing boronic acid pinacol ester and an allyl ether group 
were also well tolerated, furnishing corresponding products in good yields (Table 
6.2, entries 21 and 22). Aryl boronic esters can readily undergo transition metal 
catalysed reaction and have in fact often been applied in cross coupling reactions as 
one of the coupling partners.
[19]
 Likewise, allylic ether groups are prone to aromatic 
Claisen rearrangement and can give rise to allylic substitution.
[20]
 
Table 6.2: Regioselective dehydrogenative sp
3
 C-H functionalisation of 2-methyl 
tetrahydroquinolines 
 
Entry
[a]
 Substrate Product  
Yield 
(%)
[b]
 
1 
  
2a 76 
2 
  
2b 78 
3 
  
2c 87 
4 
  
2d 89 
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5 
  
2e 80 
6 
  
2f 86 
7 
  
2g 90 
8
[c]
 
  
2h 70 
9 
  
2i 79 
10 
  
2j 82 
11 
  
2k 89 
12 
  
2l 82 
13
[c]
 
  
2m 82 
14 
  
2n 86 
15 
  
2o 81 
16 
  
2p 88 
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17 
  
2q 84 
18 
  
2r 85 
19 
  
2s 64 
20 
  
2t 90 
21 
  
2u 78 
22 
  
2v 55 
[a] See experimental section for details. [b] Yield of isolated product. [c] Yield determined by 
1
H-
NMR spectroscopy. 
Remarkably, the coordinating 3a-b could be selectively mono- or di-alkylated, 
affording 4a-b in a good yield (Scheme 6.4). The exclusive mono-functionalisation 
of 3a suggests that the ADC proceeds via dehydrogenation rather than a direct C-H 
functionalisation at the 2-methyl position. Selective di-alkylation or mono-alkylation 
of 2-methyl phenanthrolines is challenging and is typically performed under harsh 
conditions.
[21]
 Clearly, the current protocol offers an alternative route to these 
functionalised phenanthrolines. 
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Scheme 6.4: Regioselective dehydrogenative sp
3
 C-H functionalisation of tetrahydro- and octahydro-
phenanthroline. 
6.2.3 ADC of 2-methyl tetrahydroquinolines with other electrophiles 
To further demonstrate the utility of our protocol, ADC using different electrophiles 
was investigated. As can be seen from Table 6.3, the transformation occurred; 
however, the product yield varied with both the electrophiles and nucleophiles. In 
particular, low yields were obtained with 1,1,1-trifluoroacetone and pentafluoro-
benzaldehyde (Table 6.3, entries 7 and 8), presumably as a result of their lower 
electrophilicity. Also, the electrophile 1,1,1-trifluoroacetone can interact with protic 
solvents, leading to addition products.
[22]
 Disappointedly, ADC did not proceed when 
imine electrophiles were used under the present conditions (Table 6.3, entries 9 and 
10).  
 
 
 
 
 
Chapter 6 
237 
 
Table 6.3: Dehydrogenative sp
3
 C-H functionalisation of 1 with other electrophiles 
 
Entry
[a]
 Substrate Electrophile Product  
Yield 
(%)
[b]
 
1 1a 
  
5a 74 
2 1n 
  
5b 52 
3 1c 
  
5c 62 
4 1a 
  
5d 65 
5 1f 
  
5e 28 
6 
1c   
5f 42 
7
[c]
 1a 
  
5g 22 
8
[c]
 1a 
  
5h 18 
9
[d]
 
 
1a  - - n.r. 
10
[d]
 
 
1a  - - n.r. 
[a] See experimental section for details. [b] Yield of isolated product. [c] Yield determined by 
1
H-
NMR spectroscopy. [d] No reaction observed 
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6.2.4 One-pot synthesis of 6-alkylated quinolines 
It is known that tetrahydroquinolines can undergo Friedel-Crafts reactions at the 6-
position.
[23,24]
 Indeed, 2-methyl-1,2,3,4-tetrahydroquinoline 1a was alkylated with 
TFP at this position when they were mixed in TFE in the absence of C11 (Table 6.1, 
entry 1). Following the Friedel-Crafts reaction, introduction of C11 should trigger 
dehydrogenation, leading to one-pot synthesis of 6-alkylated quinolines. This would 
provide a simple way of generating these products which are traditionally 
synthesised by using stoichiometric organometallic species, such as Grignard, 
organozinc or organolithium reagents.
[25]
 Satisfactorily, reacting 1a and 6a-e with 
TFP for 2 h followed by adding the catalyst C11 afforded 7a-f in excellent yields, 
regardless of the position of the substituents on the N-containing ring (Table 6.4, 
entries 1-6). Furthermore, functionalised indoles could also be obtained in good 
yields (Table 6.4, entries 7 and 8). Friedel-Crafts addition at the 5-position of indoles 
is challenging, as the 3-position is more reactive.
[24] 
As maybe expected, Friedel-
Crafts reaction did not proceed when 2-methyl quinoline, instead of 1a or 6, was 
used under the present conditions. 
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Table 6.4: Sequential Friedel-Crafts and dehydrogenative functionalisation of N-
heterocycles 
 
Entry
[a]
 Substrate Product  Yield (%)
[b]
 
1
[c]
 
  
7a 72 
2 
  
7b 89 
3 
  
7c 92 
4 
  
7d 91 
5 
  
7e 86 
6 
  
7f 90 
7
[c]
 
  
9a 68 
8 
  
9b 89 
[a] See experimental section for details. [b] Yield of isolated product. [c] Yield determined by 
1
H-
NMR spectroscopy. 
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6.2.5 One-pot sequential Friedel-Crafts-dehydrogenative sp
2
 and sp
3
 C-H 
functionalisation of 2-methyl-1,2,3,4-tetrahydroquinoline 
More interestingly, double functionalisation of tetrahydroquinolines becomes 
possible when the Friedel-Crafts reaction is cascaded with the ADC. Scheme 6.5 
presents the unprecedented, one pot sequential Friedel-Crafts addition and ADC 
reactions, allowing the functionalisation of both 6-position and -methyl of 1a to 
give 10a in excellent yield. Two different electrophiles can also be introduced into 
the nucleophile in this one-pot strategy, as demonstrated by the synthesis of the 
highly functionalised 11a and 12a. 
 
Scheme 6.5: One-pot sequential Friedel-Crafts-dehydrogenative C-H functionalisation of 1a. 
6.2.6 Saturated N-heterocycles by in situ reduction 
Our group had previously reported that the Iridicycles are capable of catalysing both 
hydrogenation and transfer hydrogenation.
[26]
 Thus, we postulated that saturated 
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functionalised N-heterocycles could also be obtained in a one pot fashion by 
combining ADC and reduction. Indeed, hydrogenating 2a with H2, in situ generated 
from 1a by ADC, afforded 14a in 74% yield at     C (Scheme 6.6). Surprisingly, a 
novel compound 13a was isolated in 71% yield when the reductant was switched 
from H2 to HCO2H. Most likely, the high reaction temperature together with the 
acidic reaction condition employed in the transfer hydrogenation promoted the 
formation of the lactam product. These reactions further demonstrate the versatility 
of C11 in both dehydrogenation and hydrogenation reactions. 
 
Scheme 6.6: Saturated N-heterocycles by in situ reduction of 2a in a one-pot fashion using C11. 
6.2.7 Mechanistic consideration 
Based on the mechanism proposed in Chapter 5 for the dehydrogenation of 2-methyl 
tetrahydroquinoline, a plausible reaction pathway is proposed in Scheme 6.7. In the 
presence of C11 in TFE (pKa 12.5), 1a is in equilibrium with the imino intermediate 
I, which is probably protonated by or hydrogen-bonded with the medium. 
Isomerisation of I generates the active enamine nucleophile III that attacks an 
electrophile, thus resulting in IV. The intermediate IV can equilibrate with V, which 
probably hydrogenates II, resulting in the formation of VI and 1a. Control 
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experiments shown in Scheme 6.8 also suggest that sp
3
 C-H functionalisation of 1a 
is favoured by the ADC pathway over alkylation catalysed by C11.   
 
Scheme 6.7: A plausible reaction pathway. 
 
Scheme 6.8: Control experiments. 
6.3 Conclusion 
In conclusion, this chapter describes the development of a new protocol for the 
oxidant- and base-free functionalisation of N-heterocycles to afford novel quinoline, 
phenanthroline and indole derivatives under mild conditions. The core strategy is the 
ADC chemistry, which enables acceptor-less dehydrogenation of the N-heterocycles 
and site-selective C-C bond formation thereafter. The ADC catalyst also allows the 
dehydrogenated product to be saturated under either hydrogenation or transfer 
hydrogenation conditions, giving rise to structurally diverse products.  
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6.4 Experimental 
6.4.1 General information   
Unless otherwise specified, all reagents and solvents were purchased commercially 
and used as received. 2-Methyl quinolines were prepared according to the literature 
procedure reported by Yoshida,
[27]
 Mahadevan
[28]
 and Marsden.
[29]
 Substrates 1b-v, 
3a and 6b-e were prepared by the reduction of the corresponding quinolines 
according to the method reported in Chapter 3. Substrate 3b was prepared by the 
hydrogenation of neocuproine using 5 mol% Adam’s catalyst in DCM (4  bar H2, 35 
°C, and 36 h). NMR spectra were recorded on a Bruker 400 MHz NMR spectrometer 
unless otherwise specified. Elemental Analysis and Mass Spectrometry analysis were 
carried out at the Microanalysis Centre of University of Liverpool. IR spectra were 
recorded on a Bruker Alpha FT-IR spectrometer. 
6.4.2 Representative procedure for the regioselective dehydrogenative sp
3
 C-H 
functionalisation of 2-methyl tetrahydroquinoline (1a)  
1a (73.6 mg, 0.5 mmol) was dissolved in TFE (1 mL) in a carousel tube. Meanwhile 
in separate vials C11 (3.1 mg, 5x10
-3
 mmol) was dissolved in TFE (1 mL) and ethyl 
3,3,3-trifluoropyruvate (238.1 mg, 0.19 mL, 1.4 mmol) was dissolved in TFE (1 
mL), respectively. The solution of C11 was then injected into the solution of 1a in a 
carousel tube. The tube was shaken once and the solution of ethyl 3,3,3-
trifluoropyruvate was then added slowly while shaking the tube gradually. The 
reaction mixture was then stirred at 30 °C under N2 for 12 h (carousel reactor was 
pre-heated to 30 °C). The solvent was removed under vacuum and the resulting 
crude mixture was purified using flash chromatography to give the corresponding 
product 2a as a white solid (119.1 mg, 76% yield).  
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Note: it is important that the tube is shaken prior to the addition of ethyl 3,3,3-
trifluoropyruvate in order to inhibit the side Friedel-Crafts alkylation.  
The same procedure was followed when other electrophiles were used. Products 2a, 
2b, 2g, 2h, 2i, 2j, 2q and 5a are known compounds and their NMR spectra are 
consistent with the literature. All the other products are unknown. 
6.4.3 Representative procedure for the sequential Friedel-Crafts and 
dehydrogenative functionalisation of 1a 
1a (73.6 mg, 0.5 mmol) was dissolved in TFE (2 mL) in a carousel tube and ethyl 
3,3,3-trifluoropyruvate (102.1 mg, 0.080 mL, 0.6 mmol) was added. The mixture 
was stirred at 30 °C under N2 for 2 h. A freshly prepared solution of C11 (3.1 mg, 
5x10
-3
 mmol in 1 mL of TFE) was then added and the reaction was heated to reflux 
for 14 h. The reaction mixture was cooled to room temperature and the solvent was 
removed under vacuum. The resulting crude mixture was purified using flash 
chromatography to give the corresponding product 7f as a light yellow solid (141.0 
mg, 90% yield). 
The same procedure was followed when indolines were used as substrates. 
6.4.4 Representative procedure for one pot sequential Friedel-Crafts-
dehydrogenative sp
2
 and sp
3
 C-H functionalisation of 1a to 11a 
1a (73.6 mg, 0.5 mmol) was dissolved in TFE (1 mL) in a carousel tube and ethyl 
3,3,3-trifluoropyruvate (102.1 mg, 0.080 ml, 0.6 mmol) was added. The mixture was 
stirred at 30 °C under N2 for 2 h. A solution of C11 (3.1 mg, 5x10
-3
 mmol in 1 mL of 
TFE) was then added followed by a solution of ethyl pyruvate (162.6 mg, 0.156 ml, 
1.4 mmol in 1 mL of TFE). The reaction mixture was heated to reflux for 14 h. The 
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reaction mixture was cooled to room temperature and the solvent was removed under 
vacuum. The resulting crude mixture was then purified using flash chromatography 
to give the corresponding product 11a as a yellow liquid (154.6 mg, 72% yield). 
6.4.5 Data for 2a-v 
 
Ethyl 3,3,3-trifluoro-2-hydroxy-2-(quinolin-2-ylmethyl)propanoate, 2a:
[16]
 White 
solid. 
1
H NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 8. 6 (d, J = 8.  Hz, 1H), 7.87 (d, 
J = 8.3 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.63 (t, J = 7.5 Hz, 1H), 7.46 (t, J = 7.3 Hz, 
1H), 7.24 (d, J = 8.4 Hz, 1H), 6.77 (bs, 1H), 4.16 (q, J = 6.9 Hz, 2H), 3.68 (d, J = 
15.3 Hz, 1H), 3.45 (d, J = 15.4 Hz, 1H), 1.10 (t, J = 6.9 Hz, 3H). 
19
F NMR (CDCl3, 
 76 MHz, 298 K) δ (ppm): -78.5. 13C NMR (CDCl3, 1   MHz, 298 K) δ (ppm): 
168.9, 156.4, 146.6, 137.3, 130.1, 128.5, 127.7, 127.0, 126.7, 122.2, 122.0 (q, J = 
285.7 Hz), 78.3 (q, J = 29.0 Hz), 62.8, 38.4, 13.9.  IR (neat, cm
-1
): 3049, 2989, 2941, 
1747, 1600, 1295, 1202, 1161, 1111, 1000, 750. Anal. Calc. for C15H14F3NO3 (%): C, 
57.51; H, 4.50; N, 4.47. Found: C, 57.25; H, 4.45; N, 4.34. HRMS for C15H15F3NO3 
[M+H]
+
: m/z calc., 314.1004; found, 314.1011 
 
Ethyl 3,3,3-trifluoro-2-hydroxy-2-((6-methylquinolin-2-yl)methyl)propanoate, 
2b:
[16]
 Yellow liquid. 
1
H NMR (CDCl3, 4   MHz, 29  K) δ (ppm): 8. 5 (d, J = 8.4 
Hz, 1H), 7.84 (d, J = 8.5 Hz, 1H), 7.56-7.53 (m, 2H), 7.29-7.26 (m, 1H), 7.03 (bs, 
1H), 4.22 (q, J = 7.1 Hz, 2H), 3.72 (d, J = 15.4 Hz, 1H), 3.50 (d, J = 15.4 Hz, 1H), 
2.53 (s, 3H), 1.17 (t, J = 7.1 Hz, 3H). 
19
F NMR (CDCl3,  76 MHz, 29  K) δ (ppm): -
78.4. 
13
C NMR (CDCl3, 1   MHz, 29  K) δ (ppm): 168.8, 155.4, 145.2, 1 6.7, 
132.4, 128.1, 127.0, 126.5, 124.8 (q, J = 286.0 Hz), 122.1, 78.1 (q, J = 29.2 Hz), 
62.7, 38.3, 21.6, 13.9, 1 C is not observed. IR (neat, cm
-1
): 3495, 2984, 2940, 1737, 
1600, 1503, 1302, 1232, 1176, 1137, 1066, 828. Anal. Calc. for C16H16F3NO3 (%): C, 
58.71; H, 4.93; N, 4.28. Found: C, 58.67; H, 4.92; N, 4.13. HRMS for C16H17F3NO3 
[M+H]
+
: m/z calc., 328.1155; found, 328.1165. 
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Ethyl 3,3,3-trifluoro-2-hydroxy-2-((6-methoxyquinolin-2-yl)methyl)propanoate, 
2c: Light red solid. 
1
H NMR (CDCl3, 4   MHz, 29  K) δ (ppm): 8.   (d, J = 8.  Hz, 
1H), 7.84 (d, J = 9.2 Hz, 1H), 7.36 (dd, J = 9.2, 2.8 Hz, 1H), 7.27 (d, J = 8.3 Hz, 1H), 
7.06 (d, J = 2.7 Hz, 1H), 6.91 (bs, 1H), 4.23 (q, J = 7.1 Hz, 2H), 3.93 (s, 3H), 3.70 (d, 
J = 15.2 Hz, 1H), 3.48 (d, J = 15.4 Hz, 1H), 1.18 (t, J = 7.1 Hz, 3H). 
19
F NMR 
(CDCl3,  76 MHz, 29  K) δ (ppm): -78.4. 
13
C NMR (CDCl3, 1   MHz, 29  K) δ 
(ppm): 168.9, 157.9, 153.6, 142.7, 136.0, 129.9, 128.1, 122.9, 122.5, 122.0 (q, J = 
286.4 Hz), 105.1, 78.1 (q, J = 29.1 Hz), 62.8, 55.6, 38.2, 13.9. IR (neat, cm
-1
): 3443, 
3382, 3001, 2949, 1737, 1625, 1602, 1504, 1297, 1224, 1173, 1132, 1015, 831, 705. 
Anal. Calc. for C16H16F3NO4 (%): C, 55.98; H, 4.70; N, 4.08. Found: C, 55.97; H, 
4.69; N, 3.97. HRMS for C16H17F3NO4 [M+H]
+
: m/z calc., 344.1104; found, 
344.1117. 
 
Ethyl 2-((6-(benzyloxy)quinolin-2-yl)methyl)-3,3,3-trifluoro-2-hydroxypropanoate, 
2d: White solid.
 1
H NMR (CDCl3, 4   MHz, 29  K) δ (ppm): 8. 1 (d, J = 8.4 Hz, 
1H), 7.85 (d, J = 9.2 Hz, 1H), 7.49-7.34 (m, 6H), 7.26 (d, J = 8.4 Hz, 1H), 7.13 (d, J 
= 2.7 Hz, 1H), 6.88 (bs, 1H), 5.18 (s, 2H), 4.23 (q, J = 7.1 Hz, 2H), 3.70 (d, J = 15.3 
Hz, 1H), 3.48 (d, J = 15.3 Hz, 1H), 1.18 (t, J = 7.1 Hz, 3H). 
19
F NMR (CDCl3, 376 
MHz, 29  K) δ (ppm): -78.4. 13C NMR (CDCl3, 1   MHz, 29  K) δ (ppm): 168.9, 
157.0, 153.8, 142.8, 136.3, 136.1, 130.0, 128.7, 128.3, 128.0, 127.6, 123.2, 122.5, 
122.0 (q, J = 286.0 Hz), 106.5, 78.1 (q, J = 29.2 Hz), 70.3, 62.8, 38.2, 13.9. IR (neat, 
cm
-1
): 3151, 2970, 2899, 1743, 1626, 1602, 1506, 1454, 1385, 1207, 1187, 1147, 
1066, 1017, 834, 752, 717. Anal. Calc. for C22H20F3NO4 (%): C, 63.00; H, 4.81; N, 
3.34. Found: C, 62.52; H, 4.73; N, 3.49. HRMS for C22H21F3NO4 [M+H]
+
: m/z calc., 
420.1417; found, 420.1430. 
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Ethyl 2-((5,7-dimethylquinolin-2-yl)methyl)-3,3,3-trifluoro-2-hydroxypropanoate, 
2e: White solid. 
1
H NMR (CDCl3, 4   MHz, 29  K) δ (ppm): 8.24 (d, J = 8.5 Hz, 
1H), 7.57 (s, 1H), 7.27-7.20 (m, 2H), 4.22 (q, J = 7.0 Hz, 2H), 3.72 (d, J = 15.4 Hz, 
1H), 3.50 (d, J = 15.4 Hz, 1H), 2.63 (s, 3H), 2.50 (s, 3H), 1.17 (t, J = 7.1 Hz, 3H), 
OH signal not observed. 
19
F NMR (CDCl3,  76 MHz, 29  K) δ (ppm): -78.4. 
13
C 
NMR (CDCl3, 1   MHz, 29  K) δ (ppm): 168.9, 155.8, 147.2, 14 . , 1 4.2, 1  .6, 
129.5, 125.7, 124.5, 124.9 (q, J = 286.4 Hz), 120.9, 78.4 (q, J = 28.3 Hz), 62.7, 38.1, 
21.8, 18.4, 13.9. IR (neat, cm
-1
): 3110, 2996, 2911, 1757, 1595, 1450, 1264, 1186, 
1138, 1052, 856, 703. Anal. Calc. for C17H18F3NO3 (%): C, 59.82; H, 5.32; N, 4.10. 
Found: C, 59.73; H, 5.24; N, 3.97. HRMS for C17H19F3NO3 [M+H]
+
: m/z calc., 
342.1312; found, 342.1308. 
 
Ethyl 2-((6-chloroquinolin-2-yl)methyl)-3,3,3-trifluoro-2-hydroxypropanoate, 2f: 
Light yellow solid. 
1
H NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 8. 4 (d, J = 8.5 Hz, 
1H), 7.88 (d, J = 9.0 Hz, 1H), 7.78 (d, J = 2.3 Hz, 1H), 7.63 (dd, J = 9.0, 2.3 Hz, 1H), 
7.35 (d, J = 8.5 Hz, 1H), 6.15 (bs, 1H), 4.26 (q, J = 7.1 Hz, 2H), 3.76 (d, J = 15.4 Hz, 
1H), 3.51 (d, J = 15.4 Hz, 1H), 1.20 (t, J = 7.1 Hz, 3H). 
19
F NMR (CDCl3, 376 MHz, 
298 K) δ (ppm): -78.5. 13C NMR (CDCl3, 1   MHz, 298 K) δ (ppm): 168.8, 156.5, 
145.1, 136.2, 132.4, 131.0, 130.1, 127.6, 126.3, 123.2, 121.9 (q, J = 286.6 Hz), 78.0 
(q, J = 29.2 Hz), 63.0, 38.7, 13.9. IR (neat, cm
-1
): 3465, 3010, 2950, 1733, 1601, 
1494, 1309, 1220, 1190, 1145, 1075, 953, 880, 825, 696, 628, 420. Anal. Calc. for 
C15H13ClF3NO3 (%): C, 51.81; H, 3.77; N, 4.03. Found: C, 51.75; H, 3.72; N, 3.82. 
HRMS for C15H14ClF3NO3 [M+H]
+
: m/z calc., 348.0609; found, 348.0614. 
 
Ethyl 3,3,3-trifluoro-2-((6-fluoroquinolin-2-yl)methyl)-2-hydroxypropanoate, 
2g:
[16]
 Light brown solid. 
1
H NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 8. 9 (d, J = 
8.4 Hz, 1H), 7.94 (dd, J = 9.1, 5.3 Hz, 1H), 7.50-7.42 (m, 2H), 7.35 (d, J = 8.4 Hz, 
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1H), 6.33 (bs, 1H), 4.26 (q, J = 7.1 Hz, 2H), 3.76 (d, J = 15.4 Hz, 1H), 3.52 (d, J = 
15.4 Hz, 1H), 1.20 (t, J = 7.1 Hz, 3H). 
19
F NMR (CDCl3,  76 MHz, 298 K) δ (ppm): 
-112.9, -78.5. 
13
C NMR (CDCl3, 1   MHz, 298 K) δ (ppm): 168.8, 159.2 (d, J = 
248.5 Hz), 155.5 (d, J = 2.6 Hz), 143.8, 136.5 (d, J = 5.7 Hz), 130.9 (d, J = 8.9 Hz), 
127.6 (d, J = 10.1 Hz), 123.0, 121.9 (q, J = 285.7 Hz), 120.2 (d, J = 26.1 Hz), 110.6 
(d, J = 22.4 Hz), 78.1 (q, J = 29.3 Hz), 63.0, 38.6, 13.9. IR (neat, cm
-1
): 3273, 3073, 
2989, 1737, 1606, 1508, 1300, 1201, 1171, 1109, 1004, 828, 714, 469. Anal. Calc. 
for C15H13F4NO3 (%): C, 54.39; H, 3.96; N, 4.23. Found: C, 54.40; H, 3.89; N, 4.10. 
HRMS for C15H14F4NO3 [M+H]
+
: m/z calc., 332.0904; found, 332.0907. 
 
Ethyl 3,3,3-trifluoro-2-((7-fluoroquinolin-2-yl)methyl)-2-hydroxypropanoate, 
2i:
[30]
 Brown solid. 
1
H NMR (CDCl3, 400 MHz, 298 K) δ (ppm): 8.1  (d, J = 8.4 Hz, 
1H), 7.80 (dd, J = 8.9, 6.0 Hz, 1H), 7.56 (dd, J = 9.8, 1.8 Hz, 1H), 7.36-7.27 (m, 2H), 
4.27 (q, J = 7.1 Hz, 2H), 3.76 (d, J = 15.3 Hz, 1H), 3.51 (d, J = 15.3 Hz, 1H), 1.22 (t, 
J = 7.1 Hz, 3H), OH signal not observed. 
19
F NMR (CDCl3,  76 MHz, 298 K) δ 
(ppm): -108.4, -78.5. 
13
C NMR (CDCl3, 1   MHz, 298 K) δ (ppm): 168.8, 162.1 (d, 
J = 251.3 Hz), 157.4, 147.6 (d, J = 12.5 Hz), 137.1, 129.7 (d, J = 10.2 Hz), 124.0, 
122.0 (q, J = 286.8 Hz), 121.6 (d, J = 2.5 Hz), 117.1 (d, J = 24.8 Hz), 112.2 (d, J = 
20.3 Hz), 78.1 (q, J = 29.1 Hz), 63.0, 38.7, 13.9. IR (neat, cm
-1
): 3076, 2971, 2934, 
1740, 1626, 1600, 1509, 1247, 1166, 1111, 1006, 969, 868, 630, 437. Anal. Calc. for 
C15H13F4NO3 (%): C, 54.39; H, 3.96; N, 4.23. Found: C, 54.79; H, 3.98; N, 4.34. 
HRMS for C15H14F4NO3 [M+H]
+
: m/z calc., 332.0904; found, 332.0906. 
 
Ethyl 2-((6-chloroquinolin-2-yl)methyl)-3,3,3-trifluoro-2-hydroxypropanoate, 
2j:
[16]
 Yellow liquid. 
1
H NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 8.18 (d, J = 8.3 
Hz, 1H), 7.83 (dd, J = 7.5, 1.0 Hz, 1H), 7.74 (dd, J = 8.2, 0.9 Hz, 1H), 7.47 (t, J = 7.9 
Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H), 7.10 (bs, 1H), 4.24 (q, J = 7.1 Hz, 2H), 3.84 (d, J = 
15.8 Hz, 1H), 3.57 (d, J = 15.8 Hz, 1H), 1.19 (t, J = 7.1 Hz, 3H). 
19
F NMR (CDCl3, 
 76 MHz, 298 K) δ (ppm): -78.5. 13C NMR (CDCl3, 1   MHz, 298 K) δ (ppm): 
168.6, 157.6, 142.8, 137.8, 132.8, 130.1, 128.2, 126.7, 126.6, 123.0, 121.9 (q, J = 
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285.6 Hz), 78.2 (q, J = 29.2 Hz), 62.9, 38.5, 13.8. IR (neat, cm
-1
): 3470, 2985, 1738, 
1600, 1501, 1250, 1176, 1139, 1068, 833, 760, 674, 460. Anal. Calc. for 
C15H13ClF3NO3 (%): C, 51.81; H, 3.77; N, 4.03. Found: C, 52.05; H, 3.77; N, 3.82. 
HRMS for C15H14ClF3NO3 [M+H]
+
: m/z calc., 348.0609; found, 348.0613. 
 
Ethyl 2-((6-cyanoquinolin-2-yl)methyl)-3,3,3-trifluoro-2-hydroxypropanoate, 2k: 
Light brown solid. 
1
H NMR (CDCl3, 4   MHz, 29  K) δ (ppm): 8.2 -8.19 (m, 2H), 
8.03 (d, J = 8.7 Hz, 1H), 7.85 (d, J = 8.6 Hz, 1H), 7.47 (d, J = 8.5 Hz, 1H), 5.54 (bs, 
1H), 4.32 (q, J = 7.0 Hz, 2H), 3.83 (d, J = 15.4 Hz, 1H), 3.57 (d, J = 15.4 Hz, 1H), 
1.25 (t, J = 7.1 Hz, 3H). 
19
F NMR (CDCl3,  76 MHz, 29  K) δ (ppm): -78.5. 
13
C 
NMR (CDCl3, 1   MHz, 29  K) δ (ppm): 168.8, 159.4, 147.8, 1 7.2, 1  .9, 1  .7, 
130.1, 126.3, 124.1, 121.9 (q, J = 286.3 Hz), 118.4, 110.4, 77.7 (q, J = 29.0 Hz), 
63.3, 39.2, 13.9. IR (neat, cm
-1
): 3467, 2964, 2228, 1728, 1602, 1416, 1312, 1224, 
1184, 1141, 1077, 839, 703. Anal. Calc. for C16H13F3N2O3 (%): C, 56.81; H, 3.87; N, 
8.28. Found: C, 56.58; H, 3.89; N, 8.10. HRMS for C16H13F3N2O3Na [M+Na]
+
: m/z 
calc., 361.0776; found, 361.0791. 
 
Ethyl 3,3,3-trifluoro-2-hydroxy-2-((6-(trifluoromethyl)quinolin-2-yl)methyl) 
propanoate, 2l: Light brown solid. 
1
H NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 
8.24 (d, J = 8.4 Hz, 1H), 8.14 (s, 1H), 8.06 (d, J = 8.8 Hz, 1H), 7.88 (d, J = 8.8 Hz, 
1H), 7.45 (d, J = 8.5 Hz, 1H), 4.29 (q, J = 7.1 Hz, 2H), 3.82 (d, J = 15.4 Hz, 1H), 
3.57 (d, J = 15.4 Hz, 1H), 1.23 (t, J = 7.1 Hz, 3H), OH signal not observed. 
19
F NMR 
(CDCl3,  76 MHz, 298 K) δ (ppm): -78.5, -62.4. 
13
C NMR (CDCl3, 100 MHz, 298 
K) δ (ppm): 168.8, 158.6, 147.7, 1 7.8, 129.8, 128.4 (q, J =  2.7 Hz), 126. , 125.8 
(q, J = 2.9 Hz), 125.6 (q, J = 4.4 Hz), 123.6, 122.5 (q, J = 272.3 Hz), 121.9 (q, J = 
285.9 Hz), 77.9 (q, J = 29.3 Hz), 63.1, 39.0, 13.9. IR (neat, cm
-1
): 3475, 2965, 1733, 
1608, 1316, 1288, 1188, 1131, 1114, 1063, 840, 691, 623. Anal. Calc. for 
C16H13F6NO3 (%): C, 50.40; H, 3.44; N, 3.67. Found: C, 50.89; H, 3.52; N, 3.69. 
HRMS for C16H14F6NO3 [M+H]
+
: m/z calc., 382.0872; found, 382.0880. 
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Ethyl 3,3,3-trifluoro-2-hydroxy-2-((6-(pivaloyloxy)quinolin-2-yl)methyl) 
propanoate, 2n: White solid. 
1
H NMR (CDCl3, 4   MHz, 29  K) δ (ppm): 8. 9 (d, J 
= 8.4 Hz, 1H), 7.95 (d, J = 9.1 Hz, 1H), 7.52 (d, J = 1.4 Hz, 1H), 7.42 (d, J = 9.0, 
1H), 7.33 (d, J = 8.4 Hz, 1H), 6.49 (bs, 1H), 4.25 (q, J = 7.1 Hz, 2H), 3.76 (d, J = 
15.4 Hz, 1H), 3.52 (d, J = 15.4 Hz, 1H), 1.40 (s, 9H), 1.19 (t, J = 7.1 Hz, 3H). 
19
F 
NMR (CDCl3,  76 MHz, 29  K) δ (ppm): -78.5. 
13
C NMR (CDCl3, 100 MHz, 293 
K) δ (ppm): 177.1, 168.8, 156. , 149. , 144.6, 1 6.9, 129.9, 127. , 125.4, 122.7, 
121.9 (q, J = 285.9 Hz), 118.3, 78.2 (q, J = 29.1 Hz), 62.9, 39.2, 38.5, 27.1, 13.9. IR 
(neat, cm
-1
): 3150, 2977, 1750, 1606, 1476, 1280, 1206, 1135, 1117, 1106, 1060, 
909. Anal. Calc. for C20H22F3NO5 (%): C, 58.11; H, 5.36; N, 3.39. Found: C, 57.74; 
H, 5.22; N, 3.11. HRMS for C20H23F3NO5 [M+H]
+
: m/z calc., 414.1523; found, 
414.1540. 
 
Methyl 2-(2-(ethoxycarbonyl)-3,3,3-trifluoro-2-hydroxypropyl)quinoline-6-
carboxylate, 2o: White solid.
 1
H NMR (CDCl3, 4   MHz, 29  K) δ (ppm): 8.57 (d, J 
= 1.7 Hz, 1H), 8.29 (dd, J = 8.9, 1.8 Hz, 1H), 8.24 (d, J = 8.4 Hz, 1H), 7.97 (d, J = 
8.9 Hz, 1H), 7.40 (d, J = 8.5 Hz, 1H), 6.16 (bs, 1H), 4.28 (q, J = 7.1 Hz, 2H), 4.00 (s, 
3H), 3.81 (d, J = 15.5 Hz, 1H), 3.55 (d, J = 15.5 Hz, 1H), 1.21 (t, J = 7.1 Hz, 3H). 
19
F 
NMR (CDCl3,  76 MHz, 29  K) δ (ppm): -78.5. 
13
C NMR (CDCl3, 100 MHz, 293 
K) δ (ppm): 168.8, 166.4, 158.6, 148.5, 1 8. , 1  .8, 129.6, 128.8, 128.2, 126.1, 
123.1, 121.9 (q, J = 285.0 Hz), 78.0 (q, J = 29.2 Hz), 63.1, 52.5, 38.9, 13.9. IR (neat, 
cm
-1
): 3466, 3408, 2960, 1734, 1715, 1696, 1625, 1601, 1439, 1281, 1233, 1179, 
1136, 1095, 786, 695. Anal. Calc. for C17H16F3NO5 (%): C, 54.99; H, 4.34; N, 3.77. 
Found: C, 55.41; H, 4.77; N, 3.35. HRMS for C17H17F3NO5 [M+H]
+
: m/z calc., 
372.1059; found, 372.1058. 
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Ethyl 2-((6-(diethylcarbamoyl)quinolin-2-yl)methyl)-3,3,3-trifluoro-2-hydroxy 
propanoate, 2p: Yellow liquid. 
1
H NMR (CDCl3, 4   MHz, 29  K) δ (ppm): 8.16 
(d, J = 8.3 Hz, 1H), 7.97 (d, J = 8.5 Hz, 1H), 7.84 (s, 1H), 7.69 (d, J = 8.4, 1H), 7.37 
(d, J = 8.4 Hz, 1H), 4.27 (q, J = 7.0 Hz, 2H), 3.78 (d, J = 15.6 Hz, 1H), 3.60-3.52 (m, 
3H), 3.29 (bs, 2H), 1.30-1.14 (m, 9H), OH signal not observed. 
19
F NMR (CDCl3, 
 76 MHz, 29  K) δ (ppm): -78.5. 13C NMR (CDCl3, 1   MHz, 29  K) δ (ppm): 
170.3, 168.8, 157.2, 146.6, 137.5, 135.5, 128.9, 128.1, 126.5, 125.6, 123.0, 121.9 (q, 
J = 285.3 Hz), 78.1 (q, J = 29.2 Hz), 63.0, 43.4, 39.5, 38.7, 14.3, 13.9, 12.9. IR (neat, 
cm
-1
): 3460, 2980, 2939, 1742, 1617, 1484, 1430, 1281, 1176, 1133, 1067, 1016, 
841. Anal. Calc. for C20H23F3N2O4 (%): C, 58.25; H, 5.62; N, 6.79. Found: C, 57.98; 
H, 5.46; N, 6.31. HRMS for C20H24F3N2O4 [M+H]
+
: m/z calc., 413.1688; found, 
413.1697. 
 
Ethyl 2-(benzo[f]quinolin-3-ylmethyl)-3,3,3-trifluoro-2-hydroxypropanoate, 2q:
[16]
 
White solid. 
1
H NMR (CDCl3, 4   MHz, 29  K) δ (ppm): 8.92 (d, J = 8.4 Hz, 1H), 
8.59 (d, J = 8.0 Hz, 1H), 7.99-7.93 (m, 2H), 7.83 (d, J = 9.0 Hz, 1H), 7.73-7.64 (m, 
2H), 7.48 (d, J = 8.3 Hz, 1H), 6.87 (bs, 1H), 4.25 (q, J = 6.9 Hz, 2H), 3.79 (d, J = 
15.2 Hz, 1H), 3.57 (d, J = 15.2 Hz, 1H), 1.18 (t, J = 6.9 Hz, 3H). 
19
F NMR (CDCl3, 
 76 MHz, 29  K) δ (ppm): -78.4. 13C NMR (CDCl3, 1   MHz, 29  K) δ (ppm): 
168.9, 155.5, 146.7, 132.0, 131.7, 131.6, 129.3, 128.8, 127.5, 127.4, 127.1, 124.2, 
122.5, 122.3, 122.0 (q, J = 285.8 Hz), 78.4 (q, J = 29.1 Hz), 62.8, 38.2, 13.9. IR 
(neat, cm
-1
): 3201, 2979, 2936, 1740, 1594, 1293, 1242, 1207, 1165, 1123, 1095, 
1011, 829, 759. Anal. Calc. for C19H16F3NO3 (%): C, 62.81; H, 4.44; N, 3.86. Found: 
C, 62.42; H, 4.37; N, 3.81. HRMS for C19H17F3NO3 [M+H]
+
: m/z calc., 364.1155; 
found, 364.1162. 
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Ethyl 3,3,3-trifluoro-2-hydroxy-2-((6-(thiophen-2-yl)quinolin-2-yl)methyl) 
propanoate, 2r: Yellow solid. 
1
H NMR (CDCl3, 4   MHz, 29  K) δ (ppm): 8.14 (d, 
J = 8.5 Hz, 1H), 7.99-7.93 (m, 3H), 7.45 (d, J = 3.6 Hz, 1H), 7.37 (d, J = 5.0 Hz, 
1H), 7.33 (d, J = 8.4 Hz, 1H), 7.14 (dd, J = 5.0, 3.7 Hz, 1H), 4.26 (q, J = 7.1 Hz, 2H), 
3.76 (d, J = 15.4 Hz, 1H), 3.52 (d, J = 15.4 Hz, 1H), 1.20 (t, J = 7.1 Hz, 3H), OH 
signal not observed. 
19
F NMR (CDCl3,  76 MHz, 29  K) δ (ppm): -78.4. 
13
C NMR 
(CDCl3, 1   MHz, 29  K) δ (ppm): 168.8, 156.2, 146. , 14 .2, 1 7.2, 1 2.8, 129. , 
128.6, 128.4, 127.3, 125.9, 124.2, 123.6, 122.9, 122.0 (q, J = 285.2 Hz), 78.2 (q, J = 
29.1 Hz), 62.9, 38.5, 13.9. IR (neat, cm
-1
): 3093, 2994, 1752, 1598, 1251, 1190, 
1143, 1061, 830, 698. Anal. Calc. for C19H16F3NO3S (%): C, 57.72; H, 4.08; N, 3.54. 
Found: C, 57.52; H, 3.99; N, 3.36. HRMS for C19H17F3NO3S [M+H]
+
: m/z calc., 
396.0881; found, 396.0868. 
 
Ethyl 3,3,3-trifluoro-2-hydroxy-2-((6-(pyridin-4-yl)quinolin-2-yl)methyl) 
propanoate, 2s: Yellow solid. 
1
H NMR (CDCl3, 4   MHz, 29  K) δ (ppm): 8.72-
8.71 (m, 2H), 8.22 (d, J = 8.3 Hz, 1H), 8.06-8.04 (m, 2H), 7.97 (d, J = 8.8 Hz, 1H), 
7.61-7.60 (m, 2H), 7.40 (d, J = 8.3 Hz, 1H), 6.49 (bs, 1H), 4.28 (q, J = 6.9 Hz, 2H), 
3.80 (d, J = 15.3 Hz, 1H), 3.56 (d, J = 15.3 Hz, 1H), 1.23 (t, J = 6.9 Hz, 3H). 
19
F 
NMR (CDCl3,  76 MHz, 29  K) δ (ppm): -78.4. 
13
C NMR (CDCl3, 100 MHz, 293 
K) δ (ppm): 168.8, 157.2, 15 .4, 147.3, 146.8, 137.5, 136.4, 129.5, 128.8, 127.1, 
126.1, 123.1, 122.0 (q, J = 286.3 Hz), 121.8, 78.2 (q, J = 29.1 Hz), 63.0, 38.8, 14.0. 
IR (neat, cm
-1
): 3050, 2985, 2811, 1741, 1598, 1491, 1307, 1254, 1189, 1149, 1060, 
999, 820, 671, 612. Anal. Calc. for C20H17F3N2O3 (%): C, 61.54; H, 4.39; N, 7.18. 
Found: C, 61.23; H, 4.35; N, 7.01. HRMS for C20H18F3N2O3 [M+H]
+
: m/z calc., 
391.1270; found, 391.1277. 
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Ethyl 2-((6-(5-(3-ethoxy-1,1,1-trifluoro-2-hydroxy-3-oxopropan-2-yl)furan-2-
yl)quinolin-2-yl)methyl)-3,3,3-trifluoro-2-hydroxypropanoate, 2t: Yellow brownish 
crystalline solid. 
1
H NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 8.14 (d, J = 8.5 Hz, 
1H), 8.05 (s, 1H), 7.94 (s, 2H), 7.33 (d, J = 8.5 Hz, 1H), 6.81 (d, J = 3.5 Hz, 1H), 
6.74 (d, J = 3.5 Hz, 1H), 6.49 (bs, 1H), 4.52-4.44 (m, 3H), 4.26 (q, J = 7.1 Hz, 2H), 
3.76 (d, J = 15.4 Hz, 1H), 3.52 (d, J = 15.4 Hz, 1H), 1.39 (t, J = 7.2 Hz, 3H), 1.19 (t, 
J = 7.1 Hz, 3H). 
19
F NMR (CDCl3, 376 MHz, 298 K) δ (ppm): -78.4, -76.1. 
13
C 
NMR (CDCl3, 1   MHz, 298 K) δ (ppm): 168.8, 167.2, 156.5, 154. , 146. , 146.1, 
137.3, 129.1, 128.1, 127.1, 126.4, 123.0, 122.1, 122.0 (q, J = 286.3 Hz), 120.9 (q, J = 
286.3 Hz), 112.9, 107.2, 77.9 (q, J = 29.3 Hz), 75.1 (q, J = 31.9 Hz), 64.8, 62.9, 38.6, 
13.9, 13.8. IR (neat, cm
-1
): 3438, 2987, 1740, 1690, 1602, 1474, 1302, 1232, 1173, 
1137, 1015, 838, 696. Anal. Calc. for C24H21F6NO7 (%): C, 52.47; H, 3.85; N, 2.55. 
Found: C, 52.48; H, 3.88; N, 2.46. HRMS for C24H22F6NO7 [M+H]
+
: m/z calc., 
550.1295; found, 550.1314. 
 
Ethyl 3,3,3-trifluoro-2-hydroxy-2-((6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)quinolin-2-yl)methyl)propanoate, 2u: Brown solid. 
1
H NMR (CDCl3, 400 MHz, 
298 K) δ (ppm): 8.31 (s, 1H), 8.16 (d, J = 8.4 Hz, 1H), 8.07 (d, J = 8.5 Hz, 1H), 7.91 
(d, J = 8.4 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 6.73 (bs, 1H), 4.23 (q, J = 7.1 Hz, 2H), 
3.76 (d, J = 15.5 Hz, 1H), 3.52 (d, J = 15.5 Hz, 1H), 1.39 (s, 12H), 1.16 (t, J = 7.1 
Hz, 3H). 
19
F NMR (CDCl3,  76 MHz, 298 K) δ (ppm): -78.5. 
13
C NMR (CDCl3, 100 
MHz, 298 K) δ (ppm): 168.8, 157.4, 148.1, 137.9, 135.9, 134.9, 127.5, 126.4, 124.8 
(J = 286.4 Hz), 122.2, 84.3, 78.2 (J = 29.0 Hz), 62.8, 38.6, 24.9, 13.9, one carbon 
signal is not observed. Anal. Calc. for C21H25BF3NO5 (%): C, 57.42; H, 5.74; N, 
3.19. Found: C, 56.94; H, 5.62; N, 2.98. HRMS for C21H26
10
BF3NO5 [M+H]
+
: m/z 
calc., 439.1892; found, 439.1903 and C21H26
11
BF3NO5 [M+H]
+
: m/z calc., 440.1856; 
found, 440.1861. 
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Ethyl 2-((6-(allyloxy)quinolin-2-yl)methyl)-3,3,3-trifluoro-2-hydroxypropanoate, 
2v: Light brown crystalline solid. 
1
H NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 8. 1 
(d, J = 8.4 Hz, 1H), 7.84 (d, J = 9.2 Hz, 1H), 7.39 (dd, J = 9.2, 2.7 Hz, 1H), 7.27 (d, J 
= 5.1 Hz, 1H), 7.06 (d, J = 2.7 Hz, 1H), 6.78 (bs, 1H), 6.16-6.06 (m, 1H),  5.47 (dd, J 
= 17.2, 1.3 Hz, 1H), 5.34 (dd, J = 10.5, 1.1 Hz, 1H), 4.65 (d, J = 5.2 Hz, 2H), 4.23 (q, 
J = 7.1 Hz, 2H), 3.70 (d, J = 15.3 Hz, 1H), 3.48 (d, J = 15.3 Hz, 1H), 1.18 (t, J = 7.1 
Hz, 3H). 
19
F NMR (CDCl3,  76 MHz, 298 K) δ (ppm): -78.4. 
13
C NMR (CDCl3, 100 
MHz, 298 K) δ (ppm): 168.9, 156.8, 15 .7, 142.7, 1 6. , 1 2.7, 129.9, 128. , 12 .1, 
122.5, 122.0 (q, J = 286.6 Hz), 118.1, 106.3, 78.1 (q, J = 28.9 Hz), 69.1, 62.7, 38.2, 
13.9. IR (neat, cm
-1
): 3481, 3090, 3029, 2984, 2937, 1733, 1601, 1501, 1303, 1213, 
1171, 1115, 990, 833. Anal. Calc. for C18H18F3NO4 (%): C, 58.54; H, 4.91; N, 3.79. 
Found: C, 58.44; H, 4.90; N, 3.68. HRMS for C18H19F3NO4 [M+H]
+
: m/z calc., 
370.1261; found, 370.1268. 
6.4.6 Data for 4a and 4b 
 
Ethyl 3,3,3-trifluoro-2-hydroxy-2-((9-methyl-1,10-phenanthrolin-2-yl)methyl) 
propanoate, 4a: Light brown solid. 
1
H NMR (CDCl3, 4   MHz, 29  K) δ (ppm): 
8.21 (d, J = 8.0 Hz, 1H), 8.11 (d, J = 8.1 Hz, 1H), 7.75-7.68 (m, 2H), 7.55-7.48 (m, 
2H), 4.27-4.24 (m, 2H), 3.86 (d, J = 14.6 Hz, 1H), 3.66 (d, J = 14.6 Hz, 1H), 2.88 (s, 
3H), 1.17 (t, J = 6.8 Hz, 3H), OH signal not observed. 
19
F NMR (CDCl3, 376 MHz, 
29  K) δ (ppm): -78.0. 13C NMR (CDCl3, 1   MHz, 29  K) δ (ppm): 168.9, 159.5, 
155.9, 144.6, 144.4, 137.2, 136.1, 127.4, 126.9, 126.6, 124.9, 123.9, 123.8, 122.2 (q, 
J = 286.8 Hz), 78.8 (q, J = 29.0 Hz), 62.7, 38.4, 25.6, 13.9. IR (neat, cm
-1
): 3065, 
2984, 2907, 1746, 1589, 1499, 1274, 1200, 1169, 1134, 1050, 859, 715. Anal. Calc. 
for C19H17F3N2O3 (%): C, 60.32; H, 4.53; N, 7.40. Found: C, 60.19; H, 4.36; N, 7.24. 
HRMS for C19H18F3N2O3 [M+H]
+
: m/z calc., 379.1270; found, 379.1278. 
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Diethyl 2,2'-((1,10-phenanthroline-2,9-diyl)bis(methylene))bis(3,3,3-trifluoro-2-
hydroxypropanoate), 4b: White solid. 
1
H NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 
8.22 (d, J = 8.2 Hz, 2H), 7.77 (s, 2H), 7.64-7.56 (m, 2H), 4.34-4.21 (m, 4H), 3.90-
3.82 (m, 2H), 3.71-3.59 (m, 2H), 1.16 (q, J = 7.5 Hz, 6H). 
19
F NMR (CDCl3, 376 
MHz, 298 K) δ (ppm): -78.0. 13C NMR (CDCl3, 1   MHz, 298 K) δ (ppm): 156.1, 
144.4, 136.9, 127.7, 126.2, 126.2 (q, J = 292.4 Hz), 124.6, 63.1, 29.7, 13.8, two 
carbon signals not observed due to low intensity. HRMS for C24H22F6N2O6Na 
[M+Na]
+
: m/z calc., 571.1280; found, 571.1276. 
6.4.7 Data for 5a-f 
 
Ethyl 2-hydroxy-2-methyl-3-(quinolin-2-yl)propanoate, 5a:
[30]
 Yellow liquid.
 1
H 
NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 8. 9 (d, J = 8.5 Hz, 1H), 7.98 (d, J = 8.5 
Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.70-7.66 (m, 1H), 7.52-7.48 (m, 1H), 7.27 (d, J = 
8.4 Hz, 1H), 6.23 (bs, 1H), 4.09 (q, J = 7.1 Hz, 2H), 3.56 (d, J = 15.4 Hz, 1H), 3.26 
(d, J = 15.4 Hz, 1H), 1.58 (s, 3H), 1.09 (t, J = 7.1 Hz, 3H). 
13
C NMR (CDCl3, 100 
MHz, 298 K) δ (ppm): 176. , 159.1, 146.9, 1 6.7, 129.7, 128.7, 127.5, 126.8, 126. , 
122.2, 75.1, 61.1, 46.4, 26.4, 14.1. IR (neat, cm
-1
): 3377, 3060, 2980, 2936, 1724, 
1600, 1505, 1290, 1189, 1105, 1017, 822, 752, 615. Anal. Calc. for C15H17NO3 (%): 
C, 69.48; H, 6.61; N, 5.40. Found: C, 68.99; H, 6.66; N, 5.04. HRMS for 
C15H17NO3Na [M+Na]
+
: m/z calc., 282.1106; found, 282.1100. 
 
Ethyl 2-hydroxy-2-methyl-3-(6-(pivaloyloxy)quinolin-2-yl)propanoate, 5b: Yellow 
liquid. 
1
H NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 8. 5 (d, J = 8.5 Hz, 1H), 8.   
(d, J = 9.1 Hz, 1H), 7.50 (d, J = 2.4 Hz, 1H), 7.40 (dd, J = 9.1, 2.5 Hz, 1H), 7.29 (d, J 
= 8.5 Hz, 1H), 6.19 (bs, 1H), 4.09 (q, J = 7.1 Hz, 2H), 3.56 (d, J = 15.4 Hz, 1H), 3.27 
(d, J = 15.4 Hz, 1H), 1.58 (s, 3H), 1.40 (s, 9H), 1.10 (t, J = 7.1 Hz, 3H). 
13
C NMR 
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(CDCl3, 1   MHz, 298 K) δ (ppm): 177.1, 175.9, 158.8, 148.8, 144.8, 1 6.4, 1  . , 
127.1, 125.0, 122.7, 118.1, 75.1, 61.2, 46.3, 39.2, 27.1, 26.4, 14.1. IR (neat, cm
-1
): 
3480, 2978, 2937, 2874, 1782, 1742, 1605, 1208, 1100, 1025, 905. HRMS for 
C20H26NO5 [M+H]
+
: m/z calc., 360.1811; found, 360.1819. 
 
Ethyl 2-hydroxy-3-(6-methoxyquinolin-2-yl)-2-methylpropanoate, 5c: Yellow 
liquid. 
1
H NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 7.98 (d, J = 8.4 Hz, 1H), 7.87 
(d, J = 9.2 Hz, 1H), 7.34 (dd, J = 9.2, 2.8 Hz, 1H), 7.22 (d, J = 8.4 Hz, 1H), 7.04 (d, J 
= 2.8 Hz, 1H), 6.23 (bs, 1H), 4.08 (q, J = 7.1 Hz, 2H), 3.92 (s, 3H), 3.50 (d, J = 15.3 
Hz, 1H), 3.22 (d, J = 15.3 Hz, 1H), 1.57 (s, 3H), 1.09 (t, J = 7.1 Hz, 3H). 
13
C NMR 
(CDCl3, 1   MHz, 298 K) δ (ppm): 176. , 157.6, 156.4, 14 . , 1 5.5, 1  .1, 127.8, 
122.5, 122.4, 105.1, 75.2, 61.1, 55.5, 46.1, 26.4, 14.1. IR (neat, cm
-1
): 3350, 2979, 
2937, 1726, 1600, 1500, 1379, 1229, 1107, 1024, 831. Anal. Calc. for C16H19NO4 
(%): C, 66.42; H, 6.62; N, 4.84. Found: C, 66.63; H, 6.70; N, 4.72. HRMS for 
C16H20NO4 [M+H]
+
: m/z calc., 290.1392; found, 290.1382. 
 
1,1,1-Trifluoro-3-(quinolin-2-yl)-2-(4-(trifluoromethyl)phenyl)propan-2-ol, 5d: 
White solid. 
1
H NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 8.7  (bs, 1H), 8.10 (d, J = 
8.4 Hz, 1H), 7.96 (d, J = 8.5 Hz, 1H), 7.83 (d, J = 8.3 Hz, 2H), 7.77 (d, J = 8.2 Hz, 
1H), 7.71 (d, J = 7.7 Hz, 1H), 7.57-7.51 (m, 3H), 7.24 (d, J = 8.4 Hz, 1H), 3.82 (d, J 
= 15.2 Hz, 1H), 3.67 (d, J = 15.2 Hz, 1H). 
19
F NMR (CDCl3, 376 MHz, 298 K) δ 
(ppm): -79.2, -62.7. 
13
C NMR (CDCl3, 1   MHz, 298 K) δ (ppm): 157.2, 146.2, 
142.6, 137.9, 130.4, 130.3 (q, J = 32.8 Hz), 128.3, 127.7, 127.3, 126.9, 126.8, 126.3 
(q, J = 284.7 Hz), 125.1 (q, J = 3.7 Hz), 122.6 (q, J = 272.1 Hz), 122.3, 77.5 (q, J = 
28.1 Hz), 39.9. IR (neat, cm
-1
): 3086, 2920, 1600, 1509, 1431, 1327, 1156, 1119, 
1103, 1069, 1040, 950, 839, 764, 623. Anal. Calc. for C19H13F6NO (%): C, 59.23; H, 
3.40; N, 3.64. Found: C, 59.34; H, 3.37; N, 3.47. HRMS for C19H14F6NO [M+H]
+
: 
m/z calc., 386.0980; found, 386.0968. 
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3-(6-Chloroquinolin-2-yl)-1,1,1-trifluoro-2-(4-(trifluoromethyl)phenyl)propan-2-
ol, 5e: White solid. 
1
H NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 8. 8 (s, 1H), 8.   
(d, J = 8.6 Hz, 1H), 7.88 (d, J = 9.0 Hz, 1H), 7.73 (d, J = 2.1 Hz, 1H), 7.63 (dd, J = 
9.0, 2.1 Hz, 1H), 7.56 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 8.4 Hz, 2H), 3.80 (d, J = 15.4 
Hz, 1H), 3.67 (d, J = 15.2 Hz, 1H), OH signal not observed. 
19
F NMR (CDCl3, 376 
MHz, 298 K) δ (ppm): -79.2, -62.7. 13C NMR (CDCl3, 1   MHz, 298 K) δ (ppm): 
157.5, 144.6, 142.4, 136.9, 132.7, 131.4, 130.5 (q, J = 32.4 Hz), 129.8, 127.5, 127.2, 
126.4, 125.2 (q, J = 3.9 Hz), 124.9 (q, J = 285.9 Hz), 123.9 (q, J = 271.3 Hz), 123.2, 
77.3 (q, J = 28.5), 40.0. HRMS for C19H13ClF6NO [M+H]
+
: m/z calc., 420.0584; 
found, 420.0589. 
 
1,1,1-Trifluoro-3-(6-methoxyquinolin-2-yl)-2-(3-(trifluoromethyl)phenyl)propan-
2-ol, 5f: White solid. 
1
H NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 8.74 (bs, 1H), 
7.99 (s, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.87 (d, J = 7.8 Hz, 1H), 7.81 (d, J = 9.2 Hz, 
1H), 7.49 (d, J = 7.6 Hz, 1H), 7.40 (t, J = 7.9 Hz, 1H), 7.32 (dd, J = 9.2, 2.7 Hz, 1H), 
7.16 (d, J = 8.4 Hz, 1H), 6.96 (d, J = 2.7 Hz, 1H), 3.85 (s, 3H), 3.76 (d, J = 15.2 Hz, 
1H), 3.61 (d, J = 15.4 Hz, 1H). 
19
F NMR (CDCl3,  76 MHz, 298 K) δ (ppm): -79.2, -
62.6. 
13
C NMR (CDCl3, 1   MHz, 298 K) δ (ppm): 158. , 154.4, 142.4, 1 9.9, 
136.5, 130.5 (q, J = 32.4 Hz), 130.2, 129.5, 128.7, 128.0, 125.1 (q, J = 3.9 Hz), 125.0 
(q, J = 285.9 Hz), 124.1 (q, J = 272.0 Hz), 123.8 (q, J = 3.9 Hz), 123.3, 122.5, 105.0, 
77.3 (q, J = 28.5 Hz), 55.5, 39.6. HRMS for C20H16F6NO2 [M+H]
+
: m/z calc., 
416.1080; found, 416.1077. 
6.4.8 Data for 7b-f 
 
Ethyl 3,3,3-trifluoro-2-hydroxy-2-(3-methylquinolin-6-yl)propanoate, 7b: Light 
yellow solid. 
1
H NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 8.78 (s, 1H), 8.24 (s, 1H), 
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8.10 (d, J = 9.1 Hz, 1H), 8.04 (d, J = 9.1 Hz, 1H), 7.97 (s, 1H), 5.06 (bs, 1H), 4.50-
4.38 (m, 2H), 2.52 (s, 3H), 1.40-1.36 (m, 3H). 
19
F NMR (CDCl3,  76 MHz, 298 K) δ 
(ppm): -76.0. 
13
C NMR (CDCl3, 1   MHz, 298 K) δ (ppm): 168.7, 15 .4, 146. , 
135.6, 131.3, 131.2, 129.0, 127.5, 126.6, 126.3, 121.7 (q, J = 286.5 Hz), 78.1 (q, J = 
30.4 Hz), 64.5, 18.7, 13.9. IR (neat, cm
-1
): 3070, 2984, 2745, 1742, 1505, 1446, 
1247, 1155, 1145, 1116, 1029, 896, 731. Anal. Calc. for C15H14F3NO3 (%): C, 57.51; 
H, 4.50; N, 4.47. Found: C, 57.19; H, 4.41; N, 4.21. HRMS for C15H15F3NO3 
[M+H]
+
: m/z calc., 314.1004; found, 314.1009. 
 
Ethyl 3,3,3-trifluoro-2-hydroxy-2-(4-methylquinolin-6-yl)propanoate, 7c: White 
solid. 
1
H NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 8.78 (d, J = 4.4 Hz, 1H), 8.51 (d, 
J = 1.6 Hz, 1H), 8.17-8.10 (m, 2H), 7.27-7.26 (m, 1H), 5.39 (s, 1H), 4.51-4.37 (m, 
2H), 2.73 (s, 3H), 1.38 (t, J = 7.1 Hz, 3H). 
19
F NMR (CDCl3,  76 MHz, 298 K) δ 
(ppm): -76.0. 
13
C NMR (CDCl3, 1   MHz, 298 K) δ (ppm): 168.7, 151.2, 147.9, 
145.3, 130.9, 130.0, 127.7, 127.3, 123.0, 122.4, 121.7 (q, J = 285.7 Hz), 78.2 (q, J = 
30.1 Hz), 64.4, 18.7, 13.9. IR (neat, cm
-1
): 3060, 2983, 2686, 1747, 1593, 1240, 
1162, 1128, 1017, 843, 684. Anal. Calc. for C15H14F3NO3 (%): C, 57.51; H, 4.50; N, 
4.47. Found: C, 57.38; H, 4.44; N, 4.34. HRMS for C15H15F3NO3 [M+H]
+
: m/z calc., 
314.1004; found, 314.1009. 
 
Ethyl 3,3,3-trifluoro-2-hydroxy-2-(2-phenylquinolin-6-yl)propanoate, 7d: Light 
yellow solid. 
1
H NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 8.   (d, J = 1.7 Hz, 1H), 
8.25-8.10 (m, 5H), 7.90 (d, J = 8.7 Hz, 1H), 7.54-7.44 (m, 3H), 4.59 (s, 1H), 4.53-
4.38 (m, 2H), 1.39 (t, J = 7.2 Hz, 3H). 
19
F NMR (CDCl3,  76 MHz, 298 K) δ (ppm): 
-76.0. 
13
C NMR (CDCl3, 1   MHz, 298 K) δ (ppm): 168.7, 158.6, 148.4, 1 9.4, 
137.5, 130.6, 129.9, 129.6, 129.2, 128.9, 127.7, 126.7, 126.5, 121.7 (q, J = 285.8 
Hz), 119.6, 78.0 (q, J = 30.4 Hz), 64.7, 13.9. IR (neat, cm
-1
): 3173, 2985, 1745, 1602, 
1492, 1275, 1150, 1133, 1116, 982, 843, 763, 705. Anal. Calc. for C20H16F3NO3 (%): 
C, 64.00; H, 4.30; N, 3.73. Found: C, 63.87; H, 4.25; N, 3.65. HRMS for 
C20H17F3NO3 [M+H]
+
: m/z calc., 376.1161; found, 376.1167. 
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Ethyl 3,3,3-trifluoro-2-hydroxy-2-(2-methyl-4-phenylquinolin-6-yl)propanoate, 7e: 
Light yellow solid. 
1
H NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 8.36 (s, 1H), 8.13-
8.08 (m, 2H), 7.57-7.48 (m, 5H), 7.28 (s, 1H), 4.42 (s, 1H), 4.42-4.26 (m, 2H), 2.79 
(s, 3H), 1.22 (t, J = 7.1 Hz, 3H). 
19
F NMR (CDCl3,  76 MHz, 298 K) δ (ppm): -76.2. 
13
C NMR (CDCl3, 1   MHz, 298 K) δ (ppm): 168.8, 159.9, 149.1, 148.5, 137.7, 
130.1, 129.5, 129.2, 128.7, 128.6, 127.4, 124.8, 124.4, 122.8, 121.5 (q, J = 286.4 
Hz), 78.1 (q, J = 28.2 Hz), 64.6, 25.4, 13.7. IR (neat, cm
-1
): 3223, 3060, 2973, 1739, 
1591, 1491, 1288, 1165, 1128, 1109, 1010, 971, 847, 760, 703. Anal. Calc. for 
C21H18F3NO3 (%): C, 64.78; H, 4.66; N, 3.60. Found: C, 64.60; H, 4.48; N, 3.32. 
HRMS for C21H19F3NO3 [M+H]
+
: m/z calc., 390.1312; found, 390.1324. 
 
Ethyl 3,3,3-trifluoro-2-hydroxy-2-(2-methylquinolin-6-yl)propanoate, 7f: Light 
yellow solid. 
1
H NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 8.26 (s, 1H), 8.1 -8.03 
(m, 3H), 7.33 (d, J = 8.5 Hz, 1H), 4.63 (s, 1H), 4.53-4.38 (m, 2H), 2.76 (s, 3H), 1.39 
(t, J = 7.1 Hz, 3H). 
19
F NMR (CDCl3,  76 MHz, 298 K) δ (ppm): -76.1. 
13
C NMR 
(CDCl3, 1   MHz, 298 K) δ (ppm): 168.7, 16 .5, 148. , 1 6.8, 1  .1, 128.8, 127.4, 
126.7, 125.8, 122.7, 121.6 (q, J = 285.7 Hz), 77.9 (q, J = 30.4 Hz), 64.6, 25.4, 13.9. 
IR (neat, cm
-1
): 3090, 2990, 2746, 1742, 1604, 1445, 1257, 1175, 1157, 1133, 1031, 
842, 730, 692. Anal. Calc. for C15H14F3NO3 (%): C, 57.51; H, 4.50; N, 4.47. Found: 
C, 57.39; H, 4.44; N, 4.34. HRMS for C15H15F3NO3 [M+H]
+
: m/z calc., 314.1004; 
found, 314.1014. 
6.4.9 Data for 9b 
 
Ethyl 3,3,3-trifluoro-2-hydroxy-2-(2-methyl-1H-indol-5-yl)propanoate, 9b: Deep 
red viscous liquid. 
1
H NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 7.92 (s, 2H), 7.50 
(d, J = 8.6 Hz, 1H), 7.26 (d, J = 8.7 Hz, 1H), 6.24 (d, J = 0.8 Hz, 1H), 4.49-4.33 (m, 
2H), 4.29 (s, 1H), 2.42 (s, 3H), 1.37 (t, J = 7.1 Hz, 3H). 
19
F NMR (CDCl3, 376 MHz, 
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298 K) δ (ppm): -76.2. 13C NMR (CDCl3, 1   MHz, 298 K) δ (ppm): 169.6, 136.4, 
136.3, 128.9, 124.8 (q, J = 286.3 Hz), 124.1, 119.3, 118.3, 110.0, 101.0, 78.5 (q, J = 
30.1 Hz), 64.1, 13.9, 13.7. IR (neat, cm
-1
): 3460, 3401, 2986, 1732, 1625, 1500, 
1477, 1234, 1160, 1131, 1100, 1013, 806, 733, 623. Anal. Calc. for C14H14F3NO3 + 
H2O (%): C, 52.67; H, 5.05; N, 4.39. Found: C, 52.94; H, 4.78; N, 4.10. HRMS for 
C14H14F3NO3Na [M+Na]
+
: m/z calc., 324.0823; found, 324.0824. 
6.4.10 Data for 10a, 11a and 12a 
 
Ethyl 2-((6-(3-ethoxy-1,1,1-trifluoro-2-hydroxy-3-oxopropan-2-yl)quinolin-2-
yl)methyl)-3,3,3-trifluoro-2-hydroxypropanoate, 10a: Yellow liquid. 
1
H NMR 
(CDCl3, 4   MHz, 298 K) δ (ppm): 8.30 (s, 1H), 8.19 (d, J = 8.4 Hz, 1H), 8.11 (d, J 
= 9.0 Hz, 1H), 7.97 (d, J = 9.0 Hz, 1H), 7.37 (d, J = 8.4 Hz, 1H), 6.38 (d, J = 2.9 Hz, 
1H), 4.54-4.38 (m, 2H), 4.52 (s, 1H), 4.30-4.24 (m, 2H), 3.78 (d, J = 15.4 Hz, 1H), 
3.53 (d, J = 15.4 Hz, 1H), 1.40 (t, J = 7.1 Hz, 3H), 1.25-1.20 (m, 3H). 
19
F NMR 
(CDCl3,  76 MHz, 298 K) δ (ppm): -78.5, -76.1. 
13
C NMR (CDCl3, 100 MHz, 298 
K) δ (ppm): 168.8, 168.5, 157.7, 146.8, 1 7.9, 1 1.1, 128.7 (d, J = 2.4 Hz), 128.1, 
126.9, 126.3, 124.8 (q, J = 286.1 Hz), 122.9, 121.5 (q, J = 286.1 Hz), 78.1 (q, J = 
29.7 Hz), 77.5 (q, J = 30.5 Hz), 64.8, 63.0, 38.7, 13.9 (x2). IR (neat, cm
-1
): 3469, 
2987, 1737, 1601, 1500, 1370, 1233, 1178, 1153, 1013, 831, 703, 674. Anal. Calc. 
for C20H19F6NO6 (%): C, 49.70; H, 3.96; N, 2.90. Found: C, 49.25; H, 3.87; N, 2.73. 
HRMS for C20H19F6NO6Na [M+Na]
+
: m/z calc., 506.1014; found, 506.1011. 
 
Ethyl 2-(2-(3-ethoxy-2-hydroxy-2-methyl-3-oxopropyl)quinolin-6-yl)-3,3,3-
trifluoro-2-hydroxypropanoate, 11a: Yellow liquid. 
1
H NMR (CDCl3, 400 MHz, 
298 K) δ (ppm): 8.27 (d, J = 1.8 Hz, 1H), 8.14 (d, J = 8.4 Hz, 1H), 8. 9 (d, J = 9.1 
Hz, 1H), 8.00 (d, J = 9.0 Hz, 1H), 7.33 (d, J = 8.4 Hz, 1H), 6.01 (d, J = 5.1 Hz, 1H), 
4.57 (bs, 1H), 4.54-4.38 (m, 2H), 4.13-4.07 (m, 2H), 3.58 (dd, J = 15.5, 2.6 Hz, 1H), 
3.28 (d, J = 15.4 Hz, 1H), 1.58 (s, 3H), 1.40 (t, J = 7.2 Hz, 3H), 1.15-1.10 (m, 3H). 
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19
F NMR (CDCl3,  76 MHz, 298 K) δ (ppm): -76.1. 
13
C NMR (CDCl3, 100 MHz, 
298 K) δ (ppm): 175.9 (d, J = 2.2 Hz), 168.6, 16 .5, 147. , 1 7.4, 130.7, 128.8, 
127.8, 126.8, 126.2, 122.9, 121.5 (q, J = 286.8 Hz), 77.9 (q, J = 30.3 Hz), 75.0, 64.7, 
61.2 (d, J = 2.6 Hz), 46.5, 26.4, 14.1, 13.9. IR (neat, cm
-1
): 3339, 2984, 2938, 1740, 
1601, 1371, 1234, 1182, 1155, 1107, 1017, 978, 832. Anal. Calc. for C20H22F3NO6 
(%): C, 55.94; H, 5.16; N, 3.26. Found: C, 55.52; H, 5.12; N, 3.05. HRMS for 
C20H23F3NO6 [M+H]
+
: m/z calc., 430.1477; found, 430.1475. 
 
Ethyl 3,3,3-trifluoro-2-hydroxy-2-(2-(3,3,3-trifluoro-2-hydroxy-2-(4-
(trifluoromethyl)phenyl)propyl)quinolin-6-yl)propanoate, 12a: Yellow liquid. 
1
H 
NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 8.50 (bs, 1H), 8.27 (s, 1H), 8.13 (d, J = 
8.8 Hz, 2H), 7.99 (d, J = 9.0 Hz, 1H), 7.82 (d, J = 7.8 Hz, 2H), 7.56 (dd, J = 8.2, 3.7 
Hz, 2H), 7.28 (d, J = 8.4 Hz, 1H), 4.63 (bs, 1H), 4.53-4.34 (m, 2H), 3.83 (d, J = 15.2 
Hz, 1H), 3.70 (d, J = 15.2 Hz, 1H), 1.37 (t, J = 7.1 Hz, 3H). 
19
F NMR (CDCl3, 376 
MHz, 298 K) δ (ppm): -79.3 (d, J = 25.1 Hz), -76.1, -62.8.  13C NMR (CDCl3, 100 
MHz, 298 K) δ (ppm): 168.4, 158.7, 146. , 142.4, 1 8.6 (d, J = 2.8 Hz) 1 1.4, 1  .5 
(dq, J = 2.3, 32.4 Hz), 128.5 (d, J = 1.1 Hz) 128.4 (d, J = 1.6 Hz), 127.3 (d, J = 4.4 
Hz), 127.0, 126.2, 125.2 (q, J = 2.3), 123.9 (q, J = 272.0 Hz), 123.0 (q, J = 285.9 
Hz), 123.0 (m), 122.9, 77.7 (q, J = 30.8 Hz), 77.4 (q, J = 28.5 Hz), 64.8 (t, J = 13.9 
Hz), 40.0 (t, J = 14.6 Hz), 13.8 (q, 7.7 Hz). HRMS for C24H19F9NO4 [M+H]
+
: m/z 
calc., 556.1165; found, 556.1167. 
6.4.11 Data for 13a and 14a 
 
(2RS,3aRS)-2-Hydroxy-2-(trifluoromethyl)-3,3a,4,5-tetrahydropyrrolo[1,2-
a]quinolin-1(2H)-one, 14a-major product and (2SR,3aRS)-2-hydroxy-2-
(trifluoromethyl)-3,3a,4,5-tetrahydropyrrolo[1,2-a]quinolin-1(2H)-one, 14a-minor 
product, 13a: Light off white solid. Isolated as a 7:3 mixture of isomers. 
1
H NMR 
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(DMSO-d6 with a drop of TFA, 4   MHz, 298 K) δ (ppm): 8.58 (d, J = 9.8 Hz, 1H-
major), 8.50 (d, J = 8.6 Hz, 1H-minor), 7.24-7.17 (m, 2H-major and 2H-minor), 
7.11-7.03  (m, 1H-major and 1H minor), 4.04 (dddd, J = 14.4, 11.3, 6.1, 2.5 Hz, 1H-
major), 3.87-3.78 (m, 1H-minor), 3.00-2.88 (m, 1H-major and 1H-minor), 2.88-2.78 
(m, 1H-major and 2H-minor), 2.41 (dd, J = 13.7, 6.0 Hz, 1H-major), 2.25-2.16 (m, 
1H-major and 1H- minor), 2.01 (dd, J = 13.7, 8.8 Hz, 1H-major), 1.93 (dd, J = 13.8, 
8.7 Hz, 1H-minor), 1.67-1.51 (m, 1H-major and 1H-minor). Signal at 7.41 (s, 1H-
major and 1H-minor) exchange with TFA. 
19
F NMR (DMSO-d6 with a drop of TFA, 
 76 MHz, 298 K) δ (ppm): -78.9 (minor), -78.5 (major). 13C NMR (DMSO-d6, 100 
MHz, 298 K) δ (ppm): Major: 166.8, 1 6. , 1  . , 127.2, 127. , 124.7 (q, J = 28 .6 
Hz), 124.7, 118.6, 76.6 (q, J = 30.1 Hz), 53.8, 35.2, 28.3, 27.2; Minor: 166.8, 135.8, 
130.0, 127.4, 126.9, 125.2 (q, J = 288.2 Hz), 124.9, 119.1, 76.2 (q, J = 30.1 Hz), 
53.3, 35.4, 29.2, 27.0. HRMS for C13H13F3NO2 [M+H]
+
: m/z calc., 272.0893; found, 
272.0890. Relative stereochemistry were assigned based on 
1
H-
19
F HOESY, strong 
correlation was observed between CF3 and CH in the minor isomers but was absence 
in the major isomer. 
 
(RR)-Ethyl 3,3,3-trifluoro-2-hydroxy-2-(((SR)-1,2,3,4-tetrahydroquinolin-2-
yl)methyl)propanoate and (RS)-ethyl 3,3,3-trifluoro-2-hydroxy-2-(((RS)-1,2,3,4-
tetrahydroquinolin-2-yl)methyl)propanoate, 14a: Colourless oil. Isolated as a 2:1 
mixture of isomers. 
1
H NMR (CDCl3, 4   MHz, 298 K) δ (ppm): 6.98-6.89 (m, 2H-
major and 2H-minor) 6.64-6.57 (m, 1H-major and 1H-minor), 6.46 (d, J = 8.0 Hz, 
1H-minor) 6.38 (d, J = 7.8 Hz, 1H-major), 4.66 (bs, 1H-minor), 4.39 (q, J = 7.2 Hz, 
1H-major), 4.21-4.13 (m, 2H-major and 1H-minor), 3.95-3.76 (m, 2H-major and 2H-
minor), 3.26 (t, J = 7.0 Hz, 1H-minor), 2.87-2.67 (m, 2H-major and 2H-minor), 2.37-
2.11 (m, 1H-major and 2H-minor), 1.99 (dd, J = 14.0, 3.7 Hz, 1H-major), 1.91-1.67 
(m, 2H-major and 2H-minor), 1.34 (t, J = 7.1 Hz, 3H-minor), 0.99 (t, J = 7.2 Hz, 3H-
major). 
19
F NMR (CDCl3,  76 MHz, 298 K) δ (ppm): -79.3 (minor), -78.5 (major). 
13
C NMR (CDCl3, 100 MHz, 298 K) δ (ppm): Mixture of major and minor product: 
48.5, 44.9 (d, J = 13 Hz), 37.0 (t, J = 6.9 Hz), 36.5 (t, J = 7.7 Hz), 29.5, 23.6 (t, J = 
8.5 Hz). Major: 170.8, 142.6, 129.3 (m), 126.9 (m), 123.6 (q, J = 286.7 Hz), 120.5, 
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117.4 (m), 114.5 (d, J = 6.9 Hz), 76.4 (q, J = 28.5 Hz), 64.0 (m), 26.0 (m), 13.7 (q, J 
= 6.9 Hz). Minor: 169.5, 143.9, 129.3 (m), 126.9 (m), 123.1 (q, J = 286.7 Hz), 120.4, 
117.4 (m), 114.2 (d, J = 6.9 Hz), 78.6 (q, J = 29.3 Hz), 64.0 (m), 26.0 (m), 14.0 (q, J 
= 6.9 Hz). HRMS for C15H19F3NO3 [M+H]
+
: m/z calc., 318.1312; found, 318.1311. 
Strong correlation between CF3 and CH was observed in the major product but 
absent in the minor product in 
1
H-
19
F HOESY. 
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7 Conclusion and perspectives 
The hydrogenation of unsaturated bonds is one of the most widely studied 
transformations in both academia and industry. However, there are still challenges in 
the selective reduction of imino bonds, especially N-heterocycles under mild 
conditions. In addition, single catalysts capable of reducing multiple substrates, 
while tolerating an ample variety of functionalities are rare. Throughout this PhD 
thesis, our efforts in tacking some of the major issues affecting current reduction 
methods have been presented. The cyclometalated Ir(III) complexes presented herein 
are capable of not just reducing multiple substrates but also capable of tolerating 
sensitive functionalities which have been problematic in the past. Moreover, 
reductions could be carried out under environmentally benign reaction conditions 
and using user friendly reductants. Challenging substrates such as -functionalised 
ketones and N-heterocycles were reduced in water with high yields (Scheme 7.1 and 
Scheme 7.2, respectively). In addition, the reductive amination of ketones with 
ammonium formate has also been developed with iridicycles to give direct access to 
primary amines which have been challenging to achieve in the past (Scheme 7.3).  
 
Scheme 7.1: Transfer hydrogenation of -substituted ketones in water. 
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Scheme 7.2: Transfer hydrogenation of N-heterocycles in water. 
 
Scheme 7.3: Synthesis of primary amines by direct reductive amination of ketones. 
The dehydrogenation of saturated organic molecules represents an important 
synthetic route towards unsaturated molecules, such as the conversion of amines to 
imines, or the conversion of alcohols to carbonyls. Acceptorless dehydrogenation 
permits such transformations in the absence of stoichiometric sacrificial hydrogen 
acceptors, such as benzoquinone or O2. Molecular hydrogen that is released from the 
molecules is a high energy fuel. In terms of atom economy and from an industrial 
point of view, catalysts capable of activating such molecules to release H2 are highly 
desirable. In this thesis, we have demonstrated that cyclometalated Ir(III) complexes 
are highly versatile for the acceptorless dehydrogenation of a range of N-
heterocycles that have potential hydrogen storage applications. Moreover, such 
catalysts can also be utilised for the formation of C-C bonds leading to novel 
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functionalised N-heterocycles. This work is summarised in Scheme 7.4 and Scheme 
7.5, respectively. In addition, we have also demonstrated that the reverse 
hydrogenation is also viable with the same catalysts for such molecules.   
 
Scheme 7.4: A highly versatile cyclometalated Ir(III) complex for the acceptorless dehydrogenation 
of N-heterocycles. 
 
Scheme 7.5: A new acceptor-less and base free C-C bond formation strategy. 
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Thus, cyclometalated Ir(III) complexes are “universal” catalysts capable of 
hydrogenating and dehydrogenating multiple challenging substrates, rather than 
specialised catalysts for a particular set of substrates. Their robustness and versatility 
make them ideal for industrial use. Indeed, such complexes developed are now 
commercially available.   
 
 
 
 A robust and versatile catalyst for 
hydrogenation 
 Air and moisture stable 
 Displays excellent selectivity 
 Tolerates sensitive groups 
 Successful in reductive amination 
 Wide substrate scope, with 
excellent yields 
  A robust and versatile catalyst for 
dehydrogenation 
 Air and moisture stable 
 Displays excellent selectivity 
 Tolerates sensitive groups 
 Wide substrate scope, with 
excellent yields 
Scheme 7.6: Cyclometalated Ir(III) complexes for hydrogenation and dehydrogenation. 
Hopefully, the work presented in this thesis opens up the door for further exciting 
chemistry in the future. In the area of transfer hydrogenation, a natural extension 
would be the development of asymmetric reduction systems with cyclometalated 
complexes. These complexes have also shown promise in the dehydrogenation of 
both primary and secondary alcohols. This work has not been included in this thesis; 
but preliminary results are summarised in Scheme 7.7. Future work could include 
developing a robust catalyst capable of such transformation with low catalyst 
loadings. Further, cyclometalated Ir(III) complexes could also be tested for the 
dehydrogenation of more challenging substrates, for instance alkanes to alkenes, 
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primary amines to nitriles. For acceptorless dehydrogenation coupling, chiral 
organocatalysts can be used together with iridicycles to induce chirality at the newly 
formed quaternary centres after the attack on the electrophile. 
 
Scheme 7.7: Dehydrogenation of primary and secondary alcohols. 
 
 
